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ABSTRACT
Infectious bacterial diseases in developing countries represent a major health threat. Living 
conditions and environment decrease health status such that those in developing countries are left 
vulnerable to many diseases that are seldom seen in industrialised countries. Many treatments for 
these diseases have proven very effective, making infectious bacterial disease one of the best targets 
for high yield, low cost health interventions. Antibiotics remain the primary approach in treating 
infectious bacterial disease, yet mismanagement in their use has led to unnecessary resistance making 
many major diseases difficult to treat. Additionally, poor antibiotic choices for treating diseases have 
further contributed to unnecessary resistance. The appropriate choice for treating diseases is not 
always made and many diseases continue to be treated with inappropriate drugs or combinations of 
drugs. Many treatments are chosen on the basis of their easy availability or their small cost, when in 
fact other treatments could be obtained that have a more substantial impact on decreasing the incidence 
of a given disease. This is especially true in tlie treatment of tuberculosis. Tuberculosis, once thought 
to have been almost eradicated, has been revived by the growth of HTV. TB still claims a substantial 
proportion of human lives and will be responsible for 30 million deaths in this decade alone. Of 
particular relevance is the rising incidence of drug resistant cases of TB, which is primarily due to 
inappropriate antibiotic use. Although some past research has acknowledged the influence of 
resistance on the cost of TB treatment in developing countries, few studies have thoroughly analysed 
this relationship. This thesis presents a comprehensive study of the impact of drug resistance on the 
cost of TB treatment within the context of a cost-effectiveness analysis comparing short-course 
chemotherapy and the standard drug regimen in Ethiopia. In addition, the impact of HIV on TB 
treatment is analysed together with other factors, such as case holding, in order to assess their 
respective influence on the cost of treatment. Criteria for better management of tuberculosis control 
efforts in order to eradicate this disease and control resistance are subsequently explored. Finally, a 
discussion of the broader applicability of the conclusions of these studies to many developing countries 
is presented.
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CHAPTER ONE
INTRODUCTION
Developing countries were once the ultimate frontier: a place where imperialistic powers could 
expand their wealth and influence. As many were hot and tropical locales with virtually untouched 
native cultures, there was a certain romance associated with developing countries. However, in the 
twentieth century, colonies no longer proved to be viable and imperialists granted developing countries 
the ability to govern themselves, along with the responsibilities of caring for their inhabitants. These 
countries, with little industry, mainly depend on agriculture to feed their population. However, this has 
left many countries with little money for anything else, and many areas suffer such as sanitation, 
education and nutrition, all having an impact on health. Efforts to rectify this with feeble health care 
delivery systems were obviously ineffective with so many other variables decreasing health status.
A substantial amount of literature has been written on the problems of developing countries as 
well as frustration as to why, in the late twentieth century, people in developing countries are starving 
and dying of diseases long eradicated in developed countries. This is certainly a fascinating area: the 
final frontier in challenges to global development. Improving health is one of the most immediate 
areas for this development. However, this has proven a great challenge. Global organisations such as 
the WHO have defined health, delineated several possible areas for drug rationalisation, outlined areas 
for improvement in various disease areas, discussed ways to decrease expenditure, but such semantics 
have lacked the financial drive needed to make them manifest.
The path to greater levels of health care provision differs in every developing country according 
to its cultural needs and values, resources and economic and political situation. Changes in literacy 
rates are an important step in order for people to learn how to systematically improve their quality of 
life. Also necessary is a form of established social and political order that offers stability and the 
capacity for growth. Good transportation and communication infrastructure establishment are 
important for the transport of patients and personnel to health facilities as well as supplies. Clean
water and sanitation are necessary for better hygiene and the containment of infectious diseases. In 
addition, there is a need for equality between men and women as well as more education for women. 
Also, determining better health and welfare is a well balanced agricultural economy that allows for a 
good supply of food and better nutrition, but does not hamper industrial growth. Finally, sufficient 
secondary and primary health care are essential in providing treatment and care and vaccines for those 
needing them. It is these elements that finally allow for better levels of health to be achieved, however 
these require sound financial support.
Mortality and certain types of morbidity are negatively related to GNP per capita (Feldstein, 
1993). In essence, the poorer a country is, the higher death and morbidity from infectious diseases that 
it experiences. Greater funding is the key to improving health status, however, this is not available. 
Instead, developing countries must improve health status on what little funds they have, and in some 
cases, when paired with such poor living conditions, this becomes an unrealisable task. As health 
service coverage is low, emphasis is placed on treating as many patients as possible with the meagre 
funds available. However, all too often, quality is compromised.
In an effort to treat large populations, case loads become unmanageable and supplies are poorly 
organised and often unavailable. The results of this can be significant whereby patients receive a kind 
of treatment, but no cure, and in some cases, are even harmed by treatment. Therefore, a balance must 
be achieved between the quality of treatment and the number treated. This must be correlated with the 
amount of available funding, and therefore, priorities must be set in order to treat the most pressing 
conditions. Logically, those diseases that wreak the greatest devastation in terms of morbidity and 
mortality, but are cheaply cured, rank at the top of this list. It is through finding a balance in health 
care interventions that the inadequate funding available to developing countries for health care 
delivery can be optimised.
The problem comes in setting these priorities and systematically defining health interventions 
according to their greatest utilitarian value. Such optimisation is well suited to health management and 
health economics, however, these are relatively new areas in developing countries. Compared to other 
disciplines, health economics is a relatively new area, still in its nascent stages. Notwithstanding this, 
it is not surprising that there is very little literature in health care economics specific to developing 
countries. Where there are at least a hundred books written in the area of health economics, there are 
less than five on health economics in developing countries. Many tools and applications for health 
care cost and welfare analysis have yet to be created. Systematic utility measures such as the disability 
adjusted life year (DALY) are still being developed. These efforts are hampered by poor data records 
in developing countries, so that analysis in some cases is impossible. Also, health economic analyses 
in developing countries are primarily governed and propelled by academic work because there is not
3enough of a monetary incentive for health care delivery in this area to be analysed in an industrial 
environment. Many existing specialists in industrialised countries who could aid in the analysis of 
cost and health care interventions are wooed away by larger sums offered for work applied to health 
care delivery in a developed context. Likewise, in developing countries, there are few individuals who 
have any expertise in health economics. For example, where Glaxo might have 4 health economists, 
Ethiopia, a country with approximately 55 million, does not even have one. Nevertheless, it could be 
argued that in light of their economic situation, no area in the world actually needs health economic 
analysis more than developing countries: no countries need to optimise and rationalise their health care 
delivery system more than developing countries.
It is for this reason that more research is needed in the area of health economics and health 
management in developing countries. Developing countries offer a rich and unexplored area of 
research for health economists. Poor funding and living conditions present the ultimate challenge to 
the health economist who can not only provide useful information but work with a substantial impact 
on social welfare. A logical area for health care optimisation is drug treatment of infectious bacterial 
diseases, many of which are curable but wreak large-scale devastation on low income countries. 
Drugs are generally an effective but inexpensive health care intervention, especially for infectious 
diseases. A large number of individuals with infectious diseases can be readily and cheaply treated by 
drugs with outstanding results. The drug of choice for treating bacterial infectious diseases, of course, 
is an antibiotic, a non-invasive selective intervention that only kills microscopic bacteria rather than its 
host. The use of antibiotics for the treatment of infectious bacterial disease might seem relatively 
straightforward, but their utilisation is riddled with problems. Little research has specifically dealt 
with the cost of treating bacterial resistance in developing countries, especially that of TB. Resistance 
is often mentioned in studies of antibiotics, but little more consideration on its effect on treatment 
costs is presented.
This thesis explores the impact of resistance on the cost of drug treatments for infectious 
bacterial disease, primarily concentrating on tuberculosis. Infectious disease is one of the greatest 
targets for low cost, high yield health care interventions.
In order to answer the question of the impact of resistance on the cost of tuberculosis treatments 
in developing countries, other variables affecting this question must be addressed such as health, 
health care delivery, drug management and utilisation, antibiotic management and utilisation and the 
impact of tuberculosis. This thesis consists of two fundamental parts. The first part of the thesis 
addresses the current management and cost in health care, drugs and antibiotics with recommendations 
on the improvement of delivery in these areas. These sections focus on variables affecting the cost and 
therefore, cost-effectiveness of treating infectious disease, especially resistance. The second part of
4this thesis gives a specific example of an opportunistic disease particular to developing countries, 
tuberculosis. It discusses cost effective-interventions of TB treatment, first looking at other variables 
affecting the cost-effectiveness of TB treatments and then assessing the impact of resistance on TB 
treatments.
Chapter 2 of this thesis defines health. It also shows how living conditions and environment 
have a detrimental effect on health status, and what effect health services have on health. Health care 
expenditure is analysed along with the influence of external aid on health policy formulation in low 
income countries. Having looked at these variables, the choices that developing countries face in the 
quality and quantity of health care is addressed along with the limited options available to countries' 
ministries of health. Inherent problems in health care delivery are analysed in detail in order to impart 
an understanding as to why these systems function sub-optimally. The challenge of infectious diseases 
to health care systems and the impact of these diseases are then discussed. At this point, a tool for the 
prioritising of health care interventions, the DALY, is critically analysed. The method of derivation 
for the DALY is shown alongside its attempt to measure both the disability and premature mortality 
from a given disease. The performance of this DALY in maximising the benefits of health care with 
available resources is then shown.
After this overview of health care, the influence of drug utilisation, regulation and production on 
effective health care delivery is examined in Chapter 3. The problems of ignorance in drug use are 
illustrated, showing how patients with poor education are likely to misuse drugs. In conjunction with 
this, the consequence of poor drug regulation and rationalisation are presented along with a description 
of past external efforts to improve it. Following this, drug procurement and the role of drug producers 
in drug utilisation are shown, concentrating on their influence on drug information and quality. 
Controversies within the drug industry in developing countries are addressed, clarifying the 
multitudinous literature and opinions in this area. Drug counterfeiting, generics scandals, drug testing, 
drug salesmen, and traditional medicine are also discussed in this section. Efforts to improve this 
problem are shown along with approaches in regulating drug producers and theories on the industry's 
responsibility to the consumer.
In Chapter 4, one of the most heavily relied on therapeutic groups in the world, antibiotics, is 
discussed. Antibiotic resistance is shown to have a substantial impact on these drugs’ effectiveness 
and the cost of treatment. Mechanisms of resistance are described and an economic model of 
resistance is discussed. After this, the intricate problems of antibiotics and inappropriate use in 
developing countries are explored. Developing countries, with such a high demand for antibiotics, 
also suffer from the highest amount of associated negative externalities, antibiotic resistance.
5In Chapter 5, tuberculosis and the related management of drugs, health care delivery, health care 
management and appropriate treatment for TB are discussed. Tuberculosis was chosen for analysis 
because it is the paradigm of an opportunistic disease that flourishes in the living conditions of 
developing countries: conditions that weaken immune systems. It is ideal for an analysis of the impact 
of resistance on the cost-effectiveness of drug treatments because of the fact that it is such a deadly 
disease and resistance to it proves very significant. Indeed, tuberculosis treatment is specifically 
designed to as multiple therapy in order to avoid resistance. Unlike some bacterial diseases, 
subsequent resistance to TB primarily arises from human factors that can be controlled.
A disease with devastating consequences, tuberculosis can be responsible for the premature 
mortality of as many as 10-50% of the population, depending on the quality of treatment. It is not 
generally a disease of the rich, but a disease of the very poor. Even in industrialised countries it is 
those in poor conditions, such as the homeless, that suffer from this disease. This is not considering 
the synergistic effect that tuberculosis has in conjunction with HIV. Tuberculosis has the most 
virulent effect in combination with HIV. Not only does it more quickly kill HIV patients, but 
increases an infectious tuberculosis pool that revolves in an endless cycle between HIV patients and 
other vulnerable individuals. Chapter 5 defines tuberculosis so that the reader can gain an 
understanding of approaches in managing and containing the disease. It is shown how tuberculosis 
and HFV are so closely linked to each other due to TB's progression to disease in those with weakened 
immune systems. After this the management of tuberculosis containment is shown, applied to drug 
supply, diagnosis, isolation, preventative therapy, case holding and their associated costs. The global 
impact of TB is then shown with its share of the global burden of disease expressed in costs. New 
cases of tuberculosis are on the rise because of the disease's effect in conjunction with HIV. Current 
expenditure is shown to be insufficient to diffuse the current and future threat of tuberculosis.
Chapter 6 shows the problems of tuberculosis in developing countries and how this disease has 
become problematic because of poor sanitation, malnourishment, ignorance, HIV and resistance. This 
is where the methodology of this thesis is presented. This chapter also shows prior studies on the cost 
and the cost-effectiveness of TB treatments. TB must be a priority for health care delivery, and 
developing countries need to form a standardised systematic national method for tuberculosis control. 
Although TB is a curable disease, its prevalence is inordinately high along with its mortality rate in 
developing countries. Effective management of this disease can reduce morbidity and mortality from 
the disease by as much as 45% where applied correctly. The challenge comes in formulating an 
approach to curing the disease and finding the right cures. Possible approaches in drug treatment are 
presented, focusing on types of short course chemotherapy and the older standard drug regimen. By 
using applied economics to health care, the appropriate choice for decision making in tuberculosis
6treatment becomes more apparent. Hence, the methodology of health economics applied to infectious 
diseases is discussed. After this discussion, the existing literature applying health economics to 
tuberculosis treatment in developing countries is presented with various criticisms of each.
Chapter 7 and 8 presents a case study in Ethiopia. It is in Ethiopia where the question of the 
impact of resistance on TB treatment will be more thoroughly explored. Further analysis on the 
impact of resistance on the cost-effectiveness of the two main treatments is also addressed. Ethiopia 
was chosen for this study because it is one of the very poorest developing countries with high rates of 
morbidity, structural problems, heavy dependence on agriculture, and poor health service coverage. At 
the beginning of Chapter 7, demographic, environmental, organisational and political determinants of 
health are presented. This is followed by a detailed analysis of data from the Ethiopian Department of 
Pharmacy on drug supply and especially, the management of the tuberculosis drug supplies. After 
this, a discussion of current methods in controlling tuberculosis, including recent changes in the 
control system, are presented. Tuberculosis in Ethiopia is a severe problem and efforts to control it in 
the past have been all but effective. HIV's effect in Ethiopia is then presented at the end of Chapter 7, 
giving detailed data on all reported AIDS cases from the detection of the first case to its growth up to 
1994.
In the beginning of Chapter 8, the effect of HIV and TB is shown by looking at data from the St. 
Peter's Sanatorium in Addis Ababa, where a sample of nearly 800 TB patients have actually been 
screened for HTV. Here the impact of resistance on the cost of treatment is explored in the context of 
critical TB patients. Following this, the approach to the diagnosis of TB through the screening of 
patients is analysed, showing how diagnosis is sub-optimal, incurring needless costs. Finally, the end 
of Chapter 8 presents a cost-effectiveness analysis of TB treatment between two regimens in the public 
sector of Addis Ababa. Results from nearly 500 patients are analysed in order to find their response to 
treatment. The associated costs of these two treatments are researched and the impact of several 
variables, including that of resistance, is illustrated. The impact of the Ethiopian National 
Tuberculosis Programme, when compared to two years ago, is shown. This is followed by a 
description of the problems and challenges of delivering effective TB treatment in order to stop 
resistance and the growth of the disease at each health centre. This discussion further emphasises the 
need for better control to contain the disease and avoid TB resistance.
CHAPTER TWO
AN OVERVIEW OF HEALTH CARE AND 
INFECTIOUS DISEASES IN DEVELOPING COUNTRIES
Introduction
In order to assess the impact of resistance on the cost of tuberculosis treatment in developing 
countries, it is important to first define influencing variables such as epidemiological patterns and 
health care resource capacity. The design of this chapter is to impart the reader with some background 
information into the health priorities of developing countries. This includes a description of the 
challenges in infectious diseases developing countries face and what health care delivery capacities 
these countries have in order to meet these challenges. This will later be analysed within the context of 
tuberculosis treatment.
In developing countries, one of the most interesting areas to observe changes in epidemiological 
patterns of morbidity is in the area of infectious bacterial disease. In developing countries, this is an 
area with a vast potential for change. Despite the fact that the prevalence of many infectious diseases 
remains high, the predominance of these diseases can be cured.
Section 2-1 of Chapter 2 defines health and attempts to show what variables have a significant 
impact on health, also illustrating the health problems in developing countries and why they persist. 
Section 2-2 endeavours to show the challenges of health care delivery, highlighting its constrained 
nature and significant problems that require a prioritisation of health demands. Section 2-3 focuses on 
infectious disease and its impact in developing countries. The epidemiological morbidity patterns are 
analysed and future changes are projected. Section 2-4 discusses disease priorities in health care and 
presents one methodology for measuring the utility from health care interventions with the disability 
adjusted life year (DALY). The technical basis of DALYs is critically assessed as well as examples of 
their use in prioritising health care interventions.
8Section 2-1
Defining Health and health Determining Variables
This section discusses those variables that determine health in developing countries. Health is 
defined and influencing factors on health status such as environment and living conditions are 
presented. Total health care expenditure in developing countries as well as external aid is then 
explored. Those variables that influence health status will be later shown to also be specific 
determinants of the growth of tuberculosis, more so than many other infectious diseases.
2-1:1 The Impact of Living Conditions and Environment on Health Status
The standard of health of those in developing countries is certainly poor when compared to many 
other countries. It is complicated by poor living conditions, poverty, environmental and political 
disasters. Disasters seem to wreak wider devastation on developing countries than elsewhere in the 
world. From 1980-1990 in Africa, 6 613 deaths were attributed to floods, cyclones and earthquakes, 
566 000 deaths occurred from famine, drought and food shortages while also rendering 9.3 million 
homeless refugees. Between 1961 and 1981, cyclones, earthquakes, drought and flood took 1.1 
million lives in developing countries, 345 000 lives in middle income countries and 11 300 lives in 
high income countries, although the numbers of disasters were very close (Kloos and Zein, 1992).
In six countries where widespread famine occurred in Africa, famine was attributed to rebellion 
which in 4 cases was financed externally (Kloos and Zein, 1992). Indeed, disasters have a greater 
impact on the impoverished: more buildings fall on people in earthquakes in developing countries 
because, their construction is generally of a lower quality; diseases spread faster in cities in developing 
countries because of ignorance and the extremely close living quarters; drought strikes harder because 
more people depend on agriculture to feed them.
The poor are far more likely to get sick due to the fact that they depend on an income from 
physical labour and when they get sick, they are unable to make any more money. Therefore, illnesses 
leave the poor in a worsened financial situation. This is exacerbated by poor living conditions at home 
as well as malnourishement. Indeed, the poor are more crippled from disease and more of them die 
because of it. In the late 1980's in Porto Alegre, Brazil, adult deaths in impoverished areas were 75 
percent higher than richer areas. In Kenya, for families where a mother was less educated, a child's 
probability of dying before reaching the age of two was 18.4% in areas where half the families were 
below the poverty line, but ten per cent for areas where one fifth of the families lived below the 
poverty line. (World Bank, 1993). The World Bank captures the plight of the poor:
9"The poor are exposed to greater risks from unhealthy and dangerous conditions, both at home and at work. 
Malnourishment and the legacy of past illness mean that they are more likely to fall ill and slower to recover, 
especially as they have little access to health care. When a family's breadwinner becomes ill, other members 
of the household may at first cope by working harder themselves and by reducing consumption, perhaps even 
of food. Both adjustments can harm the health of the whole family. If free health care is not available, the 
costs of treatment may drive a household deeper into debt." (World Bank, 1993: p. 21)
As compared to developed countries, developing countries suffer from lower living standards 
and higher levels of morbidity and mortality which force them to solicit outside assistance. Although 
necessary, such outside assistance only lends superficial help instead of rendering the support that the 
country needs to independently maintain a health care system. The country finds that it is in greater 
debt from this assistance whereby it is placed in a repeating pattern of increasing debt causing it to 
borrow more. World Bank data would suggest that total debt repayments are now greater in 
developing countries than the value of all new aid payments and loans per year and that these 
repayments equal 25 per cent of the monetary value of their exports (Mills and Lee, 1993): exports that 
are primarily commodities whose prices are falling. Developing countries, forced to depend on an 
economy primarily based on agriculture, find that they cannot support a health system that meets the 
standards of an industrialised country.
In 1975, a World Bank Policy paper determined that the primary causes of poor health in 
developing countries were malnutrition, poor sanitary living conditions and inadequate housing 
(World Bank, 1975). To fully understand the health problems of developing countries, one must 
explore the causes. Developing countries suffer from poverty which increases their debt and decreases 
their ability to manage themselves. Among other things, this in turn manifests itself most acutely in 
their respective health care systems which exhibit poor information infrastructures, poor quality, poor 
referral systems, poor choices in supplies and concentration and hence, poor utilisation by the 
individual. In effect, this results in health care systems without direction. With so many other things 
to compound health care delivery, problems in the effectiveness of drugs as important as antibiotics 
have the potential for dire consequences on overall health status.
2-1:2 Definitions of Health
The World Health Organisation has defined health as "...a state of complete physical, mental and 
social well-being, and not merely the absence of disease or infirmity, is a fundamental human right...” 
(WHO, 1978). Undoubtedly, the "absence of disease or infirmity" is a common definition of health, 
but "complete physical, mental and social well-being" is rather vague, and at best, extremely difficult 
for individuals to obtain on a constant basis deriving from the fact that the definition includes the word 
"complete". Such global complete health for all is a goal that is inherently unrealistic. This does, 
however, suggest the idea of health as including something other than just the absence of disease and
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remains a term that refers to the state of the body. Where the boundaries of this state should start and 
end is open to debate.
The WHO set the undeniably ambitious goal of health for all by the year 2000 at the Alma-Alta 
conference proclaiming "The attainment of all people of the world by the year 2000 of a level of health 
that will permit them to lead a social and economically productive life." (World Bank, 1993: p. 13). 
This is an impossible and idealistic goal because it suggests a curing of diseases that are far from 
curable. Indeed, this goal was set when the year 2000 seemed like it was a distant point in the future. 
In order to even begin to change overall health rates to approach this goal, each country would have to 
invests the predominance of its GNPs in its health as well as the health care of more disadvantaged 
countries.
There is a large disparity between the health of developing countries and established market 
economies. Developing countries still suffer from diseases that have long been cured in industrialised 
nations. Therefore, it is largely in developing countries where WHO must concentrate its efforts in 
trying to achieve this goal. Such efforts centre around improvements in the standard of health care, 
and also, improvements in general living conditions. One can consider health care as one of many 
inputs that contribute to the final output of health, and the relationship between these outputs can be 
termed a health production function (Feldstein, 1993).
2-1:3 The Effects of Health Care Versus Other Variables on Health Status
The question arises as to what effect health care has on the level of health as opposed to other 
improvements in living standards. The measurement of health is extremely difficult and cannot 
depend on a single variable. In addition, more often than not, health is measured according to the 
incidence of the absence of health such as the death rate and levels of morbidity and mortality. Such 
data are tautologically not a full measurement of health. Compounding this in developing countries, 
not much reliable data are available, making such an assessment difficult.
In 1960, in the United States, Auster, Leveson, and Sarachek (1961) set out to find the 
percentage change in mortality that would occur from a one percent change in the level of health 
services. Indeed, the authors concluded that environmental and individual variables have a greater 
impact on the level of mortality than does health care delivery. Their analysis also included the effect 
of other factors such as environmental variables and personal variables. Where health care only had an 
elasticity of -0.1 with respect to mortality rates, education had an elasticity of -0.2. At low income 
levels, increases in income would decrease mortality whereas at high levels of income, mortality 
increased reflecting a change in lifestyle.
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This work was supported by the work of Benham and Benham (1975), whose findings in the 
United States suggested that between 1963 and 1970, the increase in the use of health services, 
primarily catalysed by the implementation of Medicare and Medicaid, did not produce an 
improvement in health status. It is difficult to say if these studies can be generalised to cover 
developing countres. Whereas in industrialised countries, a large proportion of infectious diseases 
have been eradicted with inexpensive drugs, lifting health status to a stable level so that it is dependent 
on changes in curing chronic and non-communicable diseases. This is not the case in developing 
countries. It is possible that health care, when health service coverage is high, can increase health 
status when treating cheap and curable infectious diseases. Health status in developing countries may 
not only be dependent on changes in living environment, but also it might be significantly affected by 
health care delivery and its function in educating individuals in elements such as nutrition and 
preventative care.
In developing countries, economic factors can also be shown to have a strong influence on 
health. In 1993, child mortality declined by 60 percent in those countries whose average incomes rose 
by over 1 percent per year (World Bank, 1993). At lower levels of income, greater income increases 
are often spent on better diets, better water supplies, sanitation and housing, all of which serve to 
improve health status. Supporting this point, the WHO has suggested at the Alma-Ata conference that 
"...the attainment of the highest possible level of health is a most important world-wide social goal 
whose realisation requires the action of many other social and economic sectors in addition to the 
health sector" (WHO, 1978). Certainly, the increases in health in industrialised countries in the early 
twentieth century could be attributed as much to health care as to increases in sanitation, nutrition and 
living conditions.
Hence, Policy makers are correct in assuming that along with the role of health care, increases in 
sanitation, diet and housing have an important effect on health. In addition, this might possibly 
explain the common pattern of donor pressure for very visible aid to physical infrastructures (Lee, 
Mills and Hoare, 1993). One could argue that the discrepancy in living environments between 
developed and developing countries could also have a strong correspondence to the discrepancies in 
their overall levels of health and patterns of morbidity. This is not to say that health care delivery must 
be completely discounted, but on the contrary, suggests that it works with other factors.
Health care represents the human effort to produce health. It characterises one of the many 
inputs forming health status. There is undoubtedly decreasing marginal returns to health inputs. 
When a programme is relatively small, each input produces relatively large outputs. Then as a 
programme grows, inputs expand, but the level of output starts to decrease until it becomes less
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consequential despite additional inputs. This is partially why health care programmes in developing 
countries can have such a potential impact on health status.
Much of health care delivery is a public good (one person's use does not leave less for another), 
and some health care interventions even have the potential to provide a positive externality (or 
sometimes negative externality as shown in Chapter 4) to others. For instance, encouraging one to 
stop smoking renders a positive externality to society because it not only helps the individual, but also 
increases the utility of those around him or her by limiting passive smoke inhalation. Similarly, 
immunisation for yellow fever not only benefits the individual, but those around him or her by 
contributing to the containment of the disease. Private health markets leave excess demand for health 
care goods. This reason, combined with health service's ability to provide such strong positive 
externalities, suggests a strong case for government spending and regulation of health care.
2-1:4 Health Care Expenditure
Health care spending not only improves an individual's level of utility, but also benefits society 
economically by allowing for greater production on the part of the individual who might otherwise be 
impeded from work by illness. The effects of illness can have a substantial impact on a country's 
economy. The World Bank (1993) claims that a large decrease in the level of deformity of 645 000 
lepers in India could have added an extra US $130 million to its 1985 GNP (how this figure is reached 
is not explained, but it is based on the assumption that each 'less deformed' leper would contribute 
$US 201 to India's GNP). Even the nature of work changes according to the level of health obtained. 
Farmers in Paraguay were found to choose to grow crops of lower worth just to avoid the malaria 
season (World Bank, 1993). Greater levels of health also benefit an individual's access to education as 
he or she is not debilitated. Likewise, money that would instead be used to treat illnesses, with greater 
health, can be spent on other efforts. The greatest potential for health care delivery is for the very poor 
who stand to benefit the very most, often for the least cost. For example, inexpensive interventions 
such as vaccinations that are already experienced by many in the middle classes have the potential to 
decrease a large proportion of diseases in the poor when properly administered.
Interestingly enough, the current level of expenditure shows that industrialised countries spend 
the most on health care per capita and developing countries spend the least. According to Chaulet and 
Zidouni (1993), 1990 global expenditure on health care amounted to US $1,700 billion of which 90 
percent was accounted for by industrialised countries, and 41 percent of this was accounted for by the 
United States, approximately 12 percent of America's GNP. In contrast, developing countries spent 
170 billion US dollars, 10 percent of total global expenditure, accounting for a full 4 per cent of 
America's GNP (See Table 2-1).
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Table 2-1: Government Health Expenditure per Capita in 
Different Groups of Countries classified by GNP per Capita
Groups of countries Population per million GNP per capita $US 1989
Governmental 
health expenditure 
per capita in $US 
1988
Low-income countries
Total 2 948.4 330 2.0
China 1 113.9 350 3.0
India 832.5 340 1.0
Others 1002.0 300 1.9
Middle-income countries
Total 1 104.5 2 040 23.0
Lower part 681.8 1 360 8.5
Upper part 422.7 3 150 43.0
High-income countries 830.4 18,330 612.0
Source: Chaulet and Zidouni, 1993
2-1:5 External Aid and Its Impact on Policy Decisions
Much of the funding for health care in developing countries comes from internal sources, but 
external aid also funds many health care programmes. Because developing countries are so financially 
constrained they must sometimes rely on external assistance to help fund their health care 
programmes. This external assistance, comes from official development assistance (ODA), 
multilateral loans and nongovernmental flows. This assistance is given by bilateral agencies, which 
are organisations like USAID where each aid exchange originates from one country; multilateral 
agencies, which are organisations like the World Bank where aid originates from several countries; 
NGOs and foundations. Such aid can amount to a vast sum.
According to Michaud and Murray (1994), in 1991, total external aid amounted to approximately 
US $4800 million. However, this only amounts to 2.9% of the total expenditure for health in 
developing countries. Where Zaidi, (1994) claims that the influence of external aid is the most 
important determinant influencing health care planning, Michaud and Murray counter this with their 
results that suggest that the formulation of health policy should not depend on external aid.
Michaud and Murray make further observations from their study of external health funding. 
According to these authors, external health funding was low in the early 1980s but began to increase in 
1986 from multilateral and bilateral assistance. From 1989-1990 external aid actually outgrew 
population growth. As shown in Figure 2-1, the largest donor countries are the US, Japan and France, 
but the Netherlands and the Scandinavian countries donate the largest proportion of their GDP to 
external aid for developing countries. Nearly one half of health aid funds go towards expenditure on 
developing the infrastructure of health for improving health service delivery and hospital care. The 
remainder is spent for specific health care programmes. Of these, leprosy, onchocerciasis, tropical
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disease, STDs, HIV infection and blinding diseases take the lion's share. Behind these diseases are 
malaria and the Expanded Programme for Immunisations (EPI). Poor funding is observed for almost 
all non-communicable diseases, acute respiratory infections and injuries. According to Michaud and 
Murray, sub-Saharan Africa does not receive more aid than other regions when considering 
population, size and income. These authors maintain that the smaller and poorer a country is, the more 
aid it receives per capita. Total external aid for 1991 can be seen in Table 2-2.
Figure 2-1: Development Aid from OECD Countries 
to the Health Sector of Developing Countries, 1990
Hl Sweden 6.4%
Italy 6.3%
■ Germany 6.1%
■ UK 5.3%
■ Norway 4.3%
■ Netherlands 4.3%
□ Canada 4.1%
□ Denmark 3.1%
□ Finland 2.7%
EJ Other 5.6%
[3 US 27.5%
E5 France 12.9%
E3 Japan 11.5%
Source: Michaud and Murray, 1993
Summary of Section 2-1
The environment and living conditions in developing countries have a significant impact on 
morbidity and mortality, challenging health interventions to establish an appropriate level of health. 
Health, which is defined as an overall state of well being, devoid of disease, has proven to be an 
extremely difficult goal to accomplish. This cannot be entirely blamed on the quality of health care 
provided in developing countries. Health status has been shown to be significantly determined by 
other environmental factors besides health interventions. Still, it can be maintained that health care 
expenditure may have some impact on health status. Greater investment in health care is therefore 
necessary in order to decrease morbidity and mortality levels. External assistance is estimated to be a 
helpful factor in achieving this goal, nevertheless, total external aid is not large enough to determine 
health policy formulation.
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Table 2-2: Total External Aid to 
Developing Countries in 1990 (in thousands)
Disease Bilaterals Multilaterals NGOs Foundations Total
Communicable Diseases
Tuberculosis 11 694 4 165 16 129
STD and HIV infection 64043 120 006 622 90 184 761
Diarrhoea 31 604 23 402 55 006
V accine-preventable
childhood infection 39 654 160 109 199 763
Malaria 36 745 10 087 46 832
Worm infection
Respiratory infection 7 986 4 525 12511
Other 69 530 31 970 101 500
Hepatitis 990 990
Tropical Cluster 4 831 58 848 10 815 74 494
Trypanosomiasis 471 471
Chagas Disease
Shistosomiasis 4 360 199 4 559
Leishmaniasis
Lymphatic filariasis
Onchocerciasis 4 835 22 720 4 518 3 041 35 114
Leprosy 2 770 3 108 71 000 76 878
Trachoma 453 3 150 3 603
Subtotal 279 495 438 940 76 140 17 295 811 870
Noncommunicable Diseases
Malignant neoplasms 1 737 725 2 462
Blindness 2 080 22 720 30 661 55 461
Neuropsychiatric diseases 2 838 2 838 5 676
Cerebrovascular diseases
Cardiovascular disease 961 961
Pulmonary obstruction
Drug/alcohol dependence 6 950 2 785 7 9 742
Other 391 391
Subtotal 14 957 28 343 31393 74 693
Injuries
Unintentional 984 984
Intentional 8 024 546 8 570
Subtotal 8 024 1530 9 554
Other
Nutrition 39 910 406 533 446 443
Maternal and child health 199 863 159 606 4 149 5 800 369 418
Population activities 558 000 332 000 22 000 24 000 936 000
Hospitals 178 905 44 546 223 451
Health services 396 034 547 904 938 378 13 959 1 896 275
Subtotal 1372 712 1 490 589 964 527 43 759 3 871 587
TOTAL 1 675 188 1 959 402 1 072 060 61 054 4 767704
Source: Michaud and Murray, 1994
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Section 2-2
Challenges in Health Care delivery
This section analyses the problems of health care delivery in developing countries in order to 
show the context in which developing countries work in order to increase health status. It illustrates 
how difficult it is for developing countries to raise their health status. With this section, one will be 
able to later see how problems such as ineffective antibiotics (due to resistance) have the potential to 
cripple developing countries' health care systems in dealing with bacterial diseases.
Tautologically, the quality of health care delivery is determined by the ability of a health care 
programme to appropriately meet the health care demands of those in a developing country. This is 
influenced by the relative amount and concentration of expenditure allocated to a health budget. The 
relationship between health care quality and economic growth is somewhat circular: as an economy 
grows, often its health care system becomes more and more strongly funded and with ensuing healthier 
human capital, there is likely to be further growth in the surrounding economy. These improvements 
are likely to cause epidemiological and demographic transitions within the health of a population.
Figure 2-2: The Transition of Health as Influenced 
by Demographic and Epidemiological Factors
Health Transition
Demographic transition Epidemiologic transition
Protracted-pol arized 
epidemiologic transition
Source: Mosley, Bobadilla and Jamison, 1993
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The transition of a health care system is portrayed in a diagram by Mosley, Bobadilla and 
Jamison (1993), shown in Figure 2-2. As can be observed, with urbanisation, industrialisation, greater 
incomes, rising levels of education and improved technology for health, there is a fall in infectious 
disease and mortality. Subsequently fertility falls, people live longer and chronic and non­
communicable diseases become more common. In contrast, as a county becomes more and more 
urbanised, and inequality increases or economic recessions occur, communicable diseases are likely to 
reappear, especially in the economically disadvantaged segments of a population. This is compounded 
by the transmission of resistant forms of bacterial diseases. One of the best examples of this is 
tuberculosis in industrialised countries: once a disease that was thought to be almost eradicated, it is 
again a threat in large cities, especially among the homeless and immigrants. It is in these groups 
where there has also been observed a simultaneous rising incidence of multi-drug resistant TB.
2:2:1 The Trade-off Between Quality and Quantity
In seeking health care in developing countries, patients sometimes feel that it will be ineffective 
or too expensive to pay for, and too often they are right. Because of constrained resources, developing 
countries often have difficulties in supplying a quality-consistent level of health care or health care that 
covers a large enough percent of the population. As the proportion of those treated grows, components 
essential to proficient health care delivery such as drugs, sanitation equipment, medical tools and 
personnel are often random. It might be possible to use new disposable syringes for 100 patients at a 
small health facility, but as the number of patients grows, for instance to 200, these syringes will have 
to be reused. If the number grows to 300, this health facility might find that it is altogether depleted of 
syringes. Given limited resources, developing countries must decide what quality of health care that 
they aim to provide.
Developing as well as industrialised countries must trade quality for quantity in health care 
delivery. These countries must look at their production possibilities when planning any health care 
delivery system. Such an approach can be depicted in a production possibility curve, which defines all 
possible combinations of production (of health producing outputs) available between two outputs. 
This is illustrated in Figure 2-3 where a production possibility curve illustrates the trade-off between 
quality and quantity: two outputs that are not entirely substitutable (hence the concave shape). For 
example, technology-intensive health care on the secondary level would suggest a high quality- 
intensive health care approach that would reach very few people: a point high on the quantity-quality 
trade-off, such as point 1. In contrast, primary health care workers with limited education in medical 
care working in rural areas would suggest a concentration on quantity rather than quality. This 
approach might give access to a high percentage of people but simultaneously compromise quality: an
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approach that would appear at point 2. Lastly, point 3 represents a combination of quality and quantity 
in health care delivery that is unobtainable from a developing country's resources.
One can see from this illustrated example that those countries concentrating on quality intensive 
resources encounter the problem whereby the population that has access to this health care is very 
small. Likewise, those countries who aim for the maximum coverage of health care to treat the largest 
quantity of population possible, often result in random and poor health care delivery. It is through 
finding a balance between quality and quantity that developing countries can optimise their level of 
health care delivery. Maximising the quantity of those treated is often the predominant goal rather 
than focusing on the quality of health care in developing countries. Nevertheless, emphasis on this 
must be controlled or health care can become pointless, random and even a cause of harm.
Figure 2-3: Trade-off Between Quality 
and Quantity in Health Care Delivery
Quality
(better standard 
of care)
2-2:2 Limited Choices and the Rationalisation of Health Care
There are indeed, strong differences between the health care possibilities available to developing 
countries and industrialised countries. Mosely, Bobadilla and Jamison (1993) capture the differences 
between strong and weak health care systems in responding to rationalising health demands, as shown 
in Table 2-3. This table is formulated from the burden of disease, cost-effectiveness and the relative 
strength of a health care system. The possibilities that lie within reach of a country with a strong, well 
funded health care system are much greater than those with a weak health care system. Those with 
strong systems might choose to restrict a low cost-effective intervention with little impact on the 
burden disease, whereas a country with a weak health care system would be forced to eliminate it.
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Table 2-3: Responses of Strong and Weak 
Health Care Systems to Burden of Disease
Burden of Disease Intervention Cost- 
Effectiveness
Strong Health Care Systems Weak Health Care Systems
High High Aim for Full population coverage 
Improve quality of services provided
Reorient/train existing staff
Develop technical /management 
systems
Establish infrastructure
Low Research to improve interventions
Do not expand services
Institute cost recovery
Research to improve interventions 
Restrict or eliminate services
Low High Target high-risk groups Provide services on demand
Low Restrict services or provide cost 
recovery
Eliminate services
Source1. Mosely, Bobadilla and Jamison, 1993
2-2:3 Poor Allocation and Concentration of the Health Care Budget
There is often the underlying belief in developing countries that it is through obtaining a highly 
concentrated technology-intensive health care delivery system that these countries can begin to obtain 
the level of health care of industrialised countries. On the surface, large and costly machines provide 
impressive looking health facilities but tend to be used because they are there and perceived as 
'superior' instead of necessary. Up to 70% of government expenditure in many developing countries is 
concentrated on costly technology-intensive secondary health care delivery for those in urban areas 
(Mills, 1990), when these resources could be more cheaply and efficiently utilised on the primary level 
of health care. Some developing countries have been known to use up to 20% of their budgets on a 
sole teaching hospital when lower level health care delivery proves less costly and more effective 
(Mills and Lee, 1993). Costly efforts to treat cancer are expended when little emphasis is placed on 
low cost, high result treatments for tuberculosis and sexually transmitted diseases. Likewise, large 
amounts of money is squandered on name-brand drugs instead of generic drugs, improper supervision 
of health workers and under utilisation of hospital beds (World Bank, 1993).
2-2:3a Urban Concentration of Health Care
Inconsistencies in the concentration of inputs for health care delivery between urban areas and 
rural areas are common in developing countries. These inconsistencies, for example, arise such that in 
urban areas, one can find the most expensive and often unnecessary diagnostic equipment, whereas in 
rural areas, (although high technology is not usually necessary in the presence of a good referral 
system) one might still be hard pressed to find a microscope or a boiler for reusable syringes. The 
effect is such that basic health needs are not fulfilled. Inconsistencies develop in these countries which
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exhibit the use of the most modem drugs and health care facilities in some areas and a complete lack 
of drugs and facilities in other areas, both from a demographic and morbidity perspective. Of course, 
it cannot be denied that in urban areas there is a greater concentration of people using health care 
facilities because of those living in the area and those that travel from rural areas to urban areas. This 
makes treatment, in some cases, initially more cost-effective due to economies of scale with more 
people treated by the same health facilities and equipment. Nevertheless, rethinking the use of such 
expensive technological equipment when a less expensive, properly used method might suffice, should 
be seriously considered. Compounding this, such high levels of technology in hospitals encourage the 
greater utilisation by patients who perceive these facilities as 'better'. This can result in an overflow of 
caseload that compromises the overall level of care. This results in treatment of a random and 
inconstant standard. Hence, it is through careful consideration for the choice of technology that 
developing countries can create better health care delivery as well as influence utilisation.
Indeed, health care delivery should be relevant to both the resources and the requirements of 
developing countries: it should be technically suitable to the nature of the country's morbidity while 
being economically accessible for the country to maintain over a long period of time. As this is 
something that even developed countries have difficulty doing, it is no wonder that developing 
countries have difficulty with their more confining conditions and resources.
Such over-concentration on hospital care undermines the possibilities of treatment in a primary 
health care (PHC) environment. PHC interventions are under-utilised in many cases such as in the 
treatment of child malnutrition, child mortality, tuberculosis, prenatal care, delivery and AIDS 
education. This also highlights the cost-effectiveness of preventive care rather than treatment. The 
World Bank estimates that the majority of cost-effective interventions can be performed in primary 
health care settings rather than hospitals (World Bank, 1993). This is not to say that the use of primary 
health care is always more cost-effective than secondary care. When used prudently, hospitals have 
the potential to treat serious cases of disease more cost-effectively than health centres and clinics. 
Certainly, most clinics do not have the facility for treating life-threatening infections or open-heart 
surgery. The problem arises when hospitals are utilised for everything from serious AIDS 
complications to child delivery and the smallest cut. Used properly, primary health care should be 
contacted first in non-life-threatening situations and then, with the proper implementation of a referral 
system, those situations that clinics cannot adequately handle, should be referred to a hospital.
2-2:4 Referral
Ideally a health system in a developing country should have a hierarchy that effectively cares for 
its patients on its least expensive level. Primary health care (PHC) in the community can be a
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manifestation of the least expensive form of health care delivery, and therefore, patients should be 
given the incentives to utilise this level of health care first before going to hospitals. Nevertheless, this 
relies on an effective referral system which often fails in its efforts to effectively deliver a patient to a 
higher level of health care. Due to more pressing matters, health care workers may not have the time 
to help patients travel to referral facilities or check to see if the patient arrived. Compounding this 
matter is the over-utilisation of secondary health care. Due to overcrowding, hospitals might send 
critical patients down to primary health care centres that often do not have the beds or facilities to care 
for them. On the primary level, patients might be referred to hospitals and spend the money to travel 
there only to be turned away from the hospital and told to come back on another day. Patient 
compliance to referrals also decreases as travel to a referral facility becomes more difficult.
2-2:5 Information
Developing countries suffer from an acute lack of information about the nature of their morbidity 
which stems from the fact that they fail to have the funds to support the necessary information network 
needed. Hence, disease control priorities become skewed or unknown ensuing in poor decisions. 
Appropriate infrastructures for the exchange of information are difficult to maintain in rural areas 
where transport and communication are difficult. Methods of recording information are hard to 
enforce and often result in incorrectly taken or incomplete information making the time and effort in 
taking it a waste. Likewise, such information that does become available can also be inappropriate to 
the decision needs of a health facility. Health care providers require appropriate information on 
morbidity and mortality to supply the right amount of medical tools, drugs and training to health care 
workers. This information comes from the correct accounts of previous amounts of supplies and 
expenditures as well as a continuous recording of disease patterns of patients and effectiveness of 
efforts in curing these diseases.
2-2:6 Utilisation
The utilisation of health care services is also an important component to the overall levels of 
health. Health care utilisation is a function of supply and demand: dependent on the perception of the 
effectiveness of a health service and the costs of the service such as the length of time for treatment, 
work forgone as well as the distance travelled to the service. In Peru, over sixty percent of the poor 
must travel over an hour to get primary health care (World Bank; 1993). Health services tend to be 
concentrated in urban areas allowing very little access for those living in rural areas because of the 
distance needed to get there. Those in rural areas seeking help must often travel through remote areas 
without roads and stay with friends relatives or in the street in order to get treatment. In light of this it
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is not surprising that rural patients only seek medical care in cities when it is perceived as absolutely 
necessary and are far more likely to rely on closer pharmacies and more culturally accessible 
traditional healers. Similarly, education has an important impact on the perception of a health care 
facility and the overall demand and utilisation of it. For example, in many countries the education of 
females is discouraged. This has an adverse effect on health because many females ultimately become 
the major decision makers in families, determining family health status. It is often the women who 
decide diet, health care, fertility and lifestyle. Likewise, women are responsible for caring for their 
family's children and elderly and taking family members to health care facilities.
2-2:6 Summary of Section 2-2
With limited funds and therefore, limited health care facilities, developing countries usually 
choose to concentrate on treating the largest amount of individuals for its budget rather that 
concentrating on the quality of health care. Finding an appropriate balance between quality of care 
and quantity of those treated is an important element to raising health status under limited funding. 
Developing countries have limited choices available to them and must concentrate on those utilitarian 
interventions that have the most benefits for individuals, limiting concentration on those interventions 
which have low cost-effectiveness and a low contribution to the overall burden of disease. 
Unfortunately in practice, those interventions and levels of technology that developing countries 
choose to concentrate on do not compliment this approach. Among other things, health care systems 
in developing countries are crippled by poor referral systems, poor information infrastructures, poor 
health service coverage and therefore poor utilisation. Health status is unlikely to increase from health 
care services unless some efforts are made to improve these problems.
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Section 2-3
Measuring the Effects of Infectious disease on Health Status
This section will show the already crippling impact of infectious diseases on health status in 
developing countries. It shows that prominent among these diseases are bacterial diseases. These 
diseases are already difficult to treat for developing countries without problems of resistance to 
antibiotics.
In developing countries, seven million adults die per year of diseases that can be either prevented 
or cured (Chaulet and Zidouni, 1993). Child Mortality rates in developing countries are ten times 
higher than in industrialised countries, and indeed, if these rates were reduced to industrialised child 
mortality levels, there would be 11 million fewer deaths of children per year. Maternal mortality is 
thirty times higher than those of established market economies, 2 million of these deaths come from 
tuberculosis (Chaulet and Zidouni, 1993).
Table 2-4: Main Cause of Disease Burden in Children and 
Adults in Demographically Developing Countries in 1990
Disease and Injuries Number
Affected
(million)
Main Intervention
Children
Respiratory Infections 98 Integrated Management of the Sick Child (MSC)
Perinatal Morbidity and Mortality 96 Prenatal Delivery Care and Family Planning
Diarrhoeal Disease 92 ORS (Oral Rehydration Solution)
Childhood Cluster (diseases preventable through Expanded Programme on Immunisation (EPI)
immunisation) 65
Congenital Malformation 35 Surgical Operations
Malaria 31 Drug Treatment/Possible Vaccines
Intestinal Helminths 17 School Health Programme
Protein-energy Malnutrition 12 Expanded Education and Nutrition Aids
Vitamin-A Deficiency 12 EPI Plus
Iodine Deficiency 9 Iodine Supplementation
TOTAL 467
Adults
Sexually Transmitted Diseases 49.2 Condom Subsidy plus IEC
Tuberculosis 36.6 Short-Course Chemotherapy
Cerebrovascular disease 31.7 Case Management
Maternal Morbidity and Mortality 28.1 Prenatal and Delivery Care
Ischaemic Heart Disease 24.9 Tobacco Control Programme
Chronic Obstructive Pulmonary Disease 23.4 Tobacco Control Programme
Motor Vehicle Accidents 18.4 Alcohol control Programme
Depressive Disorders 15.7 Case Management
Per- Endo- and Myocarditis and Cardiomyopathy 12.4 Case Management
Homicide and Violence 12.2 Alcohol Control Programme
TOTAL 252.6
Adapted from\ Bobadilla et al., 1994
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It is projected that AIDS in developing countries will be responsible for 1.8 million deaths per year by 
the year 2000. Deaths due to malaria and resistant malaria is expected to double to account for 2 
million per year in the next decade. The concentration of morbidity patterns is primarily determined 
by infectious disease and malnutrition. This is shown in Table 2-4 by Bobadilla et al., (1994).
2-3:1 Comparing Epidemiological Disease Patterns between Industrialised and Developing 
Countries
Mortality rates in developing countries are alarming. A large percentage of these represent 
avoidable deaths from infectious diseases which can be cured. One only has to look at global causes 
of death to observe the large polarisation between industrialised and developing countries. 
Industrialised countries' death rates are dominated by non-communicable diseases and chronic 
diseases, whereas developing countries' death rates are primarily determined by communicable 
diseases. Lopez (1993) charts the causes of death according to disease categories which can be seen in 
Table 2-5. In all cases, the incidence of death from communicable diseases greatly outweighs that 
experienced in industrialised countries. Prominent differences in death rates are especially articulated 
in the total 504 000 deaths from parasitic diseases in industrialised countries compared to 17 000 000 
deaths from parasitic diseases in developing countries.
Table 2-5: A Comparison of Causes of Death Between Developing 
Countries and Industrialised Countries, 1985 (in thousands)
Cause of Death Total
Industrialised
Market
Economies
Total
Industrialised
Non-Market
Economies
Latin 
America 
and the 
Caribbean
Sub­
Saharan
Africa
Middle 
East 
& North 
Africa
Asia Total
Developing
Countries
Infectious and Parasitic 308 198 900 4500 2 400 9 200 17 000
Diseases
Acute Respiratory 
Infections 241 126
- - - - -
Tuberculosis 13 27 - - - - -
Neoplasms 1 607 687 300 250 200 1 750 2 500
Circulatory and Certain 3 455 2 475 900 650 550 4 400 6 500
Degenerative diseases
Ischaemic Heart Disease 1 325 1067 -
Cerebrovascular Disease 801 703 - - - - -
Diabetes 121 33 - - - - -
Complications of 1 3 35 125 80 260 500
Pregnancy
Perinatal Conditions 42 58 300 680 420 1 800 3 200
Chronic Obstructive Lung 254 131 90 60 50 2 100 2 300
Diseases
Injury and Poisoning 431 341 - - - - -
IU-defined/Extemal Causes 182 65 250 350 200 1 600 24 00
All Other Causes 535 272 425 585 400 2 090 3 500
Total 6 815 4 230 3 200 7 200 4 300 23 200 37 900
Adapted From: Lopez, 1993
Additionally striking, is the 100 000 industrial death rate from perionatal illnesses compared to 
32 000 000 for developing countries; and the 4 000 industrial death rate from pregnancy complications 
compared to 500 000 in developing countries. Lopez concludes that unlike industrialised countries, in
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developing countries, child and infant deaths account for 50-60% of total death rates. He observes that 
malaria, in some areas, can be responsible for the highest cause of death in children.
Although infectious diseases are the primary determinants of death rates in developing countries,
it should be noted that non-communicable diseases and chronic disease are on the rise due to changes
in lifestyle of sections of populations.
Figure 2-4: Life Expectancy Growth 
from 1950-1990 in Various Regions
----- □----- Sub-Saharan Africa
..... O..... India
- - - -O - - - Middle Eastern Crescent
—- Other Asia and Islands
- - -ffi - - China
- — Latin America and the Caribbean
“ " •©----- Former European Socialist Economies
-----— Established Market Economies
Source: World Bank Data, 1993
Lopez observes that in some developing countries, chronic diseases are accountable for a higher and 
higher proportion of death rates. He remarks that the proportion of cancer deaths in developing 
countries is equal to those in industrialised countries and that other chronic diseases account for nine 
million other deaths. This is partially attributed to behavioural changes in developing countries such 
as greater numbers of the population engaging in smoking. It is estimated that the death toll from 
smoking-related illnesses will rise to 6-8 million in the next thirty years. A large proportion of these
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deaths will occur in China, where smoking of manufactured cigarettes is becoming more and more 
popular.
Death rates and morbidity are all higher in developing countries due to poor living conditions, 
environment, poverty and to some extent, poor health care. World Bank data, as illustrated in Figure 
2-4, show the rise in life expectancy rates according to area. All countries have experienced rises in 
their life expectancies from 1950. However, sub-Saharan Africa and India have the lowest average life 
expectancy of around 50-55 years. In contrast, established market economies and former socialist 
economies of Europe have the highest life expectancies, ranging at around 70-78 years.
2-3:2 Summary of Section 2-3
Infectious disease has devastating effects on the health status of those in developing countries. 
Environmental conditions such as poor sanitation, poor disease control and ignorance allow infectious 
disease to quickly spread. Undoubtedly, infectious disease is the prime determinant of 
epidemiological morbidity patterns in developing countries. A comparison between infections in 
industrialised countries and developing countries suggest a vast polarisation between incidence which 
is likely to be the result of different environments and intensity of health care interventions. 
Communicable diseases are undoubtedly a strong determinant of disease patterns in developing 
countries, but this will soon be compounded by rising incidences of non-communicable and chronic 
diseases.
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Section 2-4
Setting Priorities in Health Care
This section analyses the process of defining priorities in health care. It critically assesses one 
approach to this supported by the World Bank (the DALY). From this section, it is shown how 
tuberculosis and other bacterial diseases are perceived as strong targets for health care interventions.
Recent efforts in immunisation have saved 3 million lives a year and the Expanded Programme 
on Immunisation (EPI) protects 80% of children in developing countries against six major diseases for 
only 1.4 billion each year (World Bank, 1993). These were goals which were accomplished by placing 
them on the top of health care priorities. For instance, goals for the end of this century, according to 
the World Bank, suggest the following "Implementation of the public health and essential clinical care 
packages, pursuit of economic growth strategies that reduce poverty, and increased investment in 
schooling for girls would have the largest payoffs in averting deaths and reducing disability." and 
"Scaling back public spending for tertiary care facilities, specialist training, and clinical care with 
lower cost-effectiveness would help to increase the effectiveness of health spending." (World Bank, 
1993: p.13). Prioritising health needs is undoubtedly difficult and there is always a question of 
whether these priorities are correct. Because of inadequate funding for health care in developing 
countries, it is important to purchase the health interventions that will result in the highest levels of 
health for the meagre funds available. It might even be argued that failure to minimise opportunity 
costs of health care expenditure in developing countries has a much stronger impact in terms of lives 
lost, than this failure would have in industrialised countries.
2-4:1 DALYs
There are several tools that evaluate health interventions. These can assess, for instance, the 
number of deaths averted, years of potential life lost, risk trade-offs, quantity-of-life trade-offs, cost 
and quality per life year gained from an intervention and costs per cures. One of the more recent 
applications of this, specifically targeted at developing countries, is the disability adjusted life year or 
the DALY, developed by Christopher Murray for the World Bank. This is a measure that was 
specifically developed to measure years of life lost from death and disability contributing to the global 
burden of disease {World Development Report, 1993). This measure avoids the difficulties associated 
with assigning a dollar amount to human life, only to undergo the problems of valuing it with a less 
tangible unit.
The DALY, similar to the QALY (quality adjusted life year) is defined by Jamison as "the 
number of years between the age at which a death would have occurred and the individual's expected
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age at death, given survival to the given age, with years gained in future years discounted back to the 
present at a discount rate of 3 percent per annum..." (Jamison, 1993: p. 8). What this essentially means 
is that a DALY attempts to capture the impact of total years lived with a disease from its onset and the 
total years lost if a disease causes premature death. Years lived with a disability are calculated by 
assigning a weight to measure the level of disability experienced each year, and this is subtracted from 
either premature death or the time when the illness subsides. The level of disability from a disease is 
adjusted for DALYs according to a weighing process. So, for instance, a health intervention to treat 
malaria might render weights reflecting greater levels of disability than an intervention which treats 
arthritis. Premature death is calculated by subtracting the age of premature death from the natural 
potential life expectancy without the disease. Premature years of life lost are added to the number of 
disability life years from living with a disease and the sum of these are the DALYs per individual. In 
some cases there will only be disability adjusted life years and not premature death, but this still 
contributes to the overall burden of disease. These DALYs are then discounted at a rate of 3 percent 
so that their value can be assessed in the present time.
2-4:2 The Technical Basis for DALYs
The technical basis behind DALYs was developed by Murray (1994a). His final formula for 
DALY calculation includes several variables of years of life lost, an age weight function, disability 
weighting and time preference. Years of life lost were calculated by using the standard expected years 
of life lost method (elaborated in Chapter 7), which is calculated from the formula
x-l
x=0
Where
dx - death at age x
In this case, ex is calculated from the model life table West Level 26 (See Chapter 7) which sets life 
expectancy for women at 82.5 years and life expectancy for men at 80 years. Life expectancy is set at 
the highest average observed age in industrialised countries. Murray chooses to use this calculation of 
the years of life lost due to premature death because it reflects a more egalitarian measure over 
countries and will still measure years of life lost at ages above the average life expectancy. Murray 
argues that this was necessary because it standardises the years of life lost over all countries in order to 
measure the overall burden of disease in like terms from country to country.
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2-4:2a Age-Weighting
In order to portray the value of years lost at different ages, Murray uses an age-weighting 
function, a variation of the human capital approach, in an attempt to represent the social contribution 
that changes at different stages of an individual's life. Like the human capital approach in valuing an 
individual's labour and earnings as his or her economic contribution to society, unequal age weights try 
to capture different social contributions of individuals at different stages in their life. Economic 
productivity for each year of life was not used to calculate DALYs because of inherent inequities of 
this approach. Instead, Murray used social contribution, which is different for individuals at different 
ages. Although each individual may not have the same level of productivity in their life, he or she can 
hope to be a part of every age group subsequently engaging in those social contributions associated 
with each group.
To capture these age-weights, Murray used a modified Delphi method which derives estimates 
from a panel of 'public health experts'. The Delphi technique can be inconsistent because it relies on 
estimation with a great likelihood of error. This is interesting because the potential for error, even for 
a panel of health experts in calculating weights is likely to be high. Because a panel of individuals 
agree on a particular weight or probability, does not mean that weight or probability is a predictor of 
what really occurs. These problems in the age-weight make the DALY a more arbitrary measure.
The DALY's age-weighing is captured in a continuous age-weight function in the formula.
Weight (x) = Cxe~Px
Where
C = a constant equal to 0.16243
fi = a constant for age patterns using the value 0.04
x = age
The age-weight function is shown in Figure 2-5. In this figure, it can be observed that 8 is used in 
order to dictate the age pattern so that 1/8 is the maximum weight. This means that if 8 is equal to 
0.04, 1/0.04 will make the maximum weight in this function at 25 years. C is used in order to make 
sure that the overall estimated sum of global burden of disease is not changed from what it would be 
using uniform age weights. From looking at Figure 2-5, this means that the area underneath the curve 
using these age weights is adjusted by C so that it is equal to the area underneath the uniform weight 
curve (the straight line where weight=l).
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Figure 2-5: The Age-Weight Function
Age
2-4:2b Disability Weighting
In order to measure disability, six classes of disability were formulated between perfect health 
and death. Classes were formed to reflect greater and greater degrees of welfare loss. A disability in 
the same class might be experienced in different ways and impede different functions, but their total 
effect on the individuals is estimated to be the same. Disabilities in each class have the same impact 
on individuals regardless of economic standing.
Table 2-6: Definitions for Disability Weighting
Class Description Weight
Class 1 Limited Ability to perform at least one activity in one of 
the following areas: recreation, education, procreation or 
occupation
0.096
Class 2 Limited ability to perform most activities in one of the 
following areas: recreation, education, procreation or 
occupation
0.220
Class 3 Limited ability to perform activities in two or more of the 
following areas: recreation, education, procreation or 
occupation
0.400
Class 4 Limited ability to perform most activities in all of the 
following areas: recreation, education, procreation or 
occupation
0.600
Class 5 Needs assistance with instrumental activities of daily 
living such as meal preparation, shopping or housework
0.810
Class 6 Needs assistance with activities of daily living such as 
eating, personal hygiene or toilet use
0.920
These disability weights can be observed in Table 2-6. Limited ability was defined by Murray as 50% 
or greater in decreased ability. The severity of a disability for each class is exogenous to the time it 
was anticipated to last. In essence, disability experienced by individuals who perceived their condition
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to be temporary were equal to that experienced by individuals who perceived their condition to be 
permanent. Hence, disability duration and severity are independent. Preferences for different 
disabilities were chosen by a panel of experts using a Delphi method. This is usually a method chosen 
because of the fact that there is not available evidence from literature, clinical or naturalistic trials.
To find these preferences, Murray had a choice of rating scales, magnitude estimation, time trade-off, 
person trade-off or standard gamble. Magnitude estimation was chosen (whereby individuals are 
asked direct questions about the comparative value of time endured in one state over another). 
Weights were chosen on the basis of word definitions and a set of disabling sequalae (fixed examples 
of what it might be like to experience various forms of a disability in a class) for each class. For every 
class, a number between 0 (death) and 1 (perfect health) was chosen. These numbers were averaged 
and appear in Table 2-6. The time of those who lived in these classes with a disability is multiplied by 
the class's associated weight in order to make it comparable to years lost due to premature death.
As stated earlier, DALYs attempt to measure the level of utility gained from health interventions. 
Derivation of utility weights is still a very controversial area. In looking at the sensitivity of his 
disability weights, Murray admits that the data are quite sensitive to changes within some of the 
weight classes. It would make little impact for classes 1 and 2 if weights changed 0.1, but in classes 3 
to 6, a change as little as 0.05 has a significant impact on the final DALY calculation. Indeed, the 
varying of time and those questioned, depending on whether they have only observed a condition or 
actually experienced it, influences their answer. The external validity of these estimates are difficult to 
maintain and answers might change if the sample were made of different individuals. These answers 
might also be affected if the same individuals were asked the same questions again at a different time. 
This technique can be inconsistent because it relies on estimation with a great likelihood of error. This 
in turn will effect the derivation of DALYs making their use as a tool less accurate.
2-4:2c Time Preference
The amount of life lost due to premature mortality was discounted in order to reflect time 
preferences. Time preference essentially refers to the fact that individuals would rather experience a 
benefit in the current time period and a cost in a later time period (this is elaborated in greater detail in 
Chapter 7). This formula uses a continuous discounting function of Discount(x,r)=e'r(x‘a) rather than a 
discrete discounting function, but this choice is likely to make little difference in the final value. The 
discounting function is shown in Figure 2-6 for a disability that starts at birth. Here it can be seen that 
if the individual lives, for example, to 50 with a disability, total disability years are multiplied by 
0.2231. In effect, this means that because these years are experienced in the future, the years are only 
worth 11.15 years in the present (11.15 =(50)(0.2231)).
32
Figure 2-6: Discount Function for DALYs
The decision of having a discount rate automatically integrated into this measure limits the user. 
The choice of discount rate can no longer be made and is fixed at 3%. In addition, the actual measure 
itself becomes misleading because observers may not be aware of the fact that the measure has already 
been discounted. It is possible that evidence will arise which will not only justify the use of a different 
discount rate, but require it, making this measure invalid. Many use a discount rate of 10%, 6% or 5% 
and this can vary even more in some cases (Parsonage and Neuburger, 1992; Coyle and Tolley, 1992; 
Cairns, 1994). Murray does not adequately justify why he chose to use 3%, or why he chose to make 
it an endogenous part of the DALY.
Discounting is generally an accepted method of expressing the preference for benefits in the 
current time period. One problem of discounting DALYs is that it gives interventions affecting current 
generations preference over those affecting future generations. So, for instance, future generations 
might benefit from more education on smoking whereby there will be fewer low birth rates for future 
babies, but since the benefits of such actions are so far in the future they would be secondary to such 
programmes where benefits were immediate (Parsonage and Neuburger, 1992). This is very important 
because one of the interesting things that Murray is trying to illustrate is the effect of DALYs on the 
incidence of infectious disease, which indeed, has long term future effects on both the current and 
future generations. (Lower discount rates will highlight the effect of the programmes where benefits 
are experienced in the future) Another problem is with the choice of a discount rate. With lower 
discount rates there is an accompanied reduction in the cost per DALY rating. This is not an attack on 
discounting: it is a necessary element of most economic analyses where benefits are experienced in the
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future. Nevertheless, the possible influences of discounting on results must nevertheless be 
considered, and with a discount rate automatically placed in the DALY calculation, there leaves little 
choice for these.
Parsonage and Neuburger (1992) maintain that non-monetary benefits such as the QALY (and 
DALY) should not be discounted. This is because, assuming that the welfare associated with them are 
autonomous to income, arguments relating to income (such as the argument that as society becomes 
more affluent, there is diminishing marginal utility to each pound) do not apply to non-monetary 
benefits such as the QALY or DALY (See Chapter 6 for a description of arguments for discounting). 
In fact the relationship between the value of non-monetary benefits does not appear to change with 
changes in income in different time periods. Parsonage and Neuburger go on to suggest that although 
more research is necessary, private discount rates referring to the 'pure' time preference, independent 
of income, is zero or negative. By automatically placing discounting in the formulation of DALYs, 
Murray has rendered them inflexible, especially when there is the argument that this kind of non­
monetary benefit should not be discounted.
2-4:2d The DALY Formula
Time preference, age weighting, years of life lost due to premature mortality and disability 
weights are all placed into a formula to reflect the years lost from premature death and years lost from 
living with a disability. This is shown in the formula below
x=a+L
DALYs Lost(x~)= $DCxe-pxe-r{x-a}dx
x=a
Where
a = onset of the disability
L= duration of disability or time lost due to premature mortality 
r = the discount rate (0.03)
C = age weighting correction constant (equal to 0.16243)
fi = parameter from the age-weighting function (using the value 0.04)
D = disability weight (1 for premature mortality)
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The solution for this integral is
DALYs Lost:
^^.[e-(^)W(l + (/>+r)(L + «)) - (1+03+r»]
This function is graphed in Figure 2-7. Figure 2-7 shows that the most DALYs that an individual can 
lose from premature death from a disease occurs at age 10 and is equal to 36.86 DALYs for females 
and 36.71 DALYs for males. After age 10, DALYs lost due to premature death logically decrease as 
the age of death increases.
Figure 2-7: Total Female and Male DALYs 
Lost Due to Premature Death at Each Age
Age
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Figure 2-8: Estimated Cost per DALY 
for More Complete Dengue Control*
DALY's SAVED PER YEAR (per 1 million population)
Source: Shepard and Halstead, 1993
*It should be noted that these figures are estimates which depend on the case mortality as well as other variables in the rate 
of infection and disease virulence.
DALYs like QALYs do not measure the full benefit of health care: they do not take into account 
the value of health care to patient's relatives, the value of the information provided by doctors, and the 
elimination of the burden of decision-making in the choice of health intervention (Gerard and Mooney, 
1993). This is one reason why those observations based on DALYs should not be used without other 
information in making a decision.
The World Bank has accepted DALYs as a tool for making health resource allocation decisions. 
It must be remembered that DALYs are based on a vast number of assumptions and depend on data in 
developing countries, which are unreliable. DALY conclusions have been used to justify some of the 
previous contentions in primary health care. There is a tendency to take DALY conclusions at face 
value (possibly by those who do not understand the measure). The goal of making a definitive 
standardised measure has, in effect, compromised the DALY. The DALY was designed as such a 
general measure for so many different situations, diseases and countries, that its conclusions have 
lessened validity than if it were designed for one situation.
2-4:3 The Application of DALYs for the Optimisation of Health Funding
Health interventions can be evaluated according to the number of DALYs they save as well as 
their dollar cost per DALY gained. DALYs have been used to measure global disease burdens for
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over 100 diseases in eight regions for five age groups of males and females. Through this measure, 
there have been attempts to show the impact and cost-effectiveness of efforts to more comprehensively 
contain diseases. For instance, according to Shepard and Halstead, (1993) the containment of dengue, 
a fever type of illness spread by mosquitoes, has a comparatively low cost per year when looking at 
case management, but this increases with the use of chemical vector control and then rapidly increases 
with the implementation of environmental control as is illustrated in Figure 2-8.
It should be noted that some communicable diseases have the potential to be less expensive per 
DALY saved than non-communicable disease interventions. This is simply because often the 
treatment of communicable diseases proves to be much cheaper with more significant results. This is 
especially true when quick and effective treatment such as antibiotics and antimicrobials can be 
applied (of course it should be noted that this is not always the case, as for instance, given the example 
of AIDS). Comparing costs per DALY saved across various medical conditions, one can see which 
interventions for conditions are highly effective per DALY and which are not, as seen in Figure 2-9. 
This cannot be construed as a complete priority list for disease control but may lend perspective in 
estimating which diseases require more concentration for control. For example, in looking at Figure 2­
9, if tuberculosis chemotherapy is inexpensive to cure by chemotherapy but more efforts are targeted 
to AIDS treatment, perhaps more attention should be given to the former.
Figure 2-9: Cost Effectiveness of Clinical 
Interventions for Various Diseases in Developing Countries*
&
AIDS Treatment 
Dengue 
Malaria
Schizophrenia 
ORT and Education
Rheumatic Heart Disease 
Matemal/Perinatal Health
Tetanus
Vit. A for Children w/Measles 
Acute Respiratory Infections
Cataract
Antibiotic Treatment of STDs 
Leprosy
Tuberculosis
Cost per DALY Gained
Adapted From: Jamison, 1993 
*Figures are averages and are dependent on Case Fatality and Risk of Infection
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Indeed, the analysis of DALYs point to the fact that less consideration should be given to those 
treatments that are not cost-effective. This also applies to concentration on those treatments that are 
effective but expensive. Also, the ultimate effect of a treatment should be considered. Given two 
health care interventions and a limited budget, one intervention might be slightly more cost-effective 
than the other, but the less cost-effective measure might serve to save far more lives for that fixed 
budget, making it the better choice even though it is more costly in DALY terms. It is possible when 
dealing with fixed budgets that more individuals can be treated for a less costly but less cost-effective 
treatment than treatment with a more costly, but more cost-effective treatment. This goes back to the 
previously mentioned quality versus quantity trade-off.
2-4:4 Creating National Health Care Packages to Reduce the Burden of Disease
Each country must decide what priority it will place on health. Diseases can have a strong 
burden on the productivity of a state and therefore, increasing health is a great priority for all countries. 
Following this goal, the approach to increasing health output can obviously vary in effectiveness. For 
example, Murray, Kreuser and Whang (1994) observe that a model that integrates the expansion of a 
health care infrastructure will save 40% more DALYs than a health care system that ignores the 
expansion of its infrastructure. The intensity of expenditure on different programmes to achieve goals 
must also be carefully considered to optimise existing funds. Developing countries spend very little on 
health care, but comprehensive packages for decreasing the incidence of disease are within their 
means. Bobadilla et al., (1994) observe that the primary causes of disease burden could be cost- 
effectively treated for US $12 per person in low income countries and US $22 per person in middle 
income countries. The authors estimate that these interventions, when applied according to these 
packages, could reduce the global disease burden by 21-38% in children under 15 and 10-18% in 
adults. Interventions, their relative cost per DALY and their cost per capita are depicted in Table 2-7. 
According to Bobadilla et al., the $12 per capita expenditure would require one district hospital bed 
per 1000 population, 0.1 physicians per 1000 population and 2-4 nurses per physician.
These estimates of US $12 per person for low income countries and US $22 per person for 
middle income countries, although highly attractive on paper, are unlikely to be instigated by 
developing countries in the near future. It is likely that middle income countries will adopt the US $12 
package and the low income countries will continue to struggle with what they have. Low income 
countries, who often struggle to spend even US $1 dollar per capita with health service coverage as 
low as 60%, are unlikely to be able to apply such a US $12 package for many years to come. 
Nevertheless, Bobadilla et al. provide an interesting goal to work towards that countries might be able 
to achieve if health were one of their highest priorities.
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Table 2-7: Cost-Effectiveness of the Health Interventions 
(and clusters of intervention) Included in the Minimum package 
of Health Services in Low- and Middle-income Countries
Intervention Cost per 
Beneficiary
Cost per 
Capita
DALYs
Potentially Gained 
(per 1000 
population)*1
Effectiveness^ Cost per
DALY
($US)
Low Income Countries
I. Public Health
Expanded Programme of Immunisation Plusc 14.6 0.5 45 0.77 12-17
School Health Programme 3.6 0.3 4 0.58 20-25
Tobacco and Alcohol Control Programme 0.3 0.3 12 0.14 35-55
AIDS Prevention Programme^ 112.2 1.7 35 0.58 3-5
Other Public Health Interventions 2.4 1.4 - - -
Subtotal - 4.2 - - 14
II. Clinical Services
Chemotherapy Against Tuberculosis 500.0 0.6 34 0.51 3-5
Integrated Management of the Sick Child 9.0 1.6 184 0.25 30-50
Family Planning 12.0 0.9 7 0.70 20-30
STD Treatment 11.0 0.2 26 0.42 1-3
Prenatal and Delivery Care 90.0 3.8 57 0.42 30-50
Limited Care^ 6.0 0.7 - 0.03 200-300
Subtotal - 7.8 - - -
Total 12.0
Middle Income Countries
I. Public Health
Expanded Programme of Immunisation Plusc 28.6 0.8 4 0.77 25-30
School Health Programme 6.5 0.6 5 0.58 38-43
Tobacco and Alcohol control Programme 0.3 0.3 9 0.14 45-55
AIDS Prevention Programme^ 132.3 2.0 15 0.58 13-18
Other Public Health Interventions 5.2 3.1 - - -
Subtotal - 6.9 - - -
//. Clinical Services
Chemotherapy Against Tuberculosis 275.0 0.2 6 0.51 5-7
Integrated Management of the Sick Child 8.0 1.1 21 0.25 50-100
Family Planning 20.0 2.2 6 0.70 100-150
STD Treatment 18.0 0.3 3.7 0.42 10-15
Prenatal and Delivery Care 255.0 8.8 25 0.42 60-110
Limited Care^ 13.0 2.1 - 0.03 400-600
Subtotal - 14.7 - - 133
Total 21.5
Source: Bobadilla et al., 1994
a Sum of Losses to Premature Mortality and to Disability, including losses to others because of secondary transmission of 
disease
b calculated by multiplying efficacy, diagnostic accuracy (when applicable) and compliance
c Plus refers to the vaccine against hepatitis B and Vitamin A supplementation »
d DALYs lost from AIDS include dynamic effects (probability of transmission to others) only in the first year, which 
understates the value of prevention cases and thus the cost-effectiveness of preventive interventions 
e Includes information, communication, and education on selected risk factors and health behaviours, plus vector control 
and disease surveillance
f Includes treatment of infection and minor trauma; for more complicated conditions, includes diagnosis, advice and pain 
relief, and treatment as resources permit. (Bobadilla et al., 1994: p. 657)
2-4:5 Summary of Section 2-4
The concentration of health care interventions in order to procure the largest rises in health status 
per unit expenditure is a challenge for all countries. Up until recently, there was no large measure of 
utility from a health care intervention specific to developing countries. DALYs, developed by Murray
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in conjunction with the WHO and the World Bank, is one standardised method for the measurement of 
disability and premature mortality saved per dollar for a given intervention. It is through this method 
that attempts are made to compare different interventions on the same scale. This measure has 
generated considerable literature on the appropriate concentrations of health interventions and possible 
health care packages per capita expenditure on health. Nevertheless, conclusions from DALYs must 
be carefully considered because of inherent errors in the measure and external factors to which DALYs 
fail to take into account.
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Section 2-5
CONCLUSION TO CHAPTER TWO
Infectious disease in developing countries drives mortality and morbidity to appalling rates, 
considering a large majority of infectious diseases are curable. Health status in developing countries is 
continually threatened by unsanitary living conditions, malnutrition, political problems, environmental 
problems, poor education and meagre funding. Developing a health care system on a limited budget 
that will care for the health-damaging results of these living conditions is one of the greatest 
challenges in health care delivery today. Current health programmes in developing countries have 
flawed infrastructures and a concentration on inappropriate interventions. Because of high associated 
opportunity costs for inappropriate health interventions, developing countries need to prioritise their 
health demands in order to meet those that are more pressing. Prioritising tools, such as the DALY, 
are part of a greater strategy in optimising the concentration on health care interventions. With the 
development of systematic economic methodologies for health care intervention prioritisation, it is 
possible that developing countries will be more able to facilitate the formulation of effective health 
policies. One target for greater economic analysis and a potential for better management is the area of 
pharmaceuticals, as is shown in the following chapter.
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CHAPTER THREE
THE UTILISATION AND CONTROL OF
DRUGS IN DEVELOPING COUNTRIES
To find the impact of resistance on the cost of tuberculosis treatment in developing countries, it 
is important to show the context in which drugs, including antibiotics, are utilised, managed, marketed 
and regulated. This chapter analyses the role that pharmaceuticals play in developing countries, 
tracing their use and abuse and concentrating on those elements that may impede their potential as a 
comparatively inexpensive and effective health care intervention. Drug management and control will 
later be discussed within the context of tuberculosis treatment and tuberculosis drug resistance.
In developing countries, drug usage in the past could be described as chaotic at its best. These 
countries’ lack of control of drugs and their marketing has sadly resulted in a great and unnecessary 
loss of life. Nevertheless, changes in behaviour and attitudes are allowing for an improvement in this 
much needed remedy, although there is still a significant area left for improvement. There are many 
drugs available to cure infectious diseases which are predominant in developing countries, but this 
relies on these drugs' controlled accessibility, rationalisation of their use as well as a genuine interest in 
the social welfare of those individuals affected. Section 3-1 describes the impediments to correct drug 
usage in developing countries. Section 3-2 assesses attempts to better regulate drugs with the Essential 
Drugs Programme and the Bamako initiative. Section 3-3 looks at the influence of the actions of 
pharmaceutical producers and how they have affected drug utilisation in developing countries.
Introduction
In November 1935, a little girl named Hildegard unexpectedly pricked herself with an 
embroidery needle in the soft web of muscle between her thumb and first finger. Shortly after this, the 
wound became badly infected with streptococcus which spread up her arm in red flares. Her glands
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under her armpit became swollen and she was admitted to the hospital for urgent treatment. Current 
treatment at that time was solely surgical and this girl was given fourteen lancing operations, all having 
no effect. Some days later, her glands became filled with pus, she developed a temperature of 39°C 
and her infection became blood-borne. The surgeon in charge wanted to amputate her arm in an 
attempt to save her life, nevertheless, another doctor suggested an alternative. He treated Hildegard 
with a new drug, Prontosil, and in only two days, her temperature had became normal. After repeated 
doses, she recovered completely without amputation. (Ryan, 1992).
The above story illustrates the dramatic effect that drugs can have in the treatment of disease. 
Many other health interventions pale in comparison, often leaving a patient drastically changed in 
appearance and well-being. In contrast, drugs have the potential to quickly treat a disease, restoring a 
patient back to health, with few unpleasant side effects. Modern drugs have revolutionised health care 
delivery. Compared to other procedures, modern drug therapy is relatively new, but is widely 
depended on for the treatment of most major diseases. In comparing drugs to surgery, drugs are also 
much safer. Although surgery is now considered a last resort, in many cases before drug treatment, it 
was considered the first and only resort. When considering treatment for a critical condition, given the 
choice between equally effective surgical and drug treatments, a drug treatment will almost always be 
chosen by doctors as it is assumed to be safer when compared to surgery, which is viewed as quite 
risky. Deaths in Britain from surgery are an estimated 10 times higher than deaths from drugs (Smith 
and Quelch, 1991). Also, surgery often requires a highly paid specialist to perform it, invasive 
procedures, sedatives, anaesthetics, close monitoring of the patient during and after surgery and even 
long hospital recovery time. What surgery requires is more frequently absent from drug therapy, 
making drug therapy both a more effective and less costly alternative in a monetary sense and in terms 
of a patient's time and productivity. With drug treatment, the patient can often spend more time as a 
productive member of society rather than spending that time recuperating from his or her condition. 
Additional savings come from the fact that large amounts of manpower are not needed for the 
administration of most drugs unlike the majority of other health care interventions. Pharmaceuticals 
are less labour intensive and hence, are of greater value where labour is an expensive component of 
health care delivery. Indeed, in many countries, drugs encompasses only 10-15% of all health care 
costs (Smith and Quelch, 1991). A concise example comes from examining antibiotics, which in many 
cases, are undoubtedly the most efficient method of treating bacterial infections. The majority of them 
are inexpensive, easily administered, very effective and involve fewer complications than surgery. 
Where drugs cannot be used to cure major diseases, intervention is comparatively clumsy and costly in 
terms of the funds spent by the provider, the labour and .equipment, and patient’s time and discomfort. 
In 1989, for instance, in comparing the cost of drug treatment to the cost of surgery for ulcers, the cost
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of ranitidine treatment for one month was approximately US $59.11 whereas the cost of surgery itself 
was US $7 777.00 in the United States. This is one hundred and thirty-one times the cost of ranitidine, 
excluding physician services and hospitalisation (Sonnenberg, 1989). Drugs offer an ease of treatment 
for the doctor and health worker that few, if any, other health interventions provide. Without available 
drugs for treatment, health care would be very labour intensive and very expensive. Hence, 
pharmaceuticals play an essential role in cost-effective health care.
Despite the fact that pharmaceuticals are one of the less expensive and more effective health 
interventions available to health care providers they are not available in a large enough supply to meet 
the needs of those in developing countries. In 1988, it was estimated that 25% of the world's 
population consumed 80% of manufactured drugs and 75% of the population only had access to 20% 
of all drugs. Seven years ago, the WHO estimated that between 1.3 and 2.5 billion people around the 
world had little or no access to drugs (WHO, 1988).
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Section 3-1
PROBLEMS OF DRUG UTILISATION IN DEVELOPING COUNTRIES
This section addresses problems in the drug utilisation in developing countries, including 
problems that arise from unregulated drug availability and poor education in appropriate drug uses. To 
assess the influence of resistance on the cost of antibiotics, the environment in which they are used in 
developing countries is presented. It is from this analysis of drug utilisation that it will be later shown 
why antibiotic resistant diseases, and namely tuberculosis drug resistance, arise in developing 
countries.
The nature of morbidity patterns in developing countries can be broken into four categories of 
diseases. Category one consists of diseases such as heart disease, cancer, AIDS, and arthritis which are 
experienced by both developing and industrialised countries. In contrast, category two contains those 
diseases specifically found in impoverished nations such as tuberculosis, tetanus, meningitis and 
measles. Category three is defined by diseases that have long been eliminated in developed countries 
such as cholera, parasites and leprosy. Lastly, category four consists of tropical diseases that do not 
occur in developed countries but are commonly found in developing countries, examples of these 
disease are malaria and schistosomiasis. In developed countries, many of these diseases have long 
been cured by cheap vaccines and drugs and hence, there lies the potential for these diseases to be 
cured quite cheaply with startling effectiveness in developing countries. Nevertheless, like many 
elements in developing countries, drug utilisation is complicated. Due to a lack of funds and 
convoluted political ideologies, health care delivery involving pharmaceuticals has been tainted in 
every area. At the core of this problem is the lack of government influence, control and regulation of 
pharmaceuticals. From this stems the inability to obtain drugs, control information about them, 
produce them, and finally get the correct drugs in the correct amounts to each patient.
3-1:1 Drug Availability
Governments in developing countries lack the funds to control the utilisation of drugs and 
resulting control efforts are often inconsistent. Many developing countries have made elaborate plans 
and efforts to control drugs, but have lacked the impetus to enforce these controls and existing 
regulations, allowing access to drugs to almost anyone. Notwithstanding, such a system invokes some 
degree of rationale. In order to work in an environment where access to doctors to write prescriptions 
is often costly and difficult to obtain, given the doctor to patient ratio in developing countries, access to 
drugs has been relaxed. If access to drugs were as difficult as in industrialised nations, only limited to 
doctor's prescriptions, most individuals in developing nations would never see a drug and hence, never
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benefit from it. Nevertheless, this is no justification for such poor regulation: drugs available outside 
of the context of health care facilities have led to many problems.
The control of drugs in developing countries proves to be either ineffective or non-existent. 
Anyone can walk into a pharmacy and buy any drug available there or can obtain black market drugs 
right on the street from vendors. Drugs have a substantial market value and it is not unknown for 
patients who are administered drugs in public hospitals for instance, to pretend to swallow a drug and 
then keep it to sell it later. Those finally purchasing such drugs often know nothing about them and 
are victims of the influence of cultural myths, poor education, and conjectures about these drugs.
3-1:la The Black Market
Black market drugs are available on most street corners, and they are frequented by a wide 
variety of people from children, to mothers and the elderly. To illustrate the profile of those buying 
drugs off the street, Fassin (1988) studied 10 sellers in Dakar, Senegal. In this study, 144 buyers, aged 
from 5-60 years with a sex ratio of 1 male to every 2 females, were observed buying drugs off the 
street for reasons of convenience and low cost. 77% of pharmaceuticals were bought for pain and 
fatigue and aspirin accounted for 58% of all drugs sold. A further 12% were tetracycline 
antidiarrhoeals and 7% were antimalarials (4-aminoquinolines). The authors also found that total 
expenditure at the 102 illegal sellers in markets was 11 times that spent by the public sector in drugs at 
this location. It was also observed that the closer the location of the seller to the buyer, the more 
regular visits the buyer would make.
3-l:lb Pharmacies
Another similar problem is found in developing countries with the sale in pharmacies of those 
drugs which are only available with a prescription in most industrialised countries. In contrast, in 
developing countries, a majority of these drugs are bought without a prescription on the 
recommendation of the pharmacist or are self-prescribed. Krishnaswamy, Kumar and Radhaiah's 
(1985) study of 10% of the 330 retail pharmaceutical stores of Hyderabad and Secunderabad showed 
that 51.3% of all drugs, including a large proportion of ethical drugs purchased from these stores were 
from a doctor's prescription, classifying 48.7% as either self-medication or from the pharmacist’s 
recommendation. The distribution of the types of these medicines bought without a doctor’s 
prescription was highly concentrated in analgesics and anti-inflammatories however, other medicines 
were also purchased. A proportion of them were undeniably prescription drugs, including antibiotics 
as well as those for respiratory problems and neurological disorders. Table 3-1, depicts this 
distribution which exhibits one example of the nature of self-medication in developing countries.
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Indeed, the other more common point of purchase for drugs, the pharmacy, does not just function 
as a place to buy drugs, but often as the primary point of health care: the pharmacist, acting as a doctor 
in providing drug information. Added to this, the pharmacy has an advantage over the health care 
facility in that the transaction costs of receiving care are often not as costly as a health care facility and 
the value of the care received is perceived to be equally good. It is likely that the farther away the 
pharmacy is from an urban area and the more difficult access is to a health care facility, the more likely 
a pharmacy will take on this role.
Table 3-1 Therapeutic Classes of Drugs Purchased 
in Pharmacies in Hyderabad and Secunderabad
Therapeutic Class % Self Medication % Prescribed by Doctor
Nutritional Products 19 26.5
Sulfa and Antibiotics 9.3 15.5
Analgesics/Antipyretics
Anti-inflammatories
23.8 13.0
Gastro-intestinal Disorders 11.9 9.0
Respiratory Disorders 10.8 8.3
Neurological Disorders 4.6 6.2
Cardiovascular Disorders 4.7 4.1
Hormonal Preparations 3.3 3.9
Anti-Infectives 2.7 4.2
Other 2.8 3.3
Topical Preparations 6.1 5.3
Ayurvedic Preparations 1.0 1.1
Source: Krishnaswamy, Kumar and Radhaiah 1985: p. 365
This is because the cost of travel is often prohibitive for those seeking health care, and pharmacies by 
virtue of their number, are often closer to the individual than a health care facility. In Thailand, for 
example, the ratio of physicians to population in the late eighties was 1:4 790 whereas the ratio of 
pharmacies to the population was 1:2 817 (Kunin, 1987). With nearly twice as many pharmacies as 
doctors, such ratios indicate that there is greater access to pharmacies. Another perceived advantage of 
using a pharmacy is that the pharmacist does not charge a consultation fee where a doctor might. Also, 
from a cultural perspective, pharmacists are more likely to cater to consumer needs, combining cultural 
beliefs with his or her recommendations of drugs. This was observed in a study performed by Bledsoe 
et al. (1988) in the Mende of Sierra Leone. They found that pharmacists dispensed pills according to 
colour because of the buyers' strong belief in the link between colour and effectiveness. Likewise, 
Kunin (1987) observed in Thailand that patients felt more at ease telling a pharmacist about 
embarrassing conditions such as venereal diseases. In India, Kapil (1988) observed that those 
commonly buying drugs range from the very poor to tradesmen and government employees. She also 
observed that patients more frequently use self-medication utilising a pharmacy or traditional healer 
before seeking medical attention from a doctor. This is supported by Logan (1988) whose study,
47
although based on a rather small sample size, found in 1988 that out of 48 patients living in urban 
areas in Mexico, 50-90% of patients used self-medication for treating illnesses. However, if an illness 
persisted, approximately two thirds of patients sought medical care from a physician and 
approximately 10% continued to use self medication.
Unfortunately, a pharmacist or pharmacy clerk is not often trained as a health care advisor the 
way a doctor or health personnel are, and therefore, the information he or she imparts may be more 
inappropriate for the patient. This polarisation between doctor and pharmacy can be even more 
accentuated if the person at the pharmacy dispensing pills is not a pharmacist. Although most 
developing countries stipulate that there be a licensed pharmacist at every pharmacy, this regulation is 
not adequately enforced and the pharmacist is not required to be there during business hours (Kunin, 
1987). Hence, it is possible for a patient to receive drugs and advice from a clerk not even as qualified 
as a pharmacist, which leaves a large margin for error. A drug vendor may lack medical and 
pharmaceutical knowledge combined with an enthusiastic need to sell drugs. Compounding this, many 
who request drugs can only afford to purchase a few of them so that drugs are often separated from 
their original containers making their later identification difficult. Thus, the free availability of drugs 
serves to dilute attempts to obtain better levels of health both in the micro sense considering the patient 
and in macro sense considering policy planning designed for improved health.
3-1:2 Education
Lack of education is a universal problem in developing countries penetrating all areas including 
health care. Ignorance in health care affects patients seeking treatment, those providing it such as 
doctors, nurses and medical technicians, and those disseminating information such as pharmacists and 
drug salesmen. As is illustrated by Table 3-2, patients receive little formal education compared to 
those in developed countries and also have little access to informal educational media such as 
televisions, newspapers, magazines, and radio. Even those that can afford these do not always benefit 
due to its inconsistent quality in developing countries. The case is little better for health technicians, 
nurses and doctors, because although the majority of this group receives formal education, there is still 
little opportunity to update education in health due to the cost of medical periodicals. For instance, 
medical journals from industrialised countries are often so very expensive that a hospital library, even 
in an urban area, can only maintain them through exterior charitable contributions. In some countries a 
subscription to these journals can amount to one month of a local doctor's salary. It is because of this 
that the quality of education media sources are poor. Braithwaite (1984) found that Cuba's national 
medical library only contained literature from before the revolution. Added to this, doctors, nurses and 
technicians are often so much in demand due their small numbers, that there is seldom time for them to
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peruse medical journals. This is especially true for those who are working in public sector hospitals 
and health centres. Also, drug compendia are difficult to obtain and can be of a dubious nature (see 
Silverman, 1982). The situation is worse for pharmacists, who lacking easy access to the large 
institutional libraries such as those in hospitals have even fewer opportunities to benefit from health 
media.
Table 3-2: Percentage of Each Age Group 
Enrolled in Education in Selected States*
Country Primary Education Secondary Education Tertiary
Tanzania 69 5 0
Ghana 77 38 2
Pakistan 46 21 3
Madagascar 92 19 3
Bangladesh 77 19 4
Ireland 103 101 34
Canada 107 104 99
Japan 102 97 31
New Zealand 104 84 45
United States 104 90 76
Source-. World Bank, 1993: p. 216-217 
*Data for developed countries goes over 100% because it includes 
those receiving education who are not in the 
conventional age group for each category
Compounding this, both health personnel and pharmacists often rely on pharmaceutical salesmen 
(detailers) for an update in their education in drugs for health. Unfortunately, these detailers are 
frequently poorly trained but are still given monetary incentives to sell drugs over their regular salary 
(Krishnaswami, Dinesh and Radhaiah, 1985; Taylor, 1986; Kunin et al., 1987; Lexchin, 1992). This 
can result in their often making wide-spread, biased claims about a drug that they know little about. 
This works together with ignorance to further taint the education of health personnel with 
misinformation. The results of insufficient medical education can result in an incorrect diagnosis, an 
incorrect treatment and commonly, an incorrect drug prescription. The ramifications of this ignorance 
can be serious, suggesting just how integral education is to health, as is poignantly experienced in 
developing countries.
3-1:3 Summary of Section 3-1
Developing countries suffer from a combination of problems in pharmaceutical utilisation which 
work concurrently to render drugs of dubious quality and availability. Education on drugs is poor and 
the availability of dangerous, useless or poor quality drugs is high. Efforts to regulate these drugs have 
been impotent due to a lack of available funds, higher'placed priorities and in some cases, political 
upheaval. Less concentration should be laid on irrational drugs, which must be replaced by
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appropriate drugs. Certainly, appropriate drugs need to be available at the right location, at the right 
time and in the correct amount. In order to rationalise their utilisation, doctors, health workers and 
pharmacists need to be educated on appropriate drug use. This is a process that will not occur quickly 
and will depend on the support of outside aid agencies, economic growth, and a greater placed 
emphasis on drugs in health care delivery.
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Section 3-2
Attempts to Regulate Drug use, purchase and Manufacture
After looking at drug utilisation, the following section illustrates more problems necessitating 
regulation, and then shows regulatory efforts from within developing countries and external agencies. 
It looks at the design of the Essential Drugs Programme and the Bamako Initiative and also shows 
some of the progress of these. This section is designed to show what general regulatory factors have 
attempted to influence appropriate drug usage, including antibiotics (the control of which is also meant 
to stop unnecessary antibiotic drug resistance in diseases).
Table 3-3: Drug Failures in the Past: 1930-1991
Year Place Problem UK Fatality 
Reports 
1964-1980
Result
1930s Germany Live tubercle bacilli given instead of BCG vaccine 72 deaths
1939 USA Sulphanilamide elixir produced in ethylene glycol 
solvent
107 deaths
1950s France Stalinon boils remedy contained more of tin compound 
than used in clinical trials
102 deaths
1955 USA Cutter polio vaccine unsafe even though passed by 58 cases
Laboratory Biologies Control 5 deaths
1961 USA Monase, a psychic energiser leads to blood disorders 7 deaths
1962 World-wide Thalidomide hypnotic is a teratogen 4 000-5 000 10 000
(not USA) deformed deformed
1949-1967 World-wide Aplastic anaemia from chloramphenicol 42
World-wide Aplastic anaemia from gold compounds used for 
arthritis
37
1961 Britain Formulation of isoprenaline as an aerosol led to 64 4 000 deaths
(warning 1967) overdose
1970-1976 World-wide Beta-blocker practolol turned out to cause eye damage 23 1 200-1 400
and sclerosing peritonitis damaged
1959- World-wide Phenylbutazone and oxyphenbutazone caused blood 
dyscrasias (441 deaths) and gastric bleeding (71 
deaths)
512
1958 World-wide Thromboembolism from oral contraceptives 404
(warning 1969)
World-wide
(pulmonary embolism 268, myocardial infarction 136) 
Gastric bleeding from non-steroid anti-inflammatories 
(aspirin 96; indomethacin 83; phenylbutazone see 
above; other 76)
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World-wide Osmosin (controlled release form of indomethacin) 
lodged in fold of intestine and perforated it
51 deaths
1967-80 World-wide Nephropathy from analgesics 
(aspirin 44; phenacetin 105)
149
World-wide Some antibiotics cause pseudo-membranous colitis 
(lincomycin 15; clindamycin 36; tetracyclines 2)
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World-wide Anaphylactic shock from penicillin allergy 23
1969-1983 World-wide Lactic acidosis from phenformin for diabetes 47
World-wide Hepatic necrosis from halothane 150
1934-1980 Japan Myelooptivc neuropathy from clioquinol 0 1 100 victims
antidiarrrhoeal over sustained period 700 deaths
1980-1982 World-wide Benoxaprofien anti-arthritic inadequately metabolised 
by the elderly
76 26 in US
1990 USA L-trytophan formulation causes eosinphiliamyalgia 1 478 ill
21 deaths
Source: Burstall and Reuben, 1990
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3-2:1 Problems Necessitating Regulation
In 1958, the drug thalidomide, developed by Chemie Grunenthal and used as a hypnotic was 
licensed world-wide except in the United States and could be bought over the counter in Germany. In 
some cases it was also used to treat illness in the early stages of pregnancy. Unfortunately, alarming 
evidence emerged that thalidomide was a teratogen (a substance that causes birth defects) and 
tragically became responsible for 10 000 deformed children world-wide. As illustrated in Table 3-3, 
although there had been side effects to drugs previously to this, there had never been one that caused 
such visible and wide-scale damage. Such damage brought intense scrutiny on the drug industry and 
proved to be a turning point in drug regulation. Drug companies began to realise the amount of 
liability that they could potentially face on the introduction of a drug and governments started to realise 
the importance of regulating these new drugs.
In developing countries such large-scale availability of drugs has necessitated greater 
consideration for their regulation and control, but these efforts have largely centred around decreasing 
the brands and types of drugs.
3-2:2 Regulation in Developing Countries
Unfortunately, it took a while for the importance of such regulation to reach developing 
countries. As the thalidomide disaster occurred in 1962 and regulation in industrialised countries was 
being strengthened in these areas, regulation in developing countries was not really highlighted until 
the 1970s and did not really take much effect until the late 1980s. Many developing countries, both 
emerging from unstable political situations and experiencing intense need due to unforeseen natural 
disasters, required outside assistance to help them with regulation. Efforts on the part of developing 
countries to improve drug utilisation through regulation were burdened with the poor education of its 
inhabitants as well as the unmonitored availability of drugs. Indeed, the influence of external bodies 
such as the WHO played an integral part in these countries forming better methods of drug regulation.
Internally, the effects of the lack of education and poor regulation of drugs within developing 
countries fomented large changes in drug utilisation. To make treatment with pharmaceuticals simpler, 
the ministries of health in various developing countries instigated several measures. Such measures 
included reforms to make drug prescribing simpler and an action requiring less thought. These 
reforms have either been formal programmes such as the Essential Drugs campaign, or less formal 
reforms such as more careful transport of drugs, storage of drugs and controlled access to drugs.
Drug usage and demand for pharmaceuticals began after colonisation of developing countries, 
and focused on keeping the colonising population from contracting infectious disease as well as 
keeping native work forces healthy. Concentration of health care and pharmaceuticals was limited to
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urban areas, giving little or no concern for those in rural areas (Basch, 1990). Ultimately, with 
independence, there came an increasing growth in developing countries' effective demand for drugs 
and in the 1970's large proportions of the health budgets of developing countries went towards them. 
In 1976, Thailand spent 30.4% of its budget on drugs and Bangladesh spent 63.7% on drugs 
(Mamdani, 1992). This is far greater than the budget proportion that is normally spent on drugs in 
industrialised countries . Nevertheless, the bias towards the wealthy in urban areas continued with 
those living in urban slums and remote rural areas with little access to drugs to treat infectious 
diseases. Of Tanzania's 1977 drug expenditure, 79% of drugs went to hospitals, 14% to dispensaries 
yet only 7% to health centres (Yudkin, 1980). Large remote areas of land made transport and travel 
difficult. Population in these areas was less dense and it was easier to concentrate drugs where the 
population was highly concentrated, minimising costs. Resource allocation for drugs remained 
distorted and still suffers from an urban bias. In contrast, in urban areas there could be found a surplus 
of inappropriate drugs. In the 1970s Argentina had approximately 17 000 brand names, and Brazil had 
approximately 24 000 brand names on the market (Mamdani, 1992). Still, in the 1980s, Brazil had 30 
000 different drug products for sale, and Mexico had 80 000 branded products available as compared 
to 11 000 and 12 300 in 1993, respectively (Ferguson, 1988; Hartog, 1988, SCRIP, 1995). This is a 
luxury that established market economies could afford, but it only served to confuse drug utilisation in 
developing countries. The result was a situation in the 1970's and the 1980's that exhibited great waste 
and inefficiency of funds allocated for pharmaceuticals which were irrational, dangerous and 
ineffective. In some cases, items that a poor individual could not rationalise purchasing, such as acne 
medicine and eye drops, were available when necessary antibiotics were not. This was further 
complicated by misleading and inappropriate marketing actions of transnational pharmaceutical 
companies.
Many in developing countries could not get access to drugs at all, but those that did have access, 
did not necessarily find the right drugs for their needs: drugs were often either inappropriate or past 
their expiration date. A schism developed whereby there simply were not enough of the right drugs to 
treat infectious diseases but there was a proliferation of drugs of a dangerous or dubious nature. This 
suggested that drug deprivation was not solely due to a lack of funds. This situation necessitated 
reforms to control the amount and kinds of drugs available in the public sector. In the 1970s, it caught 
the attention of many outside of developing countries such as those in aid agencies, critics of the 
pharmaceutical industry, and in the United Nations. These individuals who found this situation 
undesirable were partially responsible for causing the WHO to attempt to try to develop guidelines on 
the regulation of drugs.
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3-2:3 The Essential Drugs List
A movement towards the regulation of pharmaceuticals was reflected in 1975 when the 
Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce 
was adopted by the 28th World Health Assembly (WHA). This stipulated that all products exported 
were to have a certificate available from health authorities proving that the product was authorised in 
the exporting country and that the location of manufacture followed Good Manufacturing Practice 
(Chetley, 1990). Initially less than 33% of WHO member states adopted this.
At this same time Speight (1975), in a study in Tanzania, compared older effective drugs to 
newer brand-named drugs still on patent. The results of this concluded that newer drugs could be as 
much as 10-150 times the cost of older effective alternatives. Newer drugs were thought to be 
consuming a disproportionate amount of drug budgets in developing countries. Such realisations as 
this and previously mentioned actions in certifying drugs for export, reflected a climate whereby better 
drug policy formulation was favoured.
In 1975, the call for a policy on the part of the WHO first appeared in the director-general's 
report to the 1975 WHA. In this report, he highlighted the high expenditure on drugs and illegal and 
unethical practices associated with them in developing countries (Walt and Harnmeijer, 1992). 
Subsequently, in 1977, the WHO, formulated guidelines for countries on 220 compounds that were 
designed to meet 90% of pharmaceutical health needs (Chetley, 1990). These guidelines became 
known as the Essential Drugs Lists. The WHO's actions in establishing these guidelines were in partial 
response to pressure from other parts of the UN to regulate pharmaceuticals, but they were also a 
product of WHO's growing emphasis on primary health care (Hartog, 1993). A greater focus on these 
guidelines was designed to ensure a more regular supply of basic drugs, an important element of PHC.
Essential drugs were to be "those considered to be of utmost importance and hence basic, 
indispensable, and necessary for the health needs of the population. They should be available at all 
times, in the proper dosage forms, to all segments of society." (WHO, 1975). These drugs were known 
to be effective and the majority of them were available in a generic form (a form of drug that is beyond 
it's patent protection, and therefore, has the advantage of being less costly and of a more competitive 
price). The concept of a restricted list of drugs was not new, but was strengthened by the WHO. 
Accompanying the essential drugs guidelines, a campaign was designed to foster concentration on a 
smaller number of drugs specified in developing countries in order to articulate less management, less 
expenditure and less confusion in drug therapy. It was hoped that this would make the most essential 
drugs for treating diseases available, increasing drugs supplies or replacing those that were less useful.
In 1977, the WHO's Drug Policies and Management team (DPM) brought together an expert 
committee for creating a model essential drugs list. It also gathered information from developing
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countries in order to better assess the needs in formulating essential drugs policy. In 1978, the DPM 
proposed to create the action programme on essential drugs in order to empower developing countries 
to better utilise, obtain, produce and control the quality of essential drugs in the long term and ensure 
that necessary drugs and vaccines would be available to more of the population in the short term. This 
proposal was endorsed by the WHA in 1978, but it was three years before it was implemented (Walt 
and Hammeijer, 1992). The DPM was then abolished and became the Action Programme for Essential 
Drugs known as the Drugs Action Programme (DAP). The DAP focused on making slight changes to 
the essential drugs list and helping developing countries research their potentials for domestic drug 
production and obtaining greater drug supplies. However, the director-general was much more in 
favour of a strong policy that would increase supplies through less expenditure and purchasing 
agreements. Funding for the DAP was less than needed and progress was slow.
In 1982, the DAP was one of the agencies affected by the consensus of some that the WHO was 
moving outside of its political mandate (Walt and Harmeijer, 1992). It was unclear as to whether the 
WHO would be able to provide technical support for procurement, pricing, quality control and 
distribution of essential drugs (Walt and Hammeijer, 1992). The DAP's plan for implementation had 
become ambiguous. Change came when the medical advisor of the Danish International Development 
Agency (DANEDA), became the programme manager of the DAP and was to start implementing DAP 
in developing countries. Hence, the most important function of DAP became country support (Walt 
and Hammeijer, 1992).
Before the Essential drug programme, only a few countries were using restricted drugs lists. In 
1959, Sri Lanka had a restricted drag list followed by Cuba in 1963, Peru in 1971, and Mozambique in 
1977 (Walt and Hammeijer, 1992). With the help of the DAP and other parts of the WHO, many 
countries started to develop their own list of essential drugs, with the purpose of restricting drugs to 
only those that met basic needs. Kenya had a pilot project whereby essential drugs for 3 000 patients 
were made available using centrally packed kits of these drags to lessen breakage, theft and spoliation. 
This pilot project provided the model that catalysed more widespread instigation of essential drugs 
schemes. In 1982, Tanzania soon adopted the programme as well as Bangladesh. However, there 
were some uncertainties and resistance to this programme.
3-2:3a Uncertainties in the Essential Drugs Programme
Policy for essential drugs supported all aspects of the originally conceived essential drags 
programme by 1988 and after 1983, the DAP was central to these results. In formulating policy the 
WHO found itself in a position between radical consumer groups demanding action in favour of a 
more comprehensive policy and conservative members of industry demanding that the policy be
55
limited. The general director gave the DAP more visibility and protection in 1983, by moving it into 
his own office but this changed in 1988 when a new general-director moved them back out implying to 
some that the DAP might be given less support.
With the implementation of essential drugs programmes (EDP) in developing countries, EDP 
policy framework became dilute (Kanji, 1992). The Essential Drugs Programme was advocated by 
many who wanted to extend the concept to industrialised countries, and rationalise their overall 
respective prescribing behaviour. Some, such as Jayasuriya (1991), claimed that the design of the 
concept was only to give preference and greater availability to a group of drugs for rationalisation. In 
contrast, many others wanted to extend the policy to one not just designed to supply drugs, but that 
focused on these drugs' utilisation. Likewise, there was the heated problem of defining whether this 
policy would be limited to the public sector, or would alternatively be made compulsory in the private 
sector. The enforcement of essential drugs lists in the private sector would give the government 
greater control over drugs imported into the country as well as concentrating services in the private 
sector more on essential procedures. This, of course, would be very unpopular in the private sector as 
it would cause this sector to lose prescribing control. Private sector health facilities resented this 
enforcement because they thought that since their patients were paying for special treatment and not 
"essential treatment", it would be compromised by a mandatory essential drugs list. Regarding this, 
Taylor (1986) argued that keeping the richer, private sector from using certain drugs, would not 
necessarily make more drugs and funds available for the poor in the public sector.
There was the question of whether essential drugs lists should be made mandatory and enforced 
by the law or be optional to health care providers. Although it makes some sense to make the lists 
mandatory to maximise the rationalisation of drugs, there also is the argument to suggest that such 
compulsory lists controlling prescribing would limit a doctor's ability to prescribe drugs for patients 
with unusual conditions. This highlights the fact that restricted lists by definition only carry the most 
needed drugs rather than some rarer and less used drugs for patients with special illnesses. Some of 
this need could be satisfied by using a supplementary list of drugs outside of the essential drugs list for 
special cases. Bangladesh has only 150 essential drugs but has added a supplementary list of 100 
drugs for special cases (Srinivasan, 1986).
Undoubtedly, the utilitarian nature of an essential drugs policy causes a small minority to suffer, 
especially if the policy limits imports. This was difficult to accept as it took the decision-making for 
drugs out of the hands of the doctors and into the hands of the government and funding bodies. 
Doctors with more expertise in hospitals in urban areas might be more equipped to decide for 
themselves what appropriate drugs his or her patient might need. Such arguments suggested that the
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essential drugs policy is more suited to rural areas where there is inclined to be less expertise in 
prescribing, fewer doctors and more health care workers prescribing drugs.
Another argument was whether the essential drug policy should actually be limited to only an 
essential drugs programme (EDP) within developing countries. Although it might seem an exercise in 
semantics, Kanji (1992) suggest that limiting the idea to a programme would mean that each country 
involved would have the freedom to allow some drugs not appearing on their essential drugs list to be 
allowed in urban areas, whereas they could limit drugs in rural areas to only those that were 
"essential". In spite of the fact that this would allow for more freedom in prescribing for doctors, it 
still would allow for the possibility that irrational drugs would be prescribed in areas outside of the 
programme thereby thwarting the essential drug list's purpose of limiting costs. Arguments such as 
these continue with little agreement. These ambiguities capture the empirical problems in maintaining 
EDP policy framework within each country that attempts to adopt an essential drugs list.
3-2:3b Resistance from the Transnational Pharmaceutical Industry
The transnational pharmaceutical industry found the idea of essential drugs unpalatable by 
definition because it would determine the kinds and amounts of drugs that they could sell and the 
programme condoned the use of cheaper drugs that were no longer protected by patents. This was a 
threat to the pharmaceutical industry as it endangered potential profits and because of this threat, the 
transnational pharmaceutical industry took action to thwart the implementation of restricted drugs lists 
in developing countries, in hopes that these would never manifest. The International Federation of 
Pharmaceutical Manufacturers' Associations (IFPMA) with member associations in 47 different 
countries, lobbied the WHO regarding the Essential Drugs issue. Such pressure from an industry with 
an annual turnover of US $100 000 million, could not be ignored and was especially felt in developing 
countries where transnational pharmaceutical companies dominated a large proportion of the market 
(Walt and Harnmeijer, 1992). In these countries, many pharmaceutical companies were observed 
taking several actions that made it very difficult or impossible for these developing countries to 
implement an essential drugs programme.
In 1982, the Bangladeshi government identified 150 essential drugs and 100 supplementary 
drugs that would meet most health care needs. Of those left over, 1 500 drugs were withdrawn and out 
of this, 237 were regarded as dangerous and therefore banned (Rolt, 1985). This left a disgruntled 
pharmaceutical industry that tried to compromise the programme through a misinformation campaign 
and pressure on the governments in developing countries. This was significant because eight 
multinationals had 75% of this market. In order to alter the nature of this programme and possibly 
discredit it, a misinformation campaign started using a pharmaceutical industry funded journal, The
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Pulse. 10 000 copies of The Pulse were printed each week and distributed freely to doctors by industry 
detailers and this periodical served as a medium of information for the drug industry. These journals 
ran editorials with messages such as "Drug policy now a total failure", "Most drugs banned not 
harmful", "Shortage of right medicines spread cholera and other diseases", and other 
misrepresentations and frightening anecdotes. All of these were unfounded and served as parts of a 
harmful marketing campaign against the Bangladeshi EDP for which its government could do little to 
fight (Rolt, 1985). Indeed, the effects of this campaign were damaging because many doctors and drug 
vendors were manipulated into believing the worst about the government's essential drugs programme 
despite the fact that the country's EDP was a logical plan. Such an effective spread of misinformation 
in the absence of any effective government media to counter these claims was a powerful weapon, 
indeed. This misinformation campaign was further supported by industry salesmen who claimed that 
in response to the policy, the pharmaceutical industry had withdrawn some popular goods when in fact 
these goods were ineffective, suggesting their withdrawal for other reasons.
Political and economic pressure was the second manifestation of pharmaceutical industry 
pressure on the govemmerit of Bangladesh. Multinational pharmaceutical companies lobbied their 
own governments to act against the EDP. This kind of pressure had been successful in the past in 
1974, when the US indicated that they would cut off food aid if centralised drug purchasing was 
instigated. In this later case, it was suggested by the US State Department that the continuation of such 
a policy would deter future foreign investment and lead to legal action. Likewise, this programme was 
very strongly ridiculed by the US, German and British ambassadors. Protecting the interests of 
transnational pharmaceutical companies was a powerful motivation, indeed. In one instance, a demand 
for the withdrawal of a product of the US-based company Pfizer, was not responded to by this 
company but rather President Reagan's office, resulting in the withdrawal of the demand on the part of 
the Bangladeshi government (Rolt, 1985). Similar pressure occurred in the Philippines when President 
Aquino received a letter from Senators Cranston and Lugar in reference to the Philippino ministry of 
health's essential drugs effort that suggested that she should look at her efforts carefully as it might 
limit future investment by US firms (Tan, 1988).
These examples of political pressure on the part of the governments of industrialised nations as 
well as the pharmaceutical companies themselves is not new or uncommon. Developing countries . 
which are infinitely entangled with and dependent on industrialised countries to meet their needs, 
cannot afford to proverbially 'bite the hand that feeds it'. Such strong tactics illustrate one example of 
how powerfully entrenched is the pharmaceutical industry in developing countries and how difficult it 
is for a country to establish a policy when the industry finds it invidious. The pharmaceutical industry 
will no doubt continue to resist restricted drug lists because these lists limit each company's market.
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Such resistance is illustrated by Hartog and Schulte-Sasse (1988) whose study of German and Swiss 
drug suppliers to developing countries showed that of those drugs sent to developing countries in 1988, 
only an average of 12.5% of drugs were essential and only 44.2% appropriate. The remaining 55.8% 
were inappropriate drugs defined as those that were: (1) combination drugs, (2) drugs without good 
data on effectiveness, (3) drugs with uncertain efficacy, (4) drugs with amounts of active ingredients 
that are too high or too low, (5) drugs within an ineffective dosage form, (6) drugs considered poor 
choices when cheaper or safer alternative to them are readily available and obtainable (Hartog and 
Schulte-Sasse, 1988: p. 27). Lee (1991) also found in Panama in 1991 that of 3800 products on the 
market, 50% were vitamins, tonics and combination drugs with an added large proportion of drugs 
with dubious safety and efficacy. These examples of the lack of imported essential drugs reflect the 
fact that the Essential Drugs Programme is still new. With pressure from the WHO and changes in 
demand for essential drugs, the proportion of those imported by developing countries is likely to 
increase.
3-2:3c Aid from Transnational Pharmaceutical Companies
Once the Essential Drugs Concept was well established, many multinational companies, with
concern for their image, attempted to take part of the establishment of EDPs, but such conflicting 
interests between profit and policy ultimately resulted in their influencing the nature of these 
programmes. Three Swiss drug companies, Roche, Sandoz and Ciba-Geigy, under the name 
Interpharma, offered to help the WHO in establishing an EDP in Burundi. Shortly after, the WHO 
withdrew from its collaboration with Interpharma and this company then found funds from the Swiss 
Development Agency that offered US $300 000 which Interpharma matched. Unfortunately, the result 
of this project was that no clear policy for drugs was identified and several non-essential drugs and 
drugs under patent were contained on the essential drugs list. The attempt lacked direction and most 
funds were spent on drug storage and transport facilities (Kanji, 1992). Following this, other industry- 
driven programmes have resulted in a greater market share for multinational companies rather than 
national producers. The EDP in Colombia had multinational investment contingent on incentives such 
as tax breaks, low customs charges on imports and subsidies from the Colombian government for the 
building of plants. Kanji (1992) maintains that this had a strong influence on national production. 
Whereas national production was at 55% in 1955, it has reduced to approximately 15% in 1992. 
Needless to say, these figures do not take into account demand and the quality of those nationally 
produced drugs, nor if there was a greater benefit from national production or multinational imports, 
however, this example is still illustrative of the pitfalls involved when a party with a specific interest 
attempts to start EDP's in countries.
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3-2:4 The Progress of the Essential Drugs Programme
The Essential Drugs Programme is one approach to rationalising drug utilisation. Many 
countries have embraced the concept and established their own essential drugs list making these drugs' 
availability greater for primary health care (PHC). The WHO’s work in essential drugs has highlighted 
the need to better organise drug utilisation in developing countries and has made the issue more 
visible. The effects of this programme can be shown by the amount of developing countries that have 
developed their own essential drugs list as observed in Figure 3-1.
The Essential Drugs concept was successfully marketed through WHO members and various 
periodicals, looking to change the nature of national drug policies. In a decade, it became a successful 
project with the help of consumer groups, non-governmental organisations (NGOs) and flexible 
donors. Additionally, the project was assisted by the Drugs Action Plan (DAP) which organised 
essential drugs supplies with the United Nations Children's Fund's (UNICEF) supply division, 
organised donors to promise funding, and convinced governments of developing countries to support 
the idea.
Figure 3-1: The Number of Countries that 
Adopted Essential Drugs Lists: 1983-1989
Number of Countries with Lists
1983
1989
Adopted from: LSHTM/KIT, 1989
3-2:5 UNICEF
UNICEF has served as a basic supplier of drugs and vaccines to developing countries and the 
WHO, but became involved with the Essential Drugs Campaign in 1981 when the organisation 
instigated more direct liaisons with the WHO. In 1981 the WHO and UNICEF were linked with the 
Joint Committee on Health Policy (JCHP) whose major focus was on securing drugs and making visits 
to countries to evaluate their deficiencies and obstacles to the effective delivery of pharmaceuticals. At 
the request of thirty-three African countries, the JCHP scheme was developed to aid drug procurement
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with bulk purchasing. Aggregate purchasing had been largely unsuccessful up until this point, having 
never gone beyond a concept in South America, Africa and Asia due to its overwhelmingly intricate 
nature. The process itself is complex alone without the required legal and commercial agreements, 
funding needs and organisation. To make this more viable, UNICEF increased the volume of drugs 
bought by the UNICEF Packing and Assembly Centre (UNIPAC) in Copenhagen from US $17 million 
in 1982 to US $35 million in 1985 and to US $60 million in 1986 (Walt and Hammeijer, 1992). This 
bulk buying along with careful attention to competitive prices resulted in decreases in these bulk 
bought essential drugs of between 50% and 60%. After this success, UNICEF started to focus on its 
Bamako Initiative.
3-2:5a The Bamako Initiative
The Bamako Initiative was a resolution with the intention of improving PHC in Africa. It 
resolved to supply essential drugs for maternal and child health centres as long there would be a charge 
for these drugs. The initiative was designed so that the resulting funds that came out of these charges 
would be used to pay primary health care workers and to improve the quality of PHC. This appeared 
to be a well designed plan, but it was heavily criticised possibly in part because it was developed 
without consulting the WHO. Charging the very ill for essential drugs seemed to conflict with the 
essential drugs policy of getting essential drugs to those who most needed them, regardless of the 
patient's ability to pay. Also, there was the problem of the amount that should be charged for the 
drugs, as initially no one seemed sure whether the charges should encompass an amount that covered 
most of the cost of the drugs or just a nominal part. In addition, developing countries received many 
drugs free from donors and charging those receiving them to meet the costs of funding health care in 
rural areas was a somewhat controversial issue for those funding these drugs. Nevertheless, with some 
struggle, this initiative was executed with co-operation from the Africa Regional Office (AFRO) of the 
WHO.
Summary of Section 3-2
Efforts to regulate drugs have been made efficacious by outside agencies such as the WHO and 
UNICEF. This has primarily focused on limiting the availability of inappropriate drugs through 
restricting imports rather than regulating overall drug availability at the point of purchase. The 
adoption of the Essential Drugs concept for drug rationalisation in developing countries has been 
relatively successful proven by many countries' recent development of their own restricted drug lists. 
Although there were problems in the Essential Drugs concept and some resistance was encountered by 
the pharmaceutical industry, many have come to accept restricted drugs lists and work with them.
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UNICEF has been quite instrumental in the instigation of essential drugs lists through their endeavours 
to supply drugs at minimum costs, making them more accessible for purchase. They have also made 
attempts to improve PHC through their Bamako Initiative. Although these regulation initiatives have 
been effective, they do not represent a cure to poor drug regulation. Essential drugs lists are a 
utilitarian concept and therefore, ignore some specialised needs. Tremendous effort and dedication on 
the part of developing countries is still needed to rationalise drugs, and restricted drugs lists only 
represent a very small part of drug regulation.
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Section 3-3
DRUG PRODUCERS
In this section, the influence of the actions of pharmaceutical companies on drug utilisation will 
be discussed. The industry structure, drug procurement, generic drugs, domestic production in 
developing countries, and the marketing of drugs by domestic and transnational pharmaceutical firms 
will be presented. It is in this environment that one will be able so see how drugs, and namely, 
antibiotic utilisation, is influenced by the actions of pharmaceutical firms.
3-3:1 Industry Structure
Those companies that produce pharmaceuticals are also referred to as ethical, generic and OTC 
companies depending on the type of drugs that they manufacture. In this context, 'ethical' is referring 
to those drugs that are only available under prescription in developed countries and are not advertised 
to the general public, OTC are over-the-counter drugs and generic drugs are those ethical drugs that are 
no longer protected by intellectual property rights (see section 3-3:3).
The global drug industry is primarily formed from two parts, multinational pharmaceutical 
producers and domestic pharmaceutical producers. Most multinational companies work inside of 
several countries and quite often world-wide. The transnational pharmaceutical industry is very 
profitable, producing products that face a relatively inelastic demand in industrialised nations, both due 
to doctors acting as intermediary purchasing agents and because the perceived demand for these goods 
in saving lives. Similarly, in developing nations, where competition from domestic companies is 
small, demand can also be quite inelastic. In the past recessions between the 1970s and the 1980s, the 
small number of industries that made a profit included the pharmaceutical industry and ironically, the 
arms industry.
The transnational market for innovative pharmaceuticals includes many companies, but is 
dominated by a small number of multinational companies and is globally classified as an oligopoly. 
This is an industry where few new drug companies rise next to long-established industry world leaders. 
The nature of this industry has recently been affected by small biotechnology companies being 
acquired by large companies. For the innovative pharmaceutical market, barriers to entry are heavy 
with high entry costs, intellectual property barriers, and high research and development costs (R and 
D) with only one in 10 000 developed compounds ever making it to a market (Ciba-Geigi 
Pharmaceuticals, 1991). This case is not true in the generic drug industry. Many barriers to entry are 
removed when these companies no longer have to contend with R and D costs and intellectual property 
rights. In fact, given that many of these companies are seeking to make an identical product (with
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identical bioavailability to the original as their goal), this industry in contrast can start to approach 
perfect competition: with large innovative companies in this industry only having an advantage of 
having invented a generic drug and having previously monopolised marketing of this drug during the 
period that the drug was covered by patent.
Unlike the market for brand-name products from multinational producers, depending on the 
competition, the market for generics within developing countries can range from a monopoly 
government producer, to a market that offers more competition in pricing. This is especially true in 
those developing countries where there are few barriers to entry including the absence of patent 
property rights and more attainable start-up costs. India is a good example of one of these countries 
because drug production is widespread and there is a firmly entrenched market for generic products 
whose producers face far more competition than that experienced between multinational brand-named 
drug producers. Instead of a few, very large companies dominating a large proportion of the market, 
multinational producers of generics and domestic firms compete among each other for market power. 
Multinational firms might have the advantage of size, but domestic firms have the advantage of 
government subvention and support combined with the knowledge of a familiar market. In addition, 
the more lax is the enforcement of intellectual property rights, the more freedom domestic producers 
are given. India does not acknowledge property rights even on new drug products so that there is more 
competition between firms because the products they market can be produced to look nearly the same. 
Following this, the consumer's perception of the quality of these generic products can dramatically 
affect this market.
3-3:2 Drug Procurement
Drug procurement in developing countries can be classified according to three types of countries: 
those that have no facilities for drug production, those that have limited facilities for drug production 
and those that have strong facilities for drug production. Those countries that have no facilities to 
produce drugs must depend on multinational pharmaceutical companies to meet their drug need. 
These countries primarily rely on drug salesmen to spread information on drugs. Drugs are purchased 
from international buyers by a local company representative of a transnational pharmaceutical 
company. Foreign currency is necessary for this and is supplied by the developing country's 
government. Countries in this group are, for instance, Burundi, Mozambique and Ethiopia. In 
contrast, where countries have greater local production facilities, domestic producers are in 
competition with transnational companies for supplying drugs to buyers. Fierce competition occurs in 
these countries where many generic drugs, are produced both locally and by transnational companies. 
Countries with these facilities, for example, are Kenya and Zimbabwe. Unlike these first two groups,
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the last group contains those countries that are able to produce the majority of their drugs locally, with 
relatively sophisticated manufacturing facilities. An example of those countries with these facilities 
include India, the Philippines, Argentina, Mexico, Cuba, South Korea and Egypt. In this category of 
countries, competition is the most severe between local and international producers and incentives for 
both are often in conflict. It is not uncommon for governments to give transnational companies 
investment incentives while they will purchase their drugs from local suppliers (Kanji, 1992). In this 
way a government can encourage foreign investment and take advantage of the positive externalities 
that come from this, but they can simultaneously encourage domestic production in order to gain some 
independence from multinational drug producers as well as a better bargaining position.
3-3:3 Generic Drugs
Most domestic production in developing countries focuses on generic drugs which are often long 
established drugs whose technology for production is in many cases, more readily available. Hence, 
these drugs are less expensive and often easier to obtain. Most or all of the drugs appearing on each 
developing country's essential drugs lists are generic drugs. For this reason, there has been strong 
pressure on the part of developing countries' governments as well as external funding bodies to 
establish local companies who could produce generic drugs.
Drugs are identified by three names, a chemical name, a brand name and a non-proprietary name 
(Gupta, 1986). Hence, for instance, a popular ulcer medicine's brand name is Tagamet, its non­
proprietary name is cimetidine and its chemical name is A"-cyano-N -methyl-A " [2-[[(5-methyl-l H 
-imidazol-4-yl) methyl] thio] -ethyl]-guanidine {Physician's Desk Reference, 1992). Strictly speaking, 
generic names refer to groups of drugs with similar characteristics such as analgesics and non-steroidal 
anti-inflammatories (NSAIDS). Nevertheless, the non-proprietary name is also generally accepted to 
be a drug's generic name by the majority of people using them and so will also be assumed in this work 
for all references to 'generic drugs'. Generic names are designed to give some information about a 
drug in contrast to a brand name. Whereas brand names are meant to be easy to write and easy to 
remember by a doctor, a generic or non-proprietary name is meant to reveal information about the 
class of pharmaceuticals that a drug comes from. As stated before, generic drugs are those drugs 
distinguished by the fact that they are no longer protected by their patent and therefore can be 
produced by any company. This freedom of production allows for greater competition in the market 
for generic drugs if the drug is a simple entity without requiring overly complicated technological 
means to produce it. Without such a large differentiation between products, there is a greater emphasis 
on price competition, and because of this, invariably the prices of generic drugs are lower than brand 
named equivalents. It is predominantly the perception of the quality of these drugs that largely
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influences their prices. This is especially true in developing countries, where the governing focus of 
production for domestic pharmaceutical firms is on generic drugs because much of the technology to 
make these is readily available.
3-3:3a Controversies Involving Generic Drugs
Pertaining to quality, there is a fierce controversy over whether generic drugs are chemically 
equivalent or bioequivalent to brand-named drugs. In order for the human body to absorb the active 
ingredient in a drug, certain catalysts are often necessary and these are provided in each tablet along 
with its active ingredient. There is evidence that when the catalysts for this absorption differ in nature 
or amount, so will be the amount of active ingredient absorbed. This amount of active ingredient that a 
drug allows the body to absorb is referred to as a drug’s bioavailability. Such bioavailability is 
important as it can determine whether a drug is effective or even potentially lethal. A brand-named 
drug might have a different bioavailability of active ingredient than a generic and so generics must also 
be thoroughly checked by a drug regulatory body to make sure that their bioavailability is consistent 
both from pill to pill and with the brand-named drug. Hence, one argument against generics is that 
they do not offer the same degree of bioavailability of the original brand-named counterpart and 
therefore, do not give the same effectiveness and safety. In industrialised countries, this may be true in 
some cases, but a former FDA investigations showed in 1989 that of 30 top-selling generics tested 
including 36 000 tests on 2 500 samples, only 1.1% did not meet FDA product quality standards. 
Also, these findings showed that of 500 sample studies on bioequivalence completed at that date, only 
one was a fraud (Ingersoll, 1989). Despite this evidence of generic drugs' effectiveness, suspicion is 
still common and many doctors still stick to prescribing those drugs with which they are familiar and 
have been prescribing long before there were generic versions. This can be accentuated in many 
developing countries where the level of quality for these drugs is not particularly good or consistent. 
In addition, the brand named versions are easier to write down and remember by the doctor, cutting 
down on the transaction costs of prescribing to patients. This market is unique because the prescriber 
only acts as a purchasing agent for the patient and therefore, does not consider the cost incurred by a 
brand-named drug as opposed to a generic drug. Following this, such practices also apply in 
developing countries where brand-named drugs have grown familiar through marketing and prove 
easier to recall by doctors, consumers and pharmacists.
Generic drugs are either sold by multinational pharmaceutical companies, multinational generic 
companies or produced locally. There is considerable pressure on governments and their health 
facilities to prescribe generic drugs and this therefore, represents a market with a large potential for 
profit. Even multinational companies have increased their interests in generic drugs often making their
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own version of a generic drug which is simply the same as their brand-named drug but without the 
name. Similarly, the generic drug market has grown remarkably in the last ten years and many 
multinationals have acquired generic companies. In 1994, Bristol-Myers Squibb bought 25% of a 
German generics company, Bayer had a US $310 million stake in the generics company Schein and 
Hoechst had a US $546 million stake in the generics company Copley. Such generic ventures have 
been profitable. Marion Merril Dow Inc. had a 9% increase in earnings from US $2.8 billion to $3.1 
billion partially due to acquisitions in the US generic drugs market (SCRIP Reports, 1995).
3-3:3b Generics Scandal
With greater profits and large-scale growth, there inevitably came scandal in the generic drug 
industry in the late 1980s. Some drugs sold by local companies and multinational generic companies 
had dubious amounts of active ingredient and dubious bioavailability. Such inconsistency in these 
drugs caused many health care workers to be suspicious of them. Many doctors in Senegal, for 
instance are not comfortable with using generic drugs (Lee, Lydecker and Silverman, 1992). Such 
poor quality for drugs in developing countries has had a large impact on health when these countries 
have rationalisation policies limiting the drugs used in the public sector to generic drugs. Indonesia’s 
law stipulates that only small domestic producers, rather than multinationals, can sell generics. 
Nevertheless, production limited to only small domestic companies leaves the potential for a 
compromise in quality in a country where quality checks for drugs are difficult, expensive and often 
ignored. Limiting drugs to cheaper generic versions can be beneficial in controlling drug costs, 
however, when the quality of these generics is faulty, these drugs become a hazard to drug 
rationalisation.
Generic scandals have had an impact on both industrialised and developing countries. A large 
generic drug scandal developed in 1988, in the United States, when the generic form of Ciba-Geigy's 
Tegretol was recalled by its supplier, Pharmaceutical Basics. This generic was recalled after controlled 
trials by the Federal Drug Agency (FDA) which concluded that the pills did not dissolve well enough 
to enter the bloodstream, a complication that had resulted in seizures in some cases. This was 
compounded by evidence that those in the generic division of the FDA were being bribed to impede 
approval of generic versions of drugs (Stricharchuk, 1989). This was later proven to be true with the 
conviction of Charles Chang a chemist high in the FDA's generics division and other chemists 
overseeing drug approval. Another part of the scandal was that, in an attempt to get their version of 
brand named drugs approved by the FDA, these companies were submitting the actual drug that they 
were trying to copy rather than their own version for testing. It was inevitable that the FDA concluded 
that these drugs were identical in equivalency to the brand named drug because these were the brand
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named drug. Independent analysis of the Bolar's generic version of Sandoz's Mellaril for psychoses 
revealed during testing, as the pills became chipped, the actual logo of Sandoz could be seen 
underneath illustrating that the drug to be tested was not actually the generic that Bolar claimed it was. 
Such scandal, when there was already doubts about the bioavailability of these drugs, generated 
considerable questioning of the effectiveness of generics. The result of this was that many of these 
drugs could not be sold in industrialised countries. Hence, these were exported to developing countries 
where controls were more lax.
3-3:3c Ramifications for Developing Countries
From the repercussions of this scandal, some generic companies exported (dumped-see section 3­
3: 9c) large quantities of their substandard drugs in developing countries in order to recoup losses. 
Most developing countries lacked sophisticated testing equipment and were not able to decipher the 
quality of those imported generic drugs. This is not surprising when the FDA was challenged in 
testing these drug's quality. In 1989, the executive vice-president of Par Pharmaceuticals stated that 
the company had exported millions of inferior drugs to developing countries (Silverman, Lee and 
Lydecker, 1992). Likewise, the United States Senate Dingell committee for assessing the generic drug 
approval process, discovered that starting in 1986, generic products sold in Thailand had between 20% 
and 200% of active ingredient. Dingell discovered that many of these drugs were accepted by doctors 
and pharmacists in Thailand because of bribes. The situation was exasperated by Thailand's attempt to 
rationalise drugs by limiting their availability in the public sector to generics on the advice of the 
Government Pharmaceutical Organisation, which was a primary producer of these drugs and therefore 
had a personal interest in this action {PMA Newsletter, 1991). In essence, rationalisation, dependent on 
the quality of generic drugs, had gone wrong.
3-3:4 Domestic Production
A country that has the technology and expertise to produce drugs locally has the potential to 
maintain a consistent supply of essential drugs. Most developing countries cannot produce modem 
synthetic products, but can often produce some drugs by utilising native plants and animal products. 
Also, with careful attention to quality, generic drugs, whose production is not overly complex, can be 
readily produced in many developing countries. The availability of technology to developing countries 
is continually increasing, making domestic drug production a better option. Mehrotra (1989) shows 
the growth of technology availability in India where the production of new drugs has more than 
doubled, depicted in Figure 3-2. Indeed, by locally producing drugs, a country gains more 
independence and introduces more competition with transnational companies. Some drugs can be
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made more cheaply than they can be bought and this is especially significant for those drugs that are 
supplied free of charge in the public sector. Some estimate that as much as 60% of drug costs can be 
saved through the use of domestic production (Patel, 1983). In addition, the increased competition 
from domestic drug firms in the market serves to decrease drug prices overall.
Figure 3-2: Technology Availability 
Trends for Domestic and Foreign Firms in India
Number 
of Drugs
■ Public $ S
1965 1970 1978 1982
Year
Source: Mehrotra, 1989: p. 1059
The World Bank estimates that competition between suppliers in developing countries has reduced 
costs by 40-60% (World Bank, 1993). Likewise, these drugs will be available when there is a price 
increase or shortage in external sources. By producing its own drugs, a developing country can also 
experience externalities such as a stimulation of commerce. Nevertheless, this is a controversial area 
complicted by potential problems. Quality control is expensive, and drugs produced domestically may 
not be of the same quality as those that are produced internationally. In 1977, the WHO estimated that 
ninety developing countries had no facilities for quality control (WHO, 1977). Those who are 
earnestly trying to make drugs may not adequately check their quality, resulting in radically 
inconsistent amounts of active ingredient in each pill or injection making the drug either ineffective or 
deadly. This is compounded by those seeking profit by making counterfeit drugs that simply look like 
the real thing. Pills needed to save lives are sadly often replaced by those with inactive or ineffective 
ingredients.
3-3:4a Domestic Production is Problematic
Strong intentions on the part of the developing country to make drugs locally is often disastrous, 
resulting in the production of useless products that threaten lives. The extreme importance and means
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to establish both an external government body and internal form of effective quality control that will 
check drugs before and after they leave production must be considered first in domestic production 
before anything else. Quality control might seem beyond the means of developing countries, but 
without it, domestic production is a futile venture and should not be considered. Nevertheless, 
empirically, quality is sadly ignored. Although the implementation of the Essential Drugs Programme 
has stimulated domestic production, the quality of these products has not been consistently good. 
Bangladesh's domestic production of 45 drugs for PHC increased from 30.3% in 1981 to 64.7% in 
1984 (Srinivasin, 1986). Unfortunately, although domestic production increased, quality was ignored 
in many cases as proven by a 1984 WHO-sponsored survey of Bangladesh which studied the quality of 
the products of drug producers (Jayasuria, 1985). Interestingly, the results of this survey showed that: 
eight large multinationals and twenty-five medium sized domestic firms were rated as having good 
quality control, fifteen medium-sized firms were rated as having fairly satisfactory quality-control 
mechanisms, five to ten medium-sized firms and twenty-six small firms had poor quality control, and 
104 small firms were rated as essentially having no quality control (Jayasuria, 1985). Hence, quality 
control proves to be a particularly challenging area for domestic producers in developing countries, 
and there is some evidence that it directly correlates with size: small firms prove to have more 
difficulty in maintaining drug quality.
Table 3-4: Imported versus Locally Produced 
Drugs in Selected Latin American Countries
Country % Imported Drugs % Local Production Total Sales $US
Brazil 70.6 29.4 3 708.5 million
Mexico 70.0 30.0 3 618.5 million
Argentina 45.0 55.0 2 582.0 million
Colombia 64.0 36.0 850.0 million
Venezuela 72.0 28.0 553.5 million
Peru 61.6 38.4 386.5 million
Guatemala 76.0 24.0 112.9 million
Uruguay 35.0 65.0
Source-. SCRIP, 1993
Despite this, it is not outside of the potential for smaller local companies to make good quality drugs, 
there have been some success stories in domestic production where quality control of essential drugs 
was high and consistent as is reported by Chetley (1990) of the Gonoshasthaya Pharmaceutical 
company in 1985. This article traces the development of this company citing the strong social welfare 
motive involved. This was, for instance, illustrated by their policy of employing mostly women and 
giving these worker's children meals and a school to attend. This company proved that local firms
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have the potential to become established with local expertise and successfully make essential drugs of 
a consistently high quality, even if transnational firms were to withdraw (Chetley, 1990).
3-3:4b Current Levels of Domestic Production
The current situation in Africa is such that an average of 59% of pharmaceuticals for sale are 
imported, leaving 41% domestically produced. This is an average obtained from, for example, a low 
figure of 17% in Egypt to a high figure of 93% in Tanzania (SCRIP, 1995). Local production has been 
somewhat affected by the Essential Drugs Programme which has influenced those drugs produced. In 
Nigeria, local production has declined because local producers were forced to withdraw products not 
appearing on the country's list (SCRIP, 1995). Similarly to Africa, local production in Latin America 
averages at approximately 39% which is depicted in Table 3-4.
3-3:4c Patents
Until rather recently, domestic producers in developing countries enjoyed a good reputation in 
various consumer groups who viewed them as a better option for supplying drugs as compared to those 
supplied by transnational pharmaceutical companies. Transnational pharmaceutical companies, 
perceived as both profit-hungry and guilty of overt ethical transgressions, had a reputation that paled in 
comparison to new domestic firms who were perceived to have no interest in profits whatsoever. To 
many, these domestic firms were perceived to be healing the poor who could not obtain or afford drugs 
from transnational companies. Hence, intellectual property rights became a very heated issue as 
domestic firms such as those in India violated the drug patents of multinationals. These actions were 
justified under the pretence of stealing technology from the rich and letting the poor benefit from it, 
suggesting that these local companies were 'pharmaceutical Robin Hoods', as coined by Silverman, 
Lydecker and Lee (1992). Nevertheless, these infringements infuriated the multinational 
pharmaceutical companies that owned the patents. Many developing countries refuse to give 
pharmaceutical products infringement protection or approval for new products. For instance, 
Venezuela will not approve of a new patented drug from a national pharmaceutical company for 
import until a domestic company can make the drug and quickly get it on the market. According to 
one representative interviewed by Silverman, Lydecker and Lee, patent infringement in Taiwan cost 
Bristol-Myers 70% of its sales of one drug and 40% of sales of another drug. In 1969, Brazil reworked 
its policy on intellectual property to include other products but not pharmaceuticals. After much 
pressure from the drug industry in America, President Reagan stated that Brazil's actions were a 
violation of the Trade Act of 1974 and that he would impose sanctions against many Brazilian imports. 
A 100% tariff was imposed on Brazilian exports of paper products, electronics, and drugs to the US
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(Silverman, Lee and Lydecker, 1992). Such pressure on Brazil and other countries caused South 
Korea, Indonesia, and Taiwan to change their policy on intellectual property. Nevertheless, India, 
Pakistan, Thailand and Mexico have decided not to consider patent protection for foreign drugs until 
1997 or later.
3-3:5 Drug Counterfeiters
Drug counterfeiting can be a very profitable business, and in a developing country where jobs 
and money are hard to come by, it is very tempting. Drug counterfeiters make pills and capsules to 
mimic drugs in size, shape, colour and even packaging. These are pills that rarely contain the active 
ingredient stated, but consist of useless ingredients such as flour compounds. This is not an area where 
one will find transnational pharmaceutical companies as the perpetrator, but rather, most production is 
done either locally or smuggled in from another developing country. Profiles of counterfeit drug 
producers range from local firms and illegal companies to any individual such as a grocer or an 
architect. The elusive nature of these counterfeiters can make them very difficult to catch. In 
Bangladesh, for instance, perpetrators are hard to trace because production is of a spurious nature and 
the location of these counterfeiters is constantly changing. Counterfeiting on a massive scale was 
found in Indonesia where over 30 kinds of drugs were discovered to be fakes, including anaesthetics, 
tranquillisers, analgesics and antibiotics. This number represented 30% of all drugs for sale in 
Indonesia {Tempo, 1988). Counterfeit drug production and sale is a lucrative business. Indonesian 
counterfeiters, if successful, can earn one hundred thousand dollars per venture. Penalties for 
counterfeiters are not strong enough to dissuade profits like these. Like Indonesia, Brazil suffers from 
an acute problem of fraudulent drugs whereby an estimated 20% of items sold in non-hospital 
pharmacies are estimated to be counterfeit (Silverman, Lydecker and Lee, 1992). Silverman, Lydecker 
and Lee have been very instrumental in uncovering this problem and an example of drugs that they 
discovered included,
"•A drug labelled as Lilly's anticancer vincristin intended for intravenous administration was found to 
contain less than 20 percent of the amount stated on the label.
•Capsules of the antiepileptic phenytoin contained barely 25 percent of the labelled amount, far too little 
to control convulsions.
•Psychoactive drugs such as Valium and Librium were deliberately spiked, not by the manufacturer but 
by enterprising pharmacists, with a substance such as atropine in the mistaken belief that this, by causing 
dry mouth, would prevent drug abuse - and possibly help evade the laws covering treatment of drug 
addicts. 'Unfortunately,' says Luiz Goncalves Paulo of the Federal University of Rio de Janeiro, 'too 
many of the patients came too close to dying from atropine poisoning.'
•A supposedly remarkable new antibiotic was so highly praised that it was purchased by the welfare 
system. It was found to contain only an inert substance, fubd flour. It was promptly renamed Fubacicline 
and then thrown out." (Silverman, Lydecker and Lee, 1992: p. 154)
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Control of drugs such as these is difficult or impossible in Brazil. Corrupt government officials such 
as state drug inspectors are often guilty of taking bribes, exacerbating the situation. Some state 
inspectors are even guilty of pushing the drugs on various pharmacies by threatening to close them 
down if they do not purchase these drugs.
In addition to this, the testing of these drugs as well as the control of their marketing is hampered 
by complex legislative subtleties. In one incidence, a company claimed to have produced an eye- 
ointment containing interferon. Interferon is a rather expensive compound with many treatment 
applications, including cancer and viruses, and so this claim was thought to be dubious, so the 
ointment was tested. Brazil did not have the facility to test this ointment and so referred the ointment 
to the Pan American Health Organisation who also did not have the facilities for testing. This 
organisation therefore forwarded the testing to the National Institute of Health in Bethesda, Maryland. 
This testing institute finally concluded that there was no interferon in the ointment. Because of this, 
the license to market the drug was withdrawn. The producers of the ointment then went to court and 
won their case based on a claim that the test had no validity since it had not been performed in Brazil 
(Silverman, Lydecker and Lee, 1990). These are all examples illustrating the complex situation 
involved in controlling counterfeit drugs. Indeed, the producers are difficult to catch, the drugs are 
difficult to identify, and those who police them may be corrupt.
3-3:6 Traditional Medicine
Unlike industrialised countries, traditional medicine plays a strong role in health care in 
developing countries. In virtually every developing country there is some form of traditional curer, 
witch doctor or shop that specialises in herbals cures. Where western education has failed to permeate, 
strong cultural beliefs and values have remained along with associated beliefs in cultural medicines 
and cures for ailments. Some of these beliefs have merit. Aspirin or salicylic acid, for instance, comes 
from a bark that was used by the ancient Egyptians. Such discoveries in the past have encouraged 
pharmaceutical companies to research many traditionally cures in ayurvedic medicine to examine their 
worth. Supporting this, the WHO has encouraged research into traditional plant cures to find new 
medicines and is currently working with the World Federation of Proprietary Medicine Manufacturers 
(WFPMM) (Essential Drugs Monitor, 1991a). Unfortunately, many forms of traditional medicine are 
worthless or harmful to the patient. The treatment with drugs containing inactive ingredients only 
delay the patient in seeking effective medical care for his or her condition. Likewise, some forms of 
traditional medicine can be quite dangerous with ill effects. Silverman, Lydecker and Lee (1992) 
identified nine "sex tonics" from Indonesia, Malasia, Singapore, the Philippines, Mexico and Central 
America. These "sex tonics" claimed to increase stamina, work capacity, decrease premature senility
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and increase sexual pleasure. Those buying these tonics would be buying products with ingredients 
such as testosterone to arginine aspartate to ginseng and vitamins which would either has the potential 
to cause increased virulisation or do virtually nothing. Hence, for these reasons, this is an area that 
requires careful consideration and regulation.
3-3:7 Unscrupulous Marketing Practices of Domestic Producers of Drugs
The favourable reputation of many domestic firms did not last for long as unethical marketing 
practices of some served to change it. Unless a domestic pharmaceutical company was run by a 
developing country's government, and in some cases not even then, the absence of unscrupulous 
marketing practices could not be assured. Indeed, in an update of their studies of the marketing 
practises of domestic firms in developing countries, Silverman, Lee and Lydecker (1992) found that 
much of the unscrupulous marketing behaviour that was previously exhibited by the transnational 
industry, is now much more commonly seen in domestic firms. Their follow-up study mainly looked 
at labelling and promotion of both domestically and internationally produced drugs, and published data 
centred primarily on the disclosure of warnings for the use of these drugs. Numerous examples 
illustrate domestic firms omitting warnings for drugs. In the case of Dypyrone, an analgesic, no 
warning was given on the danger of serious or fatal agranulocytosis in 19 cases: 4 of these were 
multinational firms, the other 15 were domestic firms. Similarly, the authors note that often when a 
transnational pharmaceutical company withdrew a dangerous or inappropriate product from the market 
of a developing country, it would leave a void where a domestic firm would move in and sell the same 
product under a different name. Indeed, these authors observe that many of these firms have had 
surprising political influence and are firmly entrenched in the country. They suggest that it is not 
uncommon for those who run domestic drug companies to be related to those at the ministry of health 
or to the president of the company.
3-3:8 Incentives of the Transnational Pharmaceutical Industry
Before the actions of the pharmaceutical industry can be broached, its incentives must be 
discussed. All too often, critics of the actions of this transnational industry forget that the motives of 
the pharmaceutical industry will and should not necessarily coincide with those of developing 
countries. It is certainly the job of developing countries to regulate the actions of this industry in order 
to make these actions more compatible with the objectives of a developing country.
Like all commercial organisations, the final objective of the pharmaceutical industry is 
undeniably to make larger and larger profits and it has been rather successful at this. In 1983, globally, 
the pharmaceutical industry had invariably been either the first or the second most profitable industry
74
since 1955 (Patel, 1983). The transnational pharmaceutical industry has been able to continually 
maintain a leading profitable position due to four main factors. This is an industry which continually 
produces innovative breakthrough drugs and product differentiation is high. In addition, there are high 
barriers to entry because of the large capital needed for research and development. Also, there is very 
little pressure from purchasers, unlike other markets (McGahan, 1994).
Table 3-5: The Most Commonly Advertised 
Drug Groups Among the Top 50 Selling Drugs
Drug Group No. of ads.
H2-receptor antagonists 428
NSAIDs 409
Benzodiazepines 262
Calcium-channel blockers 241
Oral antimicrobials 184
ACE inhibitors 150
Nitrates 149
Beta-blockers 111
Beta-adrenergic bronchodilators 93
Diuretics 84
Antihistamines 80
Total 2 191
Source: Herxheimer, 
Stalsby Lundborg, and Westerholm, 1993: p. 165
It could be argued that all efforts of these firms go towards profit: research and development, 
drug production, drug marketing, drug packaging, and drug delivery. Pharmaceutical companies focus 
on producing an effective drug, for which they can charge a very high price that a very wealthy body 
will be willing to pay for, and for which they can completely monopolise intellectual property rights 
for a limited period. The majority of advertising for drugs is centred around these high profit drugs 
either by virtue of the fact that each dose is expensive, such as H2-receptor antagonists, or a very large 
amount of these can be sold, as for example, antibiotics. Table 3-5 shows a study by Herxheimer, 
St&lsby Lundborg and Westerholm (1993) of the top fifty drugs of 6 710 advertisements appearing in 
23 journals in 18 developed and developing countries over 12 months. It appears from Table 3-5 that 
the most frequently advertised drugs are not necessarily the most essential drugs or the most demanded 
by developing countries. Developing countries, frequently lacking the purchasing power to buy high 
volume or high profit-per-unit drugs, do not have their needs focused on by the advertising of 
transnational pharmaceutical companies.
Indeed, as compared to industrialised countries, developing countries lack large enough 
individuals or bodies that have the available resources to pay for expensive drugs and therefore, are 
unable to obtain them without outside assistance. Compounding this, many of the drugs that these 
countries do need are those drugs whose patents have expired, and are therefore, cheaper. Therefore,
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the driving force behind pharmaceutical R and D is determined by the morbidity patterns of 
industrialised countries: focusing on diseases such AIDS, cancer and heart disease which although also 
affect developing countries, are responsible for the lion's share of morbidity in industrialised countries. 
Indeed, in these countries is the most highly concentrated effective demand to pay for the expensive 
drugs that are the product of such research. From a free enterprise perspective, there is no reason why 
the transnational pharmaceutical industry should have to consider the specific needs of developing 
countries if it is given no incentive.
3-3:9 History: Poor Reputation and Reform in the Transnational Pharmaceutical Industry
It must be considered in looking at criticism of the transnational pharmaceutical industry that too 
much literature only considers their bad actions. The normal activities of the pharmaceutical industry 
marketing appropriate products is not captivating enough to report on whereas the idea of a rich 
industry that is harming its consumers for profit is very interesting. This factor causes the tendency to 
sensationalised and generalise from available instances. It cannot be denied that marketing is a 
problem in developing countries but the incentives of writers and critics to paint a picture of corruption 
from anecdotal evidence is high whereas the incentive to report on the industry's everyday activities is 
much lower. It must therefore, be remembered when considering the following evidence from writers 
on unethical practices, that there might be another side of the argument that remains unhighlighted.
Up until the mid-1970s the pharmaceutical industry enjoyed a favourable reputation because 
most of what they did was viewed as saving lives while engaging in R and D at the forefront of 
technology in order to improve the quality of life enjoyed by most individuals. However, in the late 
1970s and especially the early 1980s, information emerged about transnational pharmaceutical industry 
activity in developing countries that strongly affected its image. Transnational pharmaceutical 
companies who were previously held in high esteem, were accused of inappropriately marketing drugs, 
bribing officials and doctors and testing dangerous drugs on unknowing individuals in developing 
countries. Several authors were instrumental in drawing close attention to these activities, notably, 
Silverman (1976), Heller (1977), Medawar (1979), Melrose (1982), Braithwaite (1984) and Chetley 
(1990). These authors claimed that the pharmaceutical industry was responsible for the inappropriate 
use of drugs resulting in a large scale loss of lives of those in developing countries. Threatened by a 
poor public image that might hurt sales, transnational pharmaceutical companies started paying closer 
attention to their activities in developing countries to make sure that the actions instigating such 
criticism would not occur again.
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3-3:9a Silverman
Perhaps the most influential writing on the activities of pharmaceutical companies in developing 
countries is Milton Silverman. In 1976, Silverman, at the University of California School of Medicine 
at San Francisco, published The Drugging of the Americas which would later be viewed as the catalyst 
leading to an avalanche of reports of inappropriate pharmaceutical marketing. This book revealed a 
study that suggested that physician's desk references for pharmaceuticals in Latin America were not 
consistent with the US Physician's Desk Reference and that these inconsistencies were to the 
advantage of pharmaceutical companies who were trying to increase their share in this market. This 
publication showed that these references omitted counter-indications and adverse side-effects as well 
as expanded indications for pharmaceuticals. Added to this, the predominance of information in these 
publications was from the companies themselves, not an external regulatory body. Most major 
transnational pharmaceutical companies were implicated in these observed inconsistencies including 
Squibb, Schering, Boehringer, Searle, Eli Lilly, Wyeth, Merck, Upjohn, Smith Kline and French, and 
Johnson and Johnson. Counter-indications for drugs such as those that cause teratogenic effects on 
unborn foetuses were omitted as well as adverse side effects. One of the most pointed examples is that 
of chloramphenicol which is considered a somewhat dangerous drug due to its side effect of asplastic 
anaemia and blood dyscrasias. Chloramphenicol is primarily used for the treatment of typhoid fever 
and sometimes for cases of meningitis where the patient is allergic to other antibiotics, but in these 
Latin American publications, chloramphenicol was recommended for minor infections such as 
tonsillitis, pharyngitis, bronchitis, urinary tract infections, streptococcus infections and gonorrhea when 
these conditions could be effectively treated with much safer antibiotics (Silverman, 1976). Another 
example was with Ciba-Geigy, their NSAIDs Butazolidin (phenylbutazone; Tanderil 
(oxyphenbutazone); the anticonvulsant for epilepsy and neuralgia, Tegretol (carbamazebine); and the 
antidepressant Tofranil (imipramine) all were given wide claims not appearing in the Physician's Desk 
Reference and an absence of warnings and contraindications. In the case of Tegretol, only the 
Physician's Desk Reference discouraged the drug's use for minor aches and pains due to possible death 
from to aplastic anaemia. Such misinformation and lack of information undoubtedly has served to 
confuse many doctors who might otherwise have chosen drugs that they thought were safer. In another 
instance, oral contraceptives were recommended not just for contraception, but also) for pre-menstrual 
tension and menopause with little acknowledgement for thromboembolic dangers leading to dangerous 
blood clots. Likewise, Sandoz's drug Mellaril (mentioned earlier for treating psychoses) was indicated 
for such minor ailments as insomnia, bed-wetting and nail biting while none of its side effects were 
included in any Latin American countries studied except Mexico (Silverman, 1976).
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In support of Silverman's work, Yudkin (1978) compared the African MIMS (Monthly Index of 
Medical Specialities) with the version of MIMS in Britain and found evidence supporting Silverman 
that these publications were not consistent in terms of disclosed side effects and indications. MIMS 
Africa, for instance, omitted many adverse side effects and expanded drug indications where MIMS in 
Britain did not. Later work by Lasagna and Alloza (1983) compared four national drug compendia 
from Spain (Vademecum Internacional de Especialidades Farmaceuticas y Bioldgicas), Brazil 
(Dicionario de Especialidades Farmaceuticas), Mexico (Diccionario de Especialidades Farmacduticas) 
and the United States (PDR). These authors discovered that the compendia from Brazil, Spain and 
Mexico together contained only 70.5% of the words in the PDR. As well, of the 15 reference products 
studied, the PDR contained far more contraindications and adverse effects and drug interactions 
compared to the other three. This suggests that those doctors in the US who have access to the PDR 
are given a far more comprehensive education on drugs, compared to those in these developing 
countries using other compendia.
3-3:9b Heller, Medawar and Melrose
Heller, Medawar and Melrose are three other authors that were instrumental in portraying the 
transnational pharmaceutical industry as unethical. Heller's book Poor Health, Rich Profits, published 
in 1977, questions drug companies' role in the social welfare of developing countries as well as the 
applicability of some of their products to the countries' needs. Following this, Medawar (1979) 
explored the inconsistent nature of recommended dosages of drugs, further exposing the iniquitous 
actions of the transnational pharmaceutical industry. In his publication, he showed how the maximum 
recommended dosage allowances for many drugs are often expanded in developing countries with the 
suspected intent on selling more of the product. He cites that Burroughs-Wellcome's drug Migril's 
company recommended dose is twice as high or more in Africa and Asia as in the US and the UK 
Ironically, this drug used for treating migraine, is observed to give a drug-induced migraine-like 
headache at such large doses. In addition, Melrose (1982) unearthed evidence about the promotion of 
anabolic steroids for appetite stimulation in children in developing countries. One of the side effects of 
these drugs is oedema which can worsen a situation where a children is already experiencing oedema 
from kwashiorkor and marasmus, both childhood forms of malnutrition caused either by a deficiency 
of protein in the case of kwashiorkor or a severe deficiency of both protein and calories in the case of 
marasmus. It should also be added that these drugs are seldom, if at all, prescribed to children in 
industrialised countries. Supporting this work, Muller (1982) in his Health of Nations, also pointed out 
that diuretics were being marketed for the treatment of bloating or oedema caused by these two 
conditions. The use of these diuretics is a waste of money for the child as these drugs do not treat the
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problem, but only one of the symptoms. The results of this can be quite deadly because the child is not 
as likely to receive the correct cure of better nutrition, and therefore, his or her life will be at risk.
Medawar is also know for his publication with Freese, Drug Diplomacy, (1982) which describes 
Social Audit's fight against the improper use and marketing of G.D. Searle's drug, Lomatil for the 
treatment of diarrhoea. Lomatil is a drug used for the treatment of diarrhoea which presents a danger, 
especially in children, since its toxic dosage is very close to its therapeutic dosage, allowing for only a 
small margin of error. Patient response to Lomotil is unpredictable and at doses, only slightly higher 
than therapeutic levels, a child may experience respiratory depression, coma, atropism and death 
(Medawar and Freese, 1982). This is compounded because Lomotil functions by slowing down the 
motion of food through the intestines, treating the symptoms of diarrhoea instead of the diarrhoea 
itself. The WHO recommends that most diarrhoea can be effectively and ideally treated by an oral 
rehydradion solution (ORS) containing potassium, sodium salts and glucose. This allows for an 
inexpensive method of rehydrating the body that is accessible to those in developing countries. Drugs 
such as Lomotil and antibiotic-antidiarrhoeals can be dangerous because they do not rehydrate the 
body and they can hide the symptoms of fluid loss. They are furthermore, a waste of resources. In 
industrialised countries and more specifically by the FDA, Lomotil is contraindicated for children 
under two years old due to its toxicity. Nevertheless, in developing countries, it is recommended for 
the treatment of diarrhoea in infants. This is significant as diarrhoea is one of the leading causes of 
death in children in developing countries. Accentuating this, Lomatil's recommended dosage varied 
from developing country to developing country with its dosage in Thailand twice as high as in India. It 
should be noted that all of Searle's company was to blame for this inappropriate marketing. Searle 
India took the initiative for marketing the drug for infants, but US Searle recommended it in its 
International Product Disclosure for its use in infants weighing over 3 kilograms (Medawar and 
Freese, 1982: p. 46). This evidence about Lomotil is only one example of the large amount of 
inappropriate antidiarrhoeals available on the markets of developing countries. Many of these 
formulations have antibiotics or antibiotic combinations in them. Antibiotics are not recommended for 
the treatment of the majority of diarrhoea because there is little evidence that they are effective against 
it and most cases of diarrhoea will clear up without them. Indeed, they can prolong cases of diarrhoea 
and they also allow for the development of antibiotic-resistant infections, both in diarrhoea and other 
diseases. Despite this, companies still market them as diarrhoea cures. In India, Boehringer Knoll 
quoted UNICEF's "Diarrhoea is the largest killer of infants" to market the combinations of the 
dangerous antibiotics streptomycin and chloramphenicol for diarrhoea (Srinivasan, 1986). Large 
quantities of antibiotic-containing or Lomotil-like- treatments for diarrhoea are useless and 
inappropriate, but are still available on the market in abundance, overshadowing the role of ORT in
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diarrhoea treatment. Medawar and Freese cited that between 74% and 85% of antidiarrhoeals listed in 
prescribing guides in developing countries were 'undesirable', meaning they contained ingredients such 
as antibiotics or Lomotil-like substances (Medawar and Freese, 1982).
3-3:9c Braithwaite: Drug Dumping
Braithwaite (1984) was another author instrumental in revealing faults in the activities of the 
transnational pharmaceutical industry. In his book Corporate Crime in the Pharmaceutical Industry, 
he reveals how individuals and companies in the pharmaceutical industry have made mistakes and 
deliberate ethical transgressions. Both in developing countries and developed countries, he describes 
how pharmaceutical companies bribed country officials, tested dangerous drugs, used unsafe 
manufacturing practices and misleading marketing practices. Braithwaite's most interesting 
contribution to this literature is his discussion of drug dumping from industrialised countries to lesser 
developed countries and the testing of drugs. To this end, Braithwaite identifies a list of ways that a 
pharmaceutical company exports drugs in order to recoup some of its losses resulting from no longer 
being able to sell them in industrialised countries, as shown below.
•THE NAME CHANGE: A product is withdrawn from the market of an industrialised country after 
unfavourable publicity and/or adverse reactions. In order to send it to a market in a developing country, 
its name is changed and it is remarketed.
•THE LAST MINUTE PULLOUT: A drug being tested does not look as though it will be licensed by 
the drug regulatory body, so the drug company withdraws its application, and then labels it 'for export 
only' so that they can sell it in a developing nation.
•DUMP THE WHOLE FACTORY: Closing down production of a hazardous chemicals in a 
industrialised country in order to move closer to a market in a developing country and to avoid problems 
in export and regulation.
•THE FORMULA CHANGE: Slightly changing the formula of a drug in order to avoid spectrometer 
detection in exporting.
•THE SKIP: Some countries will not license drugs that have not been licensed in other countries so to 
get around this, the company will export a previously banned drug to a lax country such as Guatemala 
and after its license is awarded, re-export it into the target country
•THE INGREDIENT DUMP: Exporting a drug's ingredients separately, and then reassembling them 
once they reach their market.
Source: Braithwaite, 1984; p. 259
One of the more commonly cited examples of drug dumping is the case of A.H. Robin’s Daikon Shield 
and Upjohn's injectable contraceptive, Depo-Provera. Depo-Provera is a drug that was denied a 
license or testing in the US by the FDA due to its unpleasant side effects. The Daikon Shield is a intra­
uterine device (IUD) that was recalled by the FDA in 1973 who deemed it dangerous due to the fact 
that it was responsible for the deaths of seventeen women, over 75 cases of uterine puncture and 
several ectopic pregnancies (no sample size was given). After this, Daikon Shields were sent to over 
40 developing countries. Of course, one could argue that even with these side effects, if these 
developing countries needed this contraception, these side effects could be overlooked. Pregnancy 
itself is risky state. The ethical problem of whether the need for contraception was worth the risk of 
using these devices is not discussed by Braithwaite. Issues such as the likelihood of the survival of the
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mother and child through pregnancy, the survival of the child later and its burden to society are all 
issues that must be considered before making accusations. (Ironically, the US government Office of 
Population in conjunction with US Development Aid bought several of the Daikon Shields in order to 
help population control at a 48% discount because the devices were unsterilised, further compounding 
the device's use in the context of a developing country)
Another way of dumping drugs mentioned by Braithwaite, is the exporting by pharmaceuticals 
companies of drugs right before these reach their date of expiration. This is compounded by the 
actions of developing countries who are prone to miscalculating their needs in drugs. Drugs are over­
ordered such that many are stored for long periods of time before they can be transported to where they 
are needed and expiration is not uncommon before they reach their final destination. Some drugs past 
their expiration dates are no longer effective or become poisonous. The antibiotic tetracycline 
deteriorates into a toxic substance once past its date of expiration. In some cases, if a drug does not 
deteriorate into a poisonous substance, but simply starts to become less active, it is still damaging. An 
antibiotic beyond its date of expiration may not only be ineffective against a disease it is meant to cure, 
but in the case of infectious diseases, allows for a greater potential prevalence and infection rate added 
to resistance to that antibiotic. Of course, this is not the case for all drugs. Some drugs remain 
effective after their expiration date and given a choice between these drugs and no drugs, developing 
countries must accept them. It is important, however, to eliminate the export of drugs that will become 
dangerous after expiration. Also, those individuals treating patients with these drugs should be made 
aware that the drugs are less effective, and doses should be adjusted accordingly. Far more knowledge 
of drugs is therefore, necessary in this case, requiring knowledge not only of the drug's normal action, 
but its action after expiration.
Attempts by the WHO to control the inappropriate export of dangerous drugs and expired drugs 
was strongly opposed by the United States. Any actions that the WHO took had to be considered in 
the context of its impact on US funding to the WHO. Discussions about restricting imports of 
dangerous drugs was moved to the UN General Assembly which developed Resolution 37/137 asking 
the General Secretariat to make a Consolidated List of banned and extremely restricted drugs 
(Micklitz, 1988). This was supported in 1983 by the Council of Europe's Recommendation 969 on the 
Sales of European Pharmaceutical Products in Countries of the Third World which recommended that 
drugs to be exported from Europe undergo the same restrictions of domestic drugs. It further 
suggested that European countries should help the WHO efforts in drug rationalisation in developing 
countries (Micklitz, 1988) The Banotti report of 1986, criticising the export of banned or unregistered 
European products, caused the European Parliament to adopt the report's recommendations and in
1988, the European Commission started the process of solidifying this (Burstall and Reuben, 1990).
81
This was further supported by the EEC Treaty which insisted that these banned and restricted drugs 
were 'dangerous chemicals' under which this treaty carefully regulated the import and export. 
Furthering this attempt to regulate exports, the WHO has developed a standardised method of 
assessing the quality of those drugs moving in international markets.
3-3:9d Chetley
Finally, literature attacking the drug industry came to its peak when in 1990, Chetley published a 
book entitled A Healthy Business? World Health and the Pharmaceutical Industry which was a very 
acid attack on the activities of pharmaceutical companies. In this book, he highlighted the 
pharmaceutical industry as a profit motivated industry, and attacked the industry because of its focus of 
trying to cure diseases primarily affecting industrialised countries. He portrayed pharmaceutical 
companies as driven by unbridled ambition, often at the cost of the welfare of those in low income 
countries. He also stated that the prices of pharmaceuticals are inordinately high, and although these 
companies justified this as covering the costs of R and D, he stated that much of the price of items goes 
to cover other costs. He cited that 15-20% of each sales dollar of pharmaceutical products was for 
promotion which is higher than expenditure on research and development. Furthermore, this author 
wrote that the R and D in developing countries did not serve them that well because very little drug 
development was specific to these countries' needs (Chetley, 1990).
3-3:10 Past Drug Testing in Developing Countries by Transnational Pharmaceutical Companies
Another area of contention is in the testing of drugs. In 1964, the Helsinki Declaration, 
published by the World Medical Association, directed that all drug testing must occur under the 
explicit informed and voluntary consent of those tested (Smith and Quelch, 1991). Despite this, 
several very dangerous drugs have been tested in developing countries where many pharmaceutical 
companies can take advantage of what Braithwaite refers to as the 'least resistance to early marketing' 
(Braithwaite, 1986). What this essentially means is that those used to test drugs in developing 
countries are less likely to sue a country for injury due to poverty and laws, and similarly, laws 
governing 'informed consent’ are less likely to be observed. It also has been suggested by many that 
there is an unspoken lower value of human life for those in developing countries such that the drug 
testing and killing of those in industrialised countries is thought to be worse than the drug testing and 
killing of those in developed countries. Such claims as these are debatable, and more optimistically, 
this testing could be explained by the fact that fewer statistics and information on those who die from 
testing in developed countries exist and this is why these countries are chosen, not because of differing 
valuations on human lives. Testing these drugs in developing countries also proves to be cheaper than
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in industrialised countries and pharmaceutical companies can easily weed out chemical compounds 
from new drug applications (NDAs) to the FDA.
Unfortunately, not all ethical principles on the preservation of human life are followed and often 
very dangerous drugs are tested in developing countries at the expense of those tested. 
Balasubrahmanyan (1986) reports that in 1985, in Patancheru, India, a research site was established to 
test Schering A.G.'s injectable contraceptive Net-Oen. Many local women brought to be tested did not 
know that the drug was experimental, or that there were side effects to the drug. Those paramedics left 
to find volunteers for injection did not explain about the drug, nor did they distribute the drug's local- 
language information pamphlets describing the drug and its side effects because they feared that they 
would not be able to find anyone willing to try the injection. Once informed about the possible 
dangers of the drugs by Balasubrahmanyan and a women's activist group, only five of the thirty who 
were brought to the village to be tested stayed to be injected. One woman who refused to be injected 
was threatened by a doctor who suggested that she might have difficulty obtaining treatment at that 
health centre if she needed it in the future. Likewise, a women with who was still breast-feeding a 
child and a very young girl, both of which the drug is contraindicated, were brought in for testing. 
Ironically, those who warned the women who were to be tested were accused of jeopardising the 
family planning programme and impeding the liberation of women over their own bodies.
The testing of contraceptives is one of the more common forms of drug testing in developing 
countries. However, this evidence must be considered with the fact that this is in part, due to the 
tremendous pressure for family planning in developing countries. Nevertheless, it does not explain the 
testing of dangerous contraceptive drugs for which little is known and whose information is dependent 
on the reaction of those being tested: largely uneducated, poor women. The following list describes 
some incidences of testing that has occurred in developing countries over the past forty years.
1953 Searle test oral contraceptives in Puerto Rico. (Braithwaite, 1986)
Johnson and Johnson and Syntex test oral contraceptives in Puerto Rico,
Mexico and Haiti (Braithwaite, 1986)
1960 Syntex and Merck (Germany) test low-dose oral progesterones in Chile
Braithwaite, 1986)
1970s Various companies test intra-uterine devices in Columbia, Iran, Korea,
Taiwan and Thailand (Braithwaite, 1986)
1980s Upjohn’s Depo-Provera is tested in Brazil, Thailand, Chile, Philippines, Sri
Lanka, Hong Kong, Egypt, Honduras, Peru, Mexico, Pakistan and South
Africa. (Duggan, 1986)
Schering A.G.'s testing of the injectable contraceptive Net-Oen in India on
women who have not given "informed consent" (Balasubrahmanyan, 1986).
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From these examples, one can observe the strong role that those in developing countries have in drug 
testing of the drugs of transnational pharmaceutical companies. Transnational pharmaceutical 
companies have tested contraceptives and other drugs on citizens of developing countries without their 
informed consent and without revealing the dangers of drugs. Undoubtedly, this behaviour is 
exploitive.
3-3:11 Incorrect Claims in Promotional Media in the Past
In many developing countries, pharmaceutical literature and information is the most available 
form of information about drugs that the doctor, health worker and pharmacist receives. Although this 
has the potential to correctly educate many in this area, it also has a great potential for damage if this 
information is flawed. Those health personnel that receive incorrect information about drugs, without 
counteracting evidence, are likely to act on this information. The damage of this flawed information 
depends on the extent of the misinformation and the relative danger of the drug used. In the past, 
incorrect drug claims for drugs in developing countries on the part of the transnational pharmaceutical 
companies were common, with the suspected intent of increasing its market and hence, profit, for 
particular drugs. The following are but a few examples.
The product Orgabolin, an anabolic steroid, was marketed by the Dutch company Organon in 
Bangladesh, India and Thailand for retarded growth in children, writing that the drug "ensures normal 
growth, stimulates appetite, promotes optimal weight" when the drug has never been formally 
indicated for treating malnutrition and under nourishment (Van der Geest, 1988). The danger with this 
drug is that it can also cause liver damage and female virilisation. Organon, in response to this 
criticism, claimed that it: (l)was very careful to ensure the safety and information about its drugs, (2) it 
admitted its mistake in its advertisement of Orgabolin, (3) the company assumed that the drug would 
only be taken under a doctor's prescription and that (4) there is a difference between the public and 
private sector of medicine (suggesting its use was designed for the private sector) (Van der Geest, 
1988). Indeed, these points of defence, especially the third, suggest that the pharmaceutical company 
had no knowledge of the conditions of drug availability in developing countries. More than likely, this 
is not true, but instead, such claims suggest that the pharmaceutical company simply treats the 
marketing of drugs according to similar conditions in industrialised countries, or more likely, use this 
as an excuse for any marketing failings. Unfortunately, this appears to be a common excuse given by 
transnational pharmaceutical companies in defence of their marketing activities.
Trisha Greenhalgh reported that Merck was promoting Encephabol (pyritinol derived from 
vitamin Bg) as a brain tonic that "improves the uptake and utilisation of glucose in the brain",
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recommending it for "strokes, organic brain syndrome of the elderly, post concussion syndrome, 
perinatal distress (and) learning disorders" (Greenhalgh, 1986: p. 1319) Also, in 1985, it was 
discovered that Glaxo was marketing a compound called Almacarb for the purpose of healing gastric 
and duodenal ulcers in Bangladesh when it has never been indicated as such by any pharmaceutical 
source (Srinivasan, 1986). In India, Merind marketed the anti-allergic drug Periactin for use in 
increasing appetite which is only one of the drug's side effects and not designed for this use 
(Srinivasan, 1986) In Pakistan, Birley (1989) reports erroneous claims on benzodiazepines such as 
Sandoz's Restoril with the claim that "Restoril (temazapam) patients do not experience drug 
dependence", and Parke-Davis's Verstand (prazepam), cited as a product advantageous for those 
patients with a history of drug abuse. Such claims go directly against warnings on benzodiazepines in 
the Physician's Desk Reference that says, "Withdrawal symptoms (of the barbiturate type) have 
occurred after the abrupt discontinuation of benzodiazepines" (Physician's Desk Reference, 1992). He 
says that Roche makes the claim that its drug "Lexotanil (bromazepam) resolves anxiety and relieves 
the strain on the heart" when in fact this drug is only used for short-term treatment of anxiety 
according to MIMS in Britain and nothing is mentioned about its calming effects on the heart. Almost 
comically, Birley aptly states that "If these claims are correct, then British doctors and their patients 
are missing out on a therapeutic revolution." (Birley, 1989: p. 220).
3-3:11a Past Statistical Claims
Mismarketing in order to influence health personnel to prescribe drugs is also executed with the 
misuse of statistical claims. Cesar Victora (1982) studied 350 advertisements and promotional 
materials sent to four doctors in Pelotas, Brazil over 6 months, and made some rather interesting 
observations on the use of misleading statistics. He claims that many pharmaceutical companies used 
biased sampling, no control groups, small experimental groups, non-significant differences, flawed 
comparisons and misleading graphs. Biased sampling, for instance, is illustrated by an advertisement 
for the antibiotic phosphomycin which claimed that it was 100% effective for chronic urinary tract 
infections. However, small print showed that this information was based on a sample size of only 
eight patients who were tested for sensitivity to the drug in order to remove any patients that were 
phosphomycin-resistant. Victora also observes comparisons of efficacy of drugs that are 
pharmacologically distinct and the use of graphs that greatly distort the actual effectiveness of one 
drug over another. In addition, the authors cite data quoted out of context, with no information about 
the source, and studies lacking a visible control group (Victora, 1982).
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3-3:12 Past Problems with Detailmen
Misinformation from pharmaceutical companies was also propelled with the use of drug 
salesmen, also known as detailmen. Drug companies, adjusting to the situation in developing countries 
where labour as an input to marketing is comparatively cheaper and more effective than medical 
journal advertisements, sends out a veritable army of drug sales representatives to doctors and 
pharmacists to market their products. The large ratio of detailers to doctors is illustrated in Table 3-5 
and is striking when comparing it to ratios of 1:10 or 1:20 which are common in industrialised 
countries (Lexchin, 1992).
Table 3-5: The Ratio of Detailers to 
Doctors in Developing Comitries
Country Ratio Source
Bangladesh 1:7 (Melrose, 1982)
Brazil 1:3 (Silverman et al., 1982
Colombia 1:5 (Silverman et al., 1982)
Congo 1:9 {Lancet, 1990a)
Ecuador 1:8 (Silverman et al., 1982)
Guatemala 1:3 (Silverman et al., 1982)
Indonesia 1:2.5 (Silverman et al., 1982)
Mexico 1:3 (Silverman et al., 1982)
Philippines 1:2.5 (Silverman et al., 1982)
Nepal 1:3 (Melrose, 1982)
Tanzania 1:4 (Yudkin, 1978)
Adapted from'. Lexchin, 1992: p. 420
This proliferous use of so many drug salesmen, just by number and the fact that doctors have very little 
access to other medical information gives drug detailers the potential to be very persuasive drug 
marketing tools.
Such use of drug salesmen is very effective as it adds a personal touch to sales giving the 
prescriber the opportunity to interact with the seller of a drug and develop a more personal relationship 
with the salesman. The problem is that because the level of education that individuals reach is 
generally lower in developing countries, the pool of labour that a pharmaceutical company uses is 
likely to be less educated and need a greater amount of training in drugs as compared to recruited 
representatives in an industrialised country. Unfortunately, the education of developing country 
detailmen is sadly neglected, leading them to give incorrect information. This lack of education mixed 
with the large enthusiasm to sell drugs, not to mention sometimes incorrect information from the 
pharmaceutical companies themselves, has lead to broad and incorrect claims and recommendations of 
various drugs' uses.
The number of incorrect claims and information about various drugs is so numerous as it would 
be difficult to list them all. Indeed, pharmaceutical companies, lacking the proper social controls in
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developing countries in the late 1970s and 1980s, became heavily entangled in the unethical behaviour 
of making exaggerated claims either through ignorance or more likely for the purpose of increasing 
profits.
3-3:13 Past Controversy over Gifts and Bribes
A further area of criticism aimed at the pharmaceutical industry was it’s frequent practice of 
giving gifts to doctors and pharmacists as well as larger bribes to governments. The practice of small 
gifts is used universally by pharmaceutical companies as a marketing tool. Doctors frequently receive 
small items such as pens displaying the company name, paper pads with the company logo and various 
other small items as well as free samples of drugs. Often, in developing countries, samples to doctors 
were so proliferous that these doctors would turn and sell them to their patients for a profit. However, 
in the late seventies and eighties, it was observed that doctors were receiving gifts that were a great 
deal more valuable than either pens or paper. Transnational pharmaceutical companies were giving 
doctors expensive dinners at fine restaurants, all-expense paid trips to medical conferences in exotic 
locations, and more commonly in developing countries, items such as bicycles, televisions and in some 
cases, even the services of prostitutes (Medawar, 1979, Silverman, 1982, Smith and Quelch, 1991). 
This practice was severely criticised by consumer groups and other interest groups because of the 
motive behind these gifts which undoubtedly had the potential to influence a physician to prescribe a 
product to a patient for reasons other than medical. Critics considered these gifts as bribery on the part 
of pharmaceutical companies and found them entirely unacceptable because they are an impediment to 
rational prescription.
Large bribes to countries are another topic for scrutiny in the unethical behaviour of 
pharmaceutical companies. Most of these bribes occurred in the late seventies and the early eighties. 
Bribery as a practice is difficult to prove, but extremely damaging once discovered. Guha (1986) 
reports a few examples of these.
"•A US $960 000 bribe of the Italian government on the part of 12 drug companies in order to back an 
industry sponsored bill
•Merck gave US $2.3 million to a foreign government through its Swiss subsidiary Merck Sharp and 
Dohme and listed it as promotional expenditure
•American Home Products in 1976 spent US $3.4 million for approval of their drugs in 41 countries
•Parke Davis paid US $2.6 million in 14 countries to hasten drug approval
•Pfizer bribed US $264 000 employees of the government of three foreign countries.
•Roche gave US $14 000 to two Kenyan government officials for purchasing their tranquillisers and anti­
bacterials in a bulk amounting to 10 years of need."
Source: Guha, 1986: pp. 224-225
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Reports of such practices are seldom observed anymore, possibly suggesting that such activities are far 
less common.
3-3:14 Recent Activity and Change
An additional problem in marketing that has hampered drug utilisation is the inappropriate 
labelling of drugs. In 1993, the US Office of Technology Assessment evaluated the labelling of drugs 
sold by US-based pharmaceutical firms in four developing countries: Brazil, Kenya, Panama and 
Thailand (US Congress Office of Technology Assessment, 1994). In this study, 241 drugs were 
surveyed and of these, 66% of them were incomplete in providing a physician information on their safe 
and effective use. One example of inappropriate labelling included a magnesium containing antacid 
(which has known laxative properties and is dangerous to infants in large quantities) indicated for the 
regular use in infant formula to stop it from souring. Other examples included a drug combination of a 
corticosteroid, an antihistamine and an antipsychotic recommended for itching without information on 
the side effects of steroids, and an antinflammatory that was recommended for pain and inflammation 
without a note of the drug's serious effect in stopping the production of white blood cells. This more 
recent report suggested that progress in marketing activity regulation of and by transnational 
pharmaceutical companies still had potential for improvement.
3-3:15 Consumer Groups and Extremists
There are many means for influencing official policy regarding the pharmaceutical industry and 
consumer policy. A map of government influence has been delineated by Burstall and Reuben (1990), 
in the Figure 3-3. In attempting to influence the cabinet of a government, consumer groups can either 
go to party advisors, those in relevant professions influencing the cabinet, party officials, or they can 
try to influence public opinion through the media. Such a chart as this does not just apply to the 
governments of states but also global governing bodies such as the WHO. It is through these 
mechanisms that many proposals shaping the regulation of pharmaceuticals are developed.
Actions to influence the WHO regulation of drugs have been successful. Through the influence 
of external groups and on its own accord the WHO has made the regulation of drug promotion a strong 
priority. In order to improve the regulation of drug marketing, the WHO developed the Ethical Criteria 
for Medicinal Drug Promotion in 1988. This was a comprehensive description of the ethical marketing 
of drugs, carefully defining ethical considerations required in promotion, advertising medical 
representatives, free gifts, symposia, export of dangerous drugs and most other information media. 
The aim of this criteria was to make physician prescribing as objective as possible and make drug 
information as complete and correct as possible.
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Figure 3-3: The Influence of Outside 
Organisations on Government Policy
Source: Burstall and Reuben, 1990
Such actions have been strongly supported by many critics of the pharmaceutical industry. Some of 
these critics not only question the nature of the pharmaceutical industry but question the very 
principals of capitalism, whereas others choose to focus simply on regulation rather than revolution. 
Despite this discrepancy, many influential consumer groups have developed to regulate drug 
marketing, notably two, the Bureau Europeen des Unions des Consommateurs (BEUC) and Health 
Action International (HAI). BEUC, founded in 1962, primarily limits itself to marketing activities 
affecting the consumers in the EC whereas HAI focuses more on global issues, especially those 
affecting consumers in developing countries. HAI was formed in 1981 for monitoring drug marketing 
in developing countries. It is run from both Hague in Europe and Penang Malasia and its most visible 
members are Oxfam, the Bundeskongress Entwicklungspolitische Aktionsgruppe (BUKO), the Dutch 
International Group on Women and Pharmaceuticals (WEMOS), and the Medical Lobby for the 
Appropriate Advertising (MALAM) (Burstall and Reuben, 1990).
In the defence of some transnational pharmaceutical companies, Braithwaite traced their reform 
efforts after much criticism came to light about their subsidiaries in developing countries. He 
suggested that often subsidiaries of developing countries are portrayed as the perpetrator of many of
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these activities and it is the pharmaceutical company's powerful regulatory bodies, made up of 
"crusaders for the consumer interest", that attempt to change the marketing activities of these 
subsidiaries with powerful zeal (Braithwaite, 1986: 255). Braithwaite portrays subsidiaries in 
developing countries as disobedient children that do not necessarily obey their parent companies since 
these subsidiaries erroneously conclude that they must market their products in a less than honest way 
in order remain competitive. However, not all poor marketing in the past can be blamed on the 
subsidiaries of transnational companies. Some companies, by their inaction, allowed these practises to 
continue. In addition, many companies have had a much stronger role in the marketing of their 
products in developing countries than they would otherwise admit as is suggested with Searle's 
marketing of Lomatil, described above.
3-3:16 Ethical Considerations: The Appropriate Place of Pharmaceutical Companies
Pharmaceutical companies are somewhat insulated from consumer groups and consumer 
reactions since it is the doctor who prescribes drugs in industrialised countries. This is especially true 
in sub-therapeutic markets where a pharmaceutical company dominates the market with the intellectual 
rights to a key product, or in the case where a doctor is made to prescribe according to a strict 
formulary. This can hinder consumer actions in boycotting a drug because a patient, even if he or she 
is aware of the activities of a pharmaceutical company and wishes not to consume its products, must 
still convince his or her doctor not to prescribe them. This can be difficult if the doctor is given no 
other options in what drug to prescribe, or if the patient desperately needs the drug for his or her 
welfare. In developing countries, information and drug supplies can be so limited that even if a patient 
or doctor is informed about the poor marketing activities of a drug company, it is unlikely that he or 
she will stop consuming that company's products as they need whatever drugs that these individuals 
can obtain and do not have the luxury of choice.
Consumer influence on prescribing is just one manifestation of influencing pharmaceutical 
companies. Indeed, the methods of social control of pharmaceutical companies lie in three areas, 
legislation, market forces and moral obligation, as is illustrated in Table 3-6 (Smith and Quelch, 1991). 
All of these methods of control are flawed and therefore, the combination of all three is needed for the 
social control of firms. The over-emphasis on one such as legislation over market forces will 
eventually reduce the incentives on the part of drug firms to produce drugs, and likewise, an over­
dependence on moral obligation will not ensure that adverse side effects, contra-indications as well as 
the proper recommendations for each drug will be disclosed. Hence, a balance between all three of 
these must be found for each country and internationally for regulating the activities of transnational 
pharmaceutical firms.
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Table 3-6: Methods for Social 
Control of the Pharmaceutical Industry
Method of Control Type of Power Exerted Vulnerability Examples
Legislation Coercive Overloaded FDA
(government intervention) Force
Condign
Limited Effectiveness 
Threat to Market System
Criminal Prosecution
Market Forces Remunerative
Inducement
Compensatory
Insufficient Profit from successful 
ventures
Consumer Activism
Moral Obligation Normative Unequal IFPMA Code
Manipulation
Conditioned
Inadequate Voluntary Disclosure of drug 
Risks
Source: Smith and Quelch, 1991: 123
The influence of pharmaceutical companies is undoubtedly important, but what of endogenous 
regulation in each pharmaceutical company? According to some, the pharmaceutical industry has a 
social responsibility due to the sensitive and influential nature of their products on health. Others 
maintain that the pharmaceutical industry is not a charity, but is in fact a free body working toward the 
goal of profit maximisation and should remain unfettered to pursue this goal with limited criticism. To 
objectively clarify these opinions, Smith and Quelch (1991) maintain that all business firms can be 
classified into a model of social responsibility delineated by four levels, as is illustrated below.
"1. Profit maximisation and social irresponsibility
-Firms may do good through profit maximisation (Adam Smith’s "invisible hand") but may 
also cause harm, would not act to prevent it, and are only doing good as a result of serving 
their self-interest.
2. Profit maximisation tempered by the 'moral minimum' operating through self-regulation.
-This is avoiding causing harm. Most firms/managers are at this position.
3. Profit as a necessary but not sufficient goal, with affirmative action extending beyond self­
regulation
-Some firms/managers make efforts to not only avoid causing harm, but also prevent harm and 
possibly do good. Johnson & Johnson is the classic example.
4. Profit as a necessary but not sufficient goal, with social responsibility extending beyond self­
regulation and affirmative action to include the championing of political and moral causes 
unrelated to the corporation's business activities, perhaps even including gifts of charity but only as 
long as profitability permits.
-Gifts of charity here refers to genuine philanthropy rather than that which is primarily PR 
driven. Few firms reach this position of actively doing good as well as not causing and 
preventing harm (which many would argue is not a bad thing because of the fairness and 
legitimacy concerns identified by Friedman). Many firms do not have sufficient resources for the 
championing of political and moral causes. Classic examples of firms at this position are Ben and 
Jerry's and the Body Shop."
(Smith and Quelch, 1991: p. 125)
Regarding this model of social responsibility, Smith and Quelch claim that most pharmaceutical 
companies function on level one, 'profit maximisation and social irresponsibility' or level two, 'profit 
maximisation tempered by the moral minimum operating through self-regulation' when they should at 
least be on level three, 'profits as a necessary but not sufficient goal, extending beyond self regulation'.
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It is through functioning on this level that consumers get an adequate amount of protection from 
harmful products. The distinction between levels may not be so very clear-cut with very big firms. 
Those companies might be functioning on level three in industrialised countries because of strong 
regulation and a vocal media, but may be functioning on a lower level in developing countries. Merck 
who has been guilty of some inappropriate actions in the past in developing countries, has recently 
donated millions of doses of the drug ivermectin for the treatment of onchocerciasis, better known as 
'river blindness' (Tanouye, 1992). So, here is a company partially functioning on level four for this 
charitable contribution for social welfare, but probably only functions on level three in industrialised 
countries.
3-3:16a Responsibility of the Manufacturer
Expecting that firms to have such a high sense of social responsibility is idealistic and most firms 
should realistically function on a level where they ensure that their actions will not cause harm. Dukes 
and Swartz (1988) in Responsibility for Drug-Induced Injury, a book for lawyers, manufacturers and 
health workers, suggest that a drug firm is obliged to provide pharmaceuticals with efficacy, safety, 
quality, sound packaging and supply, information to official bodies, information to health professionals 
and the community, warranties and guarantees, limited exposure of non-users, and good research 
standards. They suggest that the written law does not adjust well to cover all situations and may be 
outdated, compelling those pharmaceutical companies to observe condign interpretations of current 
laws and regulations, study and commentary of the current situation by international organisations and 
'well-informed observers’. These suggest that drug companies have a responsibility to consider the 
opinions of critics, consumer groups and legal authorities regarding their activities. The book states 
that there is never a case where a company can ensure 100% safety or quality in packaging, and that it 
is from interacting with these bodies that they can better fill their responsibilities in this area.
3-3:17 Summary of Section 3-3
Drug Production is primarily driven by the desire to make profits. It should not be assumed that 
the activities of this form of free enterprise will subscribe to a moral standard. Past activities on the 
part of local drug producers and the transnational pharmaceutical industry in some instances have been 
inappropriate. In addition, drug quality has also suffered, especially in those drugs locally produced. 
However, some critics of the industry's behaviour often ignore how essential is this industry to health 
care delivery as well as its substantial work in promoting appropriate products. The actions of the 
pharmaceutical industry can serve health care delivery as long as it is well regulated. It is a balance of
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the consumer, government and market forces that must ultimately influence the behaviour of these 
producers.
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Section 3-4
CONCLUSION TO CHAPTER THREE
Drug therapy can be a cost-effective method in health care delivery and notably the treatment of 
infectious disease. Nevertheless, the area of drug utilisation is convoluted by the inability to regulate 
and manage these drugs' uses. Such overwhelming need and high impoverishment in these countries, 
makes the concentration on the regulation and control of drugs unfortunately a lesser priority as 
compared to other needs in the infrastructure. Developing countries, which have few resources for 
increasing health status, must have the very best management of drugs in health delivery in order to 
maximise the utility it gains from its investment. As compared to an industrialised country, a 
developing country must be more resourceful, more able to adapt to difficult situations and more able 
to deal with widespread infectious disease in order to avoid unnecessary deaths. The small amount of 
funds that requires such resourcefulness is the same reason for the lack of such expertise in order to 
accomplish this. Drugs that are greatly needed to treat diseases are mismanaged: over-supplied in 
some instances and completely absent in others. Information, which is necessitated to manage and 
dispense these drugs is difficult to obtain, unregulated and often of poor quality. The process for 
changing this is indeed slow, but nevertheless, it is not impossible. Better education of health 
personnel and patients, better regulation of drugs and better management of health care institutions will 
improve health in developing countries along with the cooperation and regulation of pharmaceutical 
companies as well as the guidance of donors, NGOs and the WHO. The lack of these in the past has 
resulted in a mismanagement of drugs, causing widespread harm. Hopefully in the future, the 
imperative of these elements will continue to be realised so that improvements in the standard of health 
delivery with drugs will perpetuate. Following this, includes improvements in health care delivery for 
drugs that treat infectious bacterial diseases. This is expanded in Chapter 4.
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CHAPTER FOUR
ANTIBIOTICS: THEIR UTILISATION AND ASSOCIATED HAZARDS
So far, health care delivery, infectious disease and the utilisation of pharmaceuticals have been 
discussed in order for an understanding of the influencing factors and the context in which the cost of 
antibiotic resistance is to be assessed. This chapter attempts to give the reader a background on the 
utilisation of antibiotics itself, and some theories on the impact of bacterial resistance on the cost of 
antibiotic treatment. Section 4-1 will discuss the mechanisms of resistance and its association with 
antibiotic abuse. Section 4-2 will present examples of poor antibiotic prescribing and an economic 
model of the use of antibiotics and related resistance. Finally, Section 4-3 will illustrate the unique 
problems of antibiotic utilisation in developing countries that contribute to greater resistance and 
higher costs in treating infections. This chapter is integral to understanding the rise of bacterial 
resistance to antibiotics and its potential cost in developing countries. Those factors applying to 
antibiotic resistance such as basic resistance mechanisms and inappropriate use are later shown more 
specifically to apply to resistance of tuberculosis bacteria to treatment.
Introduction
Many people are familiar with Kermit the Frog from a children's show responsible for making 
half a generation of British people omit the letter 'u' from the word colour. Nevertheless, what most 
people do not know is that the originator of this character, Jim Henson, died from an infection that was 
completely resistant to antibiotics. Indeed, Jim Henson was an unfortunate victim of the poor 
management of antibiotics, which causes an increased incidence of resistant micro-organisms.
Imagine a world without antibiotics. Diseases seldom seen today in industrialised countries, 
such as typhoid, dysentery, tuberculosis, meningitis, syphilis, bubonic plague, cholera and a myriad of 
other infectious diseases, would once again be a prominent part of everyday life. This may seem 
preposterous, but it approaches the cold truth that there are now versions of all of these diseases that 
few or no antibiotics can cure. Furthermore, these diseases do not lie dormant in laboratories, but are
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passed from person to person, contributing to greater morbidity and mortality. An acrid reminder of 
this occurred between 1972 and 1973, when a resistant typhoid epidemic in Mexico was responsible 
for the deaths of some 20 000 people (Braithwaite, 1984). Resistant infections are no longer an 
obscure topic for scientific discussion, but a consequential global threat.
In 1994, the global market for antibiotics was worth US $18 billion (SCRIP Reports, 1995). This 
is one of strongest therapeutic groups due to its imperative role in curing infections. It is impossible to 
discuss antibiotics without incorporating resistance. Certainly, drug resistance is the driving key to R 
& D in the market because it is the primary determinant of an antibiotic's effectiveness. Resistance to 
a particular antibiotic is primarily dependent on the intensity of use of that antibiotic. This is further 
accentuated by the inappropriate use of antibiotics through sub-therapeutic doses, length of treatment, 
and irrational prescription. Some antibiotics, which should be reserved for their specific action against 
life-threatening diseases, are instead used on general infections when other antibiotics will do. The 
cost of this resistance proves to be high. The cost of treating anti-infective resistant infections can be 
five to ten times the cost of treating anti-infective susceptible infections (Phelps, 1989). Added to this, 
antibiotic use and resistance has a negative externality contributing to an overall pool of antibiotic 
resistance that grows with the use of these drugs. Irrational use is common in industrialised countries 
but it is, nevertheless, felt quite acutely in developing countries. Developing countries lack the ability 
to regulate their antibiotics and therefore antibiotic use is uncontrolled. This uncontrolled use has 
made developing countries one of the greatest beds of resistance and many outbreaks of resistance 
have originated in these areas.
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Section 4-1
MECHANISMS OF ANTIBIOTIC RESISTANCE
This section describes how antibiotic resistance develops in bacteria and how the inappropriate 
use of antibiotics accentuates this. Throughout the human body there are many kinds of small 
organisms called bacteria (singular bacterium). Most of these bacteria are essential to maintain a 
healthy existence. Some bacteria, however, are quite virulent and when introduced to an individual, 
can start to multiply and interfere with the body's regular cell functions, resulting in infections and 
disease. It is these infections that are treatable with antibiotics, which work in several ways to destroy 
bacteria. However, a bacterium can develop the ability to withstand the attack of an antibiotic so that 
the antibiotic has no effect on it. Once this occurs the bacterium is termed as resistant.
In general, there are two ways in which a bacterium can become resistant. The first may be 
referred to as endogenous resistance. This occurs through exposure to a particular antibiotic which 
causes a bacterium to mutate in order to develop a resistance to that antibiotic. In contrast is the 
second way, which may be referred to as exogenous resistance and occurs through the exchange of 
genetic material between bacteria in the same environment. Genetic material simply refers to chains of 
molecules called genes within the bacterial cell (see Figure 4-1) which contain various instructions 
telling a cell how to function.
Figure 4-1: A Simple Bacterial Cell
4-1:1 Endogenous Resistance
Endogenous resistance occurs in bacteria because of natural mutation of bacilli in every bacterial 
colony. This resistance was first detected in the early uses of penicillin when bacteria were observed 
to be able to live and grow in increasingly high concentrations of the drug. These resistant penicillin 
mutants had stronger cell walls than their susceptible counterparts, making it difficult for penicillin to
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penetrate them (Levy, 1992). Nevertheless, this kind of resistant was thought to be easier to treat and 
less threatening in most bacteria than exogenous resistance.
Endogenous resistance is still observed in bacteria in modern times. Like exogenous resistance, 
one of the determinants to this resistance is exposure to an antibiotic. In every bacterial population 
there are some mutations which are simply more resistant to antibiotics. Often, through sub­
therapeutic doses of antibiotics, all antibiotic-susceptible bacteria are killed, picking out or selecting 
for the mutants which then remain and multiply. It is a type of 'survival of the fittest' occurrence 
whereby natural resistance helps to perpetuate a population. Nevertheless, the likelihood of the 
development of this kind of resistance is strongly dependent on the size of a bacterial colony.
Figure 4-2: The Transference of 
Resistance Between Bacterial Cells
Stage I
duplicate plasmid with the gene resistant to an antibiotic
Stage n
both bacteria now have resistance
4-1:2 Exogenous Resistance
The second type of resistance in bacteria is exogenous resistance, which can be more virulent in 
many cases. This type of resistance occurs when bacteria receive their ability to resist antibiotic 
attacks from the free floating genetic material of other bacteria. Genetic material in bacteria consists 
of two types: a long chain of genes that remains with the cell, called the chromosome, and much 
shorter chains of freely moving genes known as plasmids that can be duplicated and transferred to 
other bacterial cells. These plasmids are of great importance because it is though them that resistance 
can be passed from one bacterium to another. In essence, a gene containing the instructions for a
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bacterium to become resistant to a particular antibiotic will reside on a plasmid and can be duplicated. 
These duplicate plasmids may then move into other cells thus enabling these cells to become resistant. 
Figure 4-2 depicts this process.
To illustrate this process of transference, suppose a bacterium that resides in the intestine 
contains a gene with the instructions for resistance to the antibiotic penicillin, and happens to meet a 
more virulent bacterium, such as dysentery. The dysentery bacterium can then receive a duplicate 
gene form the intestinal bacteria rendering it resistant to penicillin. Nevertheless, one might question 
the threat of one bacterium resistant to an antibiotic such as penicillin in an infection characteristically 
containing several million bacteria. The problem occurs once this population is exposed to the 
antibiotic to which it is resistant. The antibiotic will kill every cell of bacteria that is susceptible to it, 
leaving only those resistant bacteria behind. Once this has occurred and there are only the bacteria 
with the resistant genes left, the antibiotic has selected for the resistant bacteria. This bacteria can now 
multiply faster in this environment since there are fewer other bacteria to compete with. 
Correspondingly, it can remain impregnable to any further treatment from that antibiotic.
Once an infection has become antibiotic-resistant, it can be passed to other individuals in this 
resistant form. In this situation, the individual that has been exposed and develops a resistant infection 
also cannot be treated by the respective antibiotic. In this way resistant infections can become 
predominant.
4-1:3 The Effects of Transferred Resistance
What can be concluded from these two methods of resistance development is that individual 
exposure to antibiotics can be the cause of resistance. The problem arises from repeated exposure to 
various antibiotics, there can develop a disease strain that is resistant to several different antibiotics 
characteristically used to treat it. This can make its treatment very expensive and difficult, often 
resulting in patient fatality. Furthermore, there are few new antibiotics coming onto the market. 
Antibiotics are chemicals that originate from a few basic chemical types or 'families', most of which 
have been completely exhausted.
Indeed, the mismanagement of antibiotics is common. Many doctors, can feel pressurised to 
prescribe an antibiotic for the common cold virus to which antibiotics are ineffective, or for use in the 
treatment of acne resulting in prolonged and unnecessary use. Also, insufficient exposure to 
antibiotics is also a determinant of resistance: due to the lack of education, many people who receive 
antibiotics stop taking them once they feel better, failing to complete the necessary prescription. 
Hence, the inappropriate and inefficient use of antibiotics can cause unnecessary resistance.
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4-1:4 Summary of Section 4-1
There are two methods for the development of resistance, endogenous or naturally occurring 
mutation, and exogenous resistance, through the exchange of genetic material between bacteria. The 
mechanisms of antibiotic resistance are a unique and worrying occurrence especially where resistance 
can be easily transferred from one type of bacteria to another type of bacteria in the same environment. 
To fight such resistance, serious consideration needs to be taken concerning the consumption of 
antibiotics. Certainly, many antibiotics might be considered one of the most valued scarce resources if 
actions are not taken for their better regulation.
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Section 4-2
Antibiotic utilisation and cost considerations
In this section there is an overview of the significance of antibiotic resistance. It additionally 
contains a presentation of an economic model showing how inverse demand curves for a given 
antibiotic are affected by increasing resistance to it. Theories on how bacterial resistance to antibiotics 
influences the cost of treatment are also presented in this section. This information will be further 
expanded in later chapters when it is applied to tuberculosis.
Antibiotics have served as a comparatively cheap health intervention in the treatment of bacterial 
infections that once caused widespread morbidity and mortality. Antibiotics are a relatively 'hassle 
free' method of treating infections, giving them their often referred to name in developing countries of 
the 'magic bullet'. Nevertheless, this highly efficient cure has been threatened by the growth of 
bacterial resistance to antibiotics. Bacterial resistance can grow quickly and move with ease. Indeed, 
the growth of resistance has many implications. It makes the treatment of bacterial infections far more 
difficult and in some cases impossible. Often more expensive antibiotics must be used, and in the case 
of serious resistant infections, hospital stays during treatment increase. This, of course, drastically 
increases the cost of treating such infections and therefore, has a strong economic impact on the cost of 
interventions.
Figure 4-3: Percentage of Salmonella Isolates Resistant 
to One or More Antibiotics in Three Prospective Studies
Year
Source'. Cohen, 1992
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4-2:1 The Appearance and Growth of New Strains of Resistance
Resistance is continually growing and new strains of resistance are discovered every year. 
Cohen (1992) for example, reports US Center for Disease Control (CDC) results of three prospective 
studies of Salmonella isolates' susceptibilities to 12 antibiotics. New resistance is a function of 
antibiotic use whether it is appropriate or inappropriate. As illustrated in Figure 4-3, this report shows 
that in 1979 16% of isolates were resistant to one or more antibiotic, in 1984, 24% were resistant and 
in 1989, 32% were reported resistant to one or more antibiotic. Each year greater degrees of resistance 
are observed. Resistance is not particular to older antibiotics but it is indiscriminate. The more a drug 
is used on an antibacterial population, the more likely it is that resistance will develop. Levy (1991) 
charts outbreaks of resistance as observed in Table 4-1.
Table 4-1: Outbreaks of Resistant Pathogens in the 1980s
Country Year Manifestation of Resistance
Central and South America 1985 Co-trimoxazole resistant E. coli
North America 1985 Tcr resistant Mycoplasma and Ureaplasma
Argentina 1984 Multiresistant S. aureus
1988 Penicillinase-producing N. gonorrhoeas
Australia 1985 Multiresistant 5. aureus
Australia, US, France, Belgium, Japan 1986 Tcr C. perfringens
Bangladesh 1983 Multiresistant V. cholerae El Tor
Brazil 1989 Resistant urinary tract isolates
Bulgaria 1990 Multiresistant S. sonei
China 1986 Gentamicin resistance
1988 Resistance in hospital isolates
Chile 1985 Apr Cmr H. influenzae-, multiresistant Shigella sp.;
Pnr Tcr resistant 5. Pneutnoniae
Finland 1988 Trimethoprim Resistance
GDR 1987 Multiresistant S. aureus; multiresistant 
Enterobacteriaceae
Guatemala 1989 Resistant S. pneumoniae
India 1983 Multiresistant 5. typhimurium
1984 Multiresistant S. typhi
India, West Bengal 1985 Multiresistant S. dysenteriae type 1
Iraq 1988 Resistant enteric pathogens
Philippines 1989 Resistance to new 6 lactam antibiotics
Spain 1988 Resistant pneumococcus
Sri Lanka 1987 Trimethoprim resistance
Sudan 1987 Multiresistant Enterobacteriaceae
Tanzania 1983 Multiresistant V. cholerae El Tor
U.S. 1985 Multiresistant Mycobacterium tuberculosis
1986 Penicillinase producing N. gonorrhoeae
1986 Tcr N. gonorrhoeae
1987 Vancomycin resistant S. haemolyticus
1988 Trimethoprim resistant E. coli in day care centres
1988 Penicillinase producing enterococci
Former U.S.S.R. 1989 Resistant P. aeruginosa in hospitals
Vietnam 1989 Multiresistant Shigella sp.
Various Countries 1985 Co-trimoxazole resistant enteric pathogens
Zaire 1983 Multiresistant S. dysenteriae
Source'. Levy, 1991
Resistance has become a powerful threat, in some cases, challenging doctors' abilities to treat 
common diseases. The two most clinically significantly observed incidences of resistance are
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vancomycin resistant Enterococcus faecina and penicillin resistant Streptococcus pneumoniae (Bartlett 
and Froggatt 1995). The first is resistance that threatens patients in intensive care units because it is 
usually transferred nosocomially (hospital aquired). Other drugs that exist to treat this have not proved 
particularly effective. This resistance is relatively recent, having first been a problem in infections in 
1988, nevertheless, it has started to grow at an alarming rate. Frieden et al. (1993) report that of 361 
patients with vancomycin resistant enterococci (VRE) who were identified at 38 hospitals in New 
York, that 93% of VRE patients' infections were obtained nosocomially and 83% of these patients 
were administered vancomycin or a cephalosporin 30 days before VRE was detected. The hospitals in 
this study experienced a rise in VRE from 1 in 1989 to 38 in 1991. Penicillin resistant S. pneumoniae 
has also caused many problems in treatment and completely changes the approach to the infection's
treatment.
Recent reports of the degree bacterial susceptibility suggest that resistance is a notable problem. 
Shehabi (1995) reports in Jordan between 1978-1989 that 52-90% of S. typhimurium isolates were 
resistant to one or more antibiotics. Kanavaki et al. (1994) report in Greece that of 1 002 isolates of S. 
pneumoniae from patients with community acquired pneumonia, 14% were resistant to penicillin, 20% 
were resistant to erythromycin, 26% were resistant to tetracycline and 1% were resistant to 
chloramphenicol.
Significant resistance has also appeared in rare infections in the immunocompromised, which are 
responsible for high death rates. Spencer (1995) observes resistance of Stenotrophomonas 
(Xanthomonas) Maltophilia and Burkhoderia (Pseudomonas) Capacia as a serious threat in 
nosocomial infections in immunocompromised cancer patients. Indeed, although a 7% resistance is 
observed in the UK, a 40% resistance is observed in the US. Fatal deterioration of patients in hospital 
because of these infections is very significant as far as the impact of resistance and its associated 
economic costs.
Indeed, antibiotic resistance is observed in most environments. It has appeared in animal 
livestock and in drinking water. Holmberg et al. (1984) identify 18 individuals in the midwest of the 
US who were infected by ampicillin-, carbenicillin- and teracycline- resistant Salmonella newport. 13 
of these patients who were infected with this S. newport had consumed a hamburger from the same 
herd of South Dakota beef cattle, which had been administered sub-therapeutic chlortetracycline for 
growth promotion. Another example occurred in a ground water drinking supply in the US. Mckeon, 
Calbrese and Bissonnette (1995) found that of susceptibility tests to 16 antibiotics of 250 coliform and 
noncoliform bacteria from untreated ground water, all non-coliforms and 87% of coliforms were 
resistant to at least one antibiotic. •
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4-2:2 Inappropriate Use of Antibiotics
With such a significant amount of antibiotic resistance to so many pathogens, the use of 
antibiotics cannot afford to be anything but rational and appropriate. The inappropriate use of 
antibiotics for the treatment of viral infections, or infections where they will not be effective, is a 
common phenomenon in both developing countries and industrialised countries, propelling the growth 
of resistance. Hogerzeil (1995) reports on the irrational use of antibiotics in teaching hospitals 
spanning from 1977-1991. He maintains that teaching hospitals, which are designed as role models for 
medical students, could possibly be propagating bad habits in student learning due to irrational 
antibiotic prescription procedures. In Table 4-2, one can observe irrational prescribing behaviour in 
six countries, occurring in a wide range of departments. This suggests that inappropriate use of 
antibiotic in a hospital context is not an isolated phenomenon.
Table 4-2: Inappropriate Use of Antibiotics in Teaching Hospitals
Country % Inappropriate Use Type/Department Source
Canada 42% Surgical Ward, Parenteral Achong, Hauser and Krusky,
Antibiotics 1977
50% Gynaecology Ward
12% Medical Ward
USA 41% All Inpatients Maki and Schuna, 1978
Australia 86-91% Prophylaxis Mashford and Robertson, 1979
Canada 30% Paediatric Medical Cases Schollenberg and Albritton, 1980
63% Paediatric Surgical Cases
Australia 48% All Departments Harvey, 1988
Kuwait 39% Paediatric Inpatients Najdi, etal., 1988
Australia 64% Patients Treated with Vancomycin Misan, etal., 1990
Thailand 91% All Departments Aswapokee, Vaithayapichet and 
Heller, 1990
South Africa 54% Gynaecology Inpatients Till, etal., 1991
22-100% Unrestricted Antibiotics
Thailand 41% All Departments Udomthavomsuk et al., 1991
79.7% Surgical Prophylaxis
40.2% Documented Infection
Compiled By. Hogerzeil, 1995
Efforts to curve inappropriate antibiotic use have only been somewhat successful. One of the 
most interesting cases of this occurred in Australia. Here there has been a large problem in a highly 
resistant form of enteroccus in hospitals which has become quite a threat in nosocomial infections. In 
an effort to change the prescribing behaviour of doctors, relevant to antibiotics, the Antibiotic 
Guidelines were brought out in 1977, supported by a strong marketing campaign (Harvey et al., 1986). 
This marketing campaign later in 1985 involved pharmaceutical-style marketing material and 
representatives to educate doctors in antibiotic prescribing. This approach was deemed to be effective 
in the short run, but the positive effects were diffused over time. Cost savings from better antibiotic 
prescription were observed to greatly outweigh the costs of this educational campaign (Landgren et al.,
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1988). Nevertheless, although some progress was obtained in prescribing behaviour, many doctors 
still prescribed antibiotics counter to the Antibiotic Guidelines. In a study by Harvey (1990), a sample 
of G.P.s’ prescribing behaviour was compared to the recommendations of the Guidelines. In this 
sample 50% of G.P.s prescribed norfloxacin for acute urinary uncomplicated urinary tract infection 
when its use is not recommended for this. Another 43% of 2342 prescriptions to treat tonsillitis were 
for amoxycillin and co-trimoxazole which is also counter to the Antibiotic Guidelines.
4-2:3 Economic Loss from Resistance
Bacterial Resistance creates two potential losses to the overall economic well being of society. 
The first represents the direct loss to the consumer due to inappropriate use. This is loss that a given 
consumer experiences because those antibiotics that a consumer has used inappropriately will no 
longer be useful in treating future infections that he or she might experience. The second form of loss 
is indirect loss experienced by all users of antibiotics in a society. As the overall use of antibiotics 
rises, so does the overall growth of resistance, therefore increasing the transference of resistance and 
making antibiotics less potent in fighting infection in future antibiotic users. Antibiotic use creates a 
negative externality whereby one individual's use allows for greater future bacterial resistance that will 
be experienced by others. The negative externality of antibiotic use according to Phelps (1989) is such 
that each 10% increase in use will result in a 1-10% increase in resistance.
Figure 4-4: The Expected Value 
Demand Curve for an Antibiotic
CASE A: CONSTANT LOSS FOR ALL CASE B: ANTIBIOTIC RESISTANCE
QUANTITIES CONSUMED
Quantity of Antibiotics Consumed Quantity of Antibiotics Consumed
Source: Phelps, 1989
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4-2:3a The Impact of Resistance in the Expected Value Demand Curve for Antibiotics
Phelps (1989) has derived a model for the impact of resistance on the demand for antibiotics. In
this model, shown in Figure 4-4, demand for an antibiotic is strongly affected by the level antibacterial 
resistance to it. Phelps presents two incremental value (inverse demand) curves (V*) for a given 
antibiotic. V) represents the inverse demand curve if patients were certain that their infection was 
sensitive to the antibiotic. In contrast, V2 is the curve representing the case if patients knew that their 
infection was resistant to that antibiotic. V2 in Case A reflects the 'placebo value' of taking antibiotics, 
where V2 in Case B does not take into account the 'placebo value' and therefore V2 is equal to the 
horizontal axis. This is because V2 in this second case has virtually no value to patients. In actuality, 
patients do not know for certain whether or not their infection will be susceptible to an antibiotic and 
therefore, Phelps takes the weighted average of Vj and V2 to derive the actual expected value demand 
curve for the antibiotic, represented by V* in Figure 4-4. Demand for the antibiotic will occur at the 
point where the demand curve V* and private marginal cost intersect which is at quantity Nj. The 
probability of resistance (P) is expected to rise with the intensity of an antibiotic's usage. In fact, each 
subsequent dose of antibiotic increases the probability of resistance. Therefore N, which represents the 
quantity of antibiotics used, is a determining factor of Vj, V2, P, and AV. Hence, Phelps defines the 
expected gain from any antibiotic as
V* = V1(1~P(A^)) + V2P(2V)
Where
V] = the inverse demand curve if patients were certain that their infection was sensitive to an antibiotic.
Y2 = the inverse demand curve if patients knew that their infection was resistant to an antibiotic
zlV = V]-V2 - the difference in value of an antibiotic in the case of resistance
P = the probability that a bacterial colony is resistant
C =the drug cost per treatment
106
From this, the overall welfare gain (W) net cost to society for N doses of an antibiotic is
w = f [ v, «(> - pW)+v2pW - c]dx
Where
Vj - the inverse demand curve if patients were certain that their infection was sensitive to an antibiotic. 
V2 =■ the inverse demand curve if patients knew that their infection was resistant to an antibiotic 
zlV=V7-V2 = the difference in value of an antibiotic in the case of resistance
P(N)= the probability of a resistant bacterial colony as a function of the aggregate consumption level N 
C=the drug cost per treatment
Here the area from the V* curve to C in Figure 4-4 is calculated for consumption N.
The optimum use of an antibiotic is found by identifying the point of maximum expected gain, or
where dW/dN=0 and therefore, where V%/V)=Vy(AQ(l-P(A9)+V2(A0P(/V) or
dW
dN
= V * (TV) - C - AV(x)^~i<Zx = 0
In order to find optimum use in this equation, N is substituted for N* the optimum use of the antibiotic 
in question. In Case A in Figure 4-4, AV is constant and in order to find the point of maximum 
expected gain, the equation changes to
V* = C + A V N *
dN
and dPldN is calculated at N*.
According to Phelps, these equations predict that increasing antibiotic use until expected
incremental benefits V* equal incremental costs will achieve an optimum.
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Figure 4-5: The Private and Social 
Optimum of Antibiotic Usage
Quantity of Antibiotics Consumed
The private cost, in this case is represented by C. These dynamics can be seen in Figure 4-5, where the 
private optimum N* makes expected marginal value V* equal to the private cost C. N**, the social 
optimum illustrates the negative externality of increasing resistance. SMC is equal to the social 
marginal cost which is equal to the sum of the private cost C and the negative externality from use. 
The distance of the SMC curve over the private cost C is dependent on the size of the negative 
externality. By looking at Figure 4-5, one can see the negative externality between N** and N*. 
Efforts to move AT* back to N** will represent lost welfare experienced by the individual. Possible 
methods to limit the size of this externality and motivate the individual to use antibiotics more 
carefully might include a tax on antibiotics, a subsidy for not using antibiotics, or an educational 
programme for individuals as an attempt to improve health so that overall demand for antibiotics will 
decrease in the long run. Nevertheless, each of these have their associated costs.
4-2:3b Unrecognised Costs
Aside from these costs, according to Phelps, an unrecognised cost arises from the fact that 
resistance in the individual can last for years after the initial antibiotic use. Such latent resistance may 
not affect the individual or society until many years later. This time period is represented by T years. 
Therefore, if resistance lasts for T years, in year one, the unrecognised costs are represented by
= AV, [dP, /<W,]/(l + r)'
Z=1
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Where
Nt = the rate of antibiotic use in year t
dPt/dN i = rate from at which drug administration in year 1 affects the probability of resistance in year t. 
r=the discount rate
These are a representation of the social costs of using antibiotics. Phelps estimates that these costs in 
the United States alone range from US $75 million and US $7.5 billion. These costs are expressed in 
the cost per single treatment and can be seen in Table 4-3.
Table 4-3: Annual Unrecognised Costs of a Single Treatment of 
Antibiotics for Given Various Rates of percentage Change in Resistance
Percent Change in Resistance Rate Due to a 1 Percent change in Antibiotic Use (US$)________
0.1 0.25 0.50 0.75 1.0
100 0.50 1.25 2.50 3.75 5.00
Loss in Expected Value of 250 1.25 3.12 6.25 9.37 12.50
Antibiotics Due to Resistance 500 2.50 6.25 12.50 18.75 25.00
750 3.75 9.37 18.75 28.15 37.50
1000 5.00 12.50 25.00 37.50 50.00
Source: Phelps, 1989
4-2:4 Comparative Costs Between Resistant and Susceptible Infections
According to Phelps, the size of the negative externality from antibiotic use is dependent on the 
pattern of use. This refers to the type of antibiotic that is used, the patients chosen for treatment and 
the disease that it is used to treat. Costs might encompass just the substitution of the ineffective 
antibiotic for one that the bacterial infection is susceptible. Unfortunately, the antibiotic substituted is 
usually more expensive than the initial choice. Vancomycin, a last line drug used to treat life- 
threatening resistant staphylococcal infections proves to be more toxic and more expensive than other 
antibiotics that treat susceptible staphyloccal infections. For instance, Phelps claims that tobramycin is 
ten times the cost of gentamicin, and hence, gentamicin becomes the first choice for treating 
susceptible infections. Certainly, if drugs are the only cost incurred in resistance, the difference in the 
costs between these two drugs is AV. In such cases it is obvious that a health facility is going to rely 
on the cheapest drug to which an infection is susceptible. However, when this drug is no longer 
effective, the facility must find an alternative drug which usually proves to be more expensive.
Costs from resistance can be quite high and are determined by several factors. These factors 
include the increase in death rates from infection, the failure to cure an infection, extra hospital days, 
increased doctor and nurse time, surgical procedures, the cost of more expensive antibiotics (both for 
society and the individual), spread of the resistant infection to other individuals in the environment and
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indirect costs of lost productivity from extra hospital stay and extra time spent with a debilitating 
infection. Holmberg, Solomon and Blake (1987) estimate from CDC data on resistant nosocomial 
infections, that the hospital stay for resistant infections is invariably at least twice as long as 
susceptible infections. Hence, an extra hidden cost to hospital treatment can manifest itself in resistant 
nosocomial infections. Resistant infections have the tendency to proliferate in health care 
environments and often manifest themselves in nosocomial infections (nosocomial infections are not 
always resistant, as some writers believe, but refer to infections that develop in a hospital or health care 
facility).
All of these costs are primarily a result of the intensity of use of an antibiotic. Nevertheless, 
antibiotics are undeniably one of the most effective treatments known to man. Until the costs of 
resistance outweigh the benefits of greater cures, antibiotics will continue to be used, and therefore, 
resistance will continue as an effect of antibiotic use. Supporting this, Liss and Batchelor (1987) 
estimate that the overall incidence of mortality from both antibiotic resistant and antibiotic susceptible 
infections appropriately treated with antibiotics is low. They further observe that benefits from 
treatment outweigh any social cost, including resistance. However, in the case of the inappropriate use 
of antibiotics, the ensuing resistance is altogether unnecessary. Just monitoring this use in 
industrialised countries is not sufficient: inevitably, the resistance that occurs in developing countries 
has a strong impact on industrialised countries. Sherrard and Forsyth (1994) found that 30% of 
isolates of N. gonorrhoeae from epidemiological and microbiological laboratory data confirmed that 
infections between 1983-1992 originated in the Philippines. The authors observed that although the 
first cases of resistance that were observed came from the Philippines, resistance in gonorrhoea was 
now endemic to Australia.
If resistance should indeed prove to be a real problem in the treatment of many diseases, it is 
possible that the cost of automatically using a combination of antibiotics to treat a disease may prove 
less costly than the subsequent resistance arising from therapy with only one drug. Nevertheless, new 
antimicrobial agents are likely to be less costly than antibiotic combinations (Neu, 1985). The problem 
is that the development of new antibiotics has diminished.
4-2:5 Summary of Section 4-2
The inappropriate use of antibiotics is closely linked to the growth of needless resistance. The 
current growth rate of resistance is certainly alarming, especially in cases of VRE and penicillin 
resistant Streptococcus pneumoniae, which are responsible for significant morbidity and mortality. 
With each individual consumption of antibiotics, there enlarges an already existing negative externality 
of antibiotic use, as delineated by Phelps (1989). This negative externality has its associated economic
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costs. The cost of treating resistant infections far outweighs the treatment of susceptible infections and 
therefore great savings could be achieved by limiting these resistant infections.
Ill
Section 4-3
the Problem in developing Countries
This section illustrates the specific problems of antibiotic resistance in developing countries. It 
shows the free availability of antibiotics to an individual, problems contributing to their inappropriate 
use and the incidence of antibiotic resistance of various diseases in developing countries. Possible 
strategies to specifically control and improve the usage of antibiotics are then presented. The problems 
contributing to antibiotic resistant diseases will be later applied to tuberculosis along with many of the 
mentioned strategies for decreasing resistance.
One of the areas with the largest incidence of antibiotic resistance is developing countries. This 
can be attributed to the free availability of antibiotics and the lack of their regulation. In most 
developing countries, it is possible to walk into a pharmacy and buy most reasonably priced 
antibiotics. Also, there is a lucrative black market trade in drugs, thus increasing their availability. In 
such an environment where antibiotics are so freely accessible, their frequent and unnecessary use is 
inevitably leading to a greater incidence of resistant infections. This is accentuated by the lack of 
education and the lack of funds available for health care which in turn results in individuals taking 
antibiotics indiscriminately to 'cure' problems such as a headache or sexual impotence (Kunin et al., 
1987, Ferguson, 1988, Medawar, 1976, Kapil, 1988, Lansang etal., 1990).
Resistant manifestations of bacterial diseases render these diseases more difficult to treat, 
necessitating longer treatment and less success. More time and resources have to be spent treating 
these diseases in place of other health care needs. Following this, antibiotic resistant diseases 
financially drain these countries' already strained health budgets, making available health care all the 
more feeble. In developing countries, resistant infections incur the cost of the initial antibiotic(s) used 
before resistance was detected, the cost of newer more expensive antibiotics subsequently needed and 
the extra cost of treatment in terms of hospital resources and doctor, nurse and patient time.
A further problem causing resistant strains in developing countries is the ineffective use of 
antibiotics to treat a disease. In both clinical situations, often the wrong antibiotic or antibiotic 
combination, such as a broad spectrum or an antiquated antibiotic, is used to treat many infections to 
which they are ineffective. This less than ideal use can be dictated by cost constraints or misguided 
choices. In some situations, greater resource drain and extra time and misery could be averted through 
the use of a slightly more expensive but more cost-effective antibiotic.
112
4-3:1 Unconstrained Availability
As previously discussed in Chapter 3, like other drugs, many antibiotics can be bought on the 
street or in pharmacies by any individual who has the means to pay for them in developing countries. 
In Thailand, the APUA Newsletter (1990) observed that 75% of antimicrobials are purchased through 
non-institutional channels: 50-60% through drug stores and 15-25% through clinics in the private 
sector. Lansang et al.y found that of 1608 antibiotic transactions, 66.3% were made without a 
prescription. These were most commonly for respiratory tract infections (20.2%), tuberculosis (8.8%), 
'prophylaxis' (8.6%) and gastrointestinal infections (8.3%). In addition, the therapeutic dosage period 
was in question as nearly 90% of purchases were for 10 or fewer pills or capsules. Obaseiki-Ebor, 
Akerele and Ebea (1987) in Nigeria discovered that of 500 patients, 73% consumed antibiotics before 
seeking the care of a doctor. Of those antibiotics purchased, ampicillin was used in 80% of cases, 
succeeded by tetracycline (60%), co-trimoxazole (40%), chloramphenicol (35%), oxytetracycline 
(30%), dihydrosteptomycin (30%), spectinomycin, (20%) and erythromycin (10%) (Often more than 
one antibiotic is purchased). This availability is not just taken advantage by residents of developing 
countries, those in industrialised countries also rely on self-medication obtained in developing 
countries. In Ciudad Juarez, Mexico, Solis (1993) reports that hundreds of Americans cross the border 
from Texas to purchase prescription drugs in pharmacies. Here the lure to individuals is that they can 
buy Mexican drugs unrestrained for a fifth of the cost of pharmaceuticals in the US. 25% of 800 El 
Paso residents questioned admitted to buying drugs in Ciudad Juarez. Individuals who are displeased 
that they have not received an antibiotic from an American doctor will cross the border and buy them. 
For example, in one instance, after receiving aspirin for her feverish 4 year old daughter, a woman 
rushed her daughter over the border to buy a US $2 package of ampicillin.
4-3:2 Myths Perpetuating Inappropriate Use
The incorrect belief that antibiotics are a miracle cure for most illness perpetuates. Many times 
as a result of this belief, compounded with the inappropriate marketing of antibiotics, antibiotics are 
consumed for the wrong reasons. Haak and Hardon (1988) observed in Africa that a common feature 
of antibiotic drug therapy is for a patient who has previously had a successful cure from an antibiotic to 
ask for more of it as a preventative measure against future illnesses. Burghhart (1988) found in India 
that penicillin was used by ayurvedic healers in a myriad of strange capacities. Similarly, 
Higginbotham and Streiner (1991) observe in one study that no matter what the illness, individuals will 
purchase an antibiotic due to these drugs' effectiveness in previous illnesses. In Upper Volta, the 
antibiotic-containing substance tupaye can be found in markets all over the country. 'Tupaye' is a term
113
meaning 'it heals everything' and is used for treating all ailments from toothache and backache to 
malaria (Cannon, 1995).
4-3:2a Diarrhoea
This widespread inappropriate use of antibiotics is most acutely felt in the case of diarrhoea. 
Although many antibiotic medicines are available for this condition, the best recommended treatment 
with it is ORS. The following quote captures this.
As the boat drew in to the shore we heard a strange sound from the bank. A woman was crying. We found 
her with a dead baby in her arms, and a collection of medicine bottles beside here. She had spent all her 
money on these expensive drugs. She could not understand why they had not saved her baby. This 
Bangladeshi woman had never been told what was obvious to the doctor that found her. The baby had 
become severely dehydrated with diarrhoea. Her death could have been prevented with a simple home­
made solution of water, salt and sugar. No amount of medicine could have kept her alive. (Melrose, 1982).
Today diarrhoea is a disease that is the largest killer of children under three in the world (Cannon, 
1995). Where ORS is the accepted treatment, antibiotic-containing medicines still proliferate. There 
is the psychological view in consumers that if a medicine contains an antibiotic, it must somehow be 
better. These antibiotics are not just harmful because they stop the use of ORS, but they can contain 
dangerous antibiotics. Indeed, this is not an uncommon phenomena and antidiorrhoeal preparations 
are more likely to resemble 'antibiotic cocktails' with combinations, for instance, of chloramphenicol 
and streptomycin (Srinivasan, 1988). Supporting this, in the 1980s, Health Action International (HAI) 
found that one in four antidioarrhoeals in Pakistan and India contained streptomycin, one in three in 
the Philippines contained sulphonamides, one in four in Africa contained neomycin (an antibiotic 
associated with the risk of deafness and serious intestinal problems) and surprisingly, one in ten in 
India contained chloramphenicol (Cannon, 1995). Chloramphenicol is especially dangerous, 
nevertheless, it has remained a popular drug in some developing countries, especially India. 
Greenhalgh (1986), in a study of 2 400 patients' medical consultations in India, found that 
chloramphenicol amounted to 11% of all prescriptions and was the most common antibiotic bought 
without a prescription.
4-3:2b Cultural Attitudes Towards Antibiotics in Developing Countries
Kunin et al. (1987) summarise cultural attitudes towards antibiotics maintaining that poor 
antibiotic use is propagated by several beliefs: (1) there is a 'pill for every ill' (2) antibiotics are 
'wonder drugs' and can cure a myriad of ailments (3) the effectiveness of a drug is related to how fast is 
works (4) antibiotics cure illnesses more quickly than other drugs with fewer complications (common 
belief of clinicians as well as the patient) (5) injections are more potent and effective than pills or 
liquids.
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4-3:2c Antibiotic Marketing
The marketing of drugs can perpetuate the popularity of antibiotics. For instance, Osifo (1983) 
observed that a Nigerian affiliate of Burroughs-Wellcome had five more indications and fewer adverse 
reactions and warnings on its product package inserts for Bactrim than was observed in the Physician's 
Desk Reference (PDR, 1992). The Thamlikitkul (1990) reported that in the Thailand Index of Medical 
Specialities July 1988 issue, antibiotics were incorrectly recommended for ten different indications as 
seen in Table 4-4.
Table 4-4: Inappropriate Indications for Antibiotics 
Appearing in the Thailand Index of Medical Specialities, July 1988.
Indication Drugs Inappropriately Advertised
Gonococcal infection
Pharyngitis, tonsillitis
Central nervous system
S. aureus infection
Non-specific urethritis
Biliary tract, respiratory tract 
and urinary tract infection
Prophylaxis of cholera
Gentimicin, chloramphenicol, erythromycin, amoxicillin, 
penicillin V, co-trimoxazole, rifampicin
Kanamycin, chloramphenicol, cloxacillin, co-trimoxazole, 
oflaxocin
Amikacin, tetracycline, lincomycin
Penicillin V, penicillin G, ampicillin
Ampicillin, oxacillin
Rifampicin
Penicillin V
Source: APUA Newsletter, 1990
4-3:3 Sub-therapeutic Doses and Compliance
Another problem contributing to resistance occurs from patients receiving sub-therapeutic 
dosages of antibiotics. This can happen either because the patient is given too short a treatment, the 
patient does not comply with the treatment, the patient only buys a few pills and does not receive 
enough of the treatment, or the patient takes clinically unrecommended antibiotics on a regular basis as 
a prophylaxis. This kind of antibiotic use causes resistance in two ways: through selecting naturally 
resistant mutants in a bacterial population, as in the cases of some Mycobacterium diseases, or through 
selecting bacteria with resistant plasmids, as in the case of Salmonella strains. Treatment times for 
many antibiotics can differ and some must continue for long periods of time. Many patients, once they 
feel better, fail to finish their treatment. In addition, some patients can only afford to buy one or two 
pills, and therefore, manage to only kill part of their bacterial infection. Also, it is not uncommon, 
where antibiotics are freely available, for patients to take a regular dose of penicillin or tetracycline 
just to 'make sure they don't get sick' (Levy, 1992). Antibiotic prophylaxis in prostitutes in order to 
avoid cases of gonorrhoea or syphilis is also a common phenomena. This kind of prophylaxis is likely 
to have contributed to the quick growth of resistant forms of gonorrhoea.
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4-3:4 Abuse and Inappropriate Choices
Antibiotic resistance becomes especially significant when resistance develops in an infectious 
disease that only one or a few antibiotics which can treat. Chloramphenicol, usually reserved for cases 
of typhoid fever, has been inappropriately used for all kinds of infections and indications. 
Consequently, chloramphenicol resistant typhoid has developed which is difficult to treat with other 
antibiotics. Rifampicin which is reserved to treat life threatening bacterial meningitis and tuberculosis 
is another case. Rifampicin, could be considered the most powerful new antibiotic to treat tuberculosis 
and meningitis, but has been used in other indications such as urinary tract infections, gonococcal 
infections and eye infections (Thamlikitkul, 1990).
Another problem facing developing countries is the choice of antibiotics for use in treating 
infections. Often developing countries cannot afford more expensive antibiotics and therefore must 
rely on cheaper alternatives that are not necessarily as effective in curing an infection. In some cases, 
the length of antibiotic treatments and resistance are heavily correlated. For example, it is possible that 
a shorter but more effective treatment might have greater compliance, and therefore, will have less 
associated resistance. Also, if the treatment is poor or relies on a combination of older, substandard 
antibiotics for treatment, compounded by long treatment periods, resistance becomes more significant 
because it leaves fewer drugs to treat these infections. This is indeed the case for tuberculosis. 
Conversely, an extra financial burden is imposed on developing countries when sometimes more 
expensive antibiotics are used instead of cheaper, equivalent alternatives. In essence, each antibiotic 
must be carefully considered according to its ability to cure an infection, and its appropriateness in 
curing that infection in light of alternatives and its relative cost. Finding these alternatives involves the 
evaluation of each disease and treatment, which takes time, education in cost optimisation and 
patience.
4-3:5 Damaged and Poor Quality Antibiotics
Individuals who often have to take drugs that are damaged, past their sell-by date, or in poor 
supply present a further problem. Poor conditions in the transport and storage of antibiotics can allow 
them to be damaged by heat or humidity. Also, due to the poor management of drug supply, 
antibiotics are often ordered and stored for too long or they are obtained from pharmaceutical 
companies when they are too close to their expiration date. These all cause anti-infectives to be far 
less effective. In an article that appeared in the Essential Drugs Monitor (1991b), the stability of drugs 
during international transport was measured, including work on the stability of antibiotics under high 
temperatures. 11 essential drugs were sent through in three shipments by sea from the UNICEF 
warehouse in Copenhagen through Lagos and Mombassa and by land to Kampala and then to
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Bangkok. Three sea routes taken accounted for 35 (50%) of 70 countries served by UNICEF and 40% 
of all drugs dispatched in 1987. In this study, the temperature and humidity in test packs were 
measured every three hours. Temperatures on the trip varied between -3.5°C and 42.4’C with a 
relative humidity of between 20-88%. Temperatures inside of the test pack averaged 10-26% higher 
than these outside temperatures. This is far higher than the WHO set standard of 15-25°C for the 
storage of drugs. Although the three antibiotics, ampicillin, tetracycline and procain penicillin in the 
study, did not show signs of instability, the article concludes that humidities, rather than temperature 
during storage have a large impact on antibiotic de-stabilisation.
Drugs can also be of poor quality which affects their effectiveness. One of the best examples of 
this occurred in Jakarta with the sale of ampicillin. A domestic version of Beecham's ampicillin, 
Penbritin 250 was being sold in similarly marked capsules, but instead of 250 mg inside of them, they 
had been diluted to 80 mg. Where a doctor might recommend 8-10 capsules per day of the 250 mg 
version for infections, an individual buying this black market version would have had to take 25-50 
capsules per day to get the same effect. Unfortunately, this was not readily evident from looking at the 
capsule (Silverman, Lydecker, Lee, 1992).
4-3:6 The Incidence of Resistance in Developing Countries
Antibiotics are used with great intensity in developing countries. In Africa, antibiotics are the 
leading therapeutic group, accounting for as much as 35% of drug sales (SCRIP, 1995). Globally, 
antibiotics are an extremely important, cheap and effective health care intervention for treating many 
diseases. This could be said to be especially true in developing countries where malnourishment, 
poverty, poor living conditions and poor sanitation mean that more individuals in developed countries 
are susceptible to bacterial infections than those in industrialised countries. Outbreaks of antibiotic 
resistant bacterial diseases are more commonly observed in developing countries. In fact, data from 
the Association for the Prudent Use of Antibiotics (APUA) between 1983 and 1990 (Levy, 1991) show 
that incidences of new strains of resistant infections arose in developing countries approximately 60% 
more frequently than in developed countries. Although most data for this resistance are unrecorded in 
developing countries, the percentage of outbreaks per area are shown in Figure 4-6. Population, of 
course, must be taken into account when looking at this figure.
Antibiotic resistant rates are continuing to grow at an alarming rate. The impact of antibiotic 
resistance in developing countries has been very strong as shown by the following examples. As 
shown in Figure 4-7, in only three years, incidents of resistant typhoid in India have increased by more 
than Jive times.
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Figure 4-6: Areas Where Antibiotic-Resistant 
Disease Strains Originated Between 1983-1990
Middle East Central & South
Africa 3.33% America
13.33% 20%
South East 
Asia
30%
North
America
10%
6.67%
Australia
16.67%
Europe
Adapted From: Levy, 1991
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Figure 4-7: Growth of Ampicillin and 
Co-Trimoxazole Resistant Typhoid in India
Adapted from'. Sharma, Prakash and Pillai, 1985; Prakash and Pillai, 1992
Table 4-5: Prevalence of 
Resistant Gonorrhoea in Asia and Africa
Area Prevalence of Resistance (%)
Asia
Hong Kong 47.8
Republic of Korea 46
Thailand 42
Philippines 30-40
Malaysia 37.2
Singapore 33.5
Indonesia 25
Japan 16.1
Africa
Nigeria 56
Kenya 41
Ghana 36
Zambia 25.1
Central African Republic 9.1
Source: O'Brien etal., 1987
In addition, Cannon (1995) reports that of the 248 reported cases of typhoid in the UK in 1991, 50 
(20%) were resistant to chloramphenicol and the majority of these were also resistant to ampicillin and 
trimethoprim. The majority of these resistant cases had returned from Pakistan or India, where 
resistant typhoid is common and chloramphenicol is the drug of choice in its treatment (as is also the 
case in industrialised countries due to the serious nature of the disease). Ries (1991) reports of a 1991 
epidemic of 5. dysenteriae in Burundi which proved resistant to all antibiotics available in the country.
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Knapp et al. (1991) report that data from the Gonoccocal Isolate Surveillance Project show that 
between 1988 and 1990 gonorrhoea resistance to penicillin grew from 3-10% and resistance to 
tetracycline grew from 4-6%. The prevalence of penicillin resistance in Asia is reported by O'Brien et 
al. (1987). In Table 4-5, one can observe that resistant gonorrhoea in developing countries averages at 
approximately 34.6% and is at its highest (56%) in Nigeria. Matamoros et al. (1993) observe that in 
Costa Rica in 1985, gram negative bacteria were resistant to ampicillin in 68-97% of all isolates. Such 
resistance caused the Costa Rica Pharmacotherapeutics Committee to remove the most commonly used 
form of ampicillin from their formulary. Teixeira et al. (1995) found in their study in Brazil of 5 large 
teaching hospitals and 1 community hospital, 85 of 152 isolates of Staphylococcus aureaus were 
resistant to methicillin, penicillin, erythromycin, gentamicin, cephalothin, and oxacillin; and 74% of 
these 85 isolates were also resistant to chloramphenicol, sulfamethoxazole-trimethoprim, ciprofloxacin 
and clindamycin. Most of these resistant isolates were only susceptible to vancomycin.
Resistant cholera is another challenge in developing countries. Cholera is a diorrhoeal disease 
that strikes very quickly and can prove deadly. In Peru in 1992, a multi-drug resistant form of cholera 
known as 'El Tor* caused 3 000 deaths. Also in Pakistan and Bangladesh, 'Bengal' a strain resistant to 
co-trimoxazole, caused 100 000 cases and 1 500 deaths (Cannon, 1995).
4-3:7 Strategies for Developing Countries
Without a doubt, prescribing behaviour and antibiotic use can be changed. This power lies 
within the doctor and the patient. Regarding doctors, one form of educational media with the greatest 
impact is the personal visit from an antibiotic education representative. Schaffer et al., (1983) showed 
in Tennessee that an informational campaign to physicians with a poor history of antibiotic 
prescribing, reduced antibiotic prescribing by 18% in the number of doctors, 44% in patients per 
doctor and 54% in the number of prescriptions per doctor. Reaching patients is more complicated and 
is likely to be more expensive. Industrialised countries remedy this problem by simply making 
antibiotics unavailable to the patient unless obtained through a prescribing agent. However, until 
developing countries limit the availability of antibiotics, antibiotic misuse will persist. Imperfect as 
this situation appears, individuals can still be educated. Education of pharmacists is a very important 
step to educating patients on proper utilisation, because this is commonly the point of purchase of 
antibiotics. Other education is difficult because many patients in developing countries cannot afford 
magazines, newspapers or television. A search for each country must be made to find whatever 
informational media to which a patient is exposed. This might range from billboards to educational 
posters in bars and other areas of social gathering.
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It is clear that developing countries need a more effective strategy for the management of 
antibiotics. This strategy includes the following components: (1) greater regulation to control 
antibiotic administration and to restrict black market availability on the street (2) better drug transport 
to decrease the incidence of expiration and assure their arrival in the places they are most needed (3) 
more secure drug storage to eliminate drug theft (4) closer governmental inspection of the antibiotics 
purchased internationally to ensure that products are not likely to be beyond their expiration date when 
a patient receives them (5) more careful government policy for the purchasing of drugs to be sure that 
what is actually ordered is what is actually needed, thus eliminating some of the large stores of 
unnecessary drugs that sit unused (Foster, 1993) (6) quality control of the antibiotics produced 
domestically to ensure that those available meet international standards of antibiotic quality (7) closer 
analysis of each treatment regimen for each disease to secure the implementation of the most effective 
and efficient treatment and (8) better education for doctors, pharmacists and patients both so that 
doctors and pharmacists are more aware of the correct antibiotic to give for each condition, and so that 
patients know to complete their entire treatment as well as not rely on antibiotics for inappropriate 
purposes.
4-3:7a Influencing Doctor Prescribing Behaviour
In the case of doctor intervention (8 above), there are several approaches that can be taken
toward changing prescribing practices. Avorn et al. (1987) gives a precise breakdown of the types of 
influence that can be used to change prescribing practices (reproduced in Figure 4-8). Here, influence 
is separated into three distinct strategies: re-educative and persuasive strategies, facilitative strategies 
and power strategies. Re-educative and persuasive strategies attempt to influence the doctor through 
education with media with lectures, drug information cards, audits on prescribing behaviour and 
guidelines. As mentioned earlier, this approach has been somewhat successful in Australia. 
Facilitative strategies involve specifically targeting drug programmes, diseases and patient populations 
using specialists in this area to, for instance, test for resistance or estimate the likelihood of resistance. 
Power strategies refer to enforced restriction. This involves the use of formularies such as essential 
drugs, control of drug representatives and marketing and special approval for various antibiotics. All 
these approaches should prove effective and any country that attempts to improve its antibiotic use 
should try to implement as many of these strategies that are within its means.
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Figure 4-8: Strategies for Changing Prescribing Practices
Re-educative and Persuasive Strategies 
Staff conference
Lectures by recognised authorities 
Drug information bulletins 
Feedback of prescribing data (audits)
Audio-visual programs 
Independent printed drug information 
Guidelines (requires feedback loop)
Laboratory sensitivity tests
Restriction of reports on selected agents unless requested, Information feedback to guide 
drug selection
Facilitative Strategies
Clinical-specialist consultations
Clinical microbiologists, Clinical pharmacists 
Joint specialist programs with clinical microbiologists/pharmacists co-operation 
Target drug programs
Target diseases and target patient programs 
Power Strategies
Control of contact between pharmaceutical representatives and prescribes
Registration in hospital, Appointments, Entry into patient-care areas, Displays,
Samples/gifts
Sponsoring, Advertisements, Literature,
Formularies
Effective Drug and Therapeutic Committee, Generic prescribing (encourage bid 
purchasing), Exclusion of inferior or marginal products, Limit therapeutic duplicates,
Review of new drugs via comparative drug monographs, Require written justification
for additional requests 
Restriction on use
Approval of specialists for controlled agents, Approval of Drug and Therapeutic 
Committee recommendations, Written justifications before dispensing (review these at a 
later date), Satisfaction of criteria for use, Automatic stop orders, Require consultations 
after first doses of certain drugs
Source1. Avorn et al., 1987
4-3:7b Levels of Antibiotic Regulation Enforcement
Although the above strategies are ideal in industrialised countries, they must be evaluated
according to the means of a developing country. Each country has its own system of antibiotic 
regulation enforcement. As shown in Table 4-6, Simon, Folb and Rocha (1987) classify these 
according to major categories: complete, partial, minimal, and none. Countries such as the United 
States where drug regulation is quite stringent will undoubtedly come under the category of complete 
antibiotic regulation enforcement. Countries such as Brazil and Mexico will fall in the category of 
minimal regulation. Nevertheless, the majority of low income countries, such as Bangladesh and 
Ethiopia, are more likely to fall in the enforcement category of 'none'. These categories dictate the 
environement to which antibiotic measures must be adapted. Although it would be ideal to change the 
very infrastructure of drug distribution and enforcement, this is unrealistic in the short run. Those 
countries that have a very poor enforcement of drug regulations, must work within their means to 
educate doctors and patients on the dangers and proper use of antibiotics. Highly elaborate monetary
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intensive antibiotic prescribing behaviour schemes are a lure for developing countries but will prove 
useless under their limited drug delivery systems.
Table 4-6: Application in Practice and 
Enforcement of Compliance with Regulations
Complete Tightly controlled availability; regulations rigorously enforced
Partial Incomplete enforcement of controls associated with limited
availability of antibiotics to the public for other reasons, such 
as economics and/or logistic factors
Minimal Incomplete enforcement of controls associated with
widespread availability of antibiotics as a result of failure to 
apply regulations in practice and absence of other constraining 
factors
None No restrictive legislation; widespread availability
Source; Simon, Folb and Rocha, 1987
Certainly, a complete list of these changes might seem expensive, but many are not outside the 
financial realm of most developing countries. Angunawela, Diwan and Tomson (1991) in a study of 
15 outpatient health care institutions in Sri Lanka, found that those in a control group that did not 
receive any information on correct prescribing of antibiotics wrote more prescriptions for antibiotics 
than a group that received information on correct prescribing. Information for prescribing emphasised 
the use of penicillin for common infections, contraindications of tetracycline for children and the 
improper use of antibiotics for viral infections. Each attempt to change antibiotic utilisation requires 
that there be a little more care in the handling of antibiotics. Although this may seem a little more 
costly, the benefits in terms of fewer antibiotic resistant infections, lower morbidity and mortality, 
reduced drug costs, averted treatment costs and reduced adverse side effects would outweigh the costs 
of these reforms in absolute terms.
4-3:8 Summary of Section 4-3
Developing countries have a poor system of antibiotic regulation. This is compounded by 
perpetuated myths of exaggerated antibiotic effectiveness and damaged and poor quality antibiotics 
rendering the consumption of antibiotics in sub-therapeutic doses. The effects of this improper use of 
antibiotics has been such that there is a higher incidence of resistance in developing countries. Such 
higher incidence has had a great impact. Resistance in already health constrained developing countries 
is responsible for morbidity and mortality and the high monetary costs of treating this. Indeed, it is 
possible to improve antibiotic utilisation in developing countries, but it is considerably complicated by 
the drug distribution infrastructure. Unless a concerted effort is made to improve drug use, 
inappropriate consumption and resistance will continue.
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Section 4-4
Conclusion to Chapter Four
Antibiotics are a valuable form of treatment, and undoubtedly, the most effective treatment for a 
myriad of infections. However, this effectiveness is threatened by resistance. Resistance has caused 
once inexpensively cured illnesses to be difficult or impossible to treat in some cases. In some cases, 
inexpensive antibiotics have become obsolete, and therefore, more expensive antibiotics are needed 
which often are not available or cannot be afforded. The use of antibiotics perpetuates an unavoidable 
negative externality of resistance. However, this resistance can be somewhat attenuated if care is taken 
to use antibiotics only when they are absolutely necessary. Indeed, the problem is even more 
accentuated in developing countries. Here resistance is rampant due to more inappropriate use of 
antibiotics and poor systems for their regulation. Antibiotics must be carefully evaluated for each 
disease according to their economic costs, their effectiveness and their role in curing other diseases. 
Needless resistance is likely to continue in developing and industrialised countries unless measures are 
taken to rationalise antibiotic use. Should antibiotic resistance continue, it could have potentially 
serious consequences for future generations. Some bacterial diseases can develop resistance to all 
known effective antibiotics leaving only surgery or unproven and dangerous drugs for treatment. This 
is serious when the disease is infectious and deadly. Tuberculosis is one of these diseases and because 
of sustantial levels of natural mutation on the part of the bacteria, tuberculosis resistance easily occurs. 
In addition, unlike some bacterial resistance, this is almost entirely due to inappropriate usage of 
tuberculosis antibiotics, as shown in the next chapter.
124
CHAPTER FIVE 
TUBERCULOSIS
"At the midpoint of the 20th century, tuberculosis was recognised by all as the "White Plague", undeniably the 
most dreaded enemy of the human race by any measure. Whether measured by prevalence, cost, social 
consequences, sheer misery or any yardstick, I believe that any observer of the time would consider the bacillus 
of tuberculosis as the enemy number one of the human race. None of us - myself included - believed that its 
control could be attained by medical means within this 20th century." (H. Corwin Hinshaw from Ryan, 1992: p. 
49)."
"Tuberculosis is still a leading contender for the dubious distinction of being the most important plague of 
mankind. (Comstock and Cauthen, 1993)."
"The captain of all these men of death that came against him to take him away, was the Consumption, for it was 
that that brought him down to the grave." John Bunyan, The Life and Death of Mr. Badtnan
In order to find the impact of resistance on the cost of tuberculosis, those elements specific to the 
treatment of tuberculosis must be described. This chapter traces the trends of tuberculosis infection, 
the nature of the disease and the difficulty in meeting the challenge presented by drug resistance and 
HIV combined with TB. In addition, this chapter is intended to give a comprehensive background to 
the reader so that he or she will be equipped with an understanding of the complex problems arising in 
TB treatment. Section 5-1 will begin with an overview of tuberculosis including its history, diagnosis, 
etiological epidemiology, treatment, resistance and the impact of HIV. In Section 5-2, current 
techniques of controlling tuberculosis will be presented including areas for potential improvement. 
The effectiveness of tuberculosis control will be illustrated in Section 5-3, highlighting the current 
global impact of tuberculosis and its changing nature.
Introduction
On the 21st of January, 1992, the Evening Standard in London ran the headline "HOSPITAL 
WARNING AS LETHAL SUPERGERM SPREADS". At this time at least a dozen people were 
wandering the streets of London with infectious tuberculosis (TB) that could not be treated by any 
antibiotic (Ryan, 1992). Tuberculosis which was thought by many as a plague of the past once again
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was making news. People became aware of the disease along with what many erroneously feared a 
different 'super-strain' of tuberculosis resulting in widespread alarm. Certainly, tuberculosis is still a 
dangerous infectious disease. Because it is observed less in industrialised countries than in developing 
countries, its danger to mankind is not highlighted the way are diseases such as AIDS and heart 
disease. Nevertheless, it still causes large-scale devastation in developing countries. Its pathogenicity, 
which is often ignored, should never be underestimated. Indeed, in 1990, tuberculosis killed 2.9 
million people, making it the largest cause of death from a single pathogen in the world (Murray et al.,
1991).
'White Plague', 'consumption', 'pulmonary phthisis', 'The Captain of all Men of Death': since 
the evolution of man, tuberculosis has been at his or her side, at times taking a startling 20% of lives in 
cities (Dubos & Dubos, 1987). In the last two hundred years, tuberculosis has claimed the lives of 
approximately a billion people (Ryan, 1992). Nevertheless, with modem antibiotics it was thought 
that the battle against this disease was won and it would only be a matter of time before tuberculosis 
was completely eradicated. It seemed that this prediction would manifest itself as the incidence of the 
disease fell continuously, starting in the 1950's. This made observed cases of tuberculosis more and 
more rare. However, this decrease in tuberculosis, quite surprisingly, came to an end when in 1978 its 
infection rate strangely began to rise. At first, clinicians could find no apparent reason why 
tuberculosis was on the rise, but they soon were able to link it to HIV (Human Immunodeficiency 
Virus), responsible for Acquired Immune Deficiency Syndrome (AIDS). It is no coincidence that as 
the incidence of AIDS increased in the late 1970s, so did the incidence of tuberculosis. However, 
difficulty in identifying the HIV virus, which was practically invisible until the early eighties, 
convoluted efforts to explain the rise in TB. Only time has revealed that the synergistic effects of the 
combination of these two diseases has proven deadly. In addition to this is the growing problem of the 
rise of multi-drug resistant tuberculosis, such that there is a growing percentage of cases that are 
failing to respond to conventional chemotherapy. Globally, tuberculosis remains as the leading cause 
of deaths in adults by an infectious disease (World Bank, 1993). In 1990, approximately a third of the 
world's population was infected with tuberculosis. Furthermore, of the 2.9 million people throughout 
the world that died from it in 1990, 40 000 of those deaths came from industrialised countries, leaving 
a staggering 2.86 million deaths from developing nations (Ryan, 1992). In this decade, it is predicted 
that 90 million new cases of tuberculosis will be diagnosed and 30 million will die from the disease 
(FDA Online Reports, 1995). This is especially significant because tuberculosis is a curable disease.
Efforts to reduce the incidence of tuberculosis have been effective in the past, but the AIDS virus 
presents a new challenge in treating tuberculosis, therefore representing a new era for this disease. Of 
all diseases globally, tuberculosis is the most opportunistic infection which will be strengthened by the
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increasing prevalence of HP/. HIV patients essentially represent a pool for the TB virus to continue to 
thrive and move from individual to individual.
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Section 5-1
The Nature of Tuberculosis
This section will give a description of tuberculosis, the likelihood of developing the disease, its 
diagnosis, history and treatment. Also, other problems complicating treatment and increasing its 
growth such as anti-TB drug resistance and HIV will be presented. This material introduces 
significant variables that will be later discussed in the context of the impact of TB resistance on the 
cost of TB treatment in developing countries.
5-1:1 The History of Tuberculosis
Until a cure was found, tuberculosis was a disease that as a killer did not discriminate between 
the old, the very young, the very rich or the very poor. Many well known people through history such 
as John Keats, David Herbert Lawrence, George Orwell, Emily Bronte, Frederic Chopin and Vivien 
Leigh were taken away in the prime of their career by tuberculosis. Indeed, signs of tuberculosis have 
been observed in human remains dating as far back as 8 000 BC (Ayvazian, 1993). Evidence from the 
mummies of ancient Egypt suggest that tuberculosis was a common disease as far back as 4 000 BC, 
when it proved to be a disease that thrived in the close quarters of the first ancient cities (Ryan, 1992). 
Tuberculosis has a striking capacity to mutate and it is believed that all the different strains of 
tuberculosis came from one common parent. Different strains of tuberculosis affect birds and small 
reptiles and many mammals such as elephants and cattle. For example, transmission of phthisis, a 
bovine strain of tuberculosis, was such a deadly disease for cattle that from the middle ages to the 
eighteenth century, it was responsible for large recorded periods of famine (Ayvazian, 1993). Bovine 
tuberculosis, Mycobacterium bovis, is also significant because ingesting milk from infected cattle is 
one way that humans develop tuberculosis (Snider, 1994).
Until adequate treatment was developed, the more urbanised civilisation became, the more 
tuberculosis was able to spread. At the turn of the nineteenth century, 7 million people per year were 
dying from tuberculosis and 50 million had the disease with one half of the population infected (Ryan,
1992). Yet, even late in this century, all that was really known about the disease was that animals 
could be infected with it from human tissue. It was not until 1882, when Robert Koch developed a 
staining technique to isolate and identify tuberculosis, that significant progress in treating the disease 
began. After this discovery, several chemicals were discovered that could safely destroy tubercle 
bacteria without damaging its human host. In 1935, the drug prontosil was used in the treatment of 
tuberculosis and soon after, in 1944 there was the discovery of para-amino salt of aspirin (PAS). The 
most important progress, however, was made with the discovery of streptococcus in 1944. This
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completely changed the nature of the threat of tuberculosis due to its increased effectiveness over 
previous treatments. After this, came the discovery of isoniazid in 1952 and rifampicin and 
pyrazinamide in 1963 and ethambutol in 1967 (Ryan, 1992). Triple therapy with three of these drugs 
revolutionised the treatment of tuberculosis and is still the main approach to chemotherapy for 
tuberculosis today.
5-1:2 Defining Tuberculosis
Tuberculosis (TB) is an infectious disease predominately caused by the bacterium 
Mycobacterium tuberculosis. It infects the individual by entering the body through the lungs where it 
can multiply and manifest itself as pulmonary tuberculosis in 80% of cases, and extra-pulmonary 
tuberculosis (tuberculosis that attacks organs outside of the lungs) in 20% of cases. Tuberculosis can 
attack any part of the body, but pulmonary tuberculosis is the only type of contagious tuberculosis, and 
hence, its treatment is a pinnacle element in the containment of the disease.
The spread of tuberculosis commences with the coughing, sneezing or laughing of an infectious 
patient. This activity produces small particles or droplets containing the tuberculosis micro-organisms 
which can remain floating in the air for many hours. After this, individuals entering the air around an 
infectious patient can inhale these droplets which may enter their lungs and multiply causing these 
contacts to be infected. Logically, the greater contact one has with an infectious tuberculosis person, 
the more it is likely that he or she will become infected. Those that become infected are referred to as 
positive tuberculin reactors in reference to the protein purified derivative (PPD) skin test or the 
Mantoux skin test, used to identify those infected with tuberculosis. It should be noted that there is a 
distinction between infection and disease: those that become infected may not necessarily develop 
tuberculosis. In fact, only ten to 20% of those infected will ever develop the disease, the other eighty 
to 90% will carry dormant tubercle bacilli for the rest of their lives.
5-1:2a PPD and the Mantoux Tests
The existence of tuberculosis infection is usually established by a tuberculin skin test such as the 
previously mentioned PPD or Mantoux test. The patient's forearm is scratched, punctured or injected 
in the skin, intracutaneously, with dead tuberculin bacteria. This test is effective approximately three 
weeks after initial contact with an infectious case. After this period, individuals that have been 
infected with tuberculosis should have developed some sort of immune response to it so that they will 
have antibodies that will react to the dead tuberculin. Such reactions are characterised by redness of 
the skin but more accurately by induration (hardness of the skin) at the point of the test. Indurations 
are measured 48-72 hours after the test to observe a reaction. Those who are extremely likely to have
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been exposed to tuberculosis, or are HIV positive, are considered positive at greater or equal to 5 
millimetres induration Those at a moderate risk are considered positive at greater or equal to 10 
millimetres induration. Finally, those who are tested and are perceived to be at no risk are considered 
positive only at greater or equal to 15 millimetres induration (Bass, 1993). These tests can give a 
false-negative result if the patient has extremely acute tuberculosis, immunosuppression, viral 
infections, live virus vaccination including Bacille Calmette-Guerin (BCG) vaccines, renal failure or 
malnutrition. Also, false-negatives can be the result of improper storage, improper dilution, delayed 
injection after a syringe is filled, subcutaneous injection, and improper or biased interpretation (Bass,
1993). Such tests only establish proof of infection with tuberculosis and are not guarantees of the 
presence of the disease, nor can they determine with which strain of Mycobacteria an individual has 
been infected. Nevertheless, it is a useful tool in the sense that a negative test could be used as a 
possible diagnostic determinant in ruling out tuberculosis once the likelihood of false-negatives has 
been ascertained. If a response to a test can be established in an HIV-seropositive patient such 
evidence becomes more significant due to the immunocompromised state of the individual.
5-1:3 Diagnosis
Tuberculosis is suspected when a patient experiences a continuous cough that lasts for more than 
three weeks, chest pain, shortness of breath, sputum production and sputum with blood in it, fatigue, 
night sweats, fever, malaise and loss of appetite. Most patients are symptomatic but pinpointing the 
cause of these symptoms, is sometimes difficult in the case of extra-pulmonary tuberculosis.
5-1:3a Smear Microscopy and Culture
At this point in diagnosis, a technique known as smear microscopy is commonly used. If a 
patient is suspected of pulmonary tuberculosis, the nature of his or her sputum can determine 
infectious cases of tuberculosis. Also of significance is the amount of sputum that a patient is able to 
produce, since this can be an indication of the severity of the tuberculosis. Those patients that fail to 
bring up sputum can have this induced either by inhaling saline mist or with a bronchoscopy. Once 
sputum is obtained from a suspected tuberculosis patient, it is smeared on a slide, stained using the 
Ziehl-Neelsen method, and then examined under a microscope. This process serves to determine if the 
sample contains acid-fast bacilli (AFB) which suggest tuberculosis micro-organisms. If these micro­
organisms are detected, the patient is said to be smear-positive, otherwise, the patient is suspected to 
be smear-negative, meaning that tuberculosis disease could be present, but may be in its early stages. 
Although smear-positive tuberculosis is the most infectious form of tuberculosis, smear-negative 
tuberculosis can sometimes be infectious.
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This AFB technique of detecting smear-positive tuberculosis is problematic because a positive 
smear does not mean that it is necessarily Mycobacterium tuberculosis. It could indeed be another 
kind of Mycobacterium such as Mycobacterium avium. The likelihood of such false results is 
dependent on the population being tested. Infection with Mycobacterium avium is specific to 
advanced cases of HTV and is commonly observed in industrialised countries. Hence, results from a 
population with a high incidence of advanced AIDS should be carefully evaluated. In summary, 
despite its potential to be misleading, this technique is one of the most widely used methods of 
detecting tuberculosis in patients. In a developing country, having limited funds, this technique of 
smear microscopy is often the only available form for tuberculosis diagnosis.
The culture of M. tuberculosis is considered to be one of the best ways to diagnose tuberculosis. 
This technique is very effective and sensitive, only suffering because it is a very slow process due to 
the slow-growing nature of the bacteria. Faster results can be obtained from using radiometric 
machines such as the BACTEC (Becton Dickinson, Towson, MD) machine. Such machines operate 
by detecting the release of gas during growth before any visible growth occurs (Watt, Rayner and 
Harris, 1993). Also, the use of this machine with inhibition tests allows M. tuberculosis to be 
distinguished from other Mycobacteria (Glassroth, 1993). In addition they have the advantage that 
almost any specimen can be cultured and after it is cultured, it can be tested for sensitivity to various 
drugs. Certainly, these machines can decrease the time in identifying M. tuberculosis to little more 
than a week, but such machines are often beyond the means of most labs.
5-1:3b Chest Radiographs and Fluid Analysis
Chest x-rays are a less expensive alternative to cultures, but many problems may be encountered 
when using this method since the x-rays can be difficult to read, even by competent doctors. 
Nevertheless, some erroneously recommend them over other diagnostic techniques in TB diagnosis 
(Rossman & Mayock, 1993). There is no chest radiographic picture that is particular to tuberculosis, 
which will isolate it from the chest x-rays of other diseases. Some chest radiographic patterns are 
considered suggestive of tuberculosis but they are by no means definite. Before HIV, up to one third 
of all chest radiographs were considered atypical and this has grown in the HIV era (Khan et al., 
1977). AIDS patients have exhibited as many as 59% atypical chest x-rays (Pitchenik and Robinson, 
1985). Indeed, Glassroth maintains that, "Among HTV-co-infected persons, virtually any radiographic 
presentation my be encountered, including a 'normal film.' (Glassroth, 1993: p. 152). With this 
discussion, it should also be noted that less common media such as computer tomography, ultrasound 
and magnetic response imaging, are also used, but their ability to provide conclusive diagnostic 
information is equally limited.
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Other methods of detecting the presence of tuberculosis include looking at other body fluids and 
secretions. Blood changes such as the deficiency in blood cells (cytopenias) or an excess of 
lymphocytes (products of the lymphoid tissue that function in the immune system) in isolated areas, 
abnormal levels in serum calcium, and intravascular coagulation (the formation of clots in the blood 
vessels) are all symptoms of tuberculosis. Urine samples also can show signs of tuberculosis in 20% 
of all cases. Likewise, signatures of tuberculosis can be found in changes in pleural (lung and thoracic 
cavity linings), peritoneal (membrane lining the walls of the abdomen and pelvic cavities) and 
cerebrospinal joint fluids (Glassroth, 1993). In HIV patients, where the diagnosis of tuberculosis 
proves very difficult due to anergy in skin tests, non-definitive chest radiographs and smear-negative 
sputum, such analyses of blood and fluids are an important diagnostic process. A final and somewhat 
inefficient method of diagnosis is through trial and error with treatment. Since tuberculosis is 
perceived to be quite a substantial social health threat, a lack of definite diagnostic signs of the disease 
should not necessarily deny a patient treatment. Sometimes it is only through a perceived response to 
treatment that a definite diagnosis of tuberculosis can be maintained.
Figure 5-1: The Progression of Tuberculosis After Exposure
Source'. Hopewell, 1993
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5-1:4 Etiological Epidemiology of Tuberculosis
The etiological epidemiology of tuberculosis is defined as the study of the causing and 
influencing factors of the disease. It answers the questions governing the likelihood of becoming 
infected with tuberculosis as well as the likelihood of the progression of the infection into disease. As 
is observed in Figure 5-1 by Hopewell (1993), exposure to infectious particles will result in the 
infection of only 30% of those exposed. Of these infected, tuberculosis disease will occur in only 
10%. This suggests that tuberculosis progresses into a disease in only 3% of those exposed. The 
likelihood of initial exposure to infectious tuberculosis particles turning into infection is dependent on 
nonimmunologic defences. Those that are adequate (70%) will not become infected whereas those 
that are inadequate (30%) will become infected. Of this group, those with inadequate immunologic 
defences (10%) will either contract the disease right after infection (5%) or much later in life (5%), a 
phenomenon known as endogenous reinfection. It is because of endogenous reinfection occurring 
years after initial infection, that the process of tuberculosis eradication in a population is so very slow.
5-1:4a Likelihood of Infection
Tuberculosis is a communicable disease and therefore, the probability of contracting it is highly 
correlated to the amount of exposure to a human carrier of infectious tuberculosis. This includes the 
amount of time one is exposed, the amount of contact and the level of 'infectiousness' of the carrier. 
The more concentrated a population is, the easier it is for the disease to spread. Hence, those in a very 
densely populated area are more inclined to be infected than those in rural areas. Lowell, Edwards and 
Palmer (1969) used US Navy recruit testing programs which test for tuberculosis in white males aged 
17-21 to illustrate this. Of this group, those living in metropolitan locations all their life had a 4.2% 
prevalence of positive tuberculin reactivity, whereas those in non-metropolitan locations had a 3.6% 
prevalence of positive tuberculin reactivity and those on farms had a 2.8% prevalence of positive 
tuberculin reactivity. Likewise, the greater the contact with a carrier, the more likely is an individual 
to become infected with tuberculosis. This would explain why those sharing households with 
infectious individuals are more likely to become infected with the disease. Following this, the greater 
the crowding in a household, the greater the transmission of infection. In addition, the more advanced 
and infectious the tuberculosis case, the more likely is the transmission of infection. Grzybowski, 
Barnett and Styblo (1975) showed in that 62% of those in contact with quite advanced cases of 
tuberculosis reacted positively to tuberculin reactivity tests suggesting infection, while only 16% of 
those exposed to a nominal case tested positively (Grzygowski, Barnett, and Styblo, 1975).
The amount of time a carrier of tuberculosis is infectious is also an important element in the 
spread of tuberculosis. The longer an individual is infectious, the more individuals he or she is likely
133
to infect. Nevertheless, as compared to other communicable diseases, the risk of infection from a 
tuberculosis disease carrier is far lower. Comstock and Cauthen (1993) suggest that considering the 
length of exposure, tuberculosis infectiousness is low per unit of time. These authors also suggest that 
because of greater potential contact with those with the disease, the risk of acquiring TB increases with 
age, favours males and non-whites. The likelihood of contracting TB also increases in those who are 
either voluntarily or involuntarily confined in institutions. In industrialised countries this is especially 
significant in shelters for the homeless because their lifestyle, as well as such close confinement with 
others, facilitates a greater spread of infection (Nolan et al., 1991). Hence, environment is a prominent 
factor in becoming infected with tuberculosis, however, there is also some evidence to suggest that 
there is an endogenous risk factor in the individual. Indeed, for reasons unknown, some individuals 
are more likely to be infected with tuberculosis in the same situation than others. It has been suggested 
by one study that blacks have a greater propensity for becoming infected than whites, but little more is 
known in this area (Stead et al., 1990).
5-l:4b The Progression of Infection to Disease
The probability that an individual, once infected, will develop tuberculosis is the highest 
immediately after infection and then decreases with time. Also, development of the disease from 
infection correlates with age. Those that become tuberculin reactors at a younger age are far more 
inclined to develop the disease than those who are infected at older ages. In a study of Puerto Rico, 
Comstock, Livesay and Woolpert (1974) discovered a trend supporting this. Of 82 269 tuberculin 
reactors from ages 1-18, observed for a time period of 18-20 years, 1 400 cases of tuberculosis 
primarily occurred either before the age of eight or in between the ages of 13 and 25. Additionally, 
those that were underweight were far more inclined to develop tuberculosis than those overweight.
Race has little to do with development of disease once tuberculin reactivity has been established. 
Also significant is the fact that the amount of tubercle bacilli to which a reactor is exposed can 
determine the likelihood of disease. Those who are exposed to very infectious cases and therefore far 
more tuberculosis organisms, are at a higher risk for the disease than those reactors who become 
infected by less infectious cases.
Lastly, the state an individual's immune system affects the likelihood of the progression of a TB 
infection into disease. Immunocompromised individuals such as alcoholics, the homeless, intravenous 
drug users, those with HIV or those who are malnourished, all have higher incidences of TB. In 
addition are those who inhale large amounts of toxic particles such as smokers and mine workers. 
Incidences of TB have been higher in South African mine workers than in non-mine workers in past 
studies (Packard, 1989).
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5-1:5 Treatment
The treatment of tuberculosis is predominantly through chemotherapy with antibiotics, although 
some experimentation has been performed with passive immunisation or immunotherapy (Stanford, 
Grange and Pozniak, 1991). The antibiotics that are commonly used are isoniazid (H), rifampicin (R), 
pyrazinamide (Z), ethambutol (E), thiacetazone (T) and streptomycin (S). The two most powerful of 
these are isoniazid and rifampicin due to their ability to completely eradicate or sterilise the bacilli. In 
order to be effective in the treatment of tuberculosis, chemotherapy must involve a combination of 
these drugs, be in the right dosages, and must be taken by patients on a regular basis for the duration of 
the prescribed treatment period. Treatment characteristically involves a more intensive phase in the 
beginning (usually lasting two-three months) where both more powerful drugs and a greater number of 
drugs are used to convert a patient from smear-positive to smear-negative TB. After this, a 
continuation phase is designed to protect against a relapse of the disease (usually lasting 6-18 months 
depending on the drugs used) where fewer and often less powerful drugs are administered.
5-1:5a Short-Course Chemotherapy Versus the Standard Regimen
In industrialised countries, most treatment relies on an intensive phase with two months of 
rifampicin, isoniazid, pyrazinamide, and ethambutol and a continuation phase of rifampicin and 
isoniazid for four months (commonly abbreviated as 2RHZE,4HR) (Omerod, 1990). The exception is 
for treatment of meningitis, children and some other types of extra-pulmonary tuberculosis. 
Unfortunately, this proves to be a relatively expensive regimen compared to a 12 month regimen. For 
developing countries, the International Union Against Tuberculosis and Lung Disease (IUATLD, 
1994) recommends the use of either eight month chemotherapy or twelve month chemotherapy (see 
Chapter 6 and 7 for a comparison of each regimen's effectiveness). Eight month chemotherapy, also 
referred to as a form of short-course chemotherapy (SCC) includes a 1-2 month daily intensive phase 
of treatment with 150mg of rifampicin combined with lOOmg of isoniazid, 400mg of pyrazinamide 
and 400mg of ethambutol, and a 3-8 month daily long continuation phase treatment with 50mg of 
thiacetazone and lOOmg of isoniazid combined tablets (2RHZE, 6TH). Twelve month chemotherapy, 
also referred to as the standard regimen or standard drug regimen (S.D.R.), requires daily treatment 
with 50mg of thiacetazone and lOOmg isoniazid combined tablets for twelve months, and daily 
streptomycin injections for the first two months (2SHT, 10HT). In conjunction, these drugs not only 
limit the development of resistant tubercle mutants, but each drug has a particular role in destroying 
tuberculosis bacteria at a particular phase in its development. As is illustrated in Figure 5-2, 
rifampicin, isoniazid and streptomycin are some of the most important drugs because they are 
bactericidal, killing the largest population of bacteria. Rifampicin also kills bacteria that have
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inconsistent spurts of growth between dormancy. Those remaining bacteria that are encased in an acid 
environment are destroyed by pyrazinamide (Mitchison, 1985). In addition to antibiotics, 
immunotherapy with Mycobacterium vaccae has been used in limited cases (Standford, Grange and 
Pozniak, 1991), but its degree of effectiveness is not widely known.
Figure 5-2: The Effect of Various Drugs 
on Tuberculosis Bacteria During Treatment
A
▼
Speed of 
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Growth
Isoniazid
Source: Mitchison, 1985
5-1:5b Side Effects of Drugs
There are inevitably side effects due to treatment with these drugs. These side effects can be 
minor in nature whereby the patient need only be informed of their possibility, or major, life 
threatening side effects. As illustrated in Table 5-1, the most encountered side effects to tuberculosis 
drugs is shown. Major side effects to these drugs include exfoliative dermatitis (a severe form of skin 
peeling or blistering) from thiacetazone; impaired vision from ethambutol; hepatitis often from 
isoniazid and less commonly from pyrazinamide and rifampicin; dizziness and teratogenic effects from 
streptomycin; and shock, purpura and fever caused from pyrazinamide, rifampicin and streptomycin. 
In those patients that show these major side effects, the drug should never be used again. It is difficult 
to isolate side effects in tuberculosis because these drugs are never administered alone except in the 
case of isoniazid prophylaxis. The most critical side effect to isoniazid is isoniazid-related hepatitis. 
Of 13 838 patients given isoniazid alone, the incidence of isoniazid hepatitis correlates with age: of
136
those below 20, this was 0%; those 20-34 this was 0.3%; those between 35-49% this was 1.2% and 
those 50-64 years, this was 2.3% (Kopanoff et al., 1978) (for more information on the incidence of 
side effects between SCC and SDR, see Chapters 6 and 8).
Table 5-1: Major and Minor Side Effects 
of Primary Tuberculosis Medications
RIFAMPICIN (R)
PYRAZINAMIDE (Z)
ISONIAZID (H) 
THIACETAZONE (T) 
STREPTOMYCIN (S) 
ETHAMBUTOL (E)
hepatitis, flu-like symptoms, abdominal pain, red-orange body fluids, decrease in the 
absorption of other medicines, shock, purpura (discoloration of the skin of a purple or 
reddish-brown nature caused by haemorrhage in the tissues), fever
shock, purpura fever, hepatitis, joint symptoms
hepatitis, neurologic reactions, minor skin reactions
exfoliative dermatitis,
dizziness, teratogenic effects
vision impairment
Source: PDR, 1992; IUATLD 1994
5-1:5c Follow-up in Diagnosis
After two months of intensive phase treatment, patients undergo a sputum smear examination. 
Those found to be smear-negative are placed on the continuation phase. In contrast, those who are 
smear-positive are given more of the intensive phase treatment for another two weeks and then have 
their sputum rechecked. If it proves positive, the intensive phase is given for another two weeks and 
the patient's sputum is checked again. After this point, regardless of sputum conversion, the 
continuation phase commences. At five months, all patients are again given a sputum examination and 
those who are sputum positive are pronounced as treatment failures and are given a retreatment 
regimen. Sputum is again checked at seven months and those who are sputum negative are given their 
last month's treatment if they are on an eight-month regimen and are then pronounced cured. If 
patients are on a twelve month regimen, they continue chemotherapy until the eleventh month when 
their sputum is again checked and those in this group who are sputum negative are similarly 
pronounced cured and given their last month of chemotherapy. Those appearing smear-positive at the 
seventh month or the eleventh month sputum check are diagnosed as treatment failures and must be 
given a retreatment regimen. Those who miss appointments during the continuation phase have the 
missed time added on to the duration of their treatment, totalling one year for the eight-month regimen 
and 15 months for the twelve month regimen. Any patient receiving treatment lasting longer than 
these limits is classified as a defaulter.
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5-1:6 Retreatment: Failure and Relapse
Special consideration must be given to those smear-positive patients who have previously 
received a month or more of treatment for tuberculosis. These patients usually fall into three 
categories: relapses, failures and defaulters. Those patients considered relapses are those who become 
smear-positive after having received treatment and have been diagnosed as "cured" after their 
treatment. Likewise, those patients who are considered failures are those smear-positive patients who 
continue to be smear-positive or convert back to smear-positive tuberculosis after five months of
treatment.
Relapses after patients have been classified as cured are rare, yet still occur. There are many 
explanations for relapse, but the majority centre on inadequate chemotherapy stemming from poor 
patient compliance (Comstock and Cauthen, 1993). Patients failing to take their treatment properly 
might end up killing part of the tuberculosis bacilli, reducing the colony sufficiently that the patient's 
results are smear-negative. Nevertheless, the remaining bacilli will then multiply to their previous size 
or larger. Relapse can be associated with drug resistant bacilli. This is likely due to the lag between a 
drug's elimination of most of the susceptible bacteria and the time it takes for the remaining drug- 
resistant mutants to multiply and become dominant.
Those patients who have received retreatment and are still smear-positive are classified as 
chronic cases. Chronic cases are one of the most dangerous forms of tuberculosis since they are 
predominantly resistant to H and R and remain reservoirs of infection for the transmission of 
resistance. Such resistant cases are often incurable and these patients must rely on surgery and 
treatment with rarer tuberculosis drugs for the rest of their lives. The prognosis of survival for 
tuberculosis resistant to both H and R is about 40-60%, roughly the same as for those who receive no 
treatment at all (Bloom and Murray, 1992).
5-1:7 Resistance
Resistance was soon discovered after the introduction of streptomycin. The Medical Research 
Council of Britain organised a trial in 1944, where fifty-five patients with pulmonary tuberculosis were 
given streptomycin and compared with a control group of fifty-two patients who were only given 
conventional treatment at a sanatorium. The initial results of this trial proved extraordinary as most 
treated with streptomycin had a clear chest x-ray, compared to only eight per cent of those in the 
control group. Of those in the control group, fourteen died within six months compared with just four 
in the streptomycin group, but five years later, thirty-five of the sanatorium patients and thirty-two of 
the streptomycin patients were dead (Ryan, 1992). It seemed that although streptomycin was initially 
effective, it had a poor ability in completely curing tuberculosis. This drug weakened the disease for a
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small period of time until the disease became resistant and then returned in full force, resistant to 
streptomycin. Such resistance was also observed by Pyle (1947) who traced drug resistance by using 
only streptomycin on a tubercle population and found that resistant mutants increased from 1 in 88 750 
to only 1 in 367 after 15 weeks. Essentially, the drug selected for those mutants that were resistant to 
streptomycin and then killed the remainder, leaving only streptomycin resistant mutants to multiply. 
The disease, initially weakened by the decrease in number by the attack of streptomycin, again gained 
momentum as remaining mutants started to multiply and dominate.
5-1:7a Mechanisms of Resistance
Unlike many other micro-organisms, tuberculosis can only become resistant to a drug through 
mutation. Resistance occurs through a tuberculosis drug acting as a selective agent on existing 
resistant mutants in a population. All tuberculosis bacilli populations contain a small number of 
mutant bacteria that are resistant to various drugs. However, it is only when a single drug is used on 
the population, that resistant mutants are left to multiply. In this case, the drug is said to have 
effectively selected for the mutants. The size of the overall population of a colony of tubercle bacteria 
in an individual also determines resistance. The greater the number of bacteria, the greater is the 
likelihood that there will be resistant mutants. In an average human lung cavity of a TB patient, there 
exists 1 x 10^ tubercle bacteria (Grosset, 1993). This is significant considering the probability of 
mutants to various drugs in a given population. Rifampicin's probability of resistance is 1 in 10^ 
whereas the probability of resistance for Isoniazid, Streptomycin, Ethambutol, and PAS is 1 in 10^ and 
that for periphery drugs such as Thiacetazone has a likelihood of resistance of 1 in 10^ (Grosset, 
1993). In contrast, multi-drug resistance tuberculosis (MDR-TB) occurs at a rate of 1 in 1014. MDR- 
TB is defined by some as resistance to more than one anti-tuberculosis drug but in this thesis will 
adhere to the stricter definition of resistance to both isoniazid and rifampicin.
A further characteristic predicting the development of resistance is the type of drug used and its 
effect on the bacterial population. Drugs with a high bactericidal effect are inclined to select for 
resistant mutants better than those that are less bactericidal. This is due to the fact that a drug that 
completely removes the susceptible population leaves the resistant mutants no other bacteria with 
which to compete. For instance, a case of tuberculosis that is only treated with isoniazid, will most 
certainly gain acquired resistance to that drug, rendering it completely useless in the treatment of the 
disease. Acquired resistance is defined as resistance that develops in the individual from treatment, 
and indeed, single-drug therapy is the most common reason for its development. Because each drug 
selects resistant mutants, the combined selection of multi-drug resistant mutants is more difficult 
because what one drugs selects for, another will eliminate. Grosset (1993) sites as the signature
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feature of a mutant resistant to one drug is that it is usually susceptible to other drugs. This does not 
mean that MDR-TB will not develop. MDR-TB simply takes longer to develop because there is a 
longer selection process on the part of each anti-bacterial involved. This is illustrated schematically in 
Figure 5-3: as a susceptible tuberculosis population is treated with a series of single drugs, the 
population begins to evolve into a multi-drug resistant population. This is why TB chemotherapy must 
involve more than one drug and often three or four.
As well as acquired resistance, an individual can be infected with a drug-resistant form of 
tuberculosis when he or she is exposed to an infectious case of tuberculosis that is unsusceptible to one 
or more drugs. Once the individual has been infected with this unsusceptible bacilli, it will have the 
potential to multiply into a purely drug-resistant population. This is referred to as primary resistance 
and has a strong clinical significance because it means that immediately one or more drugs will be 
ineffective in treating the disease.
Figure 5-3: The Development of Multi-Drug Resistant Tuberculosis
Figure 5-3: The development of Multi-drug Resistant Tuberculosis. A Susceptible population of 
tuberculosis receives only one drug (hypothetical Drug A) which selects mutants resistant to this 
population and then these mutants multiply to be treated with a second drug (hypothetical Drug B), 
further selecting for resistant mutants. The selection and further multiplication of these mutants 
results in a population resistant to both Drug A and Drug B. Further singular treatment with drugs 
will select for further resistance in the population rendering a super-resistant population over time.
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As the level of primary resistance to standard drugs grows, tuberculosis becomes more and more 
difficult to treat because the remaining drugs left to treat this resistant TB are far less effective. 
Therefore, the spread of primary resistance translates to the spread of a relatively untreatable form of 
tuberculosis. Its growth, in any proportion, represents a major health threat. It is because of this that 
statistics charting primary resistance are quite significant.
Those patients who cannot be classified as either having primary resistance or having acquired 
resistance are said to have initial drug resistance where it is unclear whether they have previously 
received chemotherapy. Patients are sometimes reticent admit to having received previous treatment 
because of an irrational fear that current needed treatment will be denied. Hence, it can be very 
difficult to determine the type of drug-resistance experienced by a patient and this serves to skew 
primary drug resistance data.
5-1:7b Causes of Drug Resistance
The development of drug resistance is dependent on the tuberculosis population, tuberculosis 
treatment, chemotherapy, drug administration and the patient. Low cure rates for smear-positive 
tuberculosis regimens serve to make those who would ordinarily die from the disease, develop 
resistance and survive, thus enlarging the pool of infection (Kochi, 1993). Roughly correlating to this, 
according to the author Gangadharam (1993), there are five major factors from which drug resistance 
is attributed: biological, clinical, pharmaceutical, administrative and sociological (see Figure 5-4). (1) 
Biological factors mainly centre around the favourability of the tubercle bacilli's environment in 
allowing it to multiply and mutate. An example of this would be if an individual was somehow 
immunocompromised giving the bacilli a better advantage in multiplying. (2) Clinical factors refer to 
any element of treatment that interferes with a drug's ability to kill tubercle bacilli and anything that 
allows for single-drug therapy and the selection of resistant mutants. Often in therapy, resistance 
arises to one drug and a clinician simply adds another drug to the treatment allowing for a further 
selection of drug-resistant mutants. (3) Pharmaceutical and pharmacological factors describe anything 
that weakens the effectiveness of a drug and hence, its ability to fight an infection. This includes any 
environmental factors that might weaken the action of these drugs causing them to be less effective on 
the tubercle bacilli. The shelf life of streptomycin, for instance, is three years after its date of 
manufacture while pyrazinamide, isoniazid, ethambutol and thiacetazone can be used up to five years 
after their date of manufacture (IUATLD, 1994). A close adherence to the shelf life of a drug is 
necessary to ensure they will be effective when they are administered. Ineffective doses of drugs have 
the potential to cause resistance to develop in tubercle bacilli. (4) Administrative factors refer to 
anything that impedes consistent drug treatment due to a lack of supply. Such examples of
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administrative factors would be a patient's inability to receive a regular supply of treatment due to 
inefficient storage and transport of TB drugs on the part of the health authority. (5) Sociological 
factors centre around any feature in the patient that impedes treatment. An example of this would be 
patient default due to difficulty in travelling to a health clinic, or difficulty in affording a full course of 
treatment.
Figure 5-4: Factors Influencing the Development of Resistance
1. Biological
a. Initial bacterial population
b. Local factors inside the host favourable for the 
multiplication of drug-resistant bacilli
c. Presence of drug in insufficient concentrations
d. Patient's drug inactivation status
2. Clinical
a. Treatment with single drugs
b. Inadequate dosage of the drugs
c. Insufficient duration of treatment
d. Adding a single drug to a failing regimen
e. Interference by occult or quack medicine
f. Interference by other indigenous systems of medicine
3. Pharmaceutical and Pharmacological
a. Insufficient concentration of the pure drug
b. Inadequate standardisation of the bioavailability of the drugs
c. Improper storage conditions of the preparations
d. Improper bioavailability of combined tablet preparations
e. Confusion created by the trade names of the various 
preparations of combinations tablets
f. Improper or incorrect dispensing of the drugs
4. Administrative
a. Insufficient supplies of the drugs
b Bureaucratic influence in the ordering and supply of the
drugs
c. Substandard drugs purchased because of cost considerations 
and government regulations
d. Administrative delays in the release of the drugs from the 
ports of entry
e. Administrative controls on the drug dispensing
5. Sociological (patient's co-operation)
a. Non-compliance
b. Irregularity in drug intake
c. Premature discontinuation of drug intake
d. Avoidance of other exogenous infections with drug-resistant 
bacilli
Source: Gangadharam, 1993: p. 300
5-1:7c Current Levels of Resistance
With the increase in AIDS and tuberculosis there has been a corresponding acceleration of the 
incidence of resistant tuberculosis. Resistance to the two primary drugs used to treat tuberculosis, 
isoniazid and rifampicin, has reached record levels, rising to as much as 30% in industrialised 
countries (CDC, 1993) and between 15% and 39% in developing countries (Khan et al., 1993; Wolde 
et al., 1990; Mitchison and Nunn, 1986, Ormerod, Harrison, Wright, 1990). Such multi-drug 
resistance is serious since these are the most effective drugs against TB. MDR-TB patients must rely
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on surgical resection and less effective drugs, all of which have lower survival rates. The mortality 
rate for multi-drug resistant tuberculosis is 40-60%, the same rate as for those not receiving any 
treatment. For those who are HIV-positive, this figure rises to 80% (Bloom, 1992).
In summary, many factors are responsible for the growth of resistant tuberculosis and if such 
resistance grows unchecked, it could very well prove be one of the great health threats in the twenty- 
first century. Most of those factors accountable for drug resistant tuberculosis are caused by human 
error in consumption, administration or supply of these drugs. An overwhelming problem with 
tuberculosis is patient compliance since the regimen requires many pills several times a week for such 
a long period of time. Often those receiving treatment forget to take their pills and in many cases, 
those receiving the pills stop taking them when they start to feel better, not allowing for their 
tuberculosis to be completely cleared. Problems in motivating patients to comply with their dosages 
have been so bad that in areas such as New York, it is cheaper to send out a social worker to police the 
treatment than it is to deal with resultant patient deterioration from the disease. Even if an individual 
takes his or her medicines, there is occasionally the problem that a doctor does not prescribe the 
correct dosages. Again, an awareness and education in the importance of the threat of this illness is a 
key to instigating better management of its treatment.
5-1:8 HIV anti Changing Trends in Tuberculosis
In the US in 1953, there were 84 304 recorded cases of TB from which 19 707 died. In contrast, 
in 1985, 22 201 were infected with TB and only 1 752 died from it. This illustrates a 33 year trend in 
the fall in the rate of TB infection, yet recent rises in new cases have threatened to reverse this trend 
(Murray, 1989). In the United States, new cases of TB increased 18%, from 22 255 to 26 283 between 
1984 and 1991 (FDA Consumer Online Documents , 1993). After 1985, new cases of tuberculosis 
continued to increase, rising by 4% in 1989 and a further 9.4% by 1990. Strangely, a pattern was 
developing where the incidence of tuberculosis, a curable disease, began to rise globally and although 
some could not explain this, it gradually become linked with the rise of HIV.
It is estimated by the World Bank that 2 million people have already died of AIDS and 13 
million are currently infected with HIV (World Bank, 1993). In sub-Saharan Africa, an average of one 
out of forty has the virus and in cities this rises to almost one in three. Over 90% of these individuals 
are in their most economically productive years between ages 15-59 (World Bank, 1993). The future 
situation is bleak as WHO estimates that by the year 2000, 26 million people will be infected with the 
virus and 1.8 million people per year will die from it.
The nature of tuberculosis is such that once exposed to it the healthy human body can, in most 
cases, stop its progression into disease. In a healthy human population, only 10% of those exposed to
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tuberculosis will ever develop this disease, and the remaining 90% will become carriers of non­
infectious tuberculosis bacteria. With AIDS's elimination of an individual's ability to fight disease, he 
or she becomes more vulnerable to other diseases therein increasing their spread. This is especially 
true for tuberculosis, and for those with HIV, the progression of TB infection to disease can be 30% 
higher (Murray, 1989). The annual incidence of TB becomes 8% in this group (McGowan, 1993).
Tuberculosis is such a virulent disease that on many occasions it is the first disease to affect a 
person with HIV, and indeed, a tuberculosis infection is often the first clue that an individual has 
AIDS. TB has been increasing in HIV patients. In 4 HIV specialist centers in London (King's, St. 
Goerge's, South Geng's and St. Thomas's), TB was the second most common AIDS-defining illness, 
affecting 22% of a total of 86 patients of an African origin (Ofarrell et al., 1995). From October 1990 
and July 1991 at the Department of Pediatrics and Child Health in the University Teaching Hospital 
(OTH), Lusaka, Zambia, of 1323 patients seeking care, tuberculosis was the 5th most common cause 
of admission. 69% of these TB patients were HIV-seropositive (Chintu et al., 1995). In Tamil-Naden, 
India, of 100 AIDS patients, at an incidence of 61%, the most common disease between those aged 21­
30 was TB (Kumarasamy et al., 1995).
In HIV patients, tuberculosis occurs early on in the stages before AIDS, coming 6-9 months 
before any other AIDS-defining illnesses (Daniel and Ellner, 1993). Although not conclusive, there 
now some evidence that a smear-positive HIV patient is more likely to transmit TB than a HIV- 
seronegative patient. In a study of 436 TB contacts in Spain, twice as many miro-epidemics of TB in 
intravenous drug users were generated by HTV-seropositive contact cases rather than HIV-seronegative 
contact cases (Cayla et al., 1996). HIV can also speed up the progression of tuberculosis from years to 
a matter of weeks. This acceleration of the disease provides a greater pool of infectious tuberculosis 
resulting in its exponential growth both in those that have AIDS and those that do not. There is also 
some evidence that TB accelerates the progression of HIV-1-infection (Peterson et al., 1995).
Increases in HIV suggest a greater future burden on highly populated health facilities, which will 
be to their detriment because of the two-fold problem that HIV will take the time and resources from 
that allocated for treating other diseases and it will also allow for a greater pool of infectious disease to 
disseminate. In St. Mary's Hospital in London, of 538 patients with positive Mycobacterial isolates 
between January 1987 and March 1992, there was a 2.5 fold increase in patients with mycobacterial 
infection. 57% of these isolates were TB but only 47 patients were known to be HIV positive (Taylor 
et al., 1995). The National multiple-cause mortality data in the United States shows that between 1987 
and 1992, death in HIV-seropositive patients rose from 2.9% to 4.1% (Selik et al., 1995). This would 
support the conjectures that as TB becomes more prevalant, a greater pool of infection will cause its 
incidence to rise, and that TB in those with HIV is becoming harder to treat (possibly due to
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resistance). Such a problem could be attibuted to the fact that there are not enough existing resources 
to cover the resource drain of this disease. The present amount of US $200 million in expenditure in 
developing countries for preventing AIDS is far insufficient as an estimated US $1-2 billion is thought 
to be necessary (World Bank, 1993).
5-1:8a Characteristics of TB/HIV Co-infection
There are many characteristics of TB-HIV patients separating them from other tuberculosis 
patients. There is a significant correlation between extra-pulmonary TB and HIV. One third of all 
HIV-seropositive patients are likely to have extra-pulmonary tuberculosis compared with 
approximately 18-19% HIV-seronegative patients. Zaire, for instance in 1985, had 47% HIV-extra­
pulmonary TB cases as opposed to 33% HIV smear-positive TB cases (Small et al., 1991). In 
addition, infection with HIV is the most significant known risk factor in activating a latent TB 
infection, a phenomenon also known as endogenous reinfection. The risk of contracting TB in an 
HIV-seropositive individual is 7-10% per year as compared to 10% per lifetime in a healthy HIV- 
seronegative individual. Besides endogenous reinfection those with HIV are more prone to developing 
TB through exogenous infection. The HIV-seropositive individual lacks the ability to fight TB 
infection so that it invariably progresses into a disease. Because of such increased vulnerability to 
tuberculosis, the use of isoniazid preventative therapy and isoniazid prophylaxis is common in those 
patients who are likely to have been infected or where infection has been established.
In addition to a greater vulnerability to tuberculosis, there is commonly a delay in the diagnosis 
of tuberculosis in HIV-seropositive patients. The diagnosing of tuberculosis in HIV patients can be 
difficult because a large proportion of them exhibit anergy (lack of a reaction) to tuberculin skin tests 
and therefore, evidence of infection in this manner is not an effective method. Chest radiographs and 
smear tests are likewise undependable and doctors must rely on tuberculosis cultures and blood tests to 
help them diagnose the disease. HIV patients have atypical sizes of tubercle colonies and they are 
more likely to be smear-negative than smear-positive. In Zambia, of 109 patients, 66% HIV- 
seropositive patients proved to have lower grade sputum positive or sputum-negative smear tests, 
lower colony counts in cultures and longer culturing times (Elliot et al., 1993). HTV is also inclined to 
render a patient with a negative tuberculin skin test. The greater the progression of AIDS, the less 
likely the patient will exhibit a positive skin test after tuberculosis infection. In the United States only 
39-56% of TB/HIV co-infected patients had a positive skin test, and in Uganda 68% of those TB/HIV 
co-infected patients exhibited a positive skin test (Ellner, 1990; Vjecha et al., 1991). A negative 
tuberculin skin test can reflect the fact that an individual's HIV infection is at an advanced stage, 
suggesting a potentially poorer response to treatment.
145
Those who are HIV-seropositive will respond to TB chemotherapy similarly to those who are 
HIV-seronegative. There are some differences in treatment, however. TB/HIV co-infected patients 
are more likely to die during treatment due to non-TB causes, and are also more likely to die of TB if 
the disease proves resistant. In a major referral centre in Tanzania, of 157 TB patients, 102 of which 
were HIV-seropositive, there was a 2% case fatality rate for those with HIV but a comparative 2% for 
those without the disease (Richter et al., 1995). Of 173 patients with MDR-TB between 1983 and 
1993 in New York, 50% were HIV infected and mortality for HIV patients was 70% versus 20% for 
HIV-seronegative patients. Only appropriate therapy was linked to the survival of these HIV patients 
(Park etal., 1996).
TB/HIV patients are far more likely to experience adverse side effects to the medicines, 
especially thiacetazone (Cohn and Iseman, 1993), and they are far more likely to have relapses when 
treated with the twelve-month regimen. This would suggest the use of short course chemotherapy over 
the standard regimen in HIV seropositive patients. Also, the use of streptomycin injections, required 
in the twelve month regimen, can be problematic because often needles and syringes are re-used, 
which could lead to a spread of HIV to other patients receiving injections. Another problem in the 
treatment of TB/HIV co-infection is that those with HIV offer an attractive pool of infection for MDR- 
TB, because of the ease that it can pass from an MDR-TB infected person to an HIV infected person. 
One study from the CDC (1991) found that all HIV cases of an outbreak of MDR-TB had been in a 
hospital ward near another patient who was being treated for MDR-TB. This is supported by Edlin et 
al. (1992) and Fischi, et al. (1992) who found a similar situation in MDR-TB/AEDS co-infected 
patients. In addition, regardless of whether an HIV patient already has tuberculosis, he or she can still 
be exogenously infected by a resistant strain. Such evidence has been proven by a study by Small 
(1993) who analysed the restriction-fragment-length- polymorphisms (RFLP) (an analysis of changes 
in bacterial DNA strands) of 17 TB/HIV co-infected patients to find a sudden change in four at the 
detection of MDR. This evidence suggests a strong potential for MDR-TB to be transmitted 
nosocomially where treatment of MDR-TB includes aerosol-producing medical practices such as 
endotracheal intubation, bronchoscopy, respiratory tract manipulation, autopsy and wound 
manipulation (Jarvis, 1993). The likelihood that MDR-TB can be transmitted so easily among those 
who are HIV-seropositive has stimulated discussions about isolating them. These means include, for 
instance, isolating those who are HTV positive and homeless by providing special homeless shelters for 
HIV positive persons, in order to protect them and limit the spread of this relatively incurable form of 
tuberculosis (Tynes, 1993). Containing the transmission of MDR-TB/HIV co-infection is extremely 
critical for HIV patients since the mortality rate of MDR-TB/HIV co-infection is 89% within 16 weeks 
(FDA Online Documents, 1995).
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5-1:9 Summary of Section 5-1
As an ancient disease that was thought to be almost eradicated, tuberculosis is still a very real 
health threat in modem times. It is a disease that has been well studied, revealing detailed information 
on its diagnosis, etiological epidemiology and mechanisms of resistance. Such information has been 
an invaluable help in diagnosis, treatment and retreatment of this disease. Nevertheless, erradication 
of this tuberculosis, due to its close epidemiological tie with HTV still seems a very distant reality.
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Section 5-2
Effective Management of tuberculosis Control Efforts
In this section the management of tuberculosis drug supply, containment, preventative therapy 
and case holding are explored. Also, this section discusses the costs associated with these control 
efforts. Sound management in all areas of TB control is an essential element in controlling 
tuberculosis resistance as will be discussed in further chapters.
5-2:1 Drug Supply
Much of the management of the containment of tuberculosis is dependent on chemotherapy 
which serves to limit exposure of others to the disease. Any impediments to effective chemotherapy 
and any delay in getting it will foment greater exposure. Hence, delays in the supply of drugs are 
significant impediments to tuberculosis control programmes. A balance in future drug supply must be 
correctly calculated so that precious funds are not spent on drugs that will expire before a patient can 
use them, but enough must be available so that each patient can finish his or her treatment. This is 
achieved using estimates of past drug use. In addition, to make use of these estimates requires the 
availability of an adequate amount of funds to purchase drugs. Those drugs that are purchased must be 
of high quality so that consuming them does not effectively result in no treatment or resistance. 
Similarly, even if the correct quantity of drugs is ordered, if they do not reach the patient on a 
consistent basis, this can also jeopardise a control programme. Drugs should be carefully monitored to 
make sure that they are not left susceptible to bad weather conditions on delivery docks or left to theft 
in warehouses. If drugs cannot be delivered regularly to the patient, he or she will receive intermittent 
therapy also likely resulting in a relapse or resistance.
Excluding non-commercial production and distribution of anti-TB drugs, in 1990/91, the global 
market for tuberculosis drugs was US $177 million. Drug production is dominated by two companies 
in the United States and one company in Switzerland (Weil, 1994). This is a large market with a 
strong, inelastic demand. Cost recovery for TB drugs is usually prohibited because the disease is such 
a consequential health threat. For this reason, TB drugs are seldom procured by the private sector, but 
remain the area of the government and external donors. Regarding this, drugs were estimated to 
represent from 20-40% of all costs of a tuberculosis drug programme (Murray, 1990; Murray, Styblo, 
Rouillon, 1990). The cost of procuring these drugs including service fees from procurement agencies, 
port charges, insurance and customs duties can account for as much as 20-100% over the actual cost of 
each drug (Weil, 1994). Such costs as these accentuate the fact that the current management of 
tuberculosis drugs in most countries is less than ideal and offers much room for improvement.
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5-2:la The WHO Anti-TB Drug Survey
Illustrating the requirement for better TB drug management, Weil (1994) reports on a WHO anti- 
TB survey in 1992. This was a study of the 1991 tuberculosis drug use of: 31 of 45 (68%) member 
states from AFRO (African region), 14 of 36 (38%) from AMRO (American region), 9 of 22 (40%) 
from EMRO (Eastern Mediterranean region), 5 of 11 (45%) member states from SEARO (Southeast 
Asian region), and 15 of 23 (65%) member states from WPRO (Western Pacific region). Of these 
member states, only 70% based their future ordering of drug on their past year's demand. Likewise, 
49% of respondents reported experiencing drug stock-outs meaning that at some point during the year, 
some or all of the supply of tuberculosis drugs were exhausted on a national scale. 59% of 
respondents and 68% of AFRO countries reported that drug supply financing was their greatest 
weakness to an effective tuberculosis control programme. 39% of respondents indicated that they did 
not have adequate or stable financing for their 1992 TB drug demand.
Figure 5-5: Percentage of External Aid 
Received by Respondents on a WHO Anti-TB Study
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Figure 5-5: PERCENTAGE OF EXTERNAL AID RECEIVED BY RESPONDENTS ON WHO ANTI- 
TB STUDY. 73 of respondents in this WHO anti-TB study responded to questions on the sources of their 
funding. This graph shows the percentage of responding member states that experienced full or partial external 
aid. As can be observed, African member states receive the largest amount of full external and partial external 
aid whereas Eastern Mediterranean member states receive only a small amount of partial external aid. (Weil, 
1994:p.131)
In developing countries, drug financing for tuberculosis is usually dependent on some form of external 
aid. The degree of need determines whether this external is full or partial in each country. Figure 5-5 
indicates that some member states in some regions received full external aid, meaning that their 
tuberculosis drugs were almost fully funded by an external body. In the AFRO region full external aid 
amounted to 32% of all countries that responded to the survey and amounted to 23% in AMRO. A
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further 48% and 23% of countries in AFRO and AMRO, respectively, is accounted for by partial aid. 
Less aid for TB is given in EMRO, SEARO and WPRO, EMRO and SEARO only receiving partial 
external aid for tuberculosis drugs.
In addition to funding sources, the cost-per-case was surveyed from 52 respondents (19 in 
AFRO, 12 AMRO, 7 from EMRO, 4 from SEARO and 10 from WPRO), but comparisons of these 
data are difficult due to variations in the calculation of cost-per-case. As might be expected, AFRO 
had a low cost-per-case, but SEARO had the lowest cost-per-case range. Discrepancies between a low 
cost-per-case and a high cost per case reflects each member state's incidence of TB, labour costs, 
overhead costs, case-load and cost of drug regimens (See Table 5-2 for differences in cost per case).
Table 5-2: Cost per Case Range Obtained from 
Respondents of WHO Member State Regions
Region Cost
AFRO $9-$289
AMRO $12-$667
EMRO $15-$1142
SEARO $27-$67
WPRO $7-$420
Source: Weil, 1994
One of the reasons for such a difference in the price per case could also be attributed to the prices that 
different countries pay for drugs. Such differences are widespread and differ from country to country 
and are also dependent on the drug chosen. Figure 5-6 shows the respondents' reports on the prices 
that they paid for their tuberculosis drugs which proved to be much higher than UNICEF or IDA 
(International Dispensary Associates) prices. Prices for isoniazid (H), the most popular bactericidal 
drug averages at only 2% over the price, whereas ethambutol, streptomycin and pyrazinamide proved 
to have the highest average price over its UNICEF or IDA price. It is unknown why there is such a 
difference in these percentages, but it is possibly due to the fact that there is less of a demand of these 
drugs over isoniazid and rifampicin which, under ideal conditions, without considering available 
funding, should appear in every initial drug regimen due to their superior effectiveness (discussed in 
Chapter 6).
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Type of Drug
Figure 5-6: Percentage of Average Price over IDA or UNICEF Price
Percent of Average Price over IDA or UNICEF Price
Adapted From: Weil, 1994: p. 129
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Figure 5-7: A Comparison of the US $ Cost per Drug Regimen Paid 
for IDA/UNICEF Priced Drugs and the Average Prices Paid
Drug Regimen
Smear-positive regimen: 2HRZE/4H3R3; 
Retreatment Regimen: 2HRZES/IHRZE/5H3R3E3;
Smear-negative Regimen: 2HRZ/2H3R3 (a three subscript refers to three times weekly) 
Source: Weil, 1994: p. 32
UNICEF and IDA prices are lower because they buy their drugs in an extremely high volume. Such a 
difference between the price paid for drugs over these suppliers is explained by Weil (1994) who 
attributed it to: (1) those in the government procuring drugs have limited information on suppliers and
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competing prices, (2) under-utilisation of UNICEF and IDA suppliers (3) Funding delays which cause 
a country to demand emergency drugs resulting in their higher prices and (4) Government-enforced 
importation limits on drugs to stimulate local drug production of drugs, result in the procurement of 
higher priced drugs.
The WHO anti-TB survey accentuates such differences in prices which are significant when 
considering their impact on treatment regimens. As is illustrated in Figure 5-7, with these average 
prices, treatment regimens become twice the price of those IDA and UNICEF suppliers. Considering 
drug prices alone, with more efficient procurement, twice as many patients could have been treated for 
the same amount of money.
5-2:2 Impediments to Tuberculosis Diagnosis and Treatment
Another impediment to effective containment of tuberculosis is dependent on the patient and the 
doctor. As observed in Figure 5-8, delays in chemotherapy and greater exposure of the population to 
tuberculosis is partially caused by the time lapse that occurs from when a patient becomes infected 
with tuberculosis to when he or she seeks treatment, compounded with the time lapse in the doctor's 
diagnoses between the initial consultation and treatment.
Figure 5-8: Containing the Spread of Tuberculosis After Infection
Source1. Reider, 1993: p. 168
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Patients often try to deny that they have tuberculosis, which delays treatment. This highlights the 
importance of case finding in tuberculosis to both stop the spread of infection, and to locate those who 
have been infected with tuberculosis to ascertain the likelihood of their infection's progression into 
disease (Reider, 1993). The doctor's role in containment is also essential when considering the 
importance of a quick diagnosis in stopping the spread of infection. Those doctors trying to diagnose 
the disease: (1) have problems in identifying tuberculosis due to the often endogenous difficulties in its 
diagnosis, (2) are unfamiliar with the disease, (often the case in industrialised countries due to its past 
decline) or (3) do not immediately diagnosis TB/HIV coinfection due its unusual clinical 
manifestations, a phenomenon that is becoming increasingly common (Kramer, 1990). In one study 
performed by the CDC in the United States, of 2 000 doctors, 75% misinterpreted a TB test and 27% 
used an incorrect laboratory test (Cooper, 1993). To avoid these diagnosis delays, further education to 
doctors and health personnel is necessary so that they are aware of the changing clinical appearance of 
tuberculosis as well as its growing prevalence. Finally, the lack of patient compliance can be a further 
impediment to effective chemotherapy. Those patients that default in their course of treatment allow 
for the tubercle bacteria to continue to grow or become resistant, contributing to greater exposure of 
others to the disease along with the added danger of developed resistance.
5-2:3 Physical and Technical Tuberculosis Containment Methods
5-2:3a Contact Tracing
All containment strategies are dependent on contact tracing, a term encompassing all elements of 
tuberculosis control such as prevention, containment and surveillance. Contact tracing usually begins 
with the presenting case, a patient who appears with some form of tuberculosis. This is more efficient 
in terms of costs than mass screening because, by definition, contact tracing starts looking for 
tuberculosis in areas where it is most likely to be present rather than spending resources on screening 
low risk individuals. From this point, a contact investigation begins with an attempt to find the index 
case or the person who infected the presenting case. Also, there is a search for all close contacts with 
the presenting case, defined as those who have spent several hours or days with the presenting case 
and are likely to infected. In addition, is the location of any other tuberculosis contacts.
According to Etkind (1993) the expediency of this investigation is dependent on the risk factor 
of the presenting case which centres around three components: person factors, time factors and place 
factors. Person factors depend on the relative infectiousness of the presenting case as illustrated in 
Table 5-3. If a presenting case has extra-pulmonary tuberculosis or is smear-negative, the risk of his 
or her transmitting tuberculosis is low. In contrast if the patient proves to be smear-positive with 
pulmonary tuberculosis then the risk of transmission is assessed to be quite high. Exceptional efforts
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must be given to those presenting cases that prove to have drug resistant or multi-drug resistant 
tuberculosis as these cases can prove to be the most dangerous to contacts. Time factors focus on the 
length of exposure of close contacts and tuberculosis contacts. If a presenting case is assessed to be 
highly infectious, the commencement of his or her symptoms is used as a rough guide as to what time 
period to focus on in identifying contacts with the presenting case. Place factors involve the 
environment in which the presenting case met most of his or her contacts. This is significant because 
if this environment is well ventilated or outside, the risk is low to contacts whereas if it is crowded and 
poorly ventilated, then the risk is much higher to contacts. Additionally relevant to the place of 
contact is the relative risk to those contacts. If the patient, for instance, spent a large time in contact 
with those who are HIV-seropositive such as in an HIV hospice, or if the patient spent a large 
proportion of time in the presence of children such as at a day-care centre or at a school, then the risk 
infection must be considered more seriously. Contact tracing is an important tool in the prevention of 
tuberculosis while proving prove instrumental in case finding. This is a valuable cost-effective method 
for identifying high risk groups for screening instead of using a wide scale, indiscriminate screening of 
a population. It is a method that can be applied in both developed and developing countries alike, and 
a lack of its utilisation would prove detrimental in TB containment.
Table 5-3: Personal Factors of the Presenting Case Influencing 
Contact Tracing According to Likelihood of Transmission
CLINICAL DATA HIGH LOW
TB Disease Location Laryngeal Pulmonary Extra-pulmonary Alone
Smear Status Positive Negative
Smear Source Spontaneous Specimen Induced or Clinical
Chest X-ray Cavitary Noncavitary
PPD Result Large, > 15mm -
Symptoms Cough No Cough
Anti-TB drugs No Yes (2 weeks or more)
Source: Etkind, 1993: p. 280
Indeed, contact tracing should concentrate on facilitating patient awareness that there is effective 
available treatment for tuberculosis and that quick action means less transmission to others. Passive 
case finding, involving only the patient is essential but not satisfactory. Active case finding on the part 
of the community is necessary. In order to accomplish this, it is necessary to have a strong community 
infrastructure with an added awareness of the symptoms and treatment of tuberculosis. Unfortunately,
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both in developing countries and industrialised countries, there are many unpleasant cultural attitudes 
condemning those with tuberculosis such that those who have it will wait until they can no longer 
function before they seek treatment. Changing attitudes towards tuberculosis can be extremely 
difficult when shadowed by firmly entrenched cultural beliefs. The patient must be given the incentive 
to seek treatment and this incentive, such as the need to feel better, must be stronger than any other 
factors such as his or her shame. Likewise, society must have the incentive to report cases, such as a 
perception of the benefit of the eradication of tuberculosis. Such needs highlight the key role of 
education and awareness of tuberculosis in containing its spread.
5-2:3b Environmental Control
On a different level, in containing the spread of tuberculosis, one can focus on controlling the 
environment where tuberculosis is present. One of the best ways to control the spread of tuberculosis 
is to limit contact between those with the disease and those who are susceptible to infection. 
Unfortunately, contact can only be realistically limited after the infectious case of tuberculosis has 
been identified. The use of facial masks for the patient and encouraging the patient to cover his or her 
mouth is a common practice and is surprisingly effective in keeping the infection from becoming 
airborne. This method is commonly used with very infectious cases of tuberculosis in industrialised 
countries and remains one of the only effective environmental controls within the financial means of a 
developing country. One of the areas for the greatest amount of concern is containing the spread of 
tuberculosis in hospitals. In industrialised countries, severe cases of tuberculosis are placed in 
isolation in hospitals so as not to infect the air of other hospital patients. In the United States, patients 
are not allowed to leave the area of isolation until they have had three negative sputum smear on three 
consecutive days. Also, health workers are encouraged to wear respirators when dealing with 
tuberculosis patients. Another environmental method of control is the use of air disinfection through 
Ultraviolet Radiation (UV) of 245 nm. wavelength light. Although this method of disinfection is less 
effective at high humidities, it is still used in many areas in hospitals and even some public institutions 
such as shelters for the homeless, whereby the upper air in a room is irradiated and then circulated. 
Effective use of UV radiation can reduce airborne tubercle bacilli by employing approximately 20 air 
changes per hour (ACH) (Riley, 1993). Air in a room can also be filtered through a container where it 
is irradiated or where it passed through a high-efficiency particle filter (HEPA). Unfortunately for 
developing countries, such expensive measures prove to be implausible due to financial constraints.
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5-2:4 Prevention
5~2:4a Chemoprophylaxis and Preventative Therapy
Those patients who are found to have been infected by tuberculosis can be treated with isoniazid 
to take advantage of the delay between infection and disease. Preventative therapy uses one drug, and 
its strategy in limiting the disease centres around attacking tuberculosis when the population is quite 
small and the likelihood of resistant mutants is low. Chemoprophylaxis similarly involves giving 
small doses of an antibacterial to an individual who has not yet been infected with tuberculosis but has 
had close contact with it in order to prevent infection and disease. The drug of choice for prevention 
and prophylaxis is isoniazid, quite possibly, the strongest bactericidal tuberculosis drug. Isoniazid is 
given in dosages of lOmg/kg daily in children and adolescent and 5 mg/kg daily for adults for a 
minimum of 6-12 months (Geiter, 1993). Patients considered for preventative therapy are often those 
at high risk for the disease such as those with HIV, intravenous drug users and children (CDC, 1991). 
Nevertheless, there is some controversy over the risk of isoniazid preventative therapy due to the risk 
of isoniazid induced hepatitis, usually estimated at around 14-23 cases per 100 000 (Snider and Caras, 
1992). There is also the rarer problem if an individual has been infected with an isoniazid resistant 
form of tuberculosis, in which case the drug will be ineffective. In this case, the individual is given 
two drugs to which it is assumed that the infection is sensitive. In considering isoniazid preventative 
therapy, it is important to look at the relevant population that a patient comes from.
It is difficult to determine which individuals will develop tuberculosis from infection. Those at 
high risk are obviously strong candidates for care, however, considering that only approximately 10% 
of those HIV-seronegative that are infected will develop the disease, this prevention inevitably 
concludes with the unnecessary treatment of 90% of infected individuals. It is therefore necessary to 
look at the cost of such treatment, not only in monetary terms, but in terms of the patients' quality of 
life. This treatment must then be evaluated in terms of its overall utility and effectiveness when 
compared to the opportunity cost of other treatment strategies in an existing tuberculosis control 
program. In the case of a programme funded by limited means, the opportunity costs of the use of 
preventative therapy might not be justifiable when they include the expense of drugs to treat a large 
population of infectious cases of tuberculosis.
5-2:4b The BCG Vaccine
More than seventy years ago, the Bacille Calmette-Guerin (BCG) vaccine was obtained from a 
virulent strain of Mycobacterium bovis and distributed to labs around the world for further attenuation. 
BCG is a live, enervated vaccine that functions in stopping the progression of tuberculosis infection 
into disease. This vaccine has been used on the general population of most countries except for the US
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and the Netherlands. It is generally thought to be effective, although the level of effectiveness has 
been difficult to prove and is therefore an issue for controversy. When the BCG was stopped in 
Sweden, TB increased in children by six times. In contrast, in Chile, it proved only 10% effective and 
in India, BCG proved 0% effective in a study of 200,000 (Fine and Rodrigues, 1990; Sepulveda, 
Parcha, Sorensen, 1992). Data from studies on the vaccine's effectiveness have varied from below 
10% to 80%, as is seen in Figure 5-9. There are several theories attributing this inconsistency which 
include the relative natural exposure to Mycobacterium bacteria, the effectiveness of BCG on varying 
stages of disease, physiological, geographical and genetic differences in tubercle bacteria, and the 
purity of the vaccine itself (Fine & Rodrigues, 1990). Nevertheless, the reasons for the BCG vaccine's 
effectiveness remain unanswered.
Figure 5-9: The Effectiveness of BCG Vaccination in Various Studies
♦Signifies those studies that were controlled trials; all others are observational studies.
Data compiled by. Fine, 1994: p. 63
One of the groups that the BCG vaccination offers the greatest protection to is children. There is 
even some evidence in Zambia to suggest that vaccinating HIV-1-infected children with BCG is 
advantageous in preventing the disease and has little incidence of vaccine-induced illness 
(Papaevangelou and Borkowsky, 1996). The BCG vaccination has primarily proven to be effective in
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children in preventing non-pulmonary tuberculosis. Hence, vaccination for children is of limited 
utility in preventing the spread of tuberculosis as it predominantly works to prevent non-infectious 
forms of tuberculosis. Nevertheless, it is effective in preventing miliary tuberculosis as well as 
tuberculosis meningitis which young children are more inclined to develop. Therefore, vaccination in 
a population where there is a high prevalence of tuberculosis should be performed as soon in life as 
possible (ten Dam, 1993).
BCG vaccinations can be used on a national level for immunisation, but when the risk of 
tuberculosis infection drops below certain levels, its wide scale use can no longer be justified in terms 
of protection or cost effectiveness. The author ten Dam (1993) maintains that when the risk of 
tuberculosis infection drops lower than 0.1% per year, the benefits of BCG vaccinations are 
outweighed by adverse reactions. In such cases, the author suggests that selective vaccination be used 
for those in high risk groups. Indeed, the impact of BCG immunisation at high levels of annual risk of 
infection becomes very cost-effective in terms of the annual cost per death averted. Yet, when the rate 
of the annual risk of infection drops below 1%, the cost per death averted rises with every death and 
the intervention becomes less and less cost effective. This is illustrated in Figure 5-10.
Figure 5-10: The Cost-Effectiveness of BCG Immunisation and 
Tuberculosis Case Treatment as a Function of the Annual Risk of Infection
ANNUAL RISK OF INFECTION (PERCENTAGE)
Source: Murray and Styblo, 1993
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5-2:5 Variables Influencing Case Holding
5-2:5a Causes of Patient Default
A cogent element to the successful treatment of tuberculosis is patient compliance. The greatest 
risk factor for relapse after tuberculosis treatment is non-compliance due to default from treatment 
(Brenner and Poziak, 1993). Patients who have not complied with treatment for two months or more 
are considered defaulters, although the term is used loosely for any patient that has failed to comply 
with treatment for any length of time. There is no cultural or demographic determinant of patient 
compliance (Sumartojo, 1993). According to Kilpatrick (1987) treatment compliance is dependent on 
the patient and doctor's understanding of the importance of treatment, efforts of patient and health 
worker to co-operate, a patient's reaction to the drugs, and lastly, chance. In TB chemotherapy, the 
patient must take numerous pills each week and must continue this for between eight and eighteen 
months. In light of this, it is not surprising that patients frequently do not comply with their treatment. 
Often, once a patient feels better, he or she will stop taking the medication, erroneously thinking that it 
is no longer important or that he or she is cured. Case holding becomes difficult because modern 
chemotherapy is so effective, that the patient feels better after a few weeks and simply loses the 
incentive to take any more medication. Compounding this, if patients live in circumstances whereby 
they are severely impoverished or suffer from homelessness or drug addiction, it is all the more 
difficult for them to comply. Unfortunately, these are the circumstances where tuberculosis is most 
often found, making its treatment and containment complex. If a patient forgets to take his or her 
drugs, cannot afford to buy the drugs that he or she needs or cannot afford to travel to a clinic to 
receive the drugs, this obviously impedes his or her treatment. For adequate patient compliance, 
patients must be given the incentive to take their medicines, be capable of taking their medicine, see 
the value of taking these medicines and find that taking their tuberculosis medication is not too 
inconvenient or difficult a task (CDC, 1989). In essence, the patient must view the future benefits of 
the treatment as greater than its cost. Far too often, default results from patient myopia whereby the 
patient perceives the cost of having to take such a large amount of pills over such a long time as 
outweighing the patient's subjective discounting of the future benefits of treatment.
5-2:5b Responsibility of the Health Worker
Special attention in case holding must be given to those patients who are on a retreatment 
regimen, alcoholics and those with mental or physical problems. No matter from which country a 
tuberculosis programme is run, there will always be a percentage of patients who are unwilling to take 
their medication. In considering this, all tuberculosis programmes should have some sort of network 
whereby a patient's treatment can be closely monitored. There are several ways in which patient
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compliance can be monitored, however, few of these are completely effective. These methods include 
self report, estimates, missed appointments, pill counting, pharmaceutical records, and urine testing 
(Chaulet, 1987). Blister packs protect pills against heat and humidity damage, but only act as a 
reminder, not a guarantee that a patient will take his or her medication each day (Fox, 1990). In 
addition, health worker's estimates of TB patients' medication consumption is flawed. In a study of 
patients with TB, only 32% of non-complying TB patients were identified, and 8% of those complying 
with treatment were incorrectly identified (Wardman et al., 1988). Self reporting suffers because of 
fear of those administering care or an unwillingness or forgetfulness in reporting (Chaulet, 1987). One 
study in particular showed that 28% of patients lied about taking their medicines (Preston & Miller, 
1964). Urine tests are inconsistent in measuring drug intake due to different metabolism rates between 
patients. In addition, some microelectronic devices attached to drug containers only measure whether 
a patient has opened them. These containers can be destroyed, lost, left open or repeatedly opened 
because of curiosity (Sumartojo, 1993). Those in industrialised countries are usually given their 
medication and then checked by doctors to make sure that they are taking it. Patients who are 
considered likely to fail to comply with treatment are often monitored with directly observed therapy 
(D.O.T.), whereby a worker visits the patients, and watches the patient consume each dose of his or 
her medication (Kenneth, 1992). This form of patient monitoring has become quite popular because it 
limits default and the cost of hiring a health worker still proves less than the cost of retreatment and the 
associated potential increased transmission. D.O.T. often takes a slightly different form in developing 
countries whereby during the intensive phase of treatment (usually the first two months) patients must 
come to a health facility each day and receive treatment. Those who fail to appear for their scheduled 
appointments are usually visited by an appointed nurse to discover why the patient is having trouble 
complying. Unfortunately, these efforts in case holding are quite dependent on the health-care 
personnel. The nurses that care for the patients must have a genuine interest in the programme and 
attempt to foster a good patient-nurse relationship. Programmes where apathy is prevalent cannot help 
but suffer because patients are forgotten about and their treatment is not followed-up. This can result, 
for example, in patients moving from one health facility to another receiving treatment for a short time 
and then disappearing.
Another aid to case holding is the use of tangible incentives or gifts to patients which motivate 
them either by making the process of seeking treatment easier or making their overall quality of life 
slightly better. Such examples of incentives that have been used in the United States are bus tokens, 
coats, shoes, a new car battery and gasoline. Psychological explanations for such gifts suggest that 
rather than bribe the patient to finish treatment, they serve to solidify a strong patient-nurse 
relationship which is what commits the patient to finishing his or her treatment (Brenner and Poziak,
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1993). The nurse almost takes on a maternal role for the patient, listening to problems and 
establishing trust.
5-2:5c The Use of Hospitalisation for Patient Compliance
As a last resort, hospitalisation has been used in order to ensure patient compliance for the
intensive phase of treatment. Usually, hospitalisation is reserved for very serious cases of tuberculosis, 
whereby the patient's life is in danger. For most tuberculosis cases, ambulatory care (defined as 
outpatient care) is used where the patient makes daily or monthly visits to a health facility to receive 
treatment. Hospitalisation proves to be very expensive as it inherently involves not only the drug 
treatment of patients but the costs of meeting their other needs. This drastic measure undoubtedly 
helps, however, it is often beyond the means of a developing country. Nevertheless, it could be argued 
that when compliance falls low enough, hospitalisation might be more cost-effective if it is cheaper 
than the cost of retreatment and resistance that results from patient non-compliance. The work of 
Murray et al. (1991) concerning Malawi, Mozambique and Tanzania revealed that if hospital 
admission increased the cure rate by 5%, the cost per case cured would be US $777-2 008. A cure rate 
increase of 10% would decrease the average incremental cost to US $389-1 004 per case cured. 
Finally, a cure rate increase of 15%, would decrease the incremental marginal cost per case to the same 
as the incremental marginal cost of any ambulatory drug treatment for tuberculosis, US $259-669. 
These results suggest that when hospital admission increases the cure rate of treatment above a certain 
level, and non-compliance to ambulatory care is high, then the cost-effectiveness of hospitalisation 
becomes cheaper or equivalent to ambulatory care because it eliminates or greatly reduces default.
5-2:5d Brenner and Pozsiks' Case Holding Model
To illustrate the importance of case holding, Brenner and Pozsik (1993) have developed a model
where they studied case holding's effect on the overall containment of tuberculosis. In this model, 
three examples are studied, (1) those industrialised countries with relatively good case holding, (2) 
those industrialised countries with less than satisfactory case holding and (3) a developing country . 
The purpose of the first two examples (1 & 2) in developed countries is to show that where case 
finding, access to care and efficacy of chemotherapy are all equal to each other, case holding has a 
strong impact on the overall reduction in the sources of infection: 88% versus only 72%. In comparing 
the latter two (2 & 3), the industrialised country and the developing country have the same case 
holding capacity of 80%. The developing country suffers not only from weak case holding but an 
additional host of other problems. It is shown to suffer because the proportion of cases detected, 
proportion of those beginning therapy and the efficacy of its chemotherapy are all much lower than
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this industrialised country, making its comparative reduction in sources of infection much lower: 38% 
versus 72%. Murray (1994b) maintains that unless a developing country can maintain case holding at 
80%, it is not worthwhile to concentrate on expanding case finding. Hence, in this model, one can 
observe how important case holding is to the effectiveness of a tuberculosis control programme.
Table 5-4: A Measure of the Overall Impact of Case Finding on the 
Success of Tuberculosis Control Programmes Under Changing Variables
Measure of Overall Impact = Case Finding 
and
Surveillance
X Access to 
Care
X Effectiveness 
of TB Drugs
X Case
Holding
Reduction in
Sources of Infection
= Proportion of 
Cases 
Detected
X Proportion
Beginning
Therapy
X Efficacy of 
Chemotherapy
X Proportion
Completing
Therapy
Industrialised Country 
with good 
case holding
88% = 95% X 99% X 96% X 98%
Industrialised Country 
with less than 
satisfactory case 
holding
72% = 95% X 99% X 96% X 80%
Developing 38% = 70% X 80% X 85% X 80%
Country
Source-. Brenner and Pozsik, 1993: p. 186
This model also highlights the overwhelming problems facing developing countries. It suggests that 
their problems not only centre around case holding but also around several other factors by virtue of 
the fact that there are so many more cases to be dealt with. High levels of case holding are a challenge 
to maintain and methods to ensure that patients take their medicines on a regular basis are each 
incomplete by themselves. The best functioning programs are dependent on not one method, but a 
comprehensive approach to patient compliance. Indeed, comprehensive programmes utilising patient 
monitoring and observation, verbal commitments, monetary incentives, convenient accessibility to 
care and caring and understanding staff seem to be the most successful at inducing patient adherence 
to treatment.
5-2:5e Information Documentation
Case holding is dependent on an accessible record of patients in order to keep track of their 
treatment progress. It is essential that all information about a patient, relevant to his or her treatment, 
be recorded. Information such as the treatment regimen, drug reactions, background health 
information, the patient's address and a contact person are essential as well as an accurate appointment
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attendance record. This information must be convenient to record and easy to retrieve and read if 
required. It can correspondingly be recorded on a computer or on patient treatment cards and a patient 
register book. In industrialised countries, computer programmes such as EPI-INFO developed by the 
WHO and the CDC are used to record such information. In developing countries, where the use of 
computers is often too expensive in health care institutions, the IUATLD has a specific format for the 
collection of TB information in developing countries including a patient register, patient treatment 
cards, TB laboratory registers, sputum examination registers, quarterly reports and order forms. 
Again, the correct recording or this information is strongly dependent on the health-care worker or 
equivalent. Where there is an overwhelming caseload and little available time or little interest in 
recording patient information, it will be neglected.
Figure 5-11: The Relationship Between the Annual Risk of 
Infection and the Incidence of Smear-Positive Tuberculosis
Risk of Infection (percent)
Source-. Murray, Styblo and Rouillon, 1993: p. 235
5-2:5f The Annual Risk of Infection and Prevalence
Patient information is not just important for case holding, but on a macro level, serves to predict
the future nature of a tuberculosis programme. It functions in determining the incidence of 
tuberculosis per 100 000 population and the prevalence, which is usually equal to twice the incidence 
(Broekmans, 1994). It is estimated that for every 1% of new annual infections, there are 50-60 new 
smear-positive cases of pulmonary and 50-60 new smear-negative and extra-pulmonary cases per 
100 000 population (Crofton, Home and Miller, 1992). Also, the incidence of pulmonary smear­
positive tuberculosis is accompanied by a rise in the annual risk of infection as illustrated in Figure 5­
11. For each 1% rise in the annual risk of infection there are 49 cases of smear-positive tuberculosis 
per 100 000 of the population (Murray, Styblo and Rouillon, 1993). Indeed, from these figures, future
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drug needs, personnel and facility provisions of the disease and the formation of control strategies are 
developed.
5-2:6 Costs of Control Efforts
The costs of containment measures for tuberculosis are an essential issue for consideration in any 
TB programme. Educational means for containment might prove expensive as would screening an 
entire population for tuberculosis. In all areas of the world, but especially where funds are scarce, 
economic considerations must be made as to the threat and prevalence of tuberculosis versus the 
measures taken to contain the disease. If the incidence and cost of treating tuberculosis is low and 
therefore the risk of successful spread is low, the cost of these measures might not be justifiable. 
However, in developing countries, where the risk of tuberculosis is significant, as well as the threat of 
AIDS, remuneration for such expenditures for containment is more than accounted for. In developing 
countries, where the prevalence of tuberculosis is high the current strategy could be said to be based 
around case finding and treatment, yet in industrialised countries, where the incidence of tuberculosis 
is lower, the control strategy takes on a different emphasis of surveillance and containment (Brenner 
and Pozsik, 1993).
5-2:7 Summary of Section 5-2
It is important to recognise that endeavours to manage tuberculosis involve not one but a 
combination of several factors. Control efforts should focus on managing drug supplies, information 
collection and case holding, while concentrating on containment and prevention measures and 
developing a sound administration infrastructure. The best tuberculosis programmes implement a 
balanced combination of all these variables, adjusting to the financial means of each country. It is only 
through the utilisation of all elements of tuberculosis control that efforts to manage this disease will be 
successful.
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Section 5-3
The Global Impact of TB
After looking at both the nature of tuberculosis and control efforts in the previous two sections, 
this section will explore the present global impact of tuberculosis. The changing nature of TB in the 
HIV era will be discussed as well as costs associated with new cases of tuberculosis. This section will 
also look at some recent work highlighting tuberculosis as a top disease control priority by the World 
Bank and conclude with a discussion on future burden and expenditure. In the context of high 
tuberculosis growth, there is likely to be associated growth in drug resistant tuberculosis.
Tuberculosis has had a striking global impact in the last ten years. A disease that was thought to 
have been eradicated has been revived by HIV. Evidence of this can be seen from rising rates of new 
tuberculosis cases and a halt in the overall fall in tuberculosis. From 1955-1985, new tuberculosis 
cases declined 6% per year whereas between 1985-1992 new cases actually increased by 16% (Yow 
and Demmler, 1992). This is significant considering that there are available, effective treatments for 
the disease which should logically result in a fall of the incidence of TB. In comparing figures from 
1980-1984, and 1985-1989, it is possible to see that there has been only a 2% fall in tuberculosis in 
Southeast Asia, only a 1% fall in Europe, and no change at all in Africa (On and Hershfield, 1993). 
Globally, tuberculosis accounts for more than 3% of the total burden of disease (Murray, 1994b), and 
represents 7% of all deaths and 26% of all avoidable deaths (Murray, Styblo and Rouillon, 1990).
Table 5-5: Incidence of Tuberculosis 
in Southeast Asia, Europe, and Africa
Incidence (per 100,000 population)
1980-1984 1985-1989
Southeast Asia 87 85
Europe 34 33
Africa 57 57
Source: Orr and Hershfield, 1993
5-3:1 Global Changes in the Annual Risk of Tuberculosis Infection
The epidemiological situation of tuberculosis is such that due to the better quality of care and 
smaller levels of transmission, its annual decline in industrialised countries is occurring much faster 
than in developing countries. Kochi (1991) estimates from WHO data before 1991, a decline greater 
than 10% in developing countries, but a comparative decline of only 0-3% in Sub-Saharan African and 
the Indian subcontinent, as can be seen in Table 5-6. Logically, the annual decline in the risk of
165
infection is dependent on the prevalence of TB and the availability of health resources. Area 3 
(Middle-income and East and Southeast Asia) and area 4 (Sub-Saharan African and the India 
subcontinent) both have the same annual risk of infection, but health resource availability is superior in 
area 3 and therefore it has experienced a greater annual decline in the risk of infection.
Table 5-6: The Epidemiological Pattern of Tuberculosis
Area Current Annual 
Risk of Infection
Annual Decline in 
the Risk of Infection
Health Resource 
Availability
(1) Industrialised Countries 0.1-0.01% >10% Excellent
(2) Middle-income in Latin 
America, West Asia and
North Africa
0.5-1.5% 5-10% Good
(3) Middle-income in East 
and Southeast Asia
1.0-2.5% >5% Good
(4) Sub-Saharan Africa and 
the Indian subcontinent 1.0-2.5% 0-3% Poor
Source: Kochi, 1991: p. 1-6.
5-3:2 Costs
Who could have predicted that HIV would arise and cause cases of TB to increase? Investment 
in most tuberculosis programs dwindled in the late nineteen-seventies and early nineteen-eighties due 
to the fact that tuberculosis was perceived to be a disease that was no longer a threat. As is evident, 
this lack of expenditure caused a greater proliferation of new cases of TB both in developing countries 
and industrialised countries. Bloom and Murray (1992) estimate that in the United States alone, the 
cost of new or 'excess' cases of tuberculosis since 1985 resulting in greater transmission is 
approximately equal to US $340 million, plus an added 4 400 discounted lost years of life, lost 
productivity, and social production equalling an added US $300 million. The cost of discounted years 
of life was estimated to be US $20 000 per year, discounted at 3%. These authors estimate that the 
average treatment cost per patient in the US for TB is US $25 000. Costs are five times higher for 
resistant cases of TB and ten times higher in terms of the costs of drugs. An outbreak of MDR-TB 
(see section 5-1) in ten patients in Fort Worth, Texas cost US $950 433 or an average of US $95 000 
per patient (CDC, 1990). Likewise, at the Jewish Hospital, Denver (which specialises in treating 
resistant cases of TB) MDR-TB costs US $100 000-200 000 per patient. Other estimates are that this 
form of TB can cost up to US $250 000 (FDA Online Documents, 1995)
5-3:3 DALY s and TB
Much work has been performed to emphasise the need for better global tuberculosis control. 
WHO has made tuberculosis one of its top priorities and the World Bank has highlighted the cost-
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effectiveness and high cost-utility resulting from tuberculosis control efforts in terms of years of life 
saved and corresponding disability adjusted life years (DALYs). Short-course chemotherapy for 
tuberculosis saves more DALYs than almost any other intervention because of the severe impact of the 
disease (Jamison, 1993). In terms of cost, a disease like diarrhoea will be much cheaper to treat, 
compared to tuberculosis, but the impact of TB on the life of the individual is comparatively higher. 
For instance, a £30 tuberculosis drug regimen might allows an individual to live to his or
Table 5-7: Cost per DALY Averted for 
Smear-Positive Tuberculosis Care Under Hospitalisation
Country Cost Per Case Cost per DALY Averted ($US)
Botswana 367 6.2
Malawi 103 1.8
Mozambique 161 2.7
Tanzania 132 2.2
Source: Murray, 1994b: p. 200
her life expectancy, an extra 50 disease-free years. Similarly, US $100 000 spent on tuberculosis 
chemotherapy will save 500 patients and avert 35 000 DALYs, whereas the same amount spent on 
diabetes benefiting the same amount of patients only saves 400 DALYs (World Bank, 1993). To 
better illustrate this, Murray (1994b) has calculated the potential cost per DALY averted in three states 
in sub-Saharan Africa.
Figure 5-12: Top Ten Health 
Interventions in Terms of Cost per DALY Averted
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Adapted from : Jamison and Mosley: 1994
The costs per DALY averted in Table 5-7, considering that they include the cost of hospitalisation, 
average at around US $3.22 and roughly correlate with Jamison's (1993) estimate of the cost per 
DALY for TB of US $3.00. In Jamison's (1993) estimates of the top ten 'cost-effective' interventions,
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TB is the second in priority, only lower than the targeted screening of leprosy (another Mycobacterium 
disease). Therefore, TB merits greater attention in disease control expenditure. Indeed, such a low 
cost per life saved highlights tuberculosis as a focus for funding from health care budgets. However, 
despite such high returns per dollar expenditure in comparison to other medical interventions, 
according to Murray (1994b) tuberculosis still globally accounted for approximately 46.5 million 
disability adjusted life years (DALYs) in 1990. Some of this measure can be attributed to HIV, but not 
as much as might be expected: a large proportion of it is occurring in those who are HIV-seronegative.
Table 5-8: Disability Adjusted Life Years for 
Tuberculosis in Selected areas in 1990 (in thousands)
REGION MALE FEMALE TOTAL
Established Market Economies 106 46 152
Former Socialist Economies of Europe 308 53 361
Middle East, North Africa and South-west Asia 2 165 1 880 4 045
India 6 282 4518 10 800
China 3 469 2 445 5 914
Other Asia and Pacific 5 165 3 771 8 936
Latin America and the Caribbean 1 508 1 061 2 569
Sub-Saharan Africa 7 464 6 209 13 673
Total 26 468 19 982 46450
Source'. Murray, 1994b: p. 195
It is an unfortunate, but valid assertion that expenditure on HIV-seronegative individuals results 
in better returns than treating HIV-seropositive individuals. This is primarily due to the 100% 
probability that those with HIV will progress to AIDS and have a drastically shortened life span. 
Because of a shorter life expectancy, there are fewer years of life gained from TB treatment 
interventions. Correspondingly, if considering the life expectancy of a patient that already has AIDS 
into a DALY calculation, DALYs saved for HIV-seronegative individuals are much higher than those 
gained from HIV-seropositive individuals. This highlights the fact that given the nature of this 
measure, DALYs for HIV-seropositive individuals and HIV-seronegative individuals can differ. This
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assertion is not meant to recommend that empirically HIV patients should be denied treatment because 
they are economically a greater expense, but only acts as a theoretical caution in calculating DALYs 
for TB/HIV co-infected patients. Indeed, such economic considerations must indeed be kept in check 
by the moral obligations of a society.
5-3:3a Global Burden of Disease According to HIV Status
Current TB increases cannot be only attributed to those already affected by HIV. As can be seen
from Table 5-9, only 3% of the burden of disease in DALYs was attributed to HIV in 1990, and this is 
expected to rise to only 10% in 2000 (Murray, 1994b).
Table 5-9: Disability Adjusted Life Years 
According to Type and HIV Status in 1990 (in thousands)
HlV-status Smear-positive Smear-negative Extra-pulmonary Total
HIV negative 22 5528 18 248 4 280 45 057
48.5% 39.3% 9.2% 97.0%
HIV-positive 697 543 154 1 394
1.5% 1.2% 0.3% 3.0%
Total 23 225 18 790 4 435 46 450
Source-. Murray, 1994b: p. 196
5-3:3b Priorities in Tuberculosis Control
Because there are so many smear-positive patients and they are the infectious cases of TB, this 
is usually the focus for tuberculosis control programmes since it is the most effective form of treatment 
in terms of cost and utility due to lives saved and spread containment. Smear-positive tuberculosis in 
1990 accounted for 48% of global TB burden. Murray, Styblo and Rouillon (1990) estimate that for 
every DALY averted by a smear-positive, HIV negative, patient's treatment, four are averted over the 
next two decades. In contrast, treatment of smear-negative patients under an 80% case detection rate 
is predicted to reduce only 25% of global TB burden. It is estimated that TB treatment of those who 
are smear-negative is 3.5 to 8 times the cost of treating smear-positive TB. Nevertheless, treatment of 
smear-negative patients still proves to be beneficial in terms of cost-utility as it remains low compared 
to other health interventions. Treatment of smear-negative patients is also significant because they 
often turn into smear-positive cases as their disease progresses. In contrast to smear-positive and 
smear-negative, HIV-seronegative cases, concentration on smear-positive HIV patients is estimated to 
reduce current burden at most, by 10% (Murray, 1994b). According to Murray (1994b) those 
interventions for tuberculosis that prove to have the highest cost per DALY averted can be prioritised 
starting as follows below.
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(1) S.C.C. for HIV-seronegative, smear-positive TB cases
(2) S.C.C. for HIV-seropositive, smear-positive TB cases
(3) S.C.C. treatment, HIV-seronegative pulmonary TB cases
(4) S.C.C. treatment of HIV-seropositive pulmonary TB cases
(5) chemoprophylaxis of close contact cases
(6) chemoprophylaxis of high risk contact cases
5-3:4 New Expenditure and Future Burden
Murray (1994b) estimates that in countries in different regions of the world, cost-effective 
tuberculosis control can be achieved with an expenditure of 8.4% of the public health sector budget 
and US $0.86 per capita expenditure in sub-Saharan Africa, 1.7% of the public health
Figure 5-13: Predicted TB/HIV 
Co-Infection by the Year 2000 (in thousands of cases)
Mid. East=Middle East, N. Afr.=North Africa, S.W. Asia=South West Asia 
Adapted from'. Murray, Lopez and Jamison, (1993)
sector budget and US $1.65 per capita expenditure in Latin America and the Caribbean, 4.5% of the 
public health sector budget and US $0.60 per capita expenditure in India and 2.4% of the public health 
sector budget and US $0.94 per capita expenditure in other parts of Asia and surrounding islands. The 
estimate for sub-Saharan Africa is based on that for a country that spends US $10 per capita on health. 
This amount ($0.86) might seem an extraordinarily high estimate for this, but it reflects the immense 
burden that this area experiences from tuberculosis. Indeed, tuberculosis treatment is under-funded in
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virtually all parts of the world. Globally, the current estimate of expenditure is US $300-500 million 
per year when in fact US 1.75 billion dollars should be spent per year, representing a 1.25 billion 
dollar gap.
The contribution of HIV on tuberculosis is expected to continue as is suggested by rates of co- 
infecton. Figure 5-12 illustrates the projection of both HIV and TB/HIV co-infection in 2000: as HIV 
grows, so are expected cases of TB/HIV co-infections. This suggests that unless more money is spent 
for tuberculosis control, the number of new cases of tuberculosis will continue to grow.
5-3:5 Criticisms of DALY Derived Conclusions on TB
When considering the conclusions of DALYs, it must be remembered that this measure is 
conceptually and methodologically flawed (see Chapter 2 for a more complete description and 
criticism of DALYs and their related methodology) and it is possible that their conclusions may not be 
entirely correct in their portrayal of the burden of disease. For instance, it is highly possibly that in 
calculating the burden of disease of TB due to HIV, these authors may have grossly underestimated it 
because of the fact that it can be difficult to identify HIV in TB patients.
In addition, one criticism of DALYs when considering their role in prioritising treatment is that 
they are a measure that includes the assumption that a government has taken the entire responsibility 
for all of its citizen's welfare or has the financial ability to do so. Hence, strictly speaking this is an 
approach that is highly dependent on the health care system available. If a country's health care is 
primarily provided through private sources, then the DALY becomes less relevant. Although much of 
TB treatment is provided for by the government because of its perceived critical health threat, many 
countries lack the financial resources or the incentive to make it a top health priority. Therefore, 
despite the fact that the use of DALYs concludes that TB is a highly cost-effective intervention, 
investment in its cure may not always manifest. Indeed, it is unlikely that the message of DALYs will 
have much of an impact on already economically over-burdened developing countries (Kibuga, 1994).
5-3:6 Summary of Section 5-3
The total burden of disease accounted for by tuberculosis still proves to be quite great. Although 
this disease accounted for 46.45 million DALYs in 1990, treatment for this disease represents one of 
the most cost-effective interventions available to both industrial and developing countries. Efforts to 
discount tuberculosis as an HIV disease are convoluted with the fact that a supposedly very large 
proportion of cases are HIV negative. Nevertheless, this disease's relationship with HIV cannot be 
ignored, proven by projected cases of TB/HIV co-infection which are expected to rise significantly. 
Poor records of funding for this disease suggests that such rises in TB will cause growing numbers of
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future cases in both HIV positive and HIV negative individuals. Such a rise in cases will sadly result 
in a greater future morbidity burden if imperatives to treat it are ignored.
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Section 5-4
Conclusion to Chapter Five
Tuberculosis remains one of the world's greatest health threats and still encompasses a 
disproportionate amount of the global burden of disease, considering it is a curable disease. Methods 
for the treatment of tuberculosis rely solely on drug treatment that is almost 25 years old, although the 
impact of the disease has changed in the era of HIV, proven by the rise in new TB cases. The 
synergistic effect between HIV and TB has caused the largest growth of new cases of TB in the age 
group of 15-45, the most economically productive part of an individual's life. Discounted as an 
disease of the past, tuberculosis is not a prominent health priority in many countries. This is despite 
the fact that TB treatment is considered one of the most cost-effective interventions. Undoubtedly, 
tuberculosis will continue to grow due to its movement with HIV. A lax attitude to this health threat, 
compounded with the lack of education of doctors and health authorities in recognising the disease will 
allow the disease to thrive unnoticed. Until greater attention is focused on the threat of tuberculosis, 
tuberculosis cases will continue to have the unfortunate feature of being one of the greatest causes of 
death from a single pathogen in the world. As discussed in Chapter 6, most of these deaths are likely 
to occur in developing countries, who experience the greatest burden of this disease.
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CHAPTER SIX
TUBERCULOSIS IN DEVELOPING COUNTRIES:
THE IMPACT OF CURRENT MANAGEMENT AND EXPENDITURE
Introduction
The IUATLD (1994) cites tuberculosis as the greatest single cause of death for those aged 
between 15-40 in developing countries. Over 3 million new cases of smear-positive TB occur in 
developing countries per year. Using this number, if there are 1.2 cases of smear-negative pulmonary 
TB and extra-pulmonary TB for every smear-positive case, this means a total of over 6 600 000 new 
cases of TB per year. From these new cases, 10-14% will be infected per year and 0.6-1.2% of these 
will progress into disease (Murray, Styblo, Rouillon, 1990). The annual risk of infection (ARI) in 
developing countries ranges from 1.0-2.5% (Cauthen, Pio, ten Dam, 1988), whereas in industrialised 
countries it averages to be far less than 1% (Styblo, 1989). Compounding this is the burden of HIV. 
In 1992, there was an estimated 4 million people who had TB/HIV co-infection and 95% of these were 
in developing countries (Narain, Raviglione, Kochi, 1992).
After defining tuberculosis and discussing the techniques of its management in Chapter 5, this 
chapter will familiarise the reader with the complex problem of tuberculosis in developing countries 
and present an analysis of existing literature concerning the impact of past expenditure on tuberculosis 
treatments. It will also present the methodology used in this thesis.
In order to answer the question of the impact of resistance on the cost of tuberculosis treatment 
in developing countries, it is important to know the particular challenges that developing countries face 
in containing tuberculosis. Also, past studies on those variables affecting the cost of treatment as well 
as the cost-effectiveness of treatments are integral to discussions on resistant TB's impact on cost. 
Section 6-1 will focus on developing countries and methods in which they manage tuberculosis as well 
as challenges that they face and the success of their tuberculosis programmes. Section 6-2 will give a 
comparison of various TB treatments and review methodology and past literature on the cost-
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effectiveness of these treatments. TB in developing countries is such a major health threat that 
expenditure for its treatment must be carefully considered.
175
Section 6-1
Tuberculosis in developing countries:
THE NEED FOR BETTER MANAGEMENT
Problems in the treatment of tuberculosis that are common in industrialised countries are 
accentuated by the circumstances in developing countries. In developing countries, tuberculosis 
treatment is complicated by widespread ignorance of the disease, poor drug supplies and a greater 
incidence of HIV. This section shows how TB treatment can be standardised in developing countries 
with a national tuberculosis programme. This section also presents some of the specific challenges 
that developing countries face in containing tuberculosis such as TB resistance rates and TB/HIV co­
infection. TB resistance is shown to be higher in developing countries, and reasons for this are 
explored. Hence, variables determining TB resistance, specific to developing countries, are also 
discussed. These variables will be further discussed in following chapters studying TB in Ethiopia.
6-1:1 Problems in Treating TB in Developing Countries
As a result of ignorance, those under care fail to comply with drug treatment, doctors fail to 
recognise and diagnose this disease and treatment is substandard and inconsistent. In addition to this 
problem, drug supply is limited such that, in some countries, it is difficult to get the required drugs 
needed to treat the disease. Those working to treat TB must often face extremely remote conditions 
with rudimentary medical support. In contrast to this is urban areas of developing countries where 
drugs fail to be well regulated in pharmacies, and can be purchased on the black market, making them 
quite freely available. This is particularly significant because, for treating other infections, there are 
usually drugs that are cheaper and equally effective to TB drugs. Such use of these drugs, especially 
rifampicin, results in both resistance to the drugs and a shortage of them in tuberculosis programmes 
(Research in Microbiology, 1993). Hence, a schism has formed among developing countries. Those 
with very low incomes have problems in getting the correct supplies and drugs. In contrast others 
higher income developing countries face different problems of managing existing drug supplies in 
order to avoid the frivolous use of TB drugs and therefore its associated drug resistance. Added to this 
is the more fundamental problem which relates to the actual treatment regimens used. Many countries 
lack the funding to afford more modem drugs and are therefore confined to using drug regimens which 
are less effective. In addition, such problems are also accentuated by the large incidence of AIDS, 
poor nutrition and poor sanitation that have caused the growth in an infectious pool of tuberculosis and 
its subsequent transmission (Murky et al., 1993).
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6-1:1a The Comparison Between Developing Countries and Industrialised Countries
Tables 6-1 and 6-2 present data on tuberculosis infection in developing countries and the
incidence of smear-positive TB between 1985 and 1990. From these tables, it can be observed that 
areas with a high concentration of developing countries have greater degrees of both tuberculosis 
infection and incidence of smear-positive TB than in those areas with a high concentration of 
industrialised countries.
Table 6-1: Estimates of Tuberculosis 
Infection in Developing Countries, 1985-1990
Area % Risk of Infection Annual % Decrease in Risk
Sub-Saharan Africa 1.50-2.50 1-2
North African and Western Asia 0.50-1.50 4-5
Asia 1.00-2.00 1-3
South America 0.50-1.50 2-5
Central American and the Caribbean 0.50-1.50 1-3
Source: Cauthen, Pio and ten Dam, 1988.
Table 6-2: Estimated Incidence of Smear-Positive
Tuberculosis in Developing Countries, 1985-1990
Area
Cases
Incidence 
(per 100 000)
Low Midpoint High
Sub-Saharan African 342 921 591 445 839 970 117
North African and Western 52 592 145 640 238 687 54
Asia
Asia 1 141 877 2 298 393 3 454 909 79
South America 57 937 160 440 262 943 54
Central American and the 30 022 83 138 136 266 54
Caribbean
Total 1 625 349 3 279 056 4 932 775 79
Source: Murray, Styblo and Rouillon, 1993: p. 235
It is interesting to note that sub-Saharan Africa, almost entirely composed of developing countries, has 
the highest case fatality rate and the lowest average detection rate, as shown in Table 6-3. Also, new 
cases of tuberculosis in 1990 rose the most in the Eastern Mediterranean, Western Pacific and African 
Regions. African regions also had the highest ratio of deaths to new cases as shown in Table 6-4.
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Table 6-3: Estimated Cases of Tuberculosis Detected 
and Case-Fatality Rates in Developing Countries, 1990
Case Fatality Rates
Area Cases Detected % of Total Cases 
Actually Detected
Low High
Sub-Saharan Africa 325 132 25 39 47
North African & 222 686 69 26 29
Western Asia
Asia 2 572 809 50 32 37
South America 221 856 62 28 32
Central America & 62 054 34 38 45
the Caribbean
Source: Murray, Styblo and Rouillon, 1993: p. 238 
Authors base their assumption of fatality on a
15% death rate from standard chemotherapy
Table 6-4: Estimated New Tuberculosis Cases 
and Deaths Occurring in 1990 by Region
Region New Cases Deaths Ratio of Deaths to New Cases
Europe and other industrialised 
countries
410 000 40 000 1:0.09
Eastern Mediterranean 594 000 160 000 1:0.26
Western Pacific 2 560 000 890 000 1:0.34
Southeast Asia 2 480 000 940 000 1:0.37
Americas* 560 000 220 000 1:0.39
Africa 1 400 000 660 000 1:0.47
♦Americas exclude the United States and Canada. Industrialised countries 
include Japan, US, Canada, Australia and New Zealand
Adapted from Kochi, 1991: p. 1-6
Greater annual risk of infection, mortality rates and incidence of TB, and high incidences of HIV in 
developing countries predictably cause TB to have a greater cost on the social and economic structure 
of these countries. In developing countries, there was an estimated 10.6 million deaths of those aged 
12-54 in 1990 and 18.5% of these were from tuberculosis (Murray and Feachem, 1990). The fact that 
tuberculosis affects individuals in this age group means that the disease affects those when they are the 
prime economic and social contributors to society. This is an age range where an individual has the 
most responsibility in work and raising children. Because TB strikes this age group, the effects of 
morbidity and mortality from TB have both significant direct and indirect effects. For example, 
children whose parents die are far more likely to die during childhood (Greenwood et al., 1987), and 
this is undoubtedly true for those children whose parents die from TB.
178
6-1:2 Treatment Programmes in Developing Countries
In 1991, the WHO designed a strategy for tuberculosis control in order to achieve several goals 
on the path to eradication. Among these was a global 70% smear-positive detection rate and a cure 
rate of 85% of smear-positive cases by 2000. This is a very ambitious target and may become little 
more than an unmanifested desire in many developing countries. The ability of different countries to 
achieve this target has and will vary according to available resources and level of priorities placed on 
treating tuberculosis over other health care interventions. One method that has proven cogent in 
achieving greater detection and cure rates has been the standardisation of treatment on a national scale 
and a firm commitment by a country's government to effectively reduce the incidence of TB.
In many developing countries, efforts to establish a national tuberculosis control program (NTP) 
have been effective in improving the treatment of the disease. NTPs are essential for treating 
tuberculosis because they represents a commitment on the part of a developing country to fight the 
disease, and it is a start in standardising all TB treatment. An NTP educates health workers on the 
symptoms and diagnosis of TB, it provides standard, effective treatment guidelines, and it gives health 
workers information on case holding and case finding.
Figure 6-1: Effects of a National Tuberculosis 
Programme on the Annual Risk of Infection
Year (after start of programme)
Source: Murray, Styblo and Rouillon, 1993: p. 254
As is observed in Figure 6-1, without an NTP, treatment of tuberculosis results in only very small 
changes in the annual risk of infection. Likewise, those temporary initiatives, whereby the country 
finds it can not longer fund its national tuberculosis programme, will assume the same gradient as 
those countries with no programme after falling during the enforced NTP period. It is only with a 
consistent programme that a country can maintain a consistent fall in ARI. With a consistent 
programme, the annual risk of infection should decrease by 6% per year (Murray, Styblo and Rouillon,
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1993). This analysis does not, however, take into account the large scale effect of HIV. In such 
instances, there will be perceived benefits, but they will be somewhat abated.
6-1:2a NTPs Improvements in Tuberculosis Treatments .
Past efforts in developing countries in controlling tuberculosis have suffered because health 
workers were unfamiliar with the disease and persisted in treating patients with only one drug or a 
creative mixture of several drugs and consistency of treatment regimens was often lacking, taking no 
logical pattern. For example, one doctor might administer a rifampicin and ethambutol regimen for 
one month and then an isoniazid and ethambutol regimen for four months while another doctor at the 
same health centre might administer an isoniazid and thiacetazone regimen for two months and then 
just isoniazid for twelve months. Additionally, diagnosis has also been poor in the past. Doctors, for 
instance, unfamiliar with tuberculosis and depending on chest x-rays, often would diagnose false- 
positives and false-negatives. NTPs were established to change such practices with various uniform 
procedures in TB treatment.
An effective NTP in a developing country is dependent on several components which will 
predict the success of any programme. (1) A control programme is dependent on the proficiency of 
the health care staff administering treatment in health care facilities. Health workers must be aware of 
the fact that a patient's life depends on correct treatment, and this should be communicated to the 
patient. Overworked staff or poorly educated staff are ill equipped to give good treatment to patients. 
The caseload in developing countries, especially in hospitals, continues to increase. For example, 
hospital admissions for TB patients in Uganda increased two-fold between 1985-1989 (Okat-Nwang, 
Wabwire-Mangen, Kagezi, 1993). Incompetence in the past has resulted in patient default with no 
follow-up, whereby the names and progress of individual treatment have been lost. Also, poor staff 
support of a country’s NTP can result in inappropriate treatment. In past instances patients with 
pneumonia and even cancer that have erroneously been diagnosed as TB and continually treated for 
years. It is the responsibility of health staff, for instance, to make sure that patients do not miss 
appointments, are taken off treatment that causes severe drug reactions, are quickly hospitalised and 
are not placed on monotherapy (therapy with only one drug) or continuous phase treatment instead of 
intensive phase treatment. (2) The role of case finding of clinics offering ambulatory care for 
tuberculosis is extremely important. An outpatient health facility is an essential key to case finding 
because it is the primary receiver of infectious cases of tuberculosis. With so many cases presenting 
themselves, the opportunity arises to trace any close contact the patient had with others, to discover 
those who infected him or her. It is not uncommon, for example, for a mother to come into a clinic 
seeking care, and subsequently, a clinic's search will discover that many of her children also have
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tuberculosis. (3) NTPs can also instil population confidence in health care facilities by virtue of their 
greater effectiveness in curing patients. A belief that a health care facility can cure a patient is 
extremely important. In some cases, individuals with tuberculosis put a greater trust in cultural 
remedies and beliefs and are unlikely to seek treatment at a health care facility until the disease 
progresses into its advanced stages. (4) Laboratory staff must be competent in detecting tuberculosis. 
It is important that they use the correct procedures in identifying tuberculosis, or a large proportion of 
cases that are smear-positive go unnoticed, depriving the doctor of one of the most effective diagnostic 
tools for infectious tuberculosis. This includes the proper collection of a sputum sample from a patient 
as well as staining techniques and analyses. Some patients give saliva samples rather than sputum 
samples. It is the job of the laboratory staff to make sure that they are analysing sputum rather than 
saliva or the smear is likely to be negative despite a patient's smear status. Poor laboratory techniques 
can greater jeopardise the diagnosis of tuberculosis. In rural Nepal, for example, case-finding was 
only 7% due to poor sputum preparation (Weakliam and Hamlet, 1994).
Figure 6-2: Health Service Coverage for 
Tuberculosis in Selected Areas (1988-1989)
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Adapted From: Kochi, 1991
(5) It is also important that a health care facility is able to give a population access to health care. If a 
patient cannot readily get to an area where he or she can be treated, the individual is unlikely to persist. 
Patients, for example, might travel from a rural area to an urban area and stay with friends or on the 
street when his or her tuberculosis is quite severe and after receiving a month of treatment, and feeling 
better, will go back to their rural location, motivated by an impending harvest time or a family’s 
dependence. This point highlights the fact that one of the great problems with tuberculosis control 
programmes in developing countries is that access to health services diagnosing and treating
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tuberculosis is not available to the entire population, and in some areas, covers less than half the 
population. Poor roads, extremely rural conditions, strong cultural beliefs in traditional healing and 
the lack of funds to treat tuberculosis all impede health services' efforts to penetrate areas with a high 
prevalence of tuberculosis. As suggested in Figure 6-2, between 1988-1989, areas such as the Western 
Pacific had coverage of 88% in contrast with Africa, which has experienced a pathetic coverage of 
only 24%. With such poor access to health services to treat tuberculosis, it is no wonder that the 
incidence of the disease is so high in these low coverage areas. (6) NTPs are also effective in 
recording information on patients. Past treatment of patients has been incomplete where either no 
information or only incomplete information on the patient was taken. Some countries in the past, have 
had TB facilities which were overloaded with tuberculosis patients. Treatment in these cases was 
haphazard and patients would arrive, receive a diagnosis a small amount of drug treatment and then 
disappear. Indeed, all patient statistics must be recorded, including patient progress and adverse drug 
reactions to keep track of patients and their response to treatment. Over the period of treatment, 
patients are classified according to six distinct categories of treatment: cured, where the patient has 
received a full course of treatment and has had two negative sputum smears; treatment complete, 
where the patient has received a full course of treatment, but his or her smear status is unknown; 
failure, where the patient has had a positive sputum smear after the fifth month of treatment (this 
might also includes chronic cases) and must start a retreatment regimen; died where the patient has 
died during chemotherapy either due to tuberculosis or unrelated causes; default where the patient has 
not complied with treatment for more than one month; and transferred out, where the patient has 
moved out of the treatment area. Recording a patient's statistics and progress means that the correct 
treatment appropriate to the patient can be given, and a patient can be found easily if he or she misses 
agreed appointments. Also, correct recording allows for calculating the annual incidence and annual 
risk of infection (ARI), defined as the probability that any person will be infected or reinfected with 
tuberculosis in 1 year, and TB drug needs on the part of the district and national level. This is a 
significant figure for developing countries in calculating future cases of TB. For every 1% rise in ARI, 
there are an estimated 49 new cases of smear-positive TB (Murray, Styblo, Rouillon, 1990). In the 
past, without a treatment record book, no quarterly report could be given to district health care 
facilities and therefore, a government had no clue how many cases of TB it had, nor the amount of 
drugs it would need in the future. (7) Lastly, an NTPs success is dependent on the supervision by 
district and central health authorities to ensure that the control programme is run properly. This 
includes regular visits to evaluate the procedures and activities of the health and laboratory staff, 
assess drug needs and facility capacity and ascertain the total incidence of tuberculosis. Annual and 
quarterly reports must be collected in order to evaluate case finding and the death, default and cure
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rates of the treatment programme. As would be expected, those programmes that are well supervised 
are far more successful than those that have lax supervision. Chaulet and Zidouni (1993) cite a French 
study in Algeria (Berkani et al., 1985) which showed that a well supervised area with a caseload of 1 
910 identified twice as many smear-positive patients as a poorly supervised area with a caseload of 1 
302.
Correctly implemented NTPs have served to improve the level of care for tuberculosis such that 
many more cases can be treated and the standard of treatment is likewise improved. A commitment on 
the part many developing countries' governments has increased funding for TB so that drug treatment 
is often free of charge in government health centres. Also, health workers in these centres have 
become the most equipped to recognise TB because they often see more TB cases than in private 
facilities, due to the link between poverty, TB and public sector treatment. TB is often a disease of the 
poor due to their living conditions and they will seek care in a government health centres where 
treatment is often free, as they can afford little else.
6-1:3 TB/HIV Co-infection
Undoubtedly developing countries suffer from the added challenge of a higher incidence of HIV, 
which works concurrently with TB infection to increase the incidence of TB. In Africa, for instance, 
the WHO estimates that there are an estimated 6 million people currently infected with HIV. Because 
HIV is primarily transmitted through sexual intercourse, those who have several sexual partners such 
as prostitutes, barmaids, truck drivers, those in the armed forces and those that spend a large 
proportion of time travelling are those who are most commonly infected with the virus. Likewise, it is 
in areas such as trucking roads, heavily urbanised areas and those places where there are no family 
living areas, that the infection is found (Enarson et al., 1993). Initially, most cases of tuberculosis in 
those with HIV, are likely to arise through endogenous reactivation of those already infected with TB, 
which can amount to 90% of all TB cases {FDA Online Documents, 1995).
6-1:3a The Age Correlation between HIV and TB in Developing Countries
Because of its close relationship with HIV, the spread of TB is quite dependent on the age of the 
population and whether (1) there is a high annual risk of infection with tuberculosis in the society such 
that the likelihood of infection at an early age is high and (2)there is a high incidence of HIV. In 
industrialised countries, 80% of those infected with TB are over the age of 50 whereas in developing 
countries, 75% of those who are infected are under the age of 50 (Snider, 1994). According to 
Murray, Styblo and Rouillon (1993), the age distribution in countries changes with the annual risk of 
infection. In Figure 6-3, where the incidence in Tanzania, Mozambique, Malawi and Benin is between
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one and two percent, over 80% of TB cases occur in those aged between 15 and 54 and this age 
distribution peaks between the ages 25 and 34. In contrast, in industrialised countries such as the 
United States and Norway, shown in Figure 6-4, the age distribution is far more constant after the age 
of 15. Other forms of tuberculosis, such as smear-negative and extra-pulmonary tuberculosis which 
are much harder to diagnose, prove to have a similar age distribution according to Murray, Styblo and 
Rouillon (1993). This estimate also shows a large peak in the age group 25-34 as seen in Figure 6-5.
Figure 6-3: The Age Distribution of Smear-Positive 
Tuberculosis in Four Sub-Saharan Tuberculosis Programmes
Age (years)
Source: Murray, Styblo and Rouillon, 1993: p. 236
Figure 6-4: Age Distributions of Smear-Positive Tuberculosis as a Proportion of 
all Cases of Tuberculosis in the United States (1985-1987) and Norway (1951-1972)
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Source: Murray, Styblo and Rouillon, 1993: p. 236
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According to Murray (1989), there is a high probability that almost everyone in an African state 
will have been infected with TB. This is a reflection of the relative impact of TB on a population and 
the effect of TB control efforts as cited by Raviglione et al. (1992), "Tuberculosis at its full force 
always claims its highest toll among young adults, while a shift towards the elderly population is 
epidemiologically a sign of success.". This accentuates a basic difference between developing and 
developed countries which determines HIV-aided TB infection. Those in industrialised countries who 
have been infected with TB, primarily were infected before the disease could be controlled. In 
addition, this population is not likely to have contracted HIV due to their age and the nature of their 
sexual activity, assuming that most sexual activity, and therefore transference of HIV, occurs primarily 
between the ages of 15-49 (See Figure 6-5). In contrast, in developing countries, because of the high 
prevalence of tuberculosis, (between 1.0% and 1.5%, according to Enarson et al., 1993), most have 
been infected with tuberculosis at a very early age.
Figure 6-5: An Age Distribution Estimation 
of Tuberculosis in the Developing World, 1990
Age (years)
Source: Murray, Styblo and Rouillon, 1993: p. 237
Because of this early exposure, those in the population who develop HIV are far more likely to have 
been infected with TB and hence, there is the high likelihood of endogenous TB reinfection in 
developing countries. This seems to be manifest in some data on the percentage of HIV patients in 
cases of tuberculosis in Africa, illustrated in Figure 6-6 and Table 6-5. In Figure 6-6, varying rates of
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HIV-TB co-infected patients possibly suggest either a lower incidence of co-infection or an 
inconsistent ability to detect and report HIV in tuberculosis patients. Nevertheless, data from Zambia, 
Central African Republic, Zaire, Uganda and the Ivory Coast would suggest that in these countries, 
there is a strong link between TB and HIV.
Figure 6-6: Percentage of Observed TB/HIV 
Co-Infection from Studies of Various African States
COUNTRY
PERCENTAGE WITH HIV
DATA SOURCES Malawi: Ponninghaus et al., 1991; Ivory Coast: De Cock el al., 1991; Uganda: Eriki et al., 1991; 
Zaire: Colebunders et al., 1988; Central African Republic: Mbolidi et al., 1988; Zambia: Meeran, 1989; Senegal:
Enarson etal., 1993; Benin: Enarson et al., 1993; Mozambique: Enarson etal., 1993
*Data for Zaire ranges between 22-40% between and 1987, depending on the study (Mbolidi et al, 1988, Colebunders 
etal., 1988, Mann etal., 1986)
Table 6-5: Estimates of TB/HIV 
Co-infection in Selected African States
COUNTRIES % HIV
Medium Prevalence
Burkina Faso
Guinea Bissau
Kenya
Swaziland
Zaire
20-29%
Central African Republic
Cote d'Ivoire
Zimbabwe
30-49%
High Prevalence
Burundi
Malawi
Uganda
Zambia
>50%
Source: De Cock, Soro, Coulibaly and Lucas, 1992: 1581-1587
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Hence, in sub-Saharan Africa there is also a correlation between the age and the percentage of TB/HIV 
co-infected patients. It appears that those TB patients who are in the age group of 25-34 have the 
highest incidence of HIV-seropositivity and similarly, those who are between the ages of 15-24 have 
an incidence that is only slightly less (Enarson et al., 1993). Unlike in industrial countries, this 
suggests a strong correlation between HIV and TB infection occurring roughly around the same age. 
Enarson et al. (1993) suggest that although HIV undoubtedly has a strong impact on the growth of 
tuberculosis in Africa, it is nevertheless, difficult to find conclusive evidence on this. These authors 
suggest that this is because the TB notification rates in countries with high incidences of HIV such as 
Malawi and Tanzania are very similar to the TB notification rates in those with low incidences of HIV 
such as Mozambique and Benin. It is possible that such discrepancies in reporting could very well be 
due to problems in reporting cases of HIV and tuberculosis, and to problems in detecting cases of HIV 
in TB patients, but this remains unknown. In addition, TB often appears in asymtomatic AIDS 
patients, and considering this, those patients that appear with TB are not likely to be tested for HIV- 
seropositivity due to the fact that (1) HIV testing is expensive and (2) there is a large stigma involved 
in HIV testing and most health authorities fear that people will link tuberculosis only to AIDS patients 
if all TB patients are screened for HIV. Such a link would further the stigma already associated with 
tuberculosis in these countries and those with TB might further delay in seeking treatment. In the 
current situation, patients are only likely to be tested if they show other signs of HIV or if they 
experience an adverse drug reaction such as Stevens-Johnson syndrome which is far more common in 
those with HIV.
6-1:3b The Future Impact of HIV on TB
The future prognosis for TB/HIV co-infection is grim because as HIV infection rises, so will 
tuberculosis. As can be seen in Table 6-6 by Schulzer, Fitzgerald, Enarson and Grzybowski (1991), in 
the year 2000 in sub-Saharan Africa, the total rise in smear-positive TB could vary from a 60% 
increase to an 888% increase depending on the ARI and the percentage of HTV infection.
Table 6-6: The Prevalence of TB in Sub-Saharan 
Africa in the Year 2000: Four Possible Scenarios
Scenario % ARI % Prevalence of TB 
Infection
% HIV Infection % Increase in 
Smear-Positive TB
I 1 45 2 60
II 2 60 2 52
III 2 60 10 280
IV 2 60 20 888
Source-. Schulzer, Fitzgerald, Enarson and Grzybowski, 1991: 52-58
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6-1:4 TB Resistance to Drugs in Developing Countries
Like other drugs previously discussed, the unregulated availability of tuberculosis drugs for sale 
in pharmacies and black markets of developing countries has proven to be a problem in controlling TB 
resistance. Such availability has become so serious a problem that in some countries, governments 
have prohibited the sale of many anti-TB drugs in pharmacies, limiting them to public health facilities. 
Extremely poor countries are in such desperate need for tuberculosis drugs, that their use and 
distribution is often heavily regulated such that only those seeking care in tuberculosis clinics can 
receive these drugs. These countries where the drug supply is low have lower rates of resistance, as 
drugs in such short supply are very carefully regulated and any resistance is likely to rise from 
inappropriate therapy such as monotherapy. However, in those countries such as India, and parts of 
Africa and Asia where domestic drug production is common and drug regulation is poor, supplies of 
tuberculosis drugs can be easily procured by almost anyone who can afford them. It is in these 
countries where the supply of anti-TB drugs is plentiful, that the regulation of these drugs is not so 
carefully managed and therefore, through inappropriate therapy and inappropriate use, resistance 
proliferates. In addition, resistance containment efforts are challenged by problems in the quality of 
tuberculosis drugs in developing countries whereby those that are procured prove to be substandard 
because of poor local production techniques or poor storage.
6-1:4a Rates of Resistance in Developing Countries as Compared to Industrialised Countries
Indeed, because of the poor management of TB drugs, poor drug supplies and the prevalence of 
the disease, developing countries appear to suffer more from TB resistance than do industrialised 
countries. Existing evidence of drug resistance could be attributed to two factors: faulty data 
collection and incorrect drug use. Data collection measuring resistance in developing countries is very 
difficult because in these countries, there are priorities that are perceived of greater necessity than the 
recording of information. Due to a lack of organisation and often a lack of qualified personnel to 
record information, data are often estimated. Data might be estimated, for instance, from the amount 
of patients that fail to respond to treatment, when no sensitivity test has been given. Also, sensitivity 
tests in developing countries are not always that accurate, and so what might be seen as a critical 
concentration of resistant bacilli in a patient's tuberculosis population might in fact not be this at all. 
Also, data can be misinterpreted. Bias in resistance data comes from the fact that those samples that 
are tested for sensitivity are only from those patients who have failed to respond to treatment. Bearing 
these elements in mind, there is such a great discrepancy between resistance data in industrialised 
countries and data in developing countries, that it is not entirely accounted for by problems in data 
collection.
188
Table 6-7: Drug Resistance by Region
Drug USA/Canada
Asia, Africa,
Caribbean, South
America
Isoniazid 7% 39%
Streptomycin 5% 29%
Rifampicin 7% 19%
Source: Hershfield, 1987
Table 6-7: Drug Resistance by Region. In the regions with a large proportion of developing countries, 
isoniazid can be seen to exhibit the greatest levels of resistance because this is the strongest bactericidal 
drug and it is relatively cheap to obtain. Streptomycin is ten percent lower than isoniazid and rifampicin 
is the lowest of the three possibly because the drug is more expensive as compared to isoniazid and 
streptomycin. In contrast, isoniazid and rifampicin are relatively equal in the percentage of observed 
resistance in the USA and Canada whereas streptomycin comes in at two percentage points below, 
probably due to the fact that it is seldom used to treat tuberculosis in these regions.
Of course, it is taken into consideration that resistance data comparisons between countries, are only of 
a very rough nature due to an inconsistency in data collection techniques and other important 
techniques in measuring tubercle susceptibility. Nevertheless, data can still be observed in order to get 
an inexact estimate of resistance in various countries. Bearing in mind dubious data, in Table 6-7, 
resistance in the United States and Canada is drastically lower than that observed in Asia, Africa the 
Caribbean and South America. Such resistance is approximately two to five times lower.
Laboratory
Table 6-8: Initial Drug Resistance in the United States
No. of Patients % of Resistance
Harlingen (Texas) 135 14.1
New Mexico 166 13.9
Massachusetts 188 12.2
Wisconsin 172 10.6
Miami, Florida 58 10.3
Arizona 136 9.7
Los Angeles 105 9.5
Philadelphia 58 6.9
San Francisco 322 6.5
Virginia 48 4.2
Indiana 50 2.0
Source: Gangadharam, 1993: p.316
In addition to this evidence, by Comparing Table 6-8 on initial drug resistance in the United 
States with Tables 6-9 and 6-10, and 6-11 on initial drug resistance in Africa, Latin America, India and 
Korea, resistance can be seen to average at approximately 9% in the United States, whereas in regions 
highly concentrated with developing countries, resistance percentages average at approximately 50% 
for African states, 25% in Latin American states and an average of 20% in both India and Korea. This
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suggests a difference in resistance between the United States and developing countries of between two 
and six times.
Table 6-9: Tuberculosis Drug Resistance in Selected African States
% Initial Drug Resistance
Location H S T
Senegal 18.5 18.8 18.5
Ivory Coast 5.6 6.6 -
Benin 12.8 4.8 22.4
Mauritania 16.9 12.3 45.0
Dori (RHV) 8.7 6.5 47.8
Bobo-Dioulasso 19.5 23.9 25.8
Source: Rey et. al, 1979
Table 6*10: Initial Resistance in Latin American States
% Initial Drug Resistance
Country Location H S R E T Total
Chile Santiago 5.9 5.8 0 0 0 14.7
Columbia Sucra/
Boy ace
5.0 10.0 0 0 25.0 35.0
Meta 4.0 12.0 0 0 12.0 20.0
Cesar 3.8 7.7 0 0 7.7 15.4
Antioquia 7.7 7.7 7.7 0 0 15.4
Cuba - 8.8 8.8 0 2.9 8.8 17.6
Haiti Port-au-Prince 10.0 5.0 5.0 5.0 0 20.0
Mexico Guanaj/
Hidalgo
3.1 9.4 0 0 0 15.6
Oaxaca 2.8 8.3 0 0 0 11.1
Peru Callao 31.8 54.5 13.6 4.5 4.5 54.5
lea 15.0 25.0 5.0 0 10.0 35.0
Lima 3.0 27.3 6.1 0 6.1 39.4
Source: Gangadharam, 1993: p. 314
Table 6-11: Initial Drug Resistance in Korea and India*
% Initial Drug Resistance
Country Year No. of 
Patients
H S HS R HR E HE Total
Korea 1980 108 25.0 4.6 2.8 5.6 3.8 30.6
1985 161 13.7 3.7 1.2 2.5 2.5 3.7 3.7 17.4
1990 115 13.0 6.1 1.8 - - 0.9 0.9 16.5
India 1990 436 12.2 1.8 3.7 1.8 0.9 0 0.5 21.1
Source: Gangadharam, 1993: p.315
*Of note is the rise in primary resistance to rifampicin, which in parts of India was 0% in the early 1980's (Trevedi etal., 
1988) but has risen to 3% in 1989 (Khan et al., 1993). This is significant due to the imperative action of this drug in TB 
regimens.
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In summary, this evidence suggests that there are greater degrees of resistance in developing countries 
compared to industrialised countries.
6-4:4b The Correlation Between Retreatment, Resistance and Default
Logically, resistance is also related to the number of courses of chemotherapy a patient receives.
Several retreatment regimens assume that a patient had either primary resistance at the start of 
treatment or acquired his or her resistance through treatment default. As the number of courses of 
chemotherapy a patient receives rises, the more likely it is that the patient is a defaulter and the more 
likely it is that resistant mutants to various drugs have been selected. An example of this occurred in 
Algeria in a study of 81 patients, where it was observed that those only having received one course of 
chemotherapy had resistance two thirds less than those having already received three courses of 
chemotherapy as observed in Table 6-12 (Mazouni, 1992). As might be expected, the prognosis for 
those who have received two courses of chemotherapy is extremely poor because of a greater 
likelihood of resistance to both isoniazid and rifampicin. All of those in Table 6-12 were resistant to at 
least one drug and 97% were resistant to isoniazid and rifampicin. Such resistance to two of the most 
significant bactericidal drugs leaves only less effective drugs to fight these patients' tuberculosis, 
providing that their bacilli are susceptible to these. The prognosis for such cases is estimated to be 
approximately only a 40-60% survival rate, the same rate that might be experienced with no drug 
therapy at all (Bloom and Murray, 1992).
Table 6-12: Resistance in Correlation to the Number of 
Short-Course Chemotherapy Regimens Received by 81 Patients in Algeria.
Number of Chemotherapy 
Courses Received
Number of Patients Strains Resistant to Only
One Drug
%H + R 
Resistant
One course 27 33 22
Two Courses 22 64 55
Three Courses 32 100 97
Source1. Mazouni, 1992
6-4:4c Reasons for Greater Resistance in Developing Countries
There are several reasons explaining the discrepancy in TB resistance between developing
countries. Developing countries have a greater caseload of tuberculosis due to poverty, living 
conditions, malnutrition and a large proportion of HIV. Hence, this large caseload is more challenging 
to manage and works concurrently with poor available funding to compound containment efforts. 
Such difficulties result in many patients not receiving, adequate treatment and therefore remaining 
infectious. Because of the difficulty in following up patients, many for instance, will repeatedly
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receive treatment when their tuberculosis become quite serious and then stop treatment when it starts 
to improve. Intermittent treatment allows for TB resistance to occur in these patients, often resulting 
in chronic cases. Poor management of tuberculosis is aggravated by the poor management of those 
drugs used to treat it. Drugs such as rifampicin and streptomycin are available on the black market and 
used indiscriminately for trivial infection. Rifampicin is a strong antibiotic and there is the temptation 
to use it for other infections when other antibiotics will suffice. Although rifampicin is used for 
meningitis and TB it is also sometimes used unwisely for shigellosis, for instance (Reviews in 
Microbiology, 1993). To thwart both its use in other diseases and monotherapy, rifampicin is often 
prepared in fixed-dose combinations. Unfortunately, there is some question about the bioavailability 
of rifampicin which can be compromised when it is used in combination preparations with isoniazid. 
Nevertheless, these combinations can prove more effective than separate administration of these drugs 
(Geiter, O'Brien, Combs and Snider, 1987), the bioavailabilty of rifampicin is very sensitive and 
dependent on careful production, which might be jeopardised in local production attempts, especially 
when combined with another drug. Poor bioavailability of rifampicin is tantamount to monotherapy 
with the drug it is combined with (most commonly isoniazid), leaving a strong likelihood for 
resistance to that drug. Isoniazid is another drug that has a high likelihood for resistance because of 
such heavy reliance on it. Isoniazid, with its strong bactericidal qualities is used in large quantities for 
prophylaxis, preventative therapy and in some cases, as monotherapy to treat tuberculosis. Isoniazid 
always appears on every drug regimen, provided that it is not contraindicated in the patient. It is no 
wonder that there is a growing resistance to this drug under such widespread use. Finally, even with 
the correct management and administration of effective drugs, the lack of education on the part of the 
patient causes a lack of compliance to therapy on his or her part furthering the overall percentages of 
resistance.
6-1:4d Measures to Stop Resistance
As mentioned earlier, to stop the progression of resistance, double or triple therapy is given to 
tuberculosis patients rather than only one drug. Although ideally, only those drugs to which a patient's 
tuberculosis is susceptible should be given, this is empirically impractical to achieve as developing 
countries lack the means or the time to culture each patient's bacteria for susceptibility. A more 
realistic option would be to culture the organisms from those patients who fail to respond to treatment, 
exhibiting repeated smear-positive results after treatment. Likewise, no single drug should be added to 
a failing regimen but a combination should be added (Crofton, 1994) because adding just one drug to a 
failing regimen is dangerous in that it allows for further selection of resistance. A combination of 
drugs, however, will serve to destroy any resistant mutants that would otherwise be selected by just
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one drug. In addition, those drugs that are administered should be given at regular intervals in order to 
be effective. If one drug is given infrequently and yet another drug is given daily, this will be impotent 
in staving off resistance (Gangadharam, 1993). Following this thought, drugs should always be 
dispensed together so that no preference for one particular drug develops. Fixed dosed combination 
drugs such as those combining R and H and H and T are advantageous in achieving this. Finally, 
drugs must be taken for the entire period that they are prescribed. In developing countries, this means 
that the patient must travel to the health centre every day and have his or her drug consumption 
monitored during the intensive phase of treatment and checked once a month during the continuous 
phase of treatment.
6-1:5 Summary of Section 6-1
The ability to eradicate tuberculosis in developing countries has been severely challenged by the 
correlation between age and TB/HIV co-infection, and greater levels of anti-TB drug resistance. Such 
problems are unfortunately compounded by ignorance and poor management of these anti-TB drugs. 
It is only through a systematic standardisation of treatment within each country with resource 
appropriate NTPs, that developing countries can start on the long road to eradicating TB.
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Section 6-2
RELATING COST AND EFFECTIVENESS TO TUBERCULOSIS TREATMENT
After exploring TB resistance, HIV and NTP's in the previous section, this section will analyse 
past studies on the cost and cost-effectiveness of tuberculosis treatment. This section will also present 
the methodology used in this thesis. It further analyses the costs and effectiveness advantages of two 
main treatments for tuberculosis and the impact of these treatments in containing the disease. Before 
looking at the impact of tuberculosis drug resistance to treatment costs, past literature on tuberculosis 
containment costs must first be explored.
In 1991, a startling article appeared in the Lancet by Stanford, Grange and Pozniak called 
"Is Africa lost?" and suggested that a 2 month course of chemotherapy is the current practice for TB in 
Africa. The authors further suggested treatment of just one week with rifampicin, isoniazid and 
pyrazinamide using immunotherapy on the seventh day. This type of treatment represents not only a 
futile attempt to cure tuberculosis, but such a short period of therapy has the potential to lead to higher 
levels of resistance, affecting not only developing countries, but eventually, industrialised countries 
(See Murray, Styblo and Roullon, 1993; Gangadharam, 1993; O'Brien, 1993). Such ideas reflect the 
haphazard character of treatment in developing countries, and the corresponding desperation to find a 
quick method of eradicating TB. This short treatment, which amounts to little or no treatment at all, 
will translate to a waste of resources in the majority of cases. Unfortunately, there is no quick method 
of treating TB and all treatment that is not of the nature and length of either the standard or short- 
course regimens will prove ineffective for a large proportion of those treated. Treatment in developing 
countries must vary according to the resources of each country. Determining the correct choice of 
treatment is an involved process taking into account resources, the quality of health care delivery and 
priorities. There is no standardised treatment that is appropriate for every country. All too often 
developing countries are classified as one needy body and although some generalisations about these 
countries can be made, each developing country must be carefully considered apart from other 
developing countries. This is indeed true with choosing treatments and control mechanisms for 
tuberculosis.
6-1:1 The Superiority of Short-Course Chemotherapy in Terms of Effectiveness
As was previously mentioned, treatment for tuberculosis in developing countries usually consists 
of a 12 month regimen known as the standard regimen or standard drug regimen (SDR) and a 6 to 10- 
month variation on 6-month SCC observed in industrialised countries. The standard regimen uses 
streptomycin injections plus isoniazid and thiacetazone during the intensive phase, and then
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thiacetazone and isoniazid during the continuous phase. This regimen consists of older drugs 
(streptomycin and thiacetazone) whose performance is not necessarily as good as those used in the 6- 
month and 8-month SCC regimens. In the intensive phase of the short-course regimen, treatment 
consists of combinations of isoniazid and rifampicin and varying combinations of pyrazinamide, 
ethambutol, thiacetazone and streptomycin. Isoniazid and thiacetazone is then used in the continuous 
phase of treatment.
The effectiveness of SCC and SDR is dependent on their respective cure rates, rates of resistance 
to drugs in each regimen and their impact on the risk of infection in a community. Short-course 
chemotherapy proves to be more effective due to the fact that it uses more drugs during the intensive 
phase of treatment. These drugs, such as pyrazinamide, ethambutol and rifampicin, are more effective 
in stopping resistance and preventing relapses of the disease. Such strong bactericidal and sterilisation 
effects on these drugs mean that a shorter continuation phase is needed in order to deter a relapse. For 
initial smear-positive patients, after 2 months of intensive phase treatment, only 50% of those in the 
standard regimen are likely to be sputum-negative, whereas 80-90% of those receiving short-course 
chemotherapy will be sputum-negative. In these patients, such fast cure rates for SCC have the added 
positive externality of decreasing the transmission of tuberculosis. In addition, if a patient stops his or 
her drug treatment too soon, he or she is more likely to be cured with short-course chemotherapy, a 
fact supported by data from the World Bank on chemotherapy failure illustrated in Figure 6-7.
Figure 6-7: A Two Year of Follow-up of Patients 
Failing Chemotherapy as a Function of Months of Treatment
Failures (percent)
Treatment Received (months)
Source: Murray, Styblo and 
Rouillon, 1993
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In this figure, 40% of those who default from SCC treatment at 2 months will remain uncured whereas 
after 6 months, only 10% of those who default will remain uncured. In contrast, with SDR there is a 
65-70% failure rate if default occurs at two months and a 50% failure rate if default occurs at 6 
months. The subsequent failure rate for SDR after 12 months equals 10%, the same as SCC at 6 
months (Murray, Styblo and Rouillon, 1993). Hence, the rate of default between treatments is a strong 
determinant of their effectiveness. Assuming patient compliance is partly a function of the length of 
time of treatment, it is likely to be higher with short-course chemotherapy (Haynes, 1979). Murray, 
Styblo and Rouillon (1993) cite the East African and British Medical Research Council (1977, 1979) 
and observe that there is a steady default rate all throughout treatment, suggesting that the longer the 
treatment, the greater the level of default. The difference between the cure rates of SCC and SDR are 
also dependent on the actions of the drugs they contain. Relapse rates under incomplete treatment can 
be lower in short-course chemotherapy than those experienced with the standard regimen. In addition, 
the standard regimen's effectiveness seems to suffer from higher associated levels of acquired 
resistance, which is becoming more and more common.
6-2:la Costs differences between SCC and the Standard Regimen
Although SCC is more effective in terms of higher compliance, lower resistance rates and 
relapse rates than the standard regimen, it must also be noted that it is a more expensive treatment. For 
this reason, the standard regimen is still used in many developing countries. Indeed, the intensity of 
short-course chemotherapy usage is surprisingly low in many developing countries when considering 
its effectiveness. This discrepancy in treatments is largely due to the fact that developing countries 
perceive short-course chemotherapy as too expensive for them to use.
According to Murray, Styblo and Rouillon (1993), the differences in the costs between short- 
course chemotherapy and the standard regimen are from drug costs and the levels of hospitalisation 
required by each regimen. These authors maintain that short-course chemotherapy ranges from US 
$20-25 per patient treated above the cost of 12-month SDR, which is a significant amount for low 
income countries. Treatment costs are partially determined by the supplier of the drugs in each 
regimen. Those suppliers, such as UNICEF or IDA, are characteristically cheaper than European, 
Chinese or North American suppliers. Additionally, in some developing countries, due to the high 
cure rate after 2 months for short-course chemotherapy, patients are often hospitalised during this 
phase. This represents an added cost to this treatment that is sometimes overlooked.
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6-2:2 The Current Impact of Different Treatments in Developing Countries
Of course the high incidence of TB in developing countries can by no means be attributed just to 
drug regimens, but they certainly have a prominent role in containing the disease. In Figure 6-8, a 
comparison between no chemotherapy, chemotherapy in developing countries and chemotherapy in 
Norway illustrates that in the case of the developing countries, although chemotherapy is in use, the 
death rate is still 10% and the rate of case failure is relatively similar to no treatment at all. It seems 
that from this model, the cases that would have died without chemotherapy are transferred to sputum­
negative cases and failures. In the case of Norway, however, cases that would have died are almost 
completely transferred to sputum negative, or cured cases (Gryzybowski, 1986). In effect, this 
emphasises the effectiveness that chemotherapy in developing countries has over no chemotherapy, 
but also illustrates its shortfalls over chemotherapy in industrialised countries. Developing countries, 
relying primarily on the standard regimen, prove to have a poorer outcome record of treatment than 
those relying on short-course chemotherapy. In some ways, the situation might even be exacerbated 
by poor treatment. In effect, treatment of those smear-positive cases who would have naturally died 
seems to maintain a continuing pool of infection for tuberculosis.
Figure 6-8: The Outcome of Tuberculosis Five Years After Diagnosis:
A Comparison Between Good Chemotherapy, Poor Chemotherapy and No Chemotherapy
Adapted from: Grzybowski and Enarson, 1978
Data for each is derived for No Chemotherapy: a longitudinal study in Bangalore, India, 1973; for Poor chemotherapy:
Developing Countries in the 1970s; and Good Chemotherapy: the Netherlands, 1975-1976
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6-2:2a SCC: Greater Investment in TB Control: Difficult to Justify by Developing Countries
Short-course chemotherapy, although more effective than the standard regimen, suggests a 
greater investment by a developing country to stop future cases of tuberculosis. Developing countries 
have very little resources to be making these future investments. Nevertheless, in comparing these two 
treatments, short-course chemotherapy has the potential to give better overall cures and lower 
resistance rates. The question then arises as to whether the benefit of greater cures and lower 
resistance will justify the higher cost of short-course chemotherapy. If the cost per cure of SCC is 
prohibitive for these countries, then its degree of effectiveness becomes academic.
6-2:3 Methodology Used in Evaluating the Cost and Impact of Drug Treatments for 
Tuberculosis
In light of the scarce amount of resources that developing countries have for health care delivery, 
evaluation and planning, it is necessary to find a systematic tool for allocating these resources to 
maximise their associated utility. The tool that is often best suited to aiding decisions in resource 
allocation is the economic evaluation of the impact of health care programmes.
Although methods of the economic evaluation of health care programmes are commonly used 
tools in industrialised countries, they are rarely observed in developing countries. Undoubtedly, the 
most efficient use of funding is an important priority for developing countries, arguably more so than 
in industrialised countries because of the former's limited resources. Nevertheless, these countries 
have few health economists, and few external bodies concentrate on the economic analysis of the 
impact of the health expenditure in developing countries. Those who would seek to carry out health 
care evaluations are daunted by the fact that data on the effect of various health interventions as well 
as the cost of these interventions are very difficult or sometimes impossible to obtain or calculate. 
Without these data, an economic evaluation is extremely difficult and becomes an exercise in 
estimates. Hence, most studies that do emerge are often far from complete by the standards of 
industrialised countries, accentuating health economics as an under-utilised area with great potential in 
developing countries.
6-2:3a Types of Economic Evaluations
The economic evaluation of health care interventions can be evaluated in several ways, each 
appropriate to the kind of information that is sought. These include cost-minimisation analysis, cost- 
benefit analysis (CBA), cost-effectiveness analysis (CEA) and cost-utility (CUA) analysis. Cost- 
minimisation analysis is used when the outcome of two interventions is assumed to be the same. In 
this analysis, costs are compared to see which intervention is the least expensive for the desired 
outcomes. In a cost-benefit analysis, outcomes are not assumed to be the same and costs and benefits
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of programmes are compared in terms of the monetary value of costs versus the monetary value of the 
outcome. CBAs primarily concentrate on the market value of the impact of a health intervention. 
Placing dollar values on the effects of an intervention is often problematic and dubious. It is, for 
instance, difficult and controversial to put a dollar value on a life saved. Cost-effectiveness analyses 
differ from this because these use the monetary value of costs and the value of an outcome in terms of 
its ability to obtain a particular objective. From this, CEAs express the cost per objective. An 
example of this might be measuring an intervention in terms of its cost per cure or its cost per death 
averted. Cost-utility analysis, having grown from cost-effectiveness, is a tool for determining the level 
of utility or the change in quality of life that an intervention gives a patient as well as that 
intervention's cost. This is suited to those treatments in which the outcome is not necessarily an 
immediate cure, but an intervention that improves the patient's ability to cope with a condition. Cost- 
utility is measured by calculating the willingness to pay for a given effect, the quality of life of a given 
effect, or from the comparison between the preference of one treatment over another in an intervention 
(Bootman, Townsend, McGhan, 1991). In summary, all of these methods are used for examining the 
cost of a particular health programme, and the latter three (in contrast with cost-minimisation which 
only recognises identical consequences) measure the consequences of various interventions. Cost 
minimisation, CBA, CEA and CUA are used depending on the kind of available data and the 
measurement desired. This is captured by Drummond, Stoddart and Torrance (1987) in Table 6-13.
Table 6-13: The Measurement of Costs and Consequences of Economic Evaluations
Type of Study Measurement/ 
valuation of costs in 
both alternatives
Identification of 
consequences
Measurement/valuation of 
consequences
Cost-minimisation analysis Dollars Identical in all relevant respects None
Cost-effectiveness analysis Dollars Single effect or interest, common 
to both alternatives but achieved 
to different degrees
Natural units (e.g., life-years 
gained, disability days 
saved, points of blood 
pressure reduction, etc.)
Cost-benefit analysis Dollars Single or multiple effects, not 
necessarily common to both 
alternatives, and common effects 
may be achieved to different 
degrees by the alternatives
Dollars
Cost-utility analysis Dollars Single or multiple effects, not 
necessarily common to both 
alternatives, and common effects 
may be achieved to different 
degrees by the alternatives
Healthy days or (more often) 
quality adjusted life-years
Source: Drummond, Stoddart and Torrance, 1987: p. 15
As can be observed, the major differences between these analyses vary according to the identification 
and measurement of the consequences of all examined health interventions.
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6-2:3b Cost -Effectiveness Studies
The most common tool for analysing the cost and the impact of drug treatments for tuberculosis 
is through the use of cost-effectiveness studies. In almost all cases, tuberculosis treatment relies solely 
on drugs. As mentioned in Chapter 5, tuberculosis drug treatment consists of either short-course 
chemotherapy, which is more expensive but cures more patients, or the standard drug regimen, which 
is less expensive but cures fewer patients. The question arises as to which analysis is appropriate for 
finding the better treatment in terms of cost and cures. Types of studies such as cost of illness and 
cost-minimisation, prove too simplistic for seeking such cost comparison information, added to the 
fact that the outcomes of these treatments are not identical. Cost-benefit studies are considered less 
suitable because of the complicated and inexact nature of placing a monetary value on the effects of 
treatment. Likewise, measures looking at the utility a patient gains from TB treatment is inappropriate 
because the patient is assumed to be either uncured or fully cured by the treatment and therefore, for 
practical purposes, the utility gained from the cure can be considered to be the same for each patient. 
Certainly, drug treatments giving a clear and definable cure, such as those using antibiotics, are often 
more suited to cost-effectiveness studies. In contrast, those interventions where their effects are less 
obvious, fail to manifest, or result in a combination of more than one effect, are more suited to other 
analyses, such as cost-utility. Interventions, for example, with more ambiguous effects are NSAIDS 
for arthritis treatment and loop diuretics for heart failure. With these treatments, the condition is never 
really cured, but simply attenuated. Equally unsuitable, are situations where one treatment has very 
high adverse effects but also a very high cure rate when compared to another. Since tuberculosis 
treatment involves a well defined cure and measure of effectiveness, a cost-effectiveness analysis is 
the most appropriate to its evaluation.
Cost-effectiveness analyses can be defined as a sequence of mathematical and analytical 
operations in order to choose an action from various alternative interventions (Rice, 1969). It is a tool 
for determining the dollar value (cost) per unit of effectiveness (outcome). A cost-effectiveness 
analysis usually compares at least two interventions and a 'do-nothing' alternative. For each 
intervention, its costs and effects are calculated so that they can be placed in a ratio that will illustrate 
cost per outcome. The cost per outcome is then compared over different treatments to see which 
intervention proves to be the most optimum use of funds. To perform a CEA, the optimum method for 
achieving a given health outcome must be realistically achieved and more obviously, no less than two 
methods must be viable (Bootman, Townsend, McGhan, 1991).
There are many important variables to consider when embarking on a cost-effectiveness analysis. 
Various elements which will affect the study must be defined so that subsequent costs and effects can 
be evaluated accordingly. The objective of a study must be clearly stated, all alternative treatments
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must be considered, the measurement of costs and consequences must appear in the correct units, and 
all issues relevant to the decision-maker must be presented. A cost-effectiveness study starts with 
defining the perspective of the study in order to make the study appropriate to its relevant decision 
maker. The perspective may include, for instance, the individual, the funding body or society: each 
subsequently affecting those costs considered. A perspective can encompass direct costs or indirect 
costs. Direct costs are those costs directly related to the operation and administration of a health care 
intervention while indirect costs are only those costs from lost productivity due to the time a patient 
lost from treatment (assuming that the patient could have worked normally with his or her condition 
without this treatment). All of these are classified as tangible costs, whereas those costs such as the 
mental anguish that a patient experienced because of treatment, of which there is difficulty in 
assigning a value to, are intangible costs.
Table 6-14: Types of Costs and Benefits
Costs: examples Benefits: examples
capital used capital released for uses
land, buildings, vehicles land, buildings, vehicles
revenue used revenue released
labour, supplies, support services labour, supplies, support services
more work for staff less work for staff
fewer staff training possibilities more staff training possibilities
patient/relatives/staff costs patient/relatives/staff benefits
ignorance, dissatisfaction, information, satisfaction,
decision-making burden, time lost, relief from decision making,
inconvenience, expense time saved, convenience, less expense
unheal thier patients healthier patients
less cure (more pain, disability, more cure (less pain, disability,
worse prognosis, etc.) better prognosis, etc.)
less care (more discomfort, boredom, more care (less discomfort, boredom,
worse environment, etc.) better environment, etc.)
lost output (outside health service) increased output (outside health service)
Source: McGuire, Henderson and Mooney, 1988: p. 92
Since the perspective determines the costs included, a societal perspective, for example, will include 
all direct costs such as labour and supplies, and all indirect costs, such as lost productivity and lost 
economic growth to society because of treatment. Of course, such an emphasis can be problematic. 
For example, an overemphasis on indirect costs based on lost earnings can slant a study depending on 
the amount of patients employed. In many countries, for example, those that have tuberculosis are
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homeless and unemployed and hence, their costs in terms of lost earnings during the length of various 
treatments will appear less costly than would those who are fully employed. In contrast, a societal 
perspective will consider only the costs that the patient incurs, such as the monetary amount that the 
patient pays for the intervention, transaction costs and costs due to discomfort and lost productivity. 
Examples of such costs that may be considered from varying perspectives appear in Table 6-14. As is 
evident, the level of concentration on each of these costs depends on the perspective of the study.
In tuberculosis treatment, the perspective taken is usually the funding body, such as the 
government, because a societal perspective involves protean patient's costs which are difficult to 
collect or estimate. In addition, it is the funding body that is usually the most interested in the 
outcome of such economic evaluations since they are the major decision makers.
Costs fall into several classifications when embarking on a cost-effectiveness analysis (or 
CBA/CUA). The total cost (TC), represents the cost of producing a given amount of output. Fixed 
costs (FC) are those that do not change with the amount of output produced in the short run (usually 
considered 1 year) and these change over time rather than with the quantity produced (i.e. depreciation 
of machines, housing, equipment). For a given medical intervention, this might for example, include 
things like ecography equipment, microscopes, x-ray machines and buildings. Variable costs (VC) are 
those costs that change with each level of output and are in a medical context for example, those items 
that change with the number of procedures or patients treated: these costs include the costs of drugs, 
food and consultation fees. The average cost (AC) is equal to the total cost per unit of output (TC/Q: 
where Q is equal to total quantity). Lastly, the marginal cost (MC) is equal to the extra cost of 
producing one extra unit of output (TC of n + 1 units) - (TC of n units) (Drummond, Stoddart and 
Torrance, 1987). In a medical context, this for example, represents the cost of treating one more 
patient over the current caseload.
Another important variable to consider in a cost-effectiveness analysis is the actual measure of 
effectiveness. This should have some value pertinent to optimum health care delivery. Effectiveness, 
for example, can be defined by cures, lives saved, years of life saved, or the number of correct 
diagnoses. Regardless of the measure of effectiveness, it is essential that either the objective of the 
treatment that is measured is clear in all treatments or if there is more than one measure of 
effectiveness, all interventions are capable of achieving these (Drummond, Stoddart, Torrance, 1987).
One of the problems of cost-effectiveness analyses arises when there is more than one objective 
measure of an intervention's effectiveness and relative weights must be placed on these measures 
(Mooney, 1992). In the case of tuberculosis drug treatment analyses, the measure of effectiveness can 
be clearly expressed in cures, deaths averted or years of life saved.
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There are several approaches to estimating the cost per life year saved. Murray (1994a) 
highlights the potential years of life lost, the period expected years of life lost, the cohort expected 
years of life lost, and the standard expected years of life lost methods. These measures do not consider 
a 'zero mortality assumption'. This is an assumption whereby the years of life lost due to a given 
illness are derived from a life-table that does not include deaths from that given illness (Haenszel, 
1950).
The potential years of life lost (PYLL) are calculated by finding a fixed life expectancy and 
subtracting the age of death from this life expectancy, as shown in the following formula.
x=0
Where
dx = the number of deaths at a given age x
L = the life expectancy.
This method suffers in the fact that all deaths occurring after this fixed life expectancy do not count in 
this measure. Thus, those dying from a given disease after their fixed life expectancy are not 
considered in the calculation of the amount of life years lost due to the disease. Hence, for instance, if 
the life expectancy at birth is used in calculating the number of life years lost due to tuberculosis, those 
that die after this life expectancy are not counted. More than the other measures, this method favours 
treatments for conditions that affect the very young.
The period expected years of life lost method (PEYLL) estimates total years of life lost from a 
disease by finding a potential life expectancy at each age of death. The equation for calculating this is
x—1
x=0
Where:
I = the last age group
dx - the number of deaths at a given age x
This method of calculating risks is a better estimate of the burden of disease in years of life lost than 
the potential years of life lost method. It also includes the years of life lost by those who are older, and 
therefore, is a comparatively more utilitarian measure. It is one of the more commonly used methods 
in cost-effectiveness analyses. Nevertheless, this method can suffer from the fact that there is a bias 
that develops when considering different life expectancies across countries. Thus, a premature death 
of an individual from a given disease in a developing country will yield lower life years lost than a 
death of a individual from the same disease in an industrialised country. Since the life expectancy of
203
an individual in a developing country proves to be lower than that in an industrialised country, life 
years lost subsequently prove to also be fewer.
According to Murray (1994a) this method presents a more accurate appraisal of the amount of 
life lost due to premature mortality, but this premise is based on three assumptions. (1) This method 
assumes interdependent mortality risks. Once an individual's premature death is averted by an 
intervention, this individual will not have any higher risk of mortality than any other average member 
of that population. However, this does not take into account that many of those who were initially 
threatened by premature mortality might have a chronically disabling condition making the likelihood 
of their death greater, even after their premature death from one condition is averted. Following this, 
those that are threatened by a condition like this, might be more vulnerable to another condition. 
Those that fall into this group include, for instance, those that are elderly, malnourished, alcoholics and 
drug addicts, who can have far lower immunities to various conditions. This is surely the case of those 
with tuberculosis who more often than not, have contracted the disease because of weakened immune 
systems. Indeed, for this reason, when using this method for calculating total life years saved for an 
intervention, the population concerned must be carefully considered. (2) Age-specific mortality rates 
currently observed are applied to future populations. What this effectively suggests is that future 
generations will be equally as likely to have the same age-specific epidemiological patterns that current 
populations now experience. Future technology improvements which exist in reality in health care 
delivery, eradicating various diseases, are not taken into account, nor are any other possibilities of new 
diseases. For instance, the calculation of life years saved in the 1970s for deaths averted in a 
homosexual population between 20 and 30 are unlikely to have taken into account the future effect of 
AIDS on this cohort. (3) The life expectancy and years of life lost because of premature mortality are 
based on current mortality rates, rather than future changes in mortality rates. Similar to the second 
assumption this does not take into account the effect of technology improvements in calculating an 
individual's potential life expectancy, nor corresponding changes in life years lost due to premature 
death from a disease.
There are many similar approaches, using the potential years of life lost method as a basis. 
Cohort expected years of life lost, and standard expected years of life lost are simply variations on this 
method. Cohort expected years of life lost (CEYLL) are calculated through
x=0
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Where:
I - the last age group
dx - the number of deaths at a given age x
As can be observed, this calculation differs from period expected years of life lost because the term exc 
becomes the life expectancy of a cohort, rather than a blanket life expectancy of each individual in the 
population. Murray (1994a) maintains that since future morbidity patterns, and correspondingly, the 
average life expectancy of a cohort cannot be known, these must be estimated. Such estimates, 
however, still prove to be more accurate than period life expectancies for the whole population. This 
difference is most highly pronounced in some developing countries where the rate of mortality is 
expected to decrease greatly in the future. Nevertheless, life expectancies of an age cohort will differ 
depending on the area. For example, an individual of an age cohort in a very poor area can experience 
far different morbidity patterns than an individual from the same age cohort in a more affluent 
environment.
Also similar to PEYLL is the standard expected years of life lost (SEYLL). This is the 
calculation of years of life lost due to premature mortality through an ideal standard of life expectancy:
Where:
I = the last age group
dx = the number of deaths at a given age x
In this calculation, it can be seen that the term ex is based on an ideal standard of life. Murray (1994a) 
uses this method to calculate DALYs and bases ex on this highest recorded life expectancy at birth for 
women, of 82.5. This life expectancy is worked into a model life-table called the West Level 26. Here 
the average life expectancy at birth for men is calculated to be 80, estimated from a 2-3 year observed 
biological difference in average life expectancy at birth between men and women, rather than 
behavioural and environmental hazard differences. This model life-table is shown in Table 6-15.
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Table 6-15: Standard Life Expectancy due to Premature Death at 
Each Age According to the West Level 26 Model Life-Table
Age (Years) Females Males
0 82.50 80.00
1 81.84 79.36
5 77.95 75.38
10 72.99 70.40
15 68.02 65.41
20 63.08 60.44
25 58.17 55.47
30 53.27 50.51
35 48.38 45.56
40 43.53 40.64
45 38.72 35.77
50 33.99 30.99
55 29.37 26.32
60 24.83 21.81
65 20.44 17.50
70 16.20 13.58
75 12.28 10.17
80 8.90 7.45
Source: Murray, 1994a: p. 435
The data that are to be evaluated is also an important component to a cost-effectiveness study. 
Data must be unbiased and patients must be randomly chosen for treatment. Additionally, one should 
use a control group when possible. In practice, this is seldom performed because it is considered 
inhumane to deny a patient treatment where his or her suffering is concerned. Instead, past studies on 
the effect of a disease before a treatment was available are sometimes used. Data are obtained from 
medical literature and where none exists, estimations can be extrapolated from various sources, or a 
study can be purposely created that will be relevant to the intended analysis. Of course, these data 
must be checked with a sensitivity analysis which reveals how sensitive conclusions in the study are to 
changes in the data. In effect, sensitivity analyses illustrate how strong or weak various conclusions 
are in a cost-effectiveness study and what these conclusions depend on. The upper and lower limits of 
these data are varied to find out in which area of values the conclusions of an analysis are valid and in 
which areas they are not. For example, suppose that the cost-effectiveness conclusions of particular 
treatments for cancer are dependent on the number of patients that experience adverse side-effects to 
each medicine. From literature and reports of other studies, the parameters that have been used to 
reach this conclusion are varied from the lowest plausible value limit of fewer adverse reactions to the 
highest plausible value limit of far more adverse reactions. The results of this are then monitored and 
in this way, it can be seen how dependent is the study's conclusion on adverse reactions. In particular, 
data that should be separated for a sensitivity analysis are those based on estimates, those that vary 
greatly from other studies, and those that are subject to changes due to manipulation during analysis. 
According to Drummond, Stoddart and Torrance (1987), finding the upper and lower limits in which
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to vary data values in sensitivity analyses is dependent on results from other clinical studies, current 
practice in literature and the opinions of the relevant decision makers.
The calculated costs of an intervention must have limits in what it includes as costs. Suppose 
that those in a study with TB/HIV co-infection are cured of TB and survive to be treated for AIDS 
complications. The question arises as whether the cost of the ensuing treatment for these cured 
patients should be included in the costs of treating tuberculosis. Drummond, Stoddart and Torrance 
(1987) highlight the fact that this form of applied economics is a partial equilibrium analysis and 
therefore an artificial boundary is maintained in these analyses. This means that the effects of a health 
intervention can be better concentrated on while holding all other things constant.
Once costs and benefits of an intervention are established, these can be subject to discounting. 
This is a tool used to adjust the value of the costs and benefits of an intervention that are experienced 
in the future. Discounting is a concept derived from the fact that most individuals wish to experience 
costs in the future and wish to experience benefits immediately, also known as a positive time 
preference. It is for this reason that credit cards, for instance, are so popular. Credit allows an 
individual to buy something such as a car and experience the comfort from it, deferring its costs until 
later when the individual might have saved up more money or when the individual has been able to 
earn interest by investing this money. Individuals would rather have income today rather than in the 
future. If they receive it in the future rather than the present, they expect to be remunerated for this. 
According to Parsonage and Neuburger, the extent of time preference is dependent on (1) the 
likelihood that real incomes will grow in the future (2) the rate that the marginal utility obtained from 
each extra pound decreases as real income rises and (3) 'pure' time preference, defined as those 
preferences for the future unconcerned with changes in real income (Parsonage and Neuberger, 1992: 
p. 72). This same effect is relevant to economic analyses such as cost-effectiveness.
Discreet discounting of costs and benefits are often calculated with the formula (McGuire, 
Henderson, Mooney, 1988)
£cV,(l + r)
f=0
Where:
t = time
t=0 = the present period
f=l = one year in the future
CV( - the compensating variation at time (year) f.
T = the beginning of the time period
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In this formula, the compensating variation is the largest amount that a consumer will pay for a benefit 
or the smallest amount of compensation that the individual will accept for a loss. This is similarly 
expressed by Drummond, Stoddart and Torrance (1987) with different variables. The primary 
difference lies in the fact that these authors use future costs (Fn) in place of compensating variation 
(CVr), which, empirically in the formula, have the same function.
71 = 1
Fj
(l + r) (l + r) (l + r)
-+...+
(l + r)"
+
Where:
P = the present value 
Fn ~ the future cost at year n 
r = the annual discount rate
It is not difficult to see that as the years grow in number, the denominator (l+r)" also gets larger so that
the present value becomes smaller and smaller. If benefits, for instance, are perceived to be
experienced over twenty years, then they will be discounted accordingly over this period of time so 
Fthat -—!L— will be calculated for each of these years.(l + r)" y
Although it is more logical to discount costs, there is some question as to when the benefits or 
effects of a health intervention should be discounted. If the effects of a health intervention are 
immediately experienced, then there is no need to discount these effects. Drommond, Stoddart and 
Torrance (1987) present some arguments not to discount benefits. Individuals investing and trading 
healthy years of life over time is a theoretical rather than an empirical concept. In addition, 
discounting years of life obtained in the future places a bias for current generations over future 
generations. This essentially suggests that years of life of those now living are more important than 
those in the future. This might be significant, for instance, when considering the teratogenic effects of 
a hypothetical drug on a woman's future unborn children. Such discounting would favour the mother’s 
current years of life over her future children's. Parsonage and Neuberger (1992) claim that discounting 
benefits lets analysts ignore the possibilities of benefits extending beyond a lifetime to other 
generations.
In contrast, arguments for discounting benefits include the fact that discounting costs and not 
benefits is inconsistent and leaves impossible conclusions. Drummond, Stoddart and Torrance (1987) 
maintain that those health programmes, for example, with a 1 dollar benefit per year for an infinite 
number of years become worthwhile over time no matter what the initial outlay. In this case,
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discounting is shown to take into account the decreasing value of money over time. Also, if costs are 
discounted but benefits are not, cost-effectiveness will improve the more a project is delayed.
In addition, in calculating cost-effectiveness, an incremental analysis should be performed. An 
incremental analysis shows the decision maker the extra amount paid for each extra unit of 
effectiveness achieved by the superior intervention. This value represents the incremental cost 
between two treatments divided by the incremental effectiveness. Given two interventions, in order to 
find this value, the difference between the costs of both interventions is calculated separately from the 
difference between their units of effectiveness. From these two differences of costs and units of 
effectiveness between treatments, one can find the incremental cost-effectiveness ratio.
6-2:4 Past Studies in the Cost of TB Treatment
6-2:4a Feldstein, Piot, Sundaresan
There are not many studies that have either analysed the cost in the treatment of tuberculosis or 
the cost-effectiveness between short-course chemotherapy and the standard regimen. One of the first 
analysing costs was performed by Feldstein, Piot, Sundaresan (1973) who developed a model of 
resource allocation using tuberculosis in Korea as an example.
z
Z
i
Where:
Aij = the input
xj ~ the level of activity
mi = the total availability of resources that may be utilised for tuberculosis
In this model, the authors tried establish just how much expenditure would be needed for the control of 
tuberculosis in this state. In what resembles a variation of a production function, total availability of 
resources (w;) that may be utilised for tuberculosis is calculated to be greater or equal to the sum of the 
requirement of the input (Ay) multiplied by the level of activity (xj) or the intensity to which an input is 
used.
This formula assumes that /represents any resource ranging from labour and drug supplies to 
overhead and j represents the given activity in tuberculosis treatment. The input function is then 
defined as
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Where:
Aij = the sum of the requirement of input uiT
UiT - the requirement of resource i per unit of task T 
cy = the quantity of task T used in a unit of activity j.
It is through the manipulation of this equation, that these authors calculated the resources that were 
both available and needed for the treatment of tuberculosis in Korea. Resources (/) were separated into 
constrained inputs and unconstrained inputs. Constrained inputs were the total costs, cost of 
expendable supplies, physician-time, nurse-time, technician-time and bed-days. Unconstrained inputs 
included the cost of the doctor, nurse, auxiliary nurse, technicians, auxiliary technicians, other staff, 
beds, capitals costs and administrative overheads. These costs were calculated from a long list of 
activities performed by health care staff. These encompassed all areas of time spent by staff in TB 
screening, treatment, drug distribution, drug administration, default control, hospital admission, BCG 
vaccination, and chemoprophylaxis. From these costs, a total cost is calculated per task for each 
activity.
It is through this calculation and by considering the incidence of TB in Korea at the time, that the 
authors estimated the impact of expenditure on the country's TB programme. Korea's budget for TB 
control in 1964 was estimated to be US $515 000 and effective use of this was estimated to save 55 
289 disability years (not DALYs) or 10.7 years per US dollar. Feldstein, Piot and Sundaresan 
estimated that for every US dollar spent in this programme, there was an average return of US $150 
dollars assuming a per capita annual income of US $140. This article offers an interesting method into 
calculating the costs of tuberculosis. It is one of the first articles of its kind relating cost and TB. 
Nevertheless, its immediate relevance is weak due to the fact that it is based on data that are over 30 
years old and methods for health care evaluations have changed since 1973. Furthermore, this is a pre- 
HIV study.
6-2:4b Fryatt, Bhattarai and Niroula
In addition to this study, a more modem and practical analysis of TB costs was undertaken in an 
unpublished study by Fryatt, Bhattarai and Niroula of the Britain Nepal Medical Trust. The design of 
this study was to ascertain the cost of SCC in the Terai region of east Nepal in the spring of 1991. In 
this study, 4 hill districts were analysed in order to ascertain if the programme could be run by the 
local District Public Health Office's (DPHO) budget.
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Figure 6-9: Short-Course 
Chemotherapy Programme Costs in Nepal
□ Admin: Other 3%
t~~] Admin: Nepali Staff 3%
| Admin: Expatriate Staff 9% 
| Publicity 1 %
| Trainings 3%
| Transport: Porter 2%
□ Transport: Air 2%
□ Transport: Road 4%
Field: Running Costs 6%
[71 Field: Non-TB Drugs 2% 
E3 Reid: TB Drugs 17%
□ Field: Nepali Staff 28%
H Field: Expatriate Staff 19%
Source: Fryatt, Bhattarai and Niroula, 1992
The authors subsequently found that SCC was 3.6 times the cost of standard chemotherapy. However, 
because patients receiving SCC did not require a two-month stay, clinics and hostels were 40% 
cheaper to run in SCC areas. In addition, there was less use of non-TB drugs in SCC areas, attributed 
to the regimen's greater effectiveness.
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Table 6-16: Annual Costs by Activity for Standard and 
Short-Course Programmes in Nepal (Nepalese Rupees: 1991, US $1=29.3)
Activity 
% Total
Sub-Group Standard Costs SCC Costs Ratio of 
Standard: SCC
ADMINISTRATION & Personnel
SUPPORT i. expatriate 335 950 352 500 1:1.05
ii. Nepali 128 464 110 161 1:0.86
SDR
590 537 (17%) Buildings 81715 75 961 1:0.93
SCC Equipment and Running 44 408 40 044 1:0.90
578 666(15%) costs
FIELD WORK Personnel
(4 districts) i. expatriate 740 560 740 560 1:1.00
ii. Nepali 1 050 440 1 106 284 1:1.05
SDR
2 513 417(71%) Drugs 
i. anti-TB 187 864 672 096 1:3.58
SCC
2 837 545(72%)
ii. other 115018 65 291 1:0.57
Running costs 
(clinic & hostel)
419 535 253 314 1:0.60
TRANSPORT Road 158 460 149 121 1:0.94
SDR Air (National & 95 419 96 045 1:1.00
285 993 (8%) International)
SCC
335 350 (9%)
Porter 32114 90 184 1:2.80
TRAINING OF 
GOVERNMENT STAFF
SDR
97 061 (3%)
SCC
126 683 (3%) 97 061 126 683 1:1.31
PUBLICITY
SDR
Setting up 18 080 18 080
38 530 (1%) Other 20450 20 450 1:1.00
SCC
38 530 (1%)
TOTAL 3 525 538 3 916 774 1:1.11
Source: Fryatt, Bhattarai and Niroula, 1992
Considering these three differences in costs, the authors concluded that in these areas, SCC utilisation 
incurred an 11% increase in programme costs and cost per patient was 4% higher. The percentage of 
SCC costs can be seen in Figure 6-9. The greater costs of SCC mainly reflected the costs 
accompanying training for the implementation of a new drug programme and the inaccessibility of the 
SCC districts chosen. It is for this reason that transport costs and training costs appeared to be high. A 
comparison of these costs with the standard regimen can be seen in Table 6-16 where all costs are 
broken down into their various components. This offers a rare opportunity to ascertain the actual costs
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of a SCC programme in a developing country. By many accounts, the ability to access costs of these 
programmes is rare, due to problems in cost accounting in developing countries.
6-2:5 Past Studies in the Cost-Effectiveness of TB Treatments
6-2:5a Barnum
In 1986, Barnum performed a cost-effectiveness analysis of short-course chemotherapy regimes 
containing rifampicin and ethambutol (2[months)SHRZ/6[months]HE, 2[months]SHRZ/ 
4[months]HR) and compared these to standard regimens implementing isoniazid and thiacetazone 
(2[months]STH/16[months]TH) in Botswana. In this analysis, Barnum found that despite the high 
cost of rifampicin and ethambutol per case of TB, when considering the number of people effectively 
treated, the RE regimen was half the cost of the TH regimen. The author highlighted the fact that the 
difference in these costs was primarily due to greater patient compliance to the short-course regimen 
due to its implicit shorter duration. Additionally, he credited this difference to the ability to substitute 
ambulatory care for inpatient care under RE and the fact that RE is more bacteriologically effective 
than TH.
Similarly to the Feldstein, Piot and Sundaresan study (1973), total cost was calculated by simply 
adding all the costs of each activity in tuberculosis treatment. Barnum calculated the costs for 
treatment with the standard regimen through the equation
18
Cj = 60(cy + cs + cTH) + cL + y, Blt 
3
Where:
cj = Cost per inpatient day
cs - Cost/day of streptomycin
cm = Cost/day of thiacetazone and isoniazid
ct = Cost of sputum tests
XBi, - The sum of the costs of the continuous phase of treatment (between the 3rd and the 18th month of 
treatment assuming that the patient receives ambulatory care requiring one visit per month).
It can be seen from this equation that the first term 60(c/ + cs + cth) was used to calculate the drug and 
inpatient costs of the first two months of intensive treatment. The second term (cjr,) was used to 
calculate the cost of the second month's sputum test which is independent of the intensive and 
continuous phase. The third term (Z£/f) was used to calculate all costs for each month associated with
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the remaining 16 months of treatment in the continuous phase. The cost for each month of continuous 
phase treatment (£/,) was calculated from the following formula.
B„ = fo +30cr„)W, + clN +c,N
Where:
cL = Cost per Sputum Test
cA - Cost per monthly ambulatory visit
cm = Cost/day of thiacetazone and isoniazid
Nf = The proportion of patients still complying with treatment after t months
Thus, the first term, (cA + 30CTH) Nt, represents the cost per month of one outpatient visit and a 30-day 
supply of drugs. The second term, cLNt on/=4 g 2 represents all costs from 4 sputum smears done in 
the 4th, 8th, 12th and 18th month of treatment. Lastly the third term, cajVz onf=1218, represents all costs
that were incurred from the two chest x-rays that were taken in the 12th and the 18th month of 
treatment. It can be seen in this equation that each of these three groups of costs was multiplied by Nt 
to compensate for the fluctuation in the number of patients due to falling rates of compliance.
It follows that with extrapolation the equations for the other two treatments would be for 
2SHRZ/6HE,
8
C, = 60(c, + cs +cH +cR +cz) + ^B„
3
and for 2SHRZZ4HR,
6
Q = 60(c, + cs + cH + cR + cz) + cL + y1, Blt 
3
From these equations it can be seen that Bit varies both according to the number of x-rays and the 
number of sputum smears taken for these two treatments. It must be noted that these equations do not 
take into account either the cost of initial sputum smears for patients during diagnosis or the fact that 
patients can default on treatment during the intensive phase.
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In calculating cost-effectiveness of these regimens, the author divided the cost of the regimen by 
the cure rate and the compliance rate over the entire treatment period with the equation
CE.= C,
rt./Vr
Where given regime i:
CE. = cost-effectiveness of each regime
C. =cost per patient of regime i not taking into account the rate of default 
rf- = cure rate of regime i
Nt = total compliance at the end of the treatment period for regime i
It can be seen from this equation that a fall in rjNT, which represents the measure of effectiveness, 
causes a smaller and smaller denominator such that the cost per percentage effectiveness becomes 
higher and higher. In this case, the cure rates (r,) for the standard regimens was a low -0.70 over 18 
months. Resistance to T and H and the corresponding rate of compliance (NT) was -0.50, producing 
an effectiveness of «35%. The cure rate (rf) for the short-course regimens were much higher at -0.90 
and the rate of compliance (NT) was -0.85.
Table 6-17: The Cost-Effectiveness of Various TB Treatment 
Regimens in Botswana as Calculated by Barnum (1986)
Regime no.
i
Description* Cost per person treated
(in Botswanian pula)
Ci
Cost per person
effectively treated
(in Botwanian pula)
CEi
1 3inpatientSTHZ15TH 1 374 3 437
2 2inpatientSTH/16TH 938 2 441
3 2jnpatientSHRZ/6HE 957 1 301
4 2inpatientSHRZ/4HR 968 1 213
5 2outpatientSTH/16TH 306 863
6 2outpatientSHRZ/6HE 323 475
7 2outpatientSHRZ/4HR 337 457
Source: Barnum, 1986: p. 849 
*in all regimens, the continuous phase is assumed to be outpatient care
This rendered a SCC effectiveness of -77%. Hence, as viewed in Table 6-17, the outpatient treatment 
of, for example, number 5 costs 306 Botswanian pula per person. In this example, with a cure rate of
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0.7 and a compliance rate of 0.5, CEj is equal to approximately 874 Botswanian pula, or as calculated 
by Barnum, 863 pula. In this way Barnum derived C, and CEj for each TB regimen in Botswana. 
From these findings, Barnum concluded that regimen no. 7 was the most cost-effective, followed by 
regimen no. 6 and no. 5. Barnum also found that the outpatient standard regimen number 5 was 47% 
greater in terms of the final cost per patient than the outpatient short-course regimen no. 7. 
Unfortunately, the author did not perform an incremental analysis on these data. In addition, when 
calculating cure rates, Barnum assumed that all defaulters remained uncured when this is not 
necessarily the case.
There are some other difficulties with this study. For his comparison, Bamum used only 18- 
month standard regimens instead of 12-month standard regimens which is now the normal practice. 
This is significant because cure rates might be higher when only considering a 12-month intensive 
phase standard regimen instead of the extra 6 months from an 18-month phase. Because of the link 
between time and default, the rate of default used in calculating the cure rate for a 18-month treatment 
will be abnormally high compared to a more commonly used 12-month period. The author also failed 
to mention that the high 30% resistance rate responsible for the low cure rate of the standard regimen 
could be raised if it could be determined which patients had already received treatment. This amount 
cannot be entirely attributed to primary resistance. Indeed, not much information about the patients 
was given such as smear-status, HIV-status or location, all of which can be very important 
determinants in the outcome of treatments. To highlight the difference between the two forms of drug 
treatment, Bamum compared the cost-effectiveness of inpatient care in the standard regimen to the 
most cost-effective form of ambulatory care in the short-course regimen. It is academic to compare 
these two because they are under two completely different constraints. Additionally, Barnum failed to 
highlight the fact that much of the improvement in this programme was not due to a change in drugs 
regimens, but to major changes in the government's approach to TB care. Such government efforts 
improved the training of field workers to ensure patient compliance and reduce inpatient care to only 
20% of cases. In fact, this is an analysis of revised treatment methods, not strictly an analysis of drug 
regimens.
In summary, as would be common in most analyses, Barnum's results were primarily dependent 
on the fact that there was lower resistance and higher compliance to the short-course regimens that was 
not experienced by the standard regimens. Once the variables for the standard regimen approach an 
effectiveness of the short-course regimen (0.77) then the results of this cost-effectiveness are no longer 
as strong. They then become completely reliant on the action of the drugs themselves. Nevertheless, 
the author concluded that raising cure rates and compliance to the standard regimens is much more 
difficult in Botswana than raising them for short-course regimens. It is possible that because the short-
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course regimens involved newer, more expensive drugs, extra effort went in to making sure that 
patients complied with their treatment.
6-2:5b Joesoef, Remington, and Jiptoherijanto
Another model of cost-effectiveness was performed by Joesoef, Remington, and Jiptoherijanto 
(1989). Cost-effectiveness was based on a regimen's ability to achieve the objective of preventing 
cases of TB in the future. In this study, the authors developed an epidemiological model of 
tuberculosis from which they were able to project costs. From this they calculated cases of smear­
positive TB prevented in the future by three drug regimens. These regimens consisted of a 100% 
standard course chemotherapy regimen, a 100% SCC regimen and an existing combination of 35% 
SCC and 65% standard regimen. In order to calculate the probabilities of a regimen preventing future 
cases of TB, they used a rate equation model. This rate equation model describes the probabilities that 
individuals will be infected and develop tuberculosis.
AS, = SB-5,(T12 + TI3 + D-&S7/S)
^S2 = *S^12 — *$2 (^24 + — AS7 I Sj
as3 = s1t13-s3(t34+d-as7/s)
^4 = ^2^2A ^3^34 *** *$5^54 *^6^64 “ ^4 (^45 + ^46 + ^47 + D~ AS-]/S^
as5 = %+s6T65 - s5(r54 + t56 + t57+d- as7/s)
^6 = *$4^46 + $5^56 ~ + ^65 + ” ^87/$)
AS7=S4T47+S5T57
S = iSj + S2 + 65 + S4 + S5 + S6
Where
B - the crude birth rate
D - the crude death rate
Sj = the non-infected population
S2 = the infected population
ss the BCG vaccination population
54 = the population with active radiological lesions
55 = the tubercle bacillary positive population
56 = the healed population
S? = population that has died from tuberculosis
5 = the total population
All T terms refer to the yearly transition probability of those in one group moving into another group. 
For example, when individuals of those in the tubercle bacillary positive group (S5 ) move into the 
cured group (S6 ) or individuals in the non-infected population (5;) move to the infected population
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(S2). As is evident, terms in this equation are governed by the movement of one group of individuals 
to another group. Hence, for example, in the first equation, the uninfected population increases 
with the growth of the crude birth rate B and decreases when individuals move into the BCG 
vaccinated population, the infected population, or the population of those who have died from causes 
other than tuberculosis. From this model, using 1980 data in Indonesia, Joesoef, Remington, and 
Jiptoherijanto calculated that S;= 13.70% (20 282), S2 = 33.20% (49 149), 44.50% (65 878), S4 -
2.675% (3 960) S5 = 0.255% (378), and S6 = 5.669% (8 393), D = 1.19% and 5= 3.37%. It is from 
these equations that the authors have estimated the influence of three approaches to drug treatments on 
the transition probabilities of this model. Using this, they projected each approach's influence on 
future costs and levels of tuberculosis as illustrated in Table 6-18.
Table 6-18: Projected Prevalence Rates, Costs and 
Prevented Cases Under Three Treatment Strategies
Treatment Strategy
(i)
Projected 
Prevalence in the 
year 2000 
(2)
Cumulative Costs, 
1980-2000 (in 
thousands of $US) 
(3)
Cumulative 
Prevented Cases, 
1980-2000
(4)
Cost/Prevented Case 
(in$US)
(3)/(4)
Existing 0.123% 188 355 2 784 387 67.7
Standard 0.139% 215 540 1 816 756 118.6
Short 0.090% 127 413 4 635 932 27.5
Source'. Joesoef, Remington, and Jiptoherijanto, 1989
Table 6-19: Compliance, Success, Relapse and Coverage
Rates in 1980 Under Three Different Programme Strategies in Indonesia
Rates Existing Regimen Standard Short-course
Active Radiological Lesion
Group (S4)
Compliance 60.0% 50.0% 80.0%
Success 70.0% 60.0% 80.0%
Relapse 3.6% 4.8% 2.4%
Coverage 5.0% 5.0% 5.0%
Smear-positive (S5)
Compliance 60.0% 50.0% 80.0%
Success 60.0% 50.0% 70.0%
Relapse 3.5% 4.5% 1.8%
Coverage 10.0% 10.0% 10.0% (
Source1. Joesoef, Remington, and Jiptoherijanto, 1989
The associated costs of each treatment were calculated from drug costs alone which equalled US 
$24.26 for the standard regimen and $35.93 for the short-course regimen, discounted at a rate of 10%. 
The corresponding effectiveness of these regimens can be observed in Table 6-19. From this
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projection, the authors concluded that short-course chemotherapy is the most cost-effective in 
preventing cases of tuberculosis in the future in Indonesia. The authors estimated that the rate of TB 
will be reduced by only 52% and 45% with the existing and the standard regimen respectively, but will 
decrease by 65% with the short-course regimen. Such cost-effectiveness estimates were based on the 
fact that the short-course regimen had fewer retreatment cases, and therefore, had a higher level of 
initial effectiveness.
There are fundamental methodological problems with this study. The study was from the point 
of view of the Indonesian government whose policy was only to treat smear-positive cases of 
tuberculosis. Hence, the authors only took into consideration smear-positive cases ignoring smear­
negative and extra-pulmonary cases in their calculation of the number of cases of tuberculosis 
prevented. In addition, this study used a 10% discount rate per year instead of a 3% or 5% discount 
rate per year, which suggests that costs in the future will be calculated so that they will be deceptively 
low. This study also did not define what drugs were used in each treatment, which is significant since 
there are so many variations of short and standard regimens. In addition, the authors gave little detail 
on how cost-effectiveness projections were derived. Finally, this study was only based on drug costs, 
whereas other costs, such as labour inputs, were not included. The authors defended their omission of 
these costs because they felt they were not necessary since the perspective was from the Indonesian 
government. Nevertheless, it is grossly inaccurate to assume that the only costs that the government 
will occur are drug costs when other inputs for treatment must also be calculated.
6-2:5c Murray, DeJonghe, Chum, Nyangulu, Salamao and Styblo
One of the finest works performed in the cost-effectiveness of tuberculosis treatment in 
developing countries was performed by Murray, DeJonghe, Chum, Nyangulu, Salamao and Styblo 
(herein referred to as Murray et al.) (1991). In this study, data from the Mutual Assisted Programme 
of the International Union Against Tuberculosis and Lung Disease in Malawi, Mozambique and 
Tanzania were collected in order to calculate the cost-effectiveness of short-course chemotherapy and 
the standard regimen. It calculated the cost of each programme from the perspective of those funding 
tuberculosis treatment. Costs for the tuberculosis treatments were broken into three components: fixed 
costs not associated with the TB programme, fixed costs associated with the TB programme and 
variable costs. From these costs, other variables were calculated. Average unit costs were calculated 
by diving the total fixed and variable costs by the amount of patients treated. The average incremental 
unit was calculated by dividing the sum of variable costs and fixed costs attributed to the TB 
programme by the number of patients. Lastly, marginal cost per patient was calculated from dividing 
variable costs by the total number of TB patients in the programmes. This is fundamentally flawed to
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call these the marginal costs when they are in fact the average variable costs (VC/Q). The costs of 
various treatments in the three countries are illustrated in Table 6-20. Variations in costs were 
primarily due to differences in civil service salaries and the cost per day of inpatient feeding.
Table 6-20: Costs per Case Treated 
in Malawi, Mozambique and Tanzania ($US)
Malawi Mozambique Tanzania
Short-course chemotherapy 
with hospital admission
Average 160 217 174
Average Incremental 99 155 127
Marginal 69 140 101
Standard chemotherapy with 
hospital admission
Average 91 73 72
Average Incremental 71 54 63
Marginal 42 40 37
Ambulatory short-course 
chemotherapy
Average 139 196 152
Average Incremental 75 132 103
Marginal 46 117 77
Ambulatory standard 
chemotherapy
Average 66 55 50
Average Incremental 45 36 41
Marginal 19 18 15
Retreatment chemotherapy with 
hospital admission
Average 209 323 252
Average Incremental 141 232 182
Marginal 97 206 146
Source: Murray etal., 1991: p. 1306; Murray, Styblo and Rouillon, 1993, p. 251
The effectiveness of each treatment was measured in two ways: through direct benefits and 
indirect benefits. Direct benefits represented those positive effects of treatment that were directly 
experienced by the patients treated, for instance, cures and deaths averted. In contrast, indirect 
benefits were calculated as those positive effects of treatment that did not directly affect the patient 
treated, but in fact affected the population around the patient. Indirect benefits are essentially the 
positive externality of treatment which others experience after a patient is successfully treated, such as 
less transmission of TB, more productivity or a greater social contribution by the cured patient. 
Murray et al. primarily measured these indirect benefits through less TB transmission, and referred to 
these as transmission benefits. These indirect benefits were calculated on the basis that a case of 
tuberculosis would have four cycles of transmission taking 18.5 years. During these 18.5 years, each 
untreated smear-positive case of tuberculosis would cause 5.2 deaths and 3.8 deaths when discounted
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at 3% per year. From this measure of those deaths attributed to smear-positive tuberculosis, the 
authors calculated that direct mortality would account for 18% and indirect mortality, due to 
subsequent transmission, would account for 82%.
In order to calculate the benefits in terms of the differences between cure rates, transmission 
rates and death rates of the treatments and compare them to those that remain untreated, an expected 
spontaneous cure rate of 20-35% of all smear-positive cases was not included as a benefit.
Table 6-21: Results of Chemotherapy Programmes in Malawi, 
Mozambique and Tanzania (Given as a Percentage of Patients)
Malawi Mozambique Tanzania
Treatment Results Short-Course
1984-1988
Standard
1985-1988
Short-course
1984-1988
Standard
1980-1982
Short-Course
1982-1988
Cured 87.2 43.7 70.8 38.3 76.9
Treatment complete 0.0 10.4 7.3 15.0 0.0
Failed 1.3 4.3 1.5 11.0 2.4
Died 6.5 4.7 1.5 6.7 6.5
Absconded 2.2 24.2 11.3 15.7 9.9
Transferred out 2.7 12.5 7.8 13.3 4.2
Excreting (still 3.1 29.2 8.3 33.2 7.4
infectious)
Effective cure rate 90.4 66.2 90.3 60.2 86.1
Source-. Murray etal., 1991: p. 1306
Therefore, the effective cure rate was calculated from the sum of those cured, plus 35% of those who 
defaulted and transferred out for standard chemotherapy and 65% of those who defaulted and 
transferred out for short-course chemotherapy. Effective cure rates are shown in Table 6-21. This 
difference was assumed to be due to the stronger bactericidal and bacteriostatic action of short-course 
chemotherapy. In addition, results were recalculated to account for a 5% false positive diagnosis. 
This figure was derived from Tanzania where false positives were shown to range from 2.6-5.3%. 
Overall cure rates for the standard regimen averaged at 60-65% whereas for short-course 
chemotherapy, they averaged at 85-90%.
Murray et al. calculated the cost-effectiveness of these treatments in terms of cost per cure, cost 
per direct death averted, cost of total death averted and cost per year of life saved, as shown in Table 
6-22. Total death averted referred to the amount of lives saved over a 18.5 year period due to the 
decreased transmission of TB. The authors concluded that short-course chemotherapy was the least 
expensive drug treatment for smear-positive patients. SCC was found to be more cost-effective 
compared to the standard regimen because it had a higher cure rate, a lower selection of resistant 
mutants, lower failure rates and lower associated retreatment costs. The authors pointed out how cost-
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effective this is compared to other interventions. They estimated that the cost per year of life saved in 
ambulatory short-course chemotherapy for smear-positive patients is US $1-4.
Table 6-22: Average Incremental Unit Costs ($US)
Malawi Mozambique Tanzania
Short-course chemotherapy 
with hospital admission
Per cure 165 232 202
Per direct death averted 200 267 236
Per total death averted 38 57 47
Per year of life saved 1.7 2.6 2.1
Standard chemotherapy with 
hospital admission
Per cure 215 301 270
Per direct death averted 187 272 227
Per total death averted 54 76 68
Per year of life saved 2.4 3.4 3.1
Ambulatory short-course 
chemotherapy
Per cure 107 81 101
Per direct death averted 130 94 117
Per total death averted 25 20 23
Per year of life saved 1.1 0.9 1.1
Ambulatory standard 
chemotherapy
Per cure 111 82 107
Per direct death averted 96 74 90
Per total death averted 28 21 27
Per year of life saved 1.3 0.9 1.2
Source: Murray et al., 1991: p. 1307
In contrast, other cost-effective interventions, such as measles and neonatal tetanus immunisation, 
O.R.S. and blood-bank screening for HIV, cost US $5-10 per year of life saved. Murray et al. also 
concluded that short-course chemotherapy is more cost-effective than the standard regimen in both 
ambulatory and hospital environments except when considering the marginal cost of ambulatory care.
This study gives a very accurate and interesting description the optimisation of TB treatment in 
Africa, nevertheless, some elements must be critically considered. Data for this comparison spanned 
over different time periods and were based on three countries, excluding data on the standard regimen 
in Malawi. Also, in relation to the data, there was no sensitivity analysis performed to test the strength 
of the authors’ conclusions. This study also does not perform an incremental analysis. Lastly, the 
results of this study were heavily dependent on transmission benefits in calculating cost per total death 
averted. These transmission benefits were based on many assumptions and estimations. Following 
this, such benefits could not be used for smear-negative tuberculosis.
Indeed, this analysis highlighted smear-positive tuberculosis as the most cost-effective form of 
tuberculosis to treat, however, it also considered the far less cost-effective treatment of smear-negative 
patients. The authors suggested that 15% of smear-negative cases would convert to smear-positive.
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They considered this and the large amount of averted transmission from these 15%, concluding that 
the cost per death averted of treating smear-negative tuberculosis is US $185. This is 3.5-8 times the 
cost of treating smear-positive patients (although it is not stated, it is assumed that this cost is with 
short-course chemotherapy). The authors also approached the problem of cost-effectiveness in 
treatment for TB/HIV co-infected patients. They concluded that treating TB/HIV co-infected patients 
is ten times more expensive because these patients have such a poor survival rate during and after 
treatment. However, these authors highlighted the fact that when indirect benefits are considered, such 
as decreased transmission, the treatment of smear-positive HIV-seropositive patients falls to only 25% 
more than the TB treatment of smear-positive HIV-seronegative patients. Murray et al. also found that 
screening for HIV in those with TB would be expensive and would cause a TB programme to lose 
much of its credibility if it excluded some individuals from treatment on this basis.
6-2:5d Kamolratanakul, Chunhaswasdikul, Jittinandana, Tancharoensathien, Udomrati, Akksilp
Kamolratanakul, Chunhaswasdikul, Jittinandana, Tancharoensathien, Udomrati, Akksilp (1993)
(herein referred to as Kamolratanakul et al.) performed a cost-effectiveness analysis between SDR and 
three SCC regimens in Thailand of 1642 smear-positive patients in five zonal TB centres between 
1987-1989. The study shows the cost-effectiveness of treatment with SDR to be much lower than for 
those using SCC. The SDR regimen was lower in effectiveness, mainly because of a higher number of 
drug reactions and patient default. The SDR regimen also had slightly more patients whose sputum 
did not convert (probably because of acquired resistance from previous treatment). Hence, the SDR 
regimen had an effectiveness of 47.7% whereas the SCC regimens had effectiveness ranging from 
83.7% to 93.7%, as depicted in Table 6-23.
Table 6-23: Cure Rates of Three SCC 
and an SDR Treatment in Thailand
Results of Treatment 2SHT/16TH
(N=153)
2HRZ/4HR
(N=142)
2SHRZ/6TH
(N=576)
2HRZ/4H2R2*
(N=771)
Drug Side Effects 44 (28.8%) 9 (6.3%) 147 (25.5%) 45 (5.8%)
No. Drop Outs 68 (44.4%) 8 (5.6%) 60(10.4%) 114(14.8%)
No. Complete Treatment 83 (54.2%) 132 (93.0%) 506 (87.8%) 653 (84.7%)
No. Sputum conversion 82 (53.6%) 130(91.5%) 525 (91.1%) 645 (83.7%)
No. Sputum Non- 12 (7.8%) 1 (0.7%) 9(1.6%) 8(1.0%)
conversion
No. Sputum Relapse 0 0 12 (2.1%) 4 (0.5%)
Efficacy** 85.5% 99.2% 95.8% 98.2%
Effectiveness 47.7% 93.7% 85.9% 83.7%
Source-. Kamolratanakul et al., 1993: p. 634 
♦Subscript 2's refer to 600mg. isoniazid and rifampicin taken twice weekly
♦♦Efficacy refers to the treatment's performance in an ideal setting (i.e. the action of only the drugs)
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Table 6-24: Provider and Patient 
Costs for TB treatment in Thailand
Provider Costs Consumer Costs
Regimens Routine Medical Care Total Costs Direct Costs Indirect Total Costs
Service Costs Costs
Costs
2SHT/16TH 81.04 18.63 99.67 123.07 60.95 184.02
(18 visits) 
2HRZ/4HR 27.01 43.29 70.30 81.60 36.22 117.82
(6 visits) 
2SHRZ/6HT 36.02 37.14 73.16 60.96 49.38 110.34
(8 visits) 
2HRZ/4H2R2 27.01 31.78 58.79 62.31 24.16 86.47
(6 visits)
Source: Kamolratanakul etal., 1993: p. 635 
Routine Service Costs refer to overhead costs of running TB centres.
Medical Care Costs refer to material costs of radiology, laboratory and pharmacy departments.
Table 6-25: The Cost Effectiveness of 
SDR and Three Forms of SCC in Thailand
Cost-Effectiveness Ratio ($US)
Drug Regimen Provider Perspective Patient Perspective
2SHT/16HT 208.96 385.78
2HRZ/4HR 75.03 125.74
2SHRZ/6HT 85.16 128.46
2HRZ/4H2R2 70.24 103.31
Source: Kamolratanakul et al., 1993: p. 635
The authors of this study calculated cost-effectiveness from two perspectives, the provider and 
the patient. Provider costs and cost-effectiveness were much lower than patient costs, as shown in 
Table 6-24. From these costs, the cost-effectiveness ratio per patient cured was calculated so that 
2HRZ/4H2R2 was the most cost-effective regimen followed by 2HRZZ4HR and 2SHRZ/6HT. The 
SDR regimen of 2SHT/16TH proved to be the least cost-effective regimen according to this study, as 
observed in Table 6-25.
This a well performed study with a large sample group and a large selection of drugs. It included 
the impact of adverse drug reactions on cure rates, which few studies have considered. It also used a 
wide selection of SCC treatments to explore the cost-effectiveness of each. Nevertheless, it is difficult 
to ascertain the driving forces behind the costs. Costs for the standard regimen were estimated to be 
higher because they required a chest x-ray and more service costs. The question as to why chest x-rays 
were more expensive for the standard regimen was not addressed. Service costs were defined as 
overhead costs in all sections of the TB centres during the 21 months of this study. When calculating
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this, each visit is an estimated US $4.50. This is interesting because the cost of patient visits during 
the initial phase and follow-up during the continuation phase were not separated. This is important 
because patient visits during the initial phase involve a more intense level of activity than those visits 
during the continuation phase.
Kamolratanakul et al. did perform a kind of sensitivity analysis, but only chose to test the impact 
of the substitution of the median for the mean in calculating the treatment results. Relevant factors 
such as the default rate and elements of the cost were not explored in the sensitivity analysis. Another 
criticism of this study is that Kamolratanakul et al. did not consider death rates in calculating cure 
rates for their samples, as shown in Figure 6-22. Obviously, death can signify a failure on the part of a 
treatment in curing a patient.
In addition, this study used a standard regimen that lasts for 18 months, which is no longer 
relevant (IUATLD, 1994) because 12 month regimens are now used. If the provider costs are limited 
to only 12 months, then the routine service cost will equal US $54.00 and medical care costs will equal 
US $12.42, making total provider costs US $66.42. This adjustment lowers the total provider costs 
below all but one SCC drug treatment and subsequently, lowers the cost-effectiveness of SDR to US 
$139.24 instead of US $208.96 (from the provider's perspective). This, in conjunction with the 
potential ensuing lower default rate of only twelve months of treatment, might have a significant 
impact on the results of this study.
6-2:5e Saunderson
Another cost-effectiveness study on tuberculosis treatments was performed by Saunderson 
(1995) in 1992 in Uganda. This study compared a currently operating regimen that used hospital care 
with a hypothetical alternative regimen that was completely ambulatory. The 'current regimen' was a 
treatment with hospitalisation during the intensive phase followed by an ambulatory continuation 
phase for 4-10 months (depending on the drug regimen). In the 'alternate design' that Saunderson 
suggested, ambulatory treatment was to be used for the entire course of treatment, and the costs of this 
were extrapolated from the current programme's costs. These costs had to be estimated because the 
alternative design was not in use, and therefore, there were no existing costs to obtain total costs from. 
Also, since there were no existing patients to obtain cure rates from, cure rates had to be estimated. 
The most interesting characteristic of this study is that it addresses the costs to the patient for TB 
treatment, which has been done in few other studies. Nevertheless, Saunderson's sample size was very 
small, equalling 34 patients, with 32 recordable replies. Patients were randomly selected smear­
positive cases approaching the end of their stay in hospital. Monetary costs that patients experienced
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included transportation, hotel costs, private and traditional medical care costs before TB diagnosis, 
food (both in and out of the hospital) and the costs incurred by relatives caring for the patient.
Table 6-26: Total Costs of TB Treatment 
Between the Current Practise and Alternate Design
Cost Current Practise Alternative Design
Sputum Examination 5.60 8.32
Drugs 20.40 26.33
Stationary 0.20 0.20
Health Education 1.55 4.19
Supervision 3.79 7.58
In-patient Care 12.85 -
Out-patients-initial 3.04 3.04
Out-patients-follow-up 8.16 16.32
Total cost to health service 55.59 65.98
Costs to Patient
Before diagnosis 18.50 9.25
During hospital Stay 21.00 -
Due to loss of Work 95.00 40.00
Social Cost 7 7
Total Costs to the Patient 134.50 49.25
Summary
Total Cost 190.09 115.23
Cost to Health Services 55.59 65.98
Cost to Patient 134.50 49.25
Source: Saunderson, 1995: p. 1209
Saunderson also measured the cost of time away from normal activities. The average time away from 
work was calculated from the average salary of a nursing aid, making the average loss for each patient 
equal to £95.00. This cost had no bearing on the sex of the patient. 24 of the patients were subsistence 
farmers and 8 were in paid employment. All patients interviewed, except one, said that they 
experienced lost productivity and had either produced less, as in the case of subsistence farmers, or 
stopped working, as in the case of those in paid employment. The total cost, estimated from costs 
before diagnosis, during hospital stay and due to lost work time, is shown in Table 6-26.
The cure rates for this study were estimated from various districts, but variations were commonly 
observed. Saunderson shows the cure rate for a south-west zone in Uganda to be approximately 
51.2%. This is only estimated from those who died and defaulted and transferred (1/3 of those who 
transferred were assumed to have completed treatment), as shown in Table 6-26. Failures and drug 
reactions were not considered in the cure rates. Cure rates were finally arbitrarily estimated at 50­
60%, and this was used along with a cure rate of 70%, for calculating the cost-effectiveness of each 
treatment. As observed in Table 6-28, Saunderson calculated the total cost per cure, the health service 
cost per cure and the patient cost per cure.
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Table 6-27: The Estimated Cure Rates for 
Treatment in Uganda used by Saunderson (1995)_________
Result Percent in South-west Zone
Completed Treatment 
Died
Defaulted
51.2%
11.4%
37.4%
Source: Saunderson, 1995: p. 1209
Table 6-28: The Cost-Effectiveness Between the Current 
Practice and the Alternative Design for TB Treatment in Uganda
Current Practice Alternative Design
Cure Rate 50% 60% 50% 60% 70%
Total Costs 190.09 190.09 115.23 115.23 115.23
Cost per Cure 380.18 316.82 230.46 192.05 164.61
Health Service 55.59 55.59 65.98 65.98 65.98
Cost per Cure 111.18 92.65 131.96 109.97 94.26
Patient Costs 134.50 134.50 49.25 49.25 49.25
Cost per Cure 269.00 224.17 98.50 82.08 70.36
Source: Saunderson, 1995: p. 1209
The weaknesses in this study is that it uses cure rates that have been estimated and compares 
them to a hypothetical treatment that has not been implemented. It is a reflection on the data rather 
than the study itself. Both the cure rate estimation and the cost estimation are weak: the results are 
hypothetical and it is not until the programme is implemented that true cost-effectiveness ratios can be 
compared. Caution should be taken when making decisions based on this study. However, it should 
be noted that Saunderson, constrained by poor available data, was forced to perform this study with 
hypothetical data.
The cost-effectiveness results are primarily dependent on patient costs, and especially patient 
costs due to lost work. When only considering the health service cost per cure, the current practice 
still proves to be more cost-effective by a small margin. Looking at costs for the alternative design, 
the drug costs, sputum examination costs health education costs, supervision costs and follow-up costs 
all prove to be higher than those in the current practise. The drug costs are different because the drug 
regimens compared are not the same. Those used for the current practice are 2SHRZ/6TH, which is 
the commonly used SCC regimen in developing countries. The regimen for the alternative design is 
2EHRZ/4RH, which, although the commonly used SCC regimen in industrialised countries, is a 
virtually unheard of regimen in developing countries. Saunderson does not justify this inconsistency 
and the choice of drug regimens for each treatment design appears arbitrary. It is possible that the 
drug regimen for the alternative design was chosen because it has a shorter treatment period and would
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therefore have lower time-dependent patient costs. In order to have made the results of this study 
more consistent, the drug regimens should have been the same, because indeed, the design of this 
study does not appear to compare these.
Although it is not stated, the perspective of this study is estimated to be from society because of 
the inclusion of indirect costs. From an economic perspective, one motivation for a study that 
measured costs in lost days of work, would be to discover what effect particular treatments have on 
productivity. Unfortunately, only 25% of the sample interviewed were actually wage earners. The 
other 75% were subsistence farmers whose work could be argued to have had an insignificant impact 
on productivity. Nevertheless, Saunderson calculates a productivity loss in wages of £95.00 for each 
patient. Certainly, those studies that measure patient costs are far better suited to a health care system 
where the patient has some role in decision making in the treatment that he or she receives. In many 
developing countries, TB is perceived as such a strong health threat, that treatment is provided by 
public health facilities, often free of charge. If the decision maker is far more likely to be the body 
funding the TB treatment, and not the patient, only the direct costs per cure of the TB intervention are 
relevant to this perspective. In the case of Saunderson's study, even in the absence of a two month 
hospital care period, his alternative design is still less cost-effective.
Much to Saunderson's credit, he performed a sensitivity analysis on his hypothetical estimates of 
costs and cure rates. He did not, however, present an incremental analysis for this study. Essentially, 
Saunderson highlighted his study as an HIV-era study, a study that takes into account those costs of a 
running programme, and a study that considers the costs incurred by the patient. He compared his 
study to two SCC-SDR cost-effectiveness studies (Bamum (1986) and Murray et al. (1991)), when in 
fact his study by no means involved a comparison of SCC and SDR. In addition, although Bamum 
(1986) is a pre-HTV study, and although Saunderson discussed HIV and health counselling, he did not 
integrate or discuss the impact of HIV on the estimated cure rates over those cure rates in the past. In 
fact, it is difficult to explicitly observe the difference between his study and a pre-HIV study.
In summary, the results of this cost-effectiveness study are primarily dependent on the impact of 
a shorter treatment period and the elimination of time spent in hospital on a patient's earnings. Patient 
costs may have an indirect effect on the rate of default, but this effect is unknown as cure rates were 
not available for the alternative regimen. In addition, the regimen that Saunderson used in calculating 
drug costs for the alternative regimen is so very modem and expensive, that it is unlikely that it will be 
used in developing countries on a wide scale before the year 2020 (optimistically). If the perspective 
were changed to the funding body, cost per cure in terms of health care costs still finds the current 
practice more cost-effective. In addition, the validity of these results are threatened because they are 
based on hypothetical results. This study is nevertheless, interesting in its estimation of patient costs
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which are seldom calculated, however, there is an implicit reason for this: it is determined by the 
decision maker.
6-2:6 Murray, Styblo and Rouillon and World Bank Research on the Cost of Tuberculosis 
Treatment
Some results of this cost-effectiveness analysis between short-course chemotherapy and the 
standard regimen in Malawi, Tanzania and Mozambique by Murray et al. (1991) were shown in more 
detail in Murray, Styblo and Rouillon (1993). In addition, other cost considerations in SCC and SDR 
TB treatment are considered.
6-2:6a The Costs and Impact of SCC and SDR
In a way that is identical to Murray et al. (1991), Murray, Styblo and Rouillon (1993) separated a 
TB programme's costs according to variable costs, fixed costs associated with the TB program and 
fixed costs associated with the primary health care infrastructure. Variable costs included those costs 
which were associated with the amount of patients and the amount of drugs, food and reagents for 
diagnosis that each consumes. Fixed costs associated with the TB programme included administration 
costs and vehicles. In contrast, fixed costs outside of the programme were composed of those costs 
that primarily arose from utilisation of those structures and utilities shared with other health 
programmes. This is illustrated in Figure 6-10 which shows the costs in their TB measure as a 
function of the number of patients.
Figure 6-10: Tuberculosis Program Costs
Adapted From: Murray, Styblo and Rouillon, 1993: p. 250
From these cost measures, the authors also broke costs into three unit costs. These consisted of 
marginal costs, derived from the average variable costs per case; average incremental costs which were
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derived from variable costs plus fixed tuberculosis program costs per case; and average costs which 
were equal to the total costs per case.
These costs did not include retreatment costs for failure. This seems inconsistent because the 
study went into such depth by including the indirect transmission benefits of the programme over 18.5 
years. These incremental cost calculations and cure rates are illustrated in Table 6-29.
Table 6-29: Costs and Benefits of Short-Course Chemotherapy and the 
Standard Drug Regimen Based on National Tuberculosis Programs of Malawi, 
Mozambique and Tanzania According to Murray, Styblo and Rouillon (1993)
Parameter Standard Drug Regimen Short-course Chemotherapy
Average incremental cost per year of 
life saved with hospitalisation ($US)
3.00 2.00
Cure rate 60 85
Percent of cases requiring retreatment 30 10
(percent)
Source: Murray, Styblo and Rouillon, 1993, p. 253
Cure rates for these different regimens were 60% for the standard regimen and 85% for short-course 
chemotherapy. Although the costs of retreatment were not considered, the authors still showed the 
percentage of cases that will require retreatment. 30% of those treated with standard chemotherapy 
would require retreatment, whereas this only amounted to 10% of those receiving short-course 
chemotherapy.
Murray, Styblo and Rouillon also discussed the cost-effectiveness in comparing treatments for 
smear-negative tuberculosis cases. They maintained that the cost-effectiveness of chemotherapy for 
smear-negative pulmonary tuberculosis was dependent on the predictive value of chest radiographs 
(estimated at 50%), case-fatality rates of untreated smear-negative cases (estimated at 40% from 
previous studies), the cure rate of the chemotherapy used (estimated at 50%), and the percentage of 
untreated cases that would progress into smear-positive cases. From the first three variables, the 
authors estimate a US $450 cost per death averted in treating smear-negative tuberculosis. This is ten 
times the cost per death averted for SCC in hospitalised smear-positive patients and twenty times the 
cost of that for SCC treatment of smear-positive ambulatory patients. The cost of this is mitigated 
when considering those smear-negative cases that become smear-positive, because such treatment 
stops pre-diagnosis transmission that would occur once a smear-negative case turned into a smear­
positive case. This reduced cost per death averted to US $185 assuming 15% will become infectious. 
Nevertheless, this estimate is quite conservative. In some studies, progression to a smear-positive state
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has been as much as 56% (Hong Kong Chest Service/Tuberculosis Research Centre, Madreas/British 
Medical Research Council, 1984).
Table 6-30: Estimated Average Incremental Costs in $US 
per Patient Treated in Low- and Middle-Income Countries
GDP per capita Short-course
hospitalisation
Short-course
ambulatory
Standard
hospitalisation
Standard
ambulatory
150 136 63 113 41
250 181 70 159 48
500 296 87 274 64
750 411 104 389 82
1000 526 122 504 100
1 250 641 139 619 117
1 500 756 156 734 134
Source: Murray, Styblo and Rouillon, 1993: p. 251
6-2:6b TB Treatment Costs in Countries with Varying GNPs
Murray, Styblo and Rouillon also observed that the cost of therapy varies with a country’s GNP.
In essence, as GNP rises the cost of inputs, such as labour, becomes more expensive, as shown in 
Table 6-30. Likewise, there is a greater expenditure on more expensive inputs, for instance, disposable 
syringes are used instead of reusable syringes. There is also an interesting trend between hospital care 
and ambulatory care costs as GNP changes. As can be seen from Figure 6-11, where GNP per capita 
rises, the cost difference between hospital and ambulatory care grows wider and wider, reflecting the 
much quicker increase of hospital care costs over ambulatory care costs.
Figure 6-11: Estimated Average Incremental Cost ($US) per 
Patient Treated in Low- and Middle-Income Countries
GNP per capita
Adapted from: Murray, Styblo and Rouillon, 1993
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This is possibly attributed to the cost of labour and expenditure on expensive supplies and overhead, 
which seem to rise with GNP. It should also be noted that hospital care in low income countries looks 
comparatively cheaper according to the authors, but this does not take into account the quality of 
treatment in these hospitals. A hospital in a lesser developing country often has a poor isolation 
system for patients and food for patients is often left up to the patient's family. Another interesting 
pattern that develops with rises in GNP points to the gap between standard and short-course 
ambulatory care costs and the gap between standard and short-course hospital care costs, which both 
remain relatively the same with rises in GNP. This is primarily because costs differentiating the two 
are based on drug costs with are unlikely to change with rises in a country's GNP. It must be noted 
that this relatively constant difference makes short-course chemotherapy more feasible with rises in 
GNP. To those countries with low GNPs per capita, the value of foreign currency needed for 
purchasing medical supplies proves to be much more than local currency. This makes short-course 
chemotherapy less obtainable. However, as GNP per capital rises, and the relative value of foreign 
currency to a country's local currency falls, there proves to be a smaller relative difference between the 
two treatments. This probably reflects why countries with higher GNPs per capita have adopted SCC 
because such differences in the cost between these two regimens are no longer so significant.
6-2:6c The Spread of Tuberculosis and Transmission Benefits from Treatment
Very little work has been performed concerning the average number of new cases of TB that is
caused by each smear-positive TB case. In calculating indirect transmission benefits, Murray, Styblo 
and Rouillon (1993) have produced some interesting work in charting the process and impact of TB 
transmission. Benefits of treatment are derived from an extrapolation of Berg's (1939) study of 6 162 
cases of tuberculosis. As can be seen in Figure 6-12, starting with a population of 100 000, death and 
survival from untreated TB are charted next to the number of patients still infectious at the beginning 
of each year over a period of ten years. One can observe a curvilinear trend whereby there is initially a 
sharp rise in deaths, a fall in total population and population excreting tubercle bacillus after which 
they start to become more constant. It is from these data that Murray, Styblo and Rouillon estimated 
that for every one smear-positive TB case, there will arise one more case in the future. This 
transmission cycle is estimated to be slightly over 4 years. According to these authors, transmission of 
tuberculosis of one smear-positive case of tuberculosis occurs at a rate of between ten and fourteen 
persons per year. Those who are smear positive will transmit tuberculosis for an average of two years 
which is why prevalence is calculated as twice the incidence (Styblo, 1984). This means that each 
smear-positive case is responsible for an average negative externality of twenty to twenty-eight new 
cases of tuberculosis.
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Figure 6-12: Life Table for Untreated, 
Smear-Positive Pulmonary Tuberculosis
Adapted from: Murray, Styblo and Rouillon, 1993
Such effects are illustrated in Figure 6-13. Given 100 smear-positive cases, they will in turn cause 2 
400 more infections. From this amount, a proportion will become smear-positive (100) and a 
proportion will contract other types of tuberculosis (122). Without interference by treatment, this 
process will continue to repeat itself, and from each group of TB cases, there will result an average of 
50 deaths.
Infections
Smear-Positive
Cases
Other Cases
Deaths
Figure 6-13: The Pattern of Tuberculosis Transmission
Source: Murray, Styblo and Rouillon, 1993: p. 244
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6-2:7 Drug Reactions and Complications to Drug Treatments
Another, less highlighted, problem in using the standard regimen instead of short-course 
chemotherapy, involves drug reactions and complications primarily from SDR's intensive use of 
thiacetazone and streptomycin. In developing countries, thiacetazone, whose use is banned in the US, 
is a common drug appearing in TB treatment regimens. This drug, often given in combination tablets 
with isoniazid, is a dangerous drug for those with HIV. In these co-infected patients, it is strongly 
correlated with the development of Stevens-Johnson syndrome, an adverse reaction characterised by 
haemorrhaging and a blue or purple cast to the skin. In France, Grosset (1992) found adverse reactions 
to thiacetazone in 18-20% of those HIV-seropositive cases treated with it. In Malawi where the 
incidence of HIV is high, rates of Stevens-Johnson syndrome associated with thiacetazone use rose to 
1% in 1990. In Zimbabwe, the probability of adverse drug reactions to thiacetazone was estimated to 
be five times as likely (Houston, Pozniak, Ray, 1991). Subsequent substitution of this drug for 
ethambutol has lead to a drastic decrease in this adverse effects to less than 0.2% or 1 in 500 (Enarson, 
et al., 1993). An additional problem with the use of thiacetazone is the fact that a strain of tuberculosis 
specific to West Africa, Mycobacterium africanum, has a high level of natural resistance to 
thiacetazone (Crofton, Home & Miller, 1992). The high number of reactions and possible resistance 
to this drug make it far more costly than just the monetary value of obtaining it. However, this is one 
of the main drugs used in the standard regimen, because it is so much more inexpensive than other 
drugs.
Because as much as 33-50% of those seeking treatment for tuberculosis are HIV-positive, the 
standard regimen can prove deadly. Furthermore, HIV screening of all those seeking treatment in 
itself would prove more costly than short-course chemotherapy. With greater patient compliance and 
fewer side effects for AIDS patients, cure rates are likely to be higher and resistance lower for SCC.
Another complication of therapy is the use of streptomycin injections in HIV or potential HIV 
patients. Syringes for injections are often re-used so that there is the possibility of a transference of the 
virus on a needle that has not been adequately sterilised. Enarson et al. (1993) emphasise the potential 
for HIV transmission through streptomycin injections by suggesting that in a country with 15 000 
cases of tuberculosis, 1 million injections will be given per year. If there is a 33% HTV incidence, with 
so many injections, the transmission risk is high, especially with an overloaded health staff. 
Nevertheless, the awareness in health personnel of the need to sterilise needles to prevent nosocomial 
HIV infection is high. Added to this, the virus is weak outside of the body and can survive on a needle 
for a maximum of only seven hours (personal communication: David Matthews, 1995). Hence, if 
needles are used only once a day, the likelihood of the survival of the virus on a needle the next day is 
minimal.
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6-2:8 Summary of Section 6-2
The superiority of short-course chemotherapy in treating tuberculosis is undoubtedly established 
when compared to the standard regimen. Nevertheless, the problem arises in the fact that the cost of 
SCC is much higher in relative terms for a developing country. SCC remains higher because it 
contains those drugs such as rifampicin and pyrazinamide that are newer and have more expensive 
production processes. Although most of these drugs are no longer covered by a patent, they still 
remain comparatively expensive to produce.
Ascertaining the optimum choice of regimens for treatment is a difficult task and must rely on 
cost-effectiveness analyses, a form of applied economics. Attempts at this have been carried out by a 
small number of authors, but such studies have not irrefutably established the superiority or inferiority 
of SCC in cost-effectiveness terms. Although, due to it's higher effectiveness, SCC is the obvious 
choice for industrialised countries, more research is still needed to ascertain if this is the optimum 
choice for developing countries in their attempt to both contain tuberculosis while working within their 
financial limits. With greater research in this area, external aid agencies, funding bodies and the health 
ministries of developing countries can be better aided in making the best treatment choice for the 
management tuberculosis containment. When developing countries are more influenced by the initial 
price of interventions, this kind of operational research is a way to maintain the benefits of more 
expensive, but far more effective treatments.
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Section 6-3
Conclusion to chapter Six
In developing countries, tuberculosis remains as the number one cause of death in those aged 
between fifteen and fifty-nine. This disease has a devastating effect on the population, taking its 
individuals at the peak of their potential economic and social contribution to society. This is 
surprising considering that there is an effective cure for this disease. Tuberculosis could potentially be 
eradicated for several reasons: (1) the origin or the disease resides in individuals who can be identified; 
(2) the spread rate of the disease is reduced if those with the disease are treated; (3) the transmission of 
the disease is inefficient meaning that a small reduction in the incidence has a large impact in 
decreasing the overall spread; and (4) those materials needed to treat the disease such as drugs and 
laboratory equipment can be used even in low income areas. Even in the presence of the problem of 
HIV, TB could be greatly reduced. With TB/HIV co-infection, case identification remains unchanged 
if sputum smear microscopy is used, and it is still possible to cure TB/HIV co-infection.
The use of NTPs in standardising tuberculosis treatment on a national level in each country is a 
necessary element to managing tuberculosis. In addition, greater gain could be made by implementing 
more effective drug treatments where their costs prove to be justified. Indeed, the use of SCC is still 
uncommon in many areas of developing countries, who are more inclined to depend on the standard 
regimen. Nevertheless, although expenditure on SCC is greater than the standard regimen, it's 
associated costs are lower because it achieves greater cure rates through less acquired resistance, fewer 
drug reactions and shorter treatment times. This allows for greater compliance and higher cure rates 
In essence, although SCC is more expensive, its cost in terms of less transmission of the disease, 
greater productivity of cured workers, less relapse and greater patient utility from the treatment can 
prove to be far lower than the standard regimen's. It is possible that associated resistance will have 
some impact on the cost of TB treatments and therefore change this relationship between SCC and 
SDR. This relationshiop is also dependent on the area in which TB is treated. The organisation and 
management of drug supplies, influence of HIV and context of resistance of TB in Ethiopia is hence, 
presented in the next chapter.
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CHAPTER SEVEN
TUBERCULOSIS CONTROL EFFORTS IN ETHIOPIA 
PART ONE: HEALTH CARE DELIVERY AND DETERMINANTS OF HEALTH
This chapter, 'Part One of 'Tuberculosis Control Efforts in Ethiopia', presents the first part of the 
case studies presented in order to analyse the impact of TB drug resistance on the cost of TB treatment 
in Ethiopia. It illustrates the difficult challenge of a low income developing country in fighting 
infectious bacterial disease, and will especially focus on the containment of tuberculosis in Ethiopia. 
Before looking at the impact of TB resistance on the cost of TB treatment, it is important to look at 
other factors that also have an impact on TB, and therefore, the incidence of TB and the cost of TB 
treatment. This includes the general determinants of health status in Ethiopia, drug management, 
tuberculosis control efforts and HIV. Therefore, section 7-1 describes the country's demographics 
determining health and influencing tuberculosis. After the discussion in Chapter 3 of drug 
management and the discussion in Chapter 4 examining antibiotic utilisation, Section 7-2 of this 
chapter analyses the management of tuberculosis antibiotics in Ethiopia. The recommendations in 
Chapter 5 and Chapter 6, on the management of tuberculosis are further illustrated in Section 7-3, 
which will discuss the current state of tuberculosis control efforts in Ethiopia. Also, the analyses in 
Chapter 5 and Chapter 6 of the link between TB and AIDS are further expanded in Section 7-4 which 
explores the nature and victims of HTV in Ethiopia in preparation for a discussion of the interaction 
between the two diseases in Section 8-1 in Chapter 8.
Introduction
In 1984 Ethiopia shook the world because of a famine that thereafter made it synonymous with 
most modem literary references to intense starvation. It was not surprising that famine occurred on 
such a wide scale in this country where over 80% of its people still rely on agriculture for their 
livelihood and even in the best of times, its cultivable land consists of cracking clays, which prove
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difficult to farm. Such fragile circumstances mean that crops are destroyed and families must sell what 
little they own in order to buy food when virtually any drought or flood occurs. This however, has not 
been enough in the past as proven during the drought of 1984, when over $2 billion dollars in 
emergency relief aid flowed into Ethiopia. This vast sum, if spent on long-term aid, could have 
potentially halted the high proportion of famine-caused morbidity and mortality (Cross, 1994).
Since 1984, much in Ethiopia has changed. In 1991 a revolution deposed the military dictator, 
Mengistu Haile Mariam, responsible for spending famine aid funds on military hardware. Two years 
later, the province of Eritrea separated from Ethiopia after 30 years of struggle. The result of this was 
a new democracy under Meles Zenawi with economic and political freedom which has instigated a 
transition to more intensive farming methods and industry. Nevertheless, a good wage for a day 
labourer is still only 3 birr (30 pence) and the average life expectancy is approximately 50 years for 
both men and women. Ethiopia is still ranked among the poorest countries with a per capita income of 
just $110 US dollars per year (Transitional Government of Ethiopia, Office of the Council of 
Ministers, 1993). In addition, levels of education are low. 74.4% of children are enrolled in primary 
education, 22,8% are enrolled in secondary education and 0.5% are enrolled in tertiary education. 
Although literacy rates are a high 76%, superstition and ignorance are still common. Further 
complicating this is the fact that 70 different languages and dialects are spoken, hindering 
communication.
Reasons for the low life expectancy in Ethiopia reflect large problems in nutrition, sanitation and 
housing, all having their relative impact on health. However, studying this impact is difficult for three 
distinct reasons. Dependable and complete data on rates of health are difficult to obtain if these exist 
at all, as is the case in many parts of Africa and least developed countries. In addition, Ethiopia is a 
deceivingly large country with several different altitudes over which disease patterns drastically differ, 
and therefore data generalisations cannot be readily made. Lastly, continuous environmental disasters, 
civil war in the north and political objectives incongruous with health needs, have all added unnatural 
disease etiologies whose understanding cannot be studied in a limited epidemiological context (Kloos 
and Zein, 1993).
Currently only 6% of the national budget from the Ethiopian Ministry of Finance goes to health, 
representing less than US $1 per capita per year. Of this, 35-40% is spent on hospital care (Personal 
communication: Dr. Barbiero, USAED). The WHO is currently pressuring the government to spend 
more on TB. In contrast, US AID is focusing on primary health care utilisation given the low rates of 
health service coverage. Unfortunately, TB is discounted as an AIDS-related disease and therefore 
there is a push to place funds in other areas, for instance, "well baby" and immunisation programmes.
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One of the effects of such changing dynamics and low per capita expenditure on health has been 
the relatively constant morbidity and mortality from tuberculosis. The high existing incidence of TB 
paired with malnutrition and HIV have caused the disease to flourish. Subsequent efforts to reduce the 
incidence of the disease have been all but complete failures until recently when a national 
tuberculosisprogramme was initiated.
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Section 7-1
DEMOGRAPHIC, SOCIO-ECONOMIC AND ORGANISATIONAL DETERMINANTS OF HEALTH
This section looks at the health service coverage in Ethiopia and the organisation of government 
health services. These are factors that influence the correct implementation of TB treatment and 
therefore, are influences on the development of drug resistance. This section also discusses the 
morbidity patterns of infectious diseases experienced in Ethiopia, and highlights tuberculosis as a 
significant health threat.
Ethiopia lies on the Eastern part of the African continent, an area also known as the "Hom of 
Africa". Its area encompasses 1.25 million square kilometres which are divided into three zones: the 
Dega (cold), defined as land that is at an altitude of 2 400 meters and above, the Weyna-dega 
(temperate) zone defined as land from 1 500-2 400 meters in altitude, and the Kolla (hot) zone defined 
as land 1 500 meters and below. The altitudes of these zones are significant because their 
environments predict the types of morbidity that affect their inhabitants. In the colder Dega and 
Weyna-dega zones, there is more tuberculosis, louse-borne typhus and relapsing fever, whereas those 
in areas below 1800 meters there is malaria, and below 2000 meters there is human and animal 
trypanosomiasis.
From the 1984 national census, the population in 1992 was estimated to be approximately 
53 844 700 which gives an average population density of 44.1 people per square kilometre, (including 
Eritrea which has since separated). The population growth rate is 2.98% per year, and by this 
estimate, the population in 1993 was approximately 55 449 272, and by the end of 1995, it will be 
approximately 58 803 289 (including Eritrea as statistics on Eritrea's population are not yet available). 
The 1992 male to female ratio proved to be 49.9 to 50.1 with 11.3% of the population living in urban 
areas and 88.7% living in rural areas. During this year, the population age structure was 18.6% aged 0­
4 years, 29.6% aged 5-14 years, 36.0% aged 15-44 years, 11.1% aged 45-64 years, and only 4.37% 
over 65 years. The average life expectancy at birth is estimated between 49 and 53.4 years. From 
these statistics, it can be seen that a large proportion of the population (48.2%) lies under the age of 15 
and does not work but still needs clothing, shelter, food, education and health care. A further amount 
are over 65 (4.37%) such that, 47.1% must economically support 52.9% of the population. 
Corresponding to this, 80% of the population relies on subsistence farming and animal livestock and 
90% must rely on agricultural production, leaving the remaining 10% to work in industry (Transitional 
Government of Ethiopia, Office of the Council of Ministers, 1993). The effect of this is such that the 
current economic growth rate is unable to support the population growth, and the majority of the 
population live below the United Nations defined absolute poverty level.
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The young age and economic structure point to the strain of the society in maintaining acceptable 
levels of health. Only 18.5% of the population have access to clean drinking water. Malnutrition is 
rampant, proven by a 2-6% population incidence of wasting, 18-24% of population stunting and 30­
40% of the population underweight. Infant mortality numbers 141 per 1000, and child mortality is 99 
per 1000. Total fertility amounts to 7.5 children per woman and maternal mortality is 5.7 per 1000. 
With such a large proportion living under the absolute poverty level, malnutrition, poor sanitation and 
poor housing all contribute to the development of poor immune systems and widespread disease. The 
spread of HIV is a further contribution to poor immunity, and therefore, greater disease prevalence. 
Hence, diseases dependent on the severely immunocompromised state of the individual proliferate. 
The paradigm case is indeed, tuberculosis.
7-1:1 Health Service Coverage
Exacerbating the problem of a poor living environment and a fragile economy, health service 
coverage only amounts to 45-47% of the population. Antenatal coverage equals 16% and assisted 
baby deliveries equals 5%. Utilisation is affected by the distance that has to be travelled from a 
patient's home to a health facility. Kloos et al. (1987) observe that between 35-94% of all individuals 
who seek care from a health facility live within a 2 km radius of it. In Addis Ababa, 30-36% of those 
seeking care travelled by foot and the amount of those making journeys by foot seemed to increase the
more rural the location.
Table 7-1: Distribution of Health Care 
FaciUtiesAccording to Year of Establishment
Year Hospitals Health Centres H. Stations
1891-1901 2 0 1
1902-1911 1 0 0
1912-1921 5 0 2
1922-1931 8 0 3
1932-1941 9 0 24
1942-1951 15 6 42
1952-1961 24 61 159
1962-1971 11 48 648
1972-1981 4 23 616
1981-1991 0 1 2
Other 7 18 628
Total 88 157 2125
Source'. Transitional Government of Ethiopia, Office of the Council of Ministers, 1993: p. 31
Access to care is also influenced by the available facilities and the number of health care workers. 
From Table 7-1, there are 648 882 people for every hospital (defined as large buildings with several 
wards and over 150 beds), 363 704 people for each health centre (defined as meeting primarily 
outpatient care with 10-20 treatment rooms) and 26 871 people for each health station (1-4 roomed
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facilities with limited and basic health care delivery services). For every hospital bed, there is an 
estimated 4200 people. It is no wonder that these health facilities are overwhelmed.
The majority health facilities were established before 1971 and considering the construction 
capabilities during this time, have proven to be quite outdated. Also, existing health facilities have 
become dilapidated. This is illustrated in Table 7-2 which shows that 42% of all hospitals, and close to 
20% of health centres and health stations are in need of major repair. Similarly, approximately 10% of 
all health station buildings are in need of complete replacement.
Table 7-2: Health Institutions According to Building Condition
Health Institution Good Condition Building Seeking 
Minor Repair
Building Seeking 
Major Repair
Building Seeking 
Replacement
Unknown
Hospital 29.0% 19.3% 42.0% 6.8% 6.8%
Health Centre 28.7% 42.0% 19.7% 4.5% 5.1%
Health Station 36.0% 20.8% 18.5% 9.9% 14.7%
Source: Transitional Government of Ethiopia, Office of the Council of Ministers, 1993: p. 33
Table 7-3: Distribution and Population Ratio per Health 
Worker Between Addis Ababa and the Rest of the Country, 1990
Area Medical Officer Health Officer Nurse Health Assist.
Addis 1 020 79 1 646 3 460
Ababa
Rest of the Country 638 15 1 929 6 585
Addis Ababa % 62 84 46 35
Population Ratio to 30 600:1 540200:1 14 200:1 5 100:1
Health Personnel
Area Pharmacist Pharm. Lab. X-Ray Sanitarian
Tech. Tech. Tech.
Addis 276 152 323 127 196
Ababa
Rest of the Country 101 131 270 111 193
Addis Ababa % 73 54 55 53 50
Population Ratio to
Health Personnel
134 700:1 179 400:1 85 600:1 213 300:1 130 500:1
Source: Transitional Government of Ethiopia, Office of the Council of Ministers, 1993: p. 60
7-l:la Urban Bias
Like many developing countries, Ethiopia suffers from an urban bias where a large proportion of 
health facilities and health personnel are located in heavily populated areas. As observed in Table 7-3, 
Addis Ababa, the capital of Ethiopia, has 42% of all health personnel in the country.
Table 7-3 also shows that the population per doctor ratio is extremely high at 30,600:1, the 
population per nurse is approximately half this at 14,200:1 and the population to pharmacist is even 
higher at 134,700:1. This high population to pharmacist ratio might reflect the strong dependence of 
individuals on the government to supply drugs because the low income of the country offers only a
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small market for commercial pharmacies. (Such an effect is likely to decrease as a country becomes 
more affluent allowing for a more effective demand for drugs)
7-1:2 Morbidity Patterns and Infectious Disease
Morbidity patterns in Ethiopia are dominated by infectious diseases. Of the top twelve diseases 
observed in hospitals, all but gastritis were infectious (although there is some connection to this in 
industrialised countries to H. Pylori'). The ranks of these diseases has not changed significantly over 
ten years, as shown in Table 7-4. The rank of 12 for tuberculosis in both 1981 and 1991 suggests that 
efforts to decrease its incidence have been relatively impotent and evidence from health centres and 
hospitals suggest that the incidence of this disease is, in fact, rising.
Table 7-4: Rank of the Top Twelve Diseases in 
Hospitals and Health Centres in 1981 and 1991*
Rank Disease Rank in 1981 Rank in 1991
1 Helminthiasis 1 1
2 Dysentery and Gastro-enteritis 2 2
3 Eye disease including trachoma 3 3
4 Pneumonia 4 4
5 Infection of skin and subcutaneous 
tissue
5 5
6 Acute upper respiratory infections 6 6
7 Gastritis and duodenitis 7 9
8 Malaria 8 7
9 Sexually transmitted diseases 9 8
10 Otitis media and other conditions of 
the ear
10 11
11 Bronchitis (all forms) 11 10
12 Tuberculosis (all types) 12 12
Source: Transitional Government of Ethiopia, Office of the Council of Ministers, 1993: p. 63 
* Data is limited to only those cases that received care in health care facilities. However, central statistical authorities 
conclude through a "Rural Household Sample" that there is no significant difference between these statistics and the 
morbidity experienced by those that do not seek care in health facilities.
To obtain a more extensive view of morbidity patterns, one can look at the estimates of the number of 
patients in each morbidity category per health station, per year by the Emergency Recovery and 
Reconstruction Project of 1991 (ERRP). As can be seen from Table 7-5, each health station should be 
equipped to treat almost 10 000 patients per year. From past morbidity data, it is estimated that 
malaria, tuberculosis, gonorrhoea, ear infections, rheumatic pain and accidents represent the highest 
proportions of patients seeking health care at health stations.
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Table 7-5: Estimated Number of Patients Treated 
According to Morbidity Category per Year per Health Station
Disease Estimate of those treated per health station per year
Malaria 815.50
Unknown Fever 340.70
Skin Infection 574.70
Diarrhoea 567.66
Gastritis 567.66
Other Gastrointestinal Disease 333.42
Common cold 540.43
Tonsilitis 514.65
A11TB 1033.26
Gonorrhoea 708.11
Other Sexually Transmitted Diseases 268.04
Eye Infection 157.58
Ear Infection 673.52
Tooth Diseases 247.80
Malnutrition 213.26
Intestinal Parasite 379.72
Rheumatic Pain 1003.65
Other Accidents 763.73
Anaemia 226.52
Courtesy of: Transitional Government of Ethiopia, Department of Pharmacy (unpublished)
7-1:3 Organisation of Government Health Services
Health expenditure funded by the Ministry of Health (MOH) accounted for 3.1% of the national 
budget in 1990 and 2.67 (US $0.44 in 1994) birr per capita (6 birr ~ US $1 in 1994). 89.9% of all 
hospitals, all health centres and 94% of health stations are owned by the Ministry of Health and other 
government agencies. Health services are primarily the responsibility of the Ministry of Health which 
is supervised by the Minister of health and two vice ministers. Each vice minister heads 5 departments 
and other institutions. These include the Ethiopian Pharmaceutical and Medical Supplies Corporation 
(EPHARMECOR), Ethiopian Nutrition Institute (ENI), the Jimma Health Science Institute (JHSI), 
Control of Malaria and Other Vector Disease division, and the National Research Institute of Health 
(NRIH). The organisational hierarchy of the Ministry of Health is depicted in Figure 7-1.
The health services within various districts are supervised by the regional and district health 
departments which supervise an infrastructure of hospitals, health centres, health stations, central 
referral and specialised hospitals. Health centres give preventive and curative ambulatory care to both 
referral patients and non-referral patients. These usually have 10-15 rooms, a rudimentary clinical 
laboratory, a small number of beds for mothers in labour and critical patients. Health stations are the 
most basic manifestation of health care facilities, mainly functioning in rural conditions to increase 
health service access. These contain 1-3 health care workers, have 2-3 rooms and use simple 
diagnostic tools and function for essential curative services.
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Figure 7-1: Hierarchy of the Ministry of Health in Ethiopia
Source: Transitional Government of Ethiopia, 
Office of the Council of Ministers, 1993: p. 90
Rural hospitals give 24 hour curative care and also give preventive care to inpatients. These facilities 
contain most types of health care personnel except for specialist doctors. They also have some simple 
operating theatres for less serious and emergency procedures. Regional hospitals are located in large 
towns with regional administrative bodies and these hospitals employ specialist doctors along with all 
the services offered by rural hospitals. These hospitals usually specialise in at least four areas, 
commonly surgical procedure, paediatric, obstetrics and gynaecology. Lastly, central referral and 
specialised hospitals, primarily centred in Addis Ababa, function to train health care workers and offer 
all types of specialised care and additionally act as referral centres for regional and rural hospitals.
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7-1:4 Summary of Section 7-1
In Ethiopia, a poor economic structure, poor living conditions and a poor environment has 
challenged the health care delivery system. Morbidity is driven by infectious diseases, many of which 
can be cured by antibiotics. Existing health care delivery has been pathetic in the past with poor health 
service coverage where in many rural areas it highly inaccessible. In an effort to improve the 
management of health care, the Ministry of Health has developed several specialised bodies to 
concentrate on areas where health care delivery is weak.
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Section 7-2
The Distribution and Management of Drugs and medical Supplies
This section shows the management and distribution system of medical supplies and drugs, 
tracing new developments that have occurred since the revolution. It also analyses tuberculosis drug 
distribution showing unpublished data from the Ethiopian Department of Pharmacy on the tuberculosis 
drug supply to public health facilities. A description of the distribution of TB drugs is an integral 
component to understanding the driving forces behind the cost of TB treatment.
During the revolution in 1991, in the north of Ethiopia, 345 health stations, 34 health centres and 
11 rural hospitals were destroyed, compounded by the large-scale theft of medical equipment, leaving 
the area and the country even less able to cope with meeting the health problems of its inhabitants. 
Facing the challenge of rebuilding these facilities and purchasing drugs and medical supplies, the 
country found itself intensely overburdened, unable to treat even small proportions of its population. 
As depicted in Table 7-6, the existing budget for drugs and medical supplies was far insufficient to 
meet the health demands of the country, especially considering the recent destruction of what little 
health facilities the country had in the north.
Table 7-6:1992 Budget Allocations of 
_________________ Drugs and Medical Supplies in Ethiopia_______
Area and/or Type of Health Facility Allocation
a. Addis Ababa
b. Hospitals in the remainder of the country
c. Health Centres + Health Stations
TOTAL
5 580 600 birr ($858 553.85, in US 1994 dollars)
4 182 800 birr ($643 507.69, in US 1994 dollars)
9 552 400 birr ($1 469 600.00, in US 1994 dollars) 
19 330 400 birr ($3 221 733, in US 1994 dollars)
Source’. Transitional Government of Ethiopia, Office of the Council of Ministers, 1993
7-2:1 The ERRP
Because of the wide-scale destruction of health facilities and medical equipment during the 
revolution in 1991, the WHO, the Netherlands, USAID, the World Bank, and the African Fund 
Development Bank joined the Transitional Government of Ethiopia for an emergency aid project: the 
Emergency Recovery and Reconstruction Project (ERRP). Subsequently, the ERRP has proven the 
major supplier of most drugs and medical supplies during the past three years. Together, these six 
groups initially contributed US $26.2 million which has risen to 50.4 million US dollars in aid for 
recovery (see Figure 7-2).
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Figure 7-2: Allocated Contributions of the ERRP From 
January 1992 to March 1995 (in US Millions of Dollars)
15%
57%
Q African Fund Development Bank, 28.7m 
□ Transitional Government of Ethiopia, 8.9m
| European Economic Community, 0.5m 
| Government of the Netherlands, 2.8m
■ World Bank, 7.5m
| USAID, 10m
Courtesy of: Transitional Government of Ethiopia, Department of Pharmacy (unpublished)
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Figure 7-3: The Distribution System for 
Medical Supplies and Pharmaceuticals
PRIVATE SECTOR PUBLIC SECTOR
Courtesy of: The Transnational Government of Ethiopia, 
Department of Pharmacy (unpublished)
7-2:2 Drug Supply
Drugs primarily originate from local producers, foreign manufacturers or UNICEF as is 
illustrated in Figure 7-3. These drugs in turn move to EPHARMECOR or private importers and 
distributors, often determined by whether their use will be in the private or public sector. Public sector 
drugs going to EPHARMECOR will be transported directly to hospitals or to regional stores of the 
MOH or EPHARMECOR zonal regions for distribution to hospitals, health centres and ultimately 
health stations and health workers. In contrast, the private sector moves drugs from private importers 
and distributors to pharmacies, drug shops, rural drug vendors, NGO's, other institutions and 
sometimes the public sector. Looking at Figure 7-3, it is evident that this infrastructure depends on an 
information flow to determine the future demand of drugs in order to avoid surpluses and shortages. 
The distribution and importation of drugs can come from all sources. The ERRP, for example, uses 
UNICEF and international private distributors as illustrated in Table 7-7.
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Table 7-7: Pharmaceutical Importers Used by the ERRP
Importer Drugs Registered Drugs to be Registered in the Future
Azeca 17 8
Arabian 8 0
Hoechst 5 8
Makris 3 4
Paul Ries 11 10
Pharma 14 -
Regassa Gurumen - -
Samual Deressa - -
Courtesy of: Transitional Government of Ethiopia, Department of Pharmacy, MOH, Addis Ababa (unpublished)
7-2:3 Anti-TB Drugs
Anti-TB drugs in Ethiopia have been extremely difficult to secure, especially those used in short- 
course regimens. Tuberculosis drugs, in comparison to other drugs, are far more expensive because of 
the cost of drugs themselves, and because of the quantities required as a result of the long treament 
periods. For instance, it was estimated in 1994 that at a 50% detection rate, 154 000 cases of TB 
would be detected, and of these, 69 300 would be eligible for SCC whereas the remaining 84 700 
would be placed on the standard regimen. The calculation of drug needs for both regimens are 
described in detail in Table 7-8 and Table 7-9.
Table 7-8:1994 Estimates of SCC Drug Needs in Ethiopia 
by the Department of Pharmacy, MOH (N= 69 300 patients)
Drug Amount Requirement/Patient Total Amount
Required
Number of Tins
S 1 g 60 g 4 158 000 41 580
R + S 150mg./100mg. 180 tab. 12 474 000 124 740
Z 500mg. 240 tab. 16 632 000 16 632
Water for Injection 5 ml./pt. 300 ml./pt 20 790 000 20 790
Syringes 5 ml./pt. 300 ml./pt 20 790 000 20 790
Needle 1/pt. 60 5 0820 00 5 082
Courtesy of: Mohammed Abadir Mussie, Department of Pharmacy (unpublished)
It is through these estimations that future drug needs for TB are calculated. The prevalence of TB is 
estimated and from this, groups are identified according to the regimen for which they are eligible. 
From these estimates, future demand for each TB drug is calculated accordingly. To allow for drug 
reactions and those with a low tolerance for Thiacetazone with Isoniazid (TB450), 10% of the total 
(154 000) is estimated to need ethambutol. This, for example, means an extra 12 894 120 ethambutol 
tablets will be required. In addition, from these estimates 42 296 600 of 100 mg isoniazid will be
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necessary to treat children (5%), and a further 4 714 320 extra isoniazid tablets will be needed for
those unable to tolerate TB450.
Table 7-9:1994 Estimates of the Standard Regimen Drug Needs in 
Ethiopia by the Department of Pharmacy, MOH (N=84 700 patients)
Drug Amount Requirement/Patient Total Amount 
Required
Number of Tins
S 1 g- 60 g. 5 082 000 50 820
T + H (TB450) 450mg. 360 tab. 30492 000 30 492
Water for 5 ml. 300 ml. 25 410 000 25 410
Injection
Syringes 5 ml. 300 ml. 20 790 000 207 900
Needle 1 60 5 0820 00 50 820
Courtesy of: Mohammed Abadir Mussie, Department of Pharmacy, MOH, Addis Ababa (unpublished)
Table 7-10: Anti-Tuberculosis Drug Provisions Under the ERRP 
Pharmaceutical Sector for Public Health Institutions, 1992-1993
Drug Type unit Theoretical
Annual
Requirement
Actual Procured Deficit Percent not 
Procured
E (400mg.) tab. 12 245 310 11 435 000 -810 310 6.6%
H (50mg.) tab.
H (lOOmg.) tab. 15 932 070 10 507 000 -5 425 070 34.1%
H (300mg.) tab. 4 081 770 600 000 -3 481 770 85.3%
Z (500 mg.) tab. 15 997 905 2 044 000 -13 953 905 87.2%
R(150mg.) cap. 12 047 805 5 993 200 -6 054 605 50.3%
R (300mg.) cap.
S (lgm injection) vial 9 216 900 2 794 000 -6 422 900 69.7%
TB450 tab. 40 817 700 15 395 000 -25 422 700 62.3%
Syringe 5ml + needle each 9 216 900 1 121 400 -8 095 500 87.8%
Water for injection vial 9 216 900 3 216 000 -6 000 900 65.1%
Vitamin B6 (lOOmg.) tab. 15 001 000
Courtesy of: Mohammed Abadir Mussie, Department of Pharmacy, MOH, Addis Ababa (unpublished)
This technique proves relatively effective in calculating drug needs, but it is primarily dependent on 
the accuracy of the calculation of the prevalence of tuberculosis and detection rates. After these 
calculations, there arises the challenge of procuring the demanded TB drugs, which has proven 
problematic for Ethiopia in the past. Although ERRP provides them now, this has only been 
established as a temporary programme. The most striking characteristic of Table 7-10 is the vast 
difference between the amount of drugs needed and those actually procured. This difference is 
significant, representing as much as a 60-80% deficit. Although the deficit is the lowest for isoniazid 
(lOOmg), possibly accounting for the ability to make this drug locally, this still does not account for the 
85.3% deficit for the 300mg form of this drug. Another interesting observation from this table is the 
87.8% deficit in syringes and needles for injecting streptomycin. This is indeed, reflected in various 
health centres and hospitals having to sterilise and re-use syringes. Overall, no drug has been
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completely procured, except perhaps, ethambutol. It seems that in the case of every TB drug, there has 
been difficulty in obtaining the quantity needed for treatment.
Procuring these drugs primarily comes from the ERRP, WHO, Emergency donor aid and local 
production. As can be observed in Table 7-11, a large percentage (39.5% and 35.6% respectively) of 
drugs are obtained from ERRP and local production, followed by 19.1% by the WHO. Interestingly, 
all rifampicin containing combinations essential for the short course regimen are donated by the WHO. 
This brings to light the current imperative dependence on the WHO for the delivery of short course 
chemotherapy.
Table 7-11; Anti-TB Drugs Supply in Ethiopia According to Donor, 1993-1994
Drug Name Unit ERRP Local Production WHO Emergency
E (400mg.) 1000 2 490 500
H(100mg.) 1000 2 420 12 000 3 000
H (300mg) 1000 5 333
Z(500mg.) 1000 420
R (300 mg.) 100 7 600 500
S (lgm. injection) - 16 600 13 000
TB450 1000 5 300 14 000 1 000
R + H 100 800
(300mg./100mg)
R + H 100 3 000
(300mg./150mg.)
TOTAL % 39.5% (34830) 35.6% (31333) 19.1% (16800) 5.7% (5000)
Courtesy of: Mohammed Abadir Mussie, Department of Pharmacy, MOH, Addis Ababa
7-2:4 Summary of Section 7-2
In 1991 Ethiopia found itself torn by a revolution that had significant repercussions for the 
country as a whole. Health care facilities in the north had been destroyed and many supplies had been 
stolen. These facilities had to be rebuilt and medical supplies for the country as a whole needed to be 
improved. Such improvements were made by the ERRP which has played a major part in suppying 
emergency aid for better health care delivery. A large proportion of drugs including those for TB are 
obtained through the ERRP and other organisations, nevertheless, there is still a deficit in drug needs. 
Although local production is strong even in TB drugs, there are drugs that cannot be produced locally. 
As much as 40% of TB drugs come from the ERRP. This is worrying because the ERRP was 
established as a temporary organisation, and the Ministry of Health may have to find some other way 
of procuring drugs in the future.
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Section 7-3
Current efforts to Control Tuberculosis in Ethiopia
In this section, those actions on the part of the Ethiopian Ministry of Health to control 
tuberculosis are presented. Changes in the control of TB that have occurred under the Transitional 
Government of Ethiopia, such as the establishment of an effective national tuberculosis programme, 
are discussed. Competent management of tuberculosis treatment and tuberculosis drugs are an 
important factor in decreasing treatment default, and therefore, resistance.
Tuberculosis is thought to be a disease that primarily affects the poor because poverty allows for 
malnourishment and poor living conditions where tuberculosis infection will more easily progress into 
disease. In Ethiopia, one of the poorest countries in the world, tuberculosis reaches one of its highest 
incidences. This is a disease that strikes the most impoverished in countries, it flourishes when living 
conditions or life styles of individuals are poor. For example, at the Tekur Anbessa Hospital in Addis 
Ababa, tuberculosis patients were found to be far poorer than other patients and 53% could not pay 
their bills as compared to 38% of non-TB patients reflecting the association between poverty, poor 
living standards and the development of tuberculosis (Hodes and Seyoum, 1989).
Efforts to control TB in Ethiopia have been feeble due to the lack of funds, organisation and a 
standardised system for treatment. TB centres were established in the 1950s and the 1960s and 
continued to function under archaic systems, excelling in disorganisation and providing little follow-up 
of patients. There was a general lack of laboratory equipment to diagnose TB, a lack of expertise in 
treating the disease, and sporadic, unpredictable drug regimens for patients. Furthermore, the centres 
remained separate from regular health centres, making service less integrated with other health care 
measures and far less accessible to patients. The national tuberculosis control programme offices 
opened in 1976 but were given no budget allocation and relied solely on the financial support of 
UNICEF and WHO which was not substantial enough to meet the needs of a nation-wide programme 
(Guideline for the National Tuberculosis Control Programme in Ethiopia, 1992). The resources 
needed to treat TB simply were not available. This was compounded by the incidence of HIV and 
ADDS, famine, drought and years of civil war. Hence, TB centres and efforts to control TB did little, if 
anything, to lessen its incidence.
In 1992, after the fall of the Dergue regime, efforts to change the treatment of TB were made 
with the establishment of a more effective national tuberculosis programme. Its efforts included the 
distribution of a national guideline book for TB control, yet even in 1994, this programme is still 
struggling. For the programme to be successful, there has to be a standardisation of treatment, enough 
support from the Ministry of Finance and other aid organisations, adequate training in TB treatment,
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adequate tools to diagnose TB, and a plentiful supply of TB drugs that can be assured for years to 
come (Guideline for the National Tuberculosis Control Programme in Ethiopia, 1992).
7-3:1 The High Incidence and Prevalence of Tuberculosis and Control Strategies
In 1980, it was estimated that as much as 3% of the population had active tuberculosis (Hodes 
and Azbite, 1993). In the past, tuberculosis has accounted for a large proportion of hospital 
admissions. Between the 1960s and 1970s, tuberculosis accounted for 5-7% of all hospital admissions 
(Hodes and Seyoum, 1989). In 1970-71 approximately 3.3% of all hospital admissions were for 
tuberculosis at the Ethiop-Swedish Paediatric Hospital (Ghidey, Yohannes and Habte, 1983). Later, 
between 1983-1985, 11.2% of Tekur Anbessa Hospital admissions were for tuberculosis (Hodes and 
Seyoum, 1989). Tuberculosis in 1982 was the most frequent reason for hospitalisation after child 
delivery, and was attributed to 5.8% of 161 692 admissions. In the 1980s it also accounted for the 
highest cause of death in hospital, forming 12.2% of 6256 hospital deaths (MOH, 1986). Some efforts 
have been made to prevent tuberculosis with the BCG vaccination. BCG coverage of 1-year-olds in 
Ethiopia became more intensive in the 1980s and although its effect in the country on decreasing TB in 
children is unknown, in Addis Ababa, TB incidence decreased by 14% in vaccinated children 
compared to unvaccinated children.
WHO has set up the goal of a 65% case detection and an 85% cure rate of TB by the year 2000, 
leaving only an impossible 6 years to accomplish this. Epidemiological data, although scanty at best, 
present quite a challenge to the WHO's edict. Between 1986-1987, TB was the 12th leading cause of 
outpatient morbidity, the 3rd reason for hospitalisation, and was and undoubtedly still is the leading 
cause for hospital death. The reporting of tuberculosis is chronically unreliable. Hodes and Azbite 
(1993) cite that 84 142 cases of tuberculosis were reported in 1986-1987, 149 444 were reported in 
1987-1988, and only 73 365 were reported in 1989-1990. This increase in 1987-1988 represented a 
dubious 78% total increase in Ethiopia and a 103% increase in Addis Ababa. The last reliable survey 
of the annual risk of infection was in 1978 and placed it at 3%. Now, the national tuberculosis 
programme estimates that there is a 2.5% annual risk of infection, representing 41 000 to 70 000 new 
cases of smear-positive tuberculosis per year assuming that 1% annual risk of infection represents 55 
smear-positive cases per 100 000. Likewise, it estimates between 90 000 and 154 000 cases per year 
of smear-negative cases and extra-pulmonary cases together, using the assumption that these cases 
represent 1.2 times the incidence of smear-positive cases. The prevalence, at twice the incidence, is 
thought to be approximately 180 000 to 308 000, and the rate of mortality, calculated as 50% of the 
infectious cases is estimated to be approximately 20 000-35 000 deaths per year. The annual risk of
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infection in children is an estimated 1.4% (Azbite, 1992), this suggests a possible drop in the risk of 
infection which was observed to be 3% in a 1953-1955 survey.
Contrasting data on the incidence of tuberculosis come from the IUATLD. The IUATLD 
estimates an annual risk of infection of 1.5%, and also estimates a total of 165 cases of all types of TB 
per 100 000 population. Between the 23rd of May and the 6th of June, 1993, the IUATLD visited the 
All Africa Leprosy Research and Training Centre (ALERT) to review efforts in combing treatment of 
both TB and leprosy (both Mycobacterium caused diseases). The results of this research were reported 
by Arandottir (1993) in an unpublished report. This reports estimates 55 000-95 000 cases of TB 
reported per year. Case detection varies in different regions, for instance, Butajira has a case detection 
of 83/100 000, Hosanna Hospital: 60/100 000, Shinshicho: 212/100 000, Shashamane hospital: 
692/100 000, and the Regional Health Department in Zeway: 133/100 000. This report suggests a case 
detection rate of approximately 50%. The default rate in many areas was as much as 70%, which was 
primarily attributed to a lack of drugs.
Most case finding for tuberculosis is passive whereby the facility waits for the patient to seek 
treatment. The time it takes a patient to seek treatment varies. The manifestation of TB symptoms can 
determine the length of time it takes for a smear-positive patient to seek treatment. At the TB centre in 
Addis Ababa, a survey of 163 smear-positive patients revealed that patients were far more inclined to 
report to health centres within two weeks if their TB symptoms include hemoptysis (blood stained spit 
or sputum), chest pain or dyspnea (difficulty breathing). Those only experiencing a cough were 
observed to delay in seeking treatment (Teklu, 1993).
7-3:2 Current Treatment Regimens
Currently TB is treated using the standard regimen, although some use of short course 
chemotherapy is starting to grow due to increased grants for the needed medicines. Indeed, some of 
the first experimentation with SCC in Ethiopia was at the TB Centre in Addis Ababa and St. Peter's 
Sanatorium. In a study by Wolde et al. (1992), smear-positive patients were hospitalised during the 
intensive phase of their treatment and received the standard regimen, Rifater (a combination of H, R 
and Z) and another combination preparation of H, R and Z. After two months of treatment, average 
smear conversion and culture conversion was 82% and 80% for those patients on Rifater. Those 
receiving the other combination preparation of H, R and Z had sputum conversion rates of 86-88% and 
culture conversion rates of 86%. Those receiving the standard drug regimen had an average sputum 
conversion rate of 60% and a culture conversion rate of 30% (culture conversion, as mentioned earlier, 
is more sensitive in detecting TB bacillus). This study concluded that SCC is clinically more effective
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in treating TB than SDR. The authors also noted that combination tablets can help avoid monotherapy, 
and therefore, resistance.
7-3:3 Drug Resistance
Resistance of bacteria to many drugs in Ethiopia is higher than that observed in tuberculosis. 
(Trunch, 1991; Geyid and Lemeneh, 1992; Gedebou and Tasew, 1983). Indeed, resistant TB, in 
comparison to other African countries, has been low in Ethiopia. In a report by Patty et al., (1978) 
46% of 184 TB strains tested proved resistant to isoniazid or streptomycin. However, there was no 
observed resistance to rifampicin in those strains tested, but rifampicin had not been used in treatment. 
Correspondingly, default rates of patients were 50-60%, but primary or acquired resistance was 
impossible to determine. In another study by Wolde et al. (1986), of 276 samples tested from TB 
centres in Addis Ababa, Harar and Asmara, 15.2% had some manifestation of resistant tuberculosis. 
Isoniazid resistance was found to be a high 12%, rifampicin resistance was at 1% and combination 
resistance to H, S and T was 1.4%. Resistance to pyrazinamide and ethambutol was not observed. 
This study does not reveal whether isolates came from the same patients over a period of time, or if 
each isolate came from separate patients. In a study by Lemma et al. (1987) at the Sidamo Regional 
Hospital in 1987, of 104 samples, resistance to isoniazid and streptomycin was observed whereas no 
resistance was observed to thiacetazone, rifampicin or ethambutol. Total resistance in the 104 strains 
was 7.6%, and this was all supposed to be primary resistance. However, these studies only tested those 
strains that were not responding to treatment such as relapse and treatment failures, and for this reason, 
resistance rates are unrealistically high and biased, acting only as a measure of levels of resistance in 
treatment failures rather than the entire population. Most resistance is attributed to default, but there is 
some speculation as to resistance arising in those infected with both TB and leprosy. There is the 
potential that those treated for leprosy with rifampicin could find themselves with rifampicin-resistant 
TB (Gunderson, 1987), but it is doubtful that this would be clinically significant. Indeed, the joint 
efforts of the All Africa Leprosy and Rehabilitation Training Centre (ALERT) to control leprosy and 
tuberculosis would likely be able to contain this.
7-3:4 Summary of Section 7-3
In Ethiopia, tuberculosis has had a devestating impact on the country. As an opportunistic 
disease, TB has grown with few impediments in Ethiopia, where the environment fosters poor immune 
systems in individuals. Efforts to control TB in the past have been poorly formulated, poorly funded, 
and therefore, impotent against this disease. Recent changes, however, have started to have some 
success in curing, and hence, containing this disease. Still, short course chemotherapy is relatively
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new in this country and is only used on a small scale. Past drug treatment has had little impact because 
it has not been used to its potential, which is proven by low resistance rates to drugs. More resistance 
is likely to occur with more use which will undoubtedly increase the costs of treatment.
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Section 7-4
HIV IN ETHIOPIA
When considering the containment of tuberculosis, one cannot ignore the powerful impact of 
HIV on this opportunistic disease. It is undoubtedly important to know the incidence of HIV in order 
to calculate the growth, nature and appropriate treatment for TB. This section shows the reported 
incidence of HIV in Ethiopia using unpublished data from the Ethiopian Ministry of Health. HIV has 
had a tremendous impact on the spread of TB, and therefore, its incidence which is related to TB 
treatment, must be considered.
Those with HIV are more likely to die during TB treatment, and they have much lower tolerance 
to drugs, especially thiacetazone. In addition, AIDS cases will commonly need to be hospitalised 
during treatment. Unfortunately, it is extremely difficult to obtain accurate statistics on the reporting 
of HIV. As health service coverage is so low, many cases of HIV will go unreported. Also, because of 
inherent factors in the disease, HIV-seropositive individuals will remain asymptomatic. This is 
important because TB can often strike during the late asymptomatic stages of HIV.
7-4:1 HIV Growth
HIV has not penetrated Ethiopia like it has in many African countries, but the disease is still on 
the rise. The low incidence of reported cases, as compared to other African countries, could probably 
be explained by the fact that until only recently, the country was relatively isolated by the Dergue 
regime. Nevertheless, cases are starting to rise exponentially posing a frightening health threat on an 
already overburdened country.
Between 1986-1987 some of the first cases of HIV were reported at the Tekur Anbessa Hospital 
in Addis Ababa, Ethiopia. From over 100 HIV-seropositive patients, the average age for these patients 
was 33.2. 76% of these patients were under forty and there were 70 males and 30 females in this group 
with ages ranging between 16-58. (Tsega, E., 1990). Up until this point, HIV was a relatively rare 
disease. The current situation is that it is unknown how many people are infected with HIV, but the 
National AIDS Control Programme of the MOH in Addis Ababa takes quarterly statistics on reported 
cases. According to AIDS case surveillance in Ethiopia, from the 31st of March 1994, 11 927 cases of 
AIDS had been reported from 48 hospitals. The average age of patients was 30 and there was an 
average delay of 2 months before these cases were reported. 1.6% represented paediatric cases, 34.7% 
were married, and the male to female ratio was calculated to be 1.6:1.
As can be seen in Figure 7-4, AIDS can be seen to steadily increase in growth from 0.2% in 1987 
to 51.2% in 1993. Hence, in 1993, more than half of the growth of AIDS occurred. Data on AIDS
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growth for 1994 are incomplete as the report only stretches to the middle of this year, which explains 
the deceiving fall in new cases in Figure 7-5.
Figure 7-4: Percentage of Growth of 
AIDS in Ethiopia Between 1986-1993.
[3 1986 0.0%
□ 1987 0.2%
| 1988 0.8%
■ 1989 1.9%
| 1990 4.5%
■ 1991 8.8%
□ 1992 32.5%
□ 1993 51.2%
National AIDS Control Programme of the MOH in Addis Ababa: 
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
xj
fi3z
Figure 7-5: Growth in Cases of AIDS per 
Year in Ethiopia Between 1986 and 1994*
Year
MALE
FEMALE
*Data for 1994 is not yet complete, explaining the fall in new cases in this year 
National AIDS Control Programme of the MOH in Addis Ababa:
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
7-4:2 Risk Factors for HIV
In addition to recent vast growth in AIDS, from looking at Figure 7-6, most growth in cases of 
AIDS initially occurred in males and then started to appear in females. This trend has maintained
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itself, proven by the fact that growth in males with AIDS has remained one third higher than in 
females. Reasons explaining this could possibly be due to the fact that males in Ethiopia have a 
greater opportunity to travel because of various kinds of employment. This would allow for greater 
exposure to urban areas where HIV is far more likely to be transmitted. Likewise, a greater proportion 
of young males are likely to be more promiscuous than young females. For instance, a large amount of 
males might patronise a small core of prostitutes with HIV, but fewer women will be prostitutes or 
have as great a number of sexual partners. This highlights the fact the most AIDS cases were 
transmitted sexually, with a total of 86.5% heterosexual transmission leaving only 1% homosexual 
transmission. Only 2.9% of cases were attributed to blood transfusions, maternal HIV, illegal 
injections and drug abuse. Unfortunately another 9.6% of cases could not be determined. Hence, as 
seen in Figure 7-6, the highest risk for HIV transmission in Ethiopia is from heterosexual intercourse.
Figure 7-6: Risk Factors for Reported 
Cases of AIDS in Ethiopia (1986-1993)
(3 MULTI-PARTNER SEX. CONTACT (87.5%) 
□ BLOOD TRANSFUSION (0.9%) 
ggj MATERNAL HIV (1.1%)
■ ILLEGAL INJECTION (0.8%)
B DRUG ABUSE (0.1%)
■ UNSPECIFIED (9.6%)
National AIDS Control Programme of the MOH in Addis Ababa: 
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
7-4:3 Age and Sex of AIDS Patients
Most AIDS patients were in the age-group of 20-39, probably the most sexually active ages for 
adults. If an individual feasibly became sexually active and was infected with HIV in his or her teens, 
it is highly likely that the impact of this infection in the form of AIDS would manifest itself in the ages 
from 20-39. This is indeed, supported by Figure 7-7. Also, it should be noted that HIV incidence is 
greater in females than males in the age group 15-19 and it is comparatively higher in the 20-29 age 
group than the 30-39 age group. This suggests a shift in cases, whereby future cases of AIDS will be 
more common in young females between 15-25, perhaps as much or moreso than in young males.
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Such a shift might reflect greater sexual activity of younger females in the age group 15-19 than, for 
instance, those over thirty.
Like the age-group where TB strikes in developing countries, it is in this group of those aged 20­
39 where the greatest economic and social contributors lie. Hence, diseases that strike so hard at this 
age range represent some of the greatest loss for society as compared to those diseases that primarily 
strike the elderly or the very young.
Figure 7-7: Growth in HIV 
According to Sex and Age in Ethiopia
□ FEMALE
MALE
Age Group
National AIDS Control Programme of the MOH in Addis Ababa: 
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
Table 7-12: Clinical Symptoms Experienced by 
Reported AIDS Patients in Ethiopia (1986-1993)
Clinical S^m£tom Males Females Total (%^
weight loss 6546 4051 88.85%
fever > 1 month 6221 3878 84.67%
persistent cough > 1 month 5076 3023 67.90%
diarrhoea > 1 month 4538 2798 61.51%
generalised lymphadenopathy 1968 1002 24.90%
oropharyngeal candidiasis 1497 886 19.98%
generalised pruritic dermatitis 1215 814 17.01%
TB (P/EP) 1241 719 16.43%
recurrent herpes zoster 1106 587 14.90%
pneumonia (inc. PCP) 395 217 5.13%
skin rash 116 63 1.50%
CNS derangement 123 48 1.43%
night sweats/body weakness 111 58 1.42%
chronic herpes simplex 77 58 1.13%
Kaposi's Sarcoma 30 8 0.32%
loss of appetite 19 6 0.21%
National AIDS Control Programme of the MOH in Addis Ababa: 
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
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7-4:4 Symptoms
A list of the percentage of patients that suffered from various clinical symptoms of AIDS is given 
in Table 7-12. This table shows that weight loss is the most common symptom, followed by fever and 
persistent cough. Few of these in this group experienced AIDS-related derangement or Kaposi's 
Sarcoma. This is possibly due to the fact that in Ethiopia, without such high technology in fighting 
infectious disease as well as a much higher prevalence of infectious disease, diseases such as diarrhoea 
and TB attack the system before diseases associated with more advanced stages of AIDS can attack.
7-4:5 Employment, HIV and its Urban Concentration
From observing data on the employment of reported AIDS cases, HIV appears to be a disease 
associated with the middle classes in Ethiopia, rather than the poorer classes (See Figure 7-8). In 
addition, 41% of all reported cases were residents of Addis Ababa, suggesting a further urban 
concentration of the disease. Those with the highest rates of AIDS are government workers, armed 
forces, merchants and drivers. This is followed by housewives, prostitutes and the unemployed. 
Although a large proportion of employment is unknown, all of those cases where employment is 
known except the housewife, child and farmer, have well defined jobs that are either centred in urban 
areas or involve a large amount of travel. Jobs such as government workers, merchants, sex workers, 
unemployed, servants, mechanics, beer sellers, bar workers, students and prisoners are those positions 
which require the individual to work in a highly urbanised area. Employment, for instance, in the 
armed forces or as car and truck drivers are jobs that can require a significant amount of travelling for 
the individual from urban area to urban area. It is only the classifications, such as unspecified, other, 
day labourer, child and housewife, who are in positions that could be in either rural or urban areas. 
What is surprising is that reported cases of farmers is very low, the only well defined rural job. 
Although 80% or more of the total population make their livelihood from farming, their incidence of 
AIDS is not even remotely proportionately represented. This could be partially because of an under­
representation in reporting. It could also be explained by a possible urban concentration of the disease. 
The distribution of workers with AIDS mostly from the city or in positions that require travel is that, 
like TB, HIV could be said to be a disease that thrives in urban conditions. In these areas, there is the 
increased opportunity for more sexual exchange between different people. HIV is also known to move 
between those who travel extensively. For example, in the early eighties during the Dergue military 
regime, many soldiers with new authority and weapons were not unknown to abuse this power and 
rape local women. Many of these soldiers were also thought to be quite promiscuous. This, combined 
with the large amount of continuous travel throughout the country, meant that they were an initial 
major mechanism for the transmission of AIDS in Ethiopia during the Dergue regime. Sexual
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promiscuity in drivers could also be another mechanism for transmission. HIV is known to move 
along major highways, especially in Africa. Many drivers' jobs involve extensive travel and a lonely 
lifestyle such that they are more likely to seek sexual company with a large number of strangers along 
their driving route. Another component contributing to the urban concentration of this disease is 
prostitutes. Prostitutes, which are undoubtedly a strong pool of HIV infection, are available at many 
bars, and for instance, in bars in Addis Ababa, their services can be procured for approximately 100­
200 birr or 10-20 pounds. Although this represents a month's or more wages for a farmer, servant, 
driver, day labourer, beer seller or bar worker. It can represent as little as 25-10% of the month's 
wages of a merchant, soldier or government worker. Hence, this group can take advantage of more 
effective demand for prostitutes. In essence, all these variables explain why HIV is associated with 
those holding jobs in urban areas and jobs where the wages are relatively high.
Figure 7-8: Reported AIDS Patients 
According to Type of Employment
Type of Work
National AIDS Control Programme of the MOH in Addis Ababa: 
AIDS case surveillance in Ethiopia, March 31, 1994 (unpublished)
7-4:6 Education
These high statistics reflecting heterosexual transmission suggest the need for greater education 
on the transmission of HIV. Ignorance of HIV in Ethiopia is a difficult challenge to containing the 
spread of AIDS. Patient ignorance of AIDS was revealed in an informal interview with several staff 
members at Kefetegne 13 Health Centre in Addis Ababa. This health centre, which until only recently
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specialised in sexually transmitted diseases, still had a very strong case load of patients in this area. 
Patients with AIDS were unclear as to the kind of birth control they should be using. Where 
abstinence would have been ideal, some HIV patients even refused to use recommended condoms 
during intercourse. Amazingly, HIV patients would ask for the pill, diaphragm or IUD, all which have 
little proven ability to stop HIV transmission. Indeed, education on the transmission and severity of 
HIV is not widespread and HIV is likely to continue its high rate of growth without such education.
7-4:7 Summary of Section 7-4
HIV in Ethiopia will continue to grow, especially considering recent political changes 
encouraging outside investment and travel from other African countries. Already, new reported cases 
of AIDS are on the rise. There appears to be an urban concentration of this disease making the risk 
factors highest for male, middle-class individuals living in urban areas aged between 20-39, with 
multiple sexual partners. Women represent approximately two-thirds the amount of males affected 
with HIV, but this proportion is likely to change with increased transmission. The growth in new cases 
of AIDS and HIV are expected to be dependent on education and awareness of the disease coupled 
with a concerted effort on the part of those aged between 15-55 to use appropriate precautions.
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SECTION 7-5
CONCLUSION
Ethiopia is undoubtedly one of the very poorest countries in the world. It is hampered by poor 
living conditions, a changing political climate and environmental disasters. Recent changes in the 
political system after the revolution of 1991 have fomented several significant changes in Ethiopia 
which have had an impact on health and the economy. Still, over 80% of Ethiopians survive by 
farming and 48% of the population are under the age of 15. Health service coverage is a mere 47% 
with an urban concentration of health facilities. Infectious disease still proves to be one of the greatest 
health threats in this country. To facilitate health care delivery after the destruction from the 
revolution, the MOH of Ethiopia, the WHO and other aid organisations instigated the ERRP. The 
ERRP has been instrumental in rebuilding health facilities, providing equipment and drugs. The 
supply of drugs for Ethiopia is increasing, but in the case of TB there is still a large deficit, even with 
the ERRP. A major health threat on the rise is HIV in Ethiopia. Unlike other African countries, this 
disease has just recently started to rise due to prior isolation of the country before 1991.
Health service coverage, tuberculosis drug management, HIV and tuberculosis control 
programmes are all likely to have some impact on the cost of treatment. Poor health service coverage 
for TB contributes to the spread of TB and the implementation of better TB programmes is designed to 
improve this situation. Likewise, correctly calculating TB drug needs from past information on disease 
incidence can bypass problems arising from a surplus or deficit of drugs. As reported from other 
studies described in earlier parts of this thesis, a surplus of drugs can lead to a waste of resources and 
drug expiration with the possibility that expired drugs, which might not be as effective, will be used. 
These expired drugs can cause resistance. Likewise, a deficit of drugs may mean that TB treatment 
becomes intermittent, also allowing for TB drug resistance to develop. In the case of HIV, there are 
likely to be more complications such as drug reactions which add to the cost of TB treatments. 
Therefore, the incidence of HIV as it relates to TB/HIV co-infection becomes important. From this 
information, some signs of the incidence of TB/HIV co-infection in Ethiopia will be explored in the 
next chapter.
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CHAPTER EIGHT
TUBERCULOSIS CONTROL EFFORTS IN ETHIOPIA 
PART TWO: CASE STUDIES IN ADDIS ABABA
Introduction
After exploring some of the health problems, health care management and organisation of health 
care delivery in Chapter Seven, Part One of 'Tuberculosis efforts in Ethiopia', this chapter, 'Part Two of 
Tuberculosis Control Efforts in Ethiopia' will show the impact of TB resistance on the cost of TB 
treatment, focusing on specific case studies that analyse data collected in August and September of 
1994 in Addis Ababa. Following Section 7-4 in Chapter Seven on Aids in Ethiopia, Section 8-1 
further shows the interaction between HIV and TB at St. Peter's Sanatorium in Addis Ababa. When 
looking at the impact of resistance on the cost of TB, it is also important to look at the dynamics of the 
treatment group, including the incidence of HIV. As shown in Chapter 5, antibiotic resistance in those 
who are HIV-seropositive can have more complications than those who are HIV-seronegative. Those 
who are HIV-seropositive are likely to need more and longer hospitalisation. They have less tolerance 
to some drugs, and therefore, some drugs cannot be used in these patients because of their life- 
threatening effects. These patients are likewise, more likely to die from resistance, and the time from 
diagnosis to death is much quicker. Tying into the examination in Chapter 2 of technology 
concentration, Section 8-2 of this chapter discusses the inappropriate concentration of technology at 
the National Tuberculosis Centre in Addis Ababa and cost considerations in its diagnostic procedures. 
When looking at the total cost of TB treatment, the cost of diagnosis can be significant. Choices in the 
type of screening are fundamental aspects determining TB treatment cost. Lastly, Section 8-3 presents 
a cost-effectiveness analysis between SCC and SDR in the public sector of Addis Ababa. It is 
specifically in this study that the impact of resistance on the cost of TB treatment is explored. This 
section also discusses the impact that TB drug resistance will have on the cost-effectiveness of 
treatments. In addition to this, it further builds on the description in Chapter 6 of the optimisation of
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TB treatments in developing countries, showing that through the use of cost-effectiveness analysis, the 
most appropriate treatment can be identified. It is hoped that through these case studies, the reader will 
obtain a greater understanding of the dynamics and challenges to cost-containment and management of 
a health condition, such as TB, in a low income developing country in sub-Saharan Africa, especially 
considering the challenges of HIV and anti-TB drug resistance.
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Section 8-1
St. Peter's Sanatorium in Addis Ababa
This section will show the treatment results of over 1500 critical patients that received treatment 
at St. Peter's Sanatorium in Addis Ababa. It also includes the results of over 762 patients screened for 
HIV, including those with TB/HIV co-infection that died. The distribution of types of TB in these 
patients is presented with a discussion on the changes in patient response to treatment in the HIV era. 
In those screened for HIV, a total of 31% were HIV-seropositive. Resistance in the sanatorium is 
further discussed from observations and an interview with the medical director. A resistance rate of 
approximately 10-20% is observed by the medical director. The incidence of TB/HIV co-infection and 
the incidence of resistance will be considered in discussions in the last section of this chapter.
It is difficult to ascertain the amount of HIV/TB co-infection in patients in Ethiopia because TB 
patients are seldom screened and a large proportion of data either comes from severe AIDS cases or 
informal estimates by doctors. Nevertheless, the amount of TB in HIV patients is thought to be quite 
high, possibly one of the commonest infections in those with HIV in some areas. Tsenga (1990) 
reports that of the clinical presentations of 100 HTV patients at the Tekur Anbessa Hospital in Addis 
Ababa, tuberculosis was the most observed infection and it aggressively manifested itself in 
uncommon forms.
This section will show tuberculosis at its most critical manifestation at St. Peter's Sanatorium in 
Addis Ababa. These are data that were collected in Addis Ababa by visiting the sanatorium in 
September 1994 and recording data records from 1992-1994, kept by the current medical director on 
all clinical test and outcomes of treatment for patients. This analysis will include smear status, patient 
origin, treatment results and a report on HIV/TB co-infection. Information on the incidence of 
TB/HIV co-infection is difficult to obtain if it exists at all. An interesting characteristic about the 
patients at St. Peter's Sanatorium is that many have been screened for HIV, and therefore, some 
representation of TB/HIV co-infection can be derived.
8-1:1 Patient TB Distribution
The St. Peter's Sanatorium is a hospital in Addis Ababa that only treats tuberculosis and only 
accepts those patients that have been referred from the TB Centre in Addis Ababa. TB patients arrive 
at the sanatorium twice weekly and all patients at this hospital have extremely critical TB necessitating 
hospitalisation. The hospital contains 200 beds occupied by patients for approximately two months 
after which these patients are referred back to the TB Centre for ambulatory treatment. Tuberculosis
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patients include both males and females in separate wards. All patients at this hospital receive SCC 
due to the higher death rate associated with SDR.
In 1993 a total of 928 patients were treated at St. Peter's Sanatorium and from these, there was an 
average of one third more males than females. The male to female ratio was a low 0.75 males to every 
1 female between the ages of 0-14 years and then continued to grow so that the male to female ratio 
was 1.2:1 for the ages of 15-24 years and peaked at the ages of 35-44 years with a 2.58:1 male to 
female ratio. As seen in Figure 8-1, after the ages of 0-14, the number of males hospitalised is 
consistently higher than females. The predominance of patients hospitalised proved to be smear­
positive, with the remainder of patients smear-negative including extra-pulmonary patients. A total of 
381 (50%) patients in 1993 proved smear-positive and 346 (45%) patients were smear-negative with a 
remaining 35 (5%) classified as unknown, as illustrated in Figure 8-2. The disproportionate level of 
smear-positive cases in this group reflects the severity of this most infectious form of TB.
Figure 8-1: Total Caseload in 1993 at St. Peter's Sanatorium
■ MALES 
[zj FEMALES
■ TOTAL
Age
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Figure 8-2: Smear Classification of Patients at St. Peter's Sanatorium
Number of Patients
8-1:2 Results of Treatment
In 1994, a total of 472 (71%) patients treated for TB at the sanatorium improved, but 154 (23%) 
died, 13 (2%) insisted on discharging themselves and 22 (3%) were referred to other areas as 
illustrated in Figure 8-3. The high death rate of 23% reflects the extremely critical state of patient's TB 
and the fact that many of these patients were HIV-positive.
Figure 8-3: Results of Treatment for Patients at St. Peter's Sanatorium, 1994
Number of Patients
8-1:3 Changes in Patient Response to Treatment in the HIV Era
It is interesting to look at St. Peter's Sanatorium in a pre-HIV context to compare current figures 
to those over ten years ago. In the early eighties at the St. Peter's Sanatorium in Addis Ababa, Feleke 
and Teklu (1983) reported that of 861 patients treated over one year, 63% were young males from 
Addis Ababa with TB in its advanced stages. In 1993 this dropped to 51% males and 34% of these 
were under the age of 35. This change in the male to female ratio reflects a trend where more females 
were being treated at the St. Peter's Sanatorium.
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Table 8-1: Age and Sex Distribution of TB 
Patients at St. Peter’s Sanatorium from 1978-1979 
Male Female Total Retreatment
number % number % number % number %
16-30 347 69.00 219 69.00 593 69.00 94 57.30
31-45 129 23.80 71 22.30 200 23.10 57 34.80
46-60 31 5.50 23 7.20 54 6.30 9 5.50
Over 60 7 1.30 4 1.20 11 1.30 3 1.80
No Record 2 0.04 1 0.30 3 0.30 1 0.60
Total 543 100.00 318 100.00 861 100.00 164 100.00
Source: Feleke and Teklu, 1983: p. 445
In the Feleke and Teklu study, 70% of all patients were under the age of 31 and 92% were under the 
age of 45. In 1993, 76% of all patients were under the age of 35 and 89% were under the age of 45. 
The average time for hospitalisation was three months or less in 90% of all cases, which is very similar 
to the amount of time spent now. One of the most interesting changes in the HTV era is that Teklu and 
Feleke report a mortality rate of 9.2% in contrast to the 23% mortality rate in 1994 (See Table 8-1). 
This suggests that the rate of death has more than doubled in over ten years at this health facility. 
Treatment, however has improved to the clinically more effective SCC treatment. Such an increases in 
the death rate could reflect the impact of HIV on tuberculosis treatment.
8-1:4 Patients with TB/HIV Co-infection
In this hospital, many patients have been screened for HIV because of the serious nature of their 
symptoms. Cases of HIV range from asymptomatic HIV to very severe AIDS. Many patients were 
given other antibiotics because of chronic diarrhoea and other AIDS related infections. Some patients 
also experienced severe drug reactions to TB medicine, which is another common HIV-related 
phenomenon. It was not uncommon for these patients to experience usually rare isoniazid-related 
hepatitis. More common was exfoliative dermatitis, also known as Stevens Johnson's syndrome, 
consisting of a severe blue discoloration of their skin with severe peeling from adverse drug reactions 
to thiacetazone.
8-1:5 The Source of Patients
A large proportion of patients screened for HIV have come from outside of Addis Ababa. As 
shown in Figure 8-4, 41.7% came from within Addis Ababa, 0.26% were from unknown areas and a 
high 58% came from other areas. This suggests a great cost in travel to 58% of these patients, 
illustrating the serious nature of their TB since they travelled from outside of the city to seek treatment.
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In addition, this reflects the popularity of the TB Centre in Addis Ababa which is virtually always 
overloaded in treating cases of tuberculosis both from outside of Addis Ababa and within.
Figure 8-4: Area of Origin of Those 
Patients Screened for HIV at St. Peter's Sanatorium
Total Cared For
8-1:5 The Results of HIV Screened TB Patients
A total of 235 out of 762 (31%) screened patients were HIV positive in 1993 at St. Peter's 
Sanatorium according to the National AIDS Control Programme of the MOH in Addis Ababa. 
Nevertheless, the sanatorium later reports up to 260 (74%). The concentration of these cases proved to 
be much higher in the age group of 15-49 than a normal age/sex distribution for TB as depicted in 
Figure 8-5. The largest number of cases of TB/HIV co-infection occur in the age group of 20-29 years, 
and this was only slightly less in the 30-39 age group. The age group of 20-39 seems to be where the 
highest proportion of TB/HIV co-infection lies, representing a total of 72% of all cases. Hence, those 
in this age range are most at risk for TB/HIV co-infection and this should be considered when 
screening TB patients for the HTV.
Figure 8-5: Total TB/HIV Co-infected Patients at 
St. Peter's Sanatorium According to Age and Sex, 1993
TB/HIV Co-infected Patients
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Figure 8-6: Male Ward for Patients at St. Peter's Sanatorium
Figure 8-7: Paediatric Ward at St. Peter's Sanatorium
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TB/HIV co-infection has a striking impact on patients in this sanatorium. Figure 8-6 shows a 
room in the male ward of St. Peter's Santorium where both HIV and thiacetazone drug reactions are 
not uncommon. TB/HIV co-infection can also be devestating for those around the patient. One of the 
boys in Figure 8-7 is one of two children whose mother had TB. On top of this their mother died of 
AIDS related causes (unknown if it was in fact TB) the day this photograph was taken.
Figure 8-8: Total TB/HIV Co-Infected 
Cases per Year at St. Peter's Sanatorium*
Year
CASES PER YEAR
*1994 data is not complete
Figure 8-9: A Comparison Between Total TB/HIV Co-Infected Cases per Year 
at St. Peter's Sanatorium with Total Growth per Year of AIDS Cases in Ethiopia*
* 1994 data is not complete
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Data in Figure 8-8 starting in 1986, show growth in TB/HIV co-infected patients. This closely 
reflects HIV growth per year illustrated in Figure 7-5 in Section 7-4. A comparison of these two
growth rates is made in Figure 8-9. Except for the rise in patients in 1990 at St. Peter's Sanatorium, the 
growth between these proves to be quite similar (the reader is again reminded that data for 1994 in 
both cases are incomplete, reflecting the deceptive drop in the curves of these figures). Such curves 
suggest that the growth of HIV will continue to provide more and more TB/HIV co-infected cases in 
the future.
8-1:5a Death and TB/HIV Co-infection
Of those HIV screened patients who died, 18 (21%) were HIV-seronegative, and 44 (51%) were 
HIV-seropositive and in 23 (27%), no result could be determined. In these results, over half of those 
screened who died were HIV-positive, which might reflect that a large proportion of those with TB 
who die, die from HIV-related causes: either TB or other infections, as shown in Figure 8-10.
Figure 8-10: HIV-SeroIogy of 
Patient Deaths St. Peter's Sanatorium
Number of Deaths
MALE
FEMALE
8-1:6 Drug Resistance at the Sanatorium
Resistance causes problems in treating patients at the St. Peter's Sanatorium and proves to be 
higher than in health centres because many patients' TB has become critical due to repeated default. 
Dr. Heiwot, the medical director at St. Peters states that resistance to isoniazid, thiacetazone, and 
streptomycin is commonly observed, but she has observed rising levels of rifampicin resistance. 
Patients are suspected of resistance based on their history and lack of response to two months of 
treatment. If a patient has previously received 2-3 months of treatment of a particular drug, then other 
types of drugs are substituted. Resistance is estimated in approximately 10-20% of cases, but it is 
difficult to culture these samples because results take 8 weeks when often the patient has already 
become smear-negative. When resistance is suspected, 5 different drugs are administered for the first 
2 months, and a continuing dose of four drugs in the third month and with a culture after one year.
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Some doctors only give rifampicin and isoniazid, however, which contributes to a greater resistance 
selection, especially if the patient was already resistant to these drugs.
8-1:7 Summary of Section 8-1
Out of a total of 762 patients treated in 1993, a total of 235 patients were HIV positive. This 
represents approximately 30% of all patients treated, which proves to be quite close to statistics on 
HIV/TB co-infection in other African countries, but these statistics are somewhat unclear. Although 
TB/HIV co-infection was only 16.43% in nationally reported AIDS cases, an extra 67.90% suffered 
from a persistent cough, 1.42% suffered from night sweats and an added 0.21% suffered from a loss of 
appetite: all symptoms of other diseases, but also symptoms of tuberculosis. TB/HIV co-infection 
probably accounts for a much higher percentage of patients considering that TB often develops in 
patients before any AIDS defining illnesses appear.
The percentage of those TB cases that can be attributed to HIV is difficult to calculate. Some 
estimates can be made from TB/HIV co-infection national AIDS data, but these are inaccurate. More 
accurate estimates can be determined from greater screening of TB patients to catch asymptomatic 
HIV cases, but this is unlikely to occur unless patients are critical. The TB/HIV co-infection rate is an 
important epidemiological determinant in explaining changes in the TB data in the era of HIV, and in 
illustrating the burden of disease of HIV on TB.
The fact that the medical director observed an average of 10-20% of resistance in patients to the 
ordinary treatment is alarming, considering the fact that there is little isolation between patients at the 
sanatorium, allowing for the spread of primary resistance to normally drug-sensitive TB cases. The 
cost of using five drugs to treat resistant patients increases the drug cost of treatment, but also TB 
treatment costs are increased because of longer associated hospitalisation of patients. In addition, there 
is the cost of more deaths due to resistant TB.
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Section 8-2
The National Tuberculosis Centre in Addis Ababa:
Cost considerations in Diagnostic procedures
In this section, the approach to TB screening primarily at the National Tuberculosis Centre in 
Addis Ababa is analysed. The sex, TB type (extra-pulmonary, smear-positive, smear-negative) and 
age structure of the case load which was comprised of a sample size of 29 295 screened patients 
between 1992 and 1993 can be used as an estimate of the general incidence and manifestation of TB in 
Addis Ababa and outside the city. An analysis of the cost of screening for TB in both the TB centre 
and in other areas of the public health sector in Addis Ababa is presented with possible 
recommendations for improving screening from a cost perspective. This analysis is meant to show 
those elements in the diagnosis of TB that influence cost and is further designed to support the analysis 
in the next section.
The National Addis Ababa Tuberculosis Demonstration and Training Centre (TB Centre) at one 
time was completely responsible for treating almost all cases of TB in its area which account for 
several thousand (See Figures 8-11 and 8-12). This is a centre that has come under considerable 
criticism because of its inability to maintain patient compliance after initial diagnosis of tuberculosis. 
The overwhelming numbers of patients that came to the TB Centre for diagnosis were simply too 
difficult to manage. As this centre was the only public institution designed for treating TB in its area, 
it was ill equipped to treat so many patients by virtue of its small size and funding. Hence, the centre 
had a caseload that it could not realistically deal with, resulting in patients receiving two months of 
intensive treatment and being discharged for their continuous phase treatment with little follow-up. 
Indeed, the centre suffered with a record default rate of 86% meaning that even by a generous estimate, 
its cure rate averaged at only around 30%. The TB Centre continued to suffer from mismanagement 
and problems in tracing patients until only recently when the task of treating TB was delegated to local 
health centres and hospitals. Recent improvements, with the support of the WHO emergency fund, has 
allowed for the treatment within health centres with short course chemotherapy as well as a more 
accessible non-pilot programme for treatment with the standard drug regimen. The TB Centre has 
been integrated into this treatment programme for those that live locally. It still diagnoses TB in 
patients from outside of Addis Ababa. Now the TB centre has a more manageable caseload, but by far, 
still diagnoses the greatest number of cases in the area and surrounding areas. Their caseload, 
however, remains heavy because of a widespread belief by those seeking care that the centre is either 
still the only treatment centre, or that they are somehow better than local health centres. Due to such a 
large caseload diagnosed at the National TB Centre in Addis Ababa. It is possible to see a large
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Figure 8-11: Nurses at the TB Centre in Addis Ababa
Figure 8-12: The X-Ray Machine and X-Ray Technician at the TB Centre
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sample distribution of cases of TB over the past years in Ethiopia. In addition, the diagnostic 
procedures will also be discussed in detail.
8-2:1 Caseload at the TB Centre
Between September 1992 and September 1993, the TB Centre screened over 29 295 patients for 
tuberculosis. Of this group, only 5353 (18%) of those were diagnosed with TB, resulting in an extra 
cost of 23 942 (82%) screened that did not have TB. Of those with TB, a total of 39% were smear­
positive, 58% were smear-negative and 3% were extra-pulmonary tuberculosis cases as illustrated in 
Figure 8-13.
Figure 8-13: Smear Classification of TB Patients from the TB 
Centre in Addis Ababa from September 1992-September 1993.
| Smear Positive (39%)
| | Smear Negative (58%)
| Extrapulmonary (3%)
Figure 8-14: Smear Status According to Sex
| Males 
BI Females
TB Classification
Again a large proportion of these proved to be males rather than females. On average there were 2 
males for every one female treated for tuberculosis. 66% males to 34% females in the smear-positive
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smear-positive, 67% males to 33% females in the smear-negative group, and 59% males to 41% 
females in the extra-pulmonary group as can be seen in Figure 8-14.
Indeed, tuberculosis affects more males than females, as has been the case in other countries. 
For unknown reasons, TB seems to strike in males more than females (See Figure 8-15). This could 
possibly be exacerbated by the fact that more males seem to be HIV-positive as described in 
Section 7-4 and more males have a greater incidence of TB/HIV co-infection . This disease is far 
more costly in economic terms from the perspective of a society if males are the major producers and 
wage earners of that society.
Figure 8-15: Age and Sex Distribution at the TB Centre from 
AH Available Reports from September 1992 to September 1994
Age
| Males 
r~1 Females
8-2:2 Diagnostic Procedures
It is the policy of the TB Centre in Addis Ababa to screen all patients by giving them a smear test 
and a chest x-ray (See Figure 8-12). Indeed, although a chest x-ray (CXR) can reveal some 
information about a patient, it has to be used in conjunction with other diagnostic tools and patient 
symptoms in order to diagnose tuberculosis. CXRs are essential for use in paediatric age groups, 
especially when they have had contact with a tuberculosis patient, a TB/HIV co-infected patient, a 
miliary tuberculosis patient or a pleurisy patient. However, as was revealed in Chapter 5, there is no 
definitive chest x-ray particular to tuberculosis. Chest x-rays are difficult to read and x-rays of TB 
infected cases can be quite similar to other chest diseases. They cannot be the sole indicator of 
tuberculosis but need other clinical support. Nevertheless, since this diagnostic tool is relatively 
technologically intensive, it is often perceived as better than other diagnostic tools, when in fact this is 
not necessarily the case. Sputum examination is a cheaper alternative in the diagnosis of TB as 
compared to chest x-rays, but there are problems in this diagnostic tool as well. Many patients have
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difficulty giving sputum samples, often giving useless saliva samples instead of sputum. Nevertheless, 
for those patients that can be diagnosed smear-positive by sputum examination, this proves to be a 
cheaper alternative to x-rays.
The use of CXRs in those patients who can be diagnosed as smear-positive by a sputum smear 
represents a superfluous use of this diagnostic tool, and is a sub-optimum use of resources. In ideal 
circumstances, a chest x-ray in conjunction with a smear test might be an appropriate aid to a clinician 
seeking extra information in diagnosis, but not in areas that are so financially constrained. Instead, all 
patients should undergo a smear test before receiving a chest x-ray in order to isolate those patients 
who have smear-positive TB. Indeed, if these patients can be diagnosed with TB by a smear test, they 
do not need a chest x-ray to re-determine this. Instead, by using the CXR on suspected smear-negative 
and extra-pulmonary cases, it can be used more efficiently to determine tuberculosis.
This superfluous use of x-rays on smear-positive patients proves costly. The costs of x-rays has 
been calculated to be approximately 15.35 birr from estimates of the cost per x-ray in other local 
hospitals, including film and reagents, doctor costs, technician costs and machine costs (See Table 8­
2).
Table 8-2: Total Value of X-Rays from Smear-positive Cases of 
Tuberculosis at the TB Centre from Available Data Between 1992-1994
Year Total Smear + 
Patients
Costs of X- rays $ US Dollar Value This Figure in 
SCC Patients
This Figure in 
SDR. Patients
1992-1993 2051 31482.85 birr $4843.52 119 197
1991 quarter 408 6262.80 birr $963.51 24 39
1993-1994 2113 32434.55 birr $4989.93 123 203
TOTAL 4572 70180.2 birr $10796.95 266 439
Considering this, according to Table 8-2, for the cost of these extra x-rays for smear-positive patients, 
266 patients could have been treated with SCC and 439 could have been treated under SDR.
Total lost expenditure for x-rays was estimated to be approximately 70 180.20 Ethiopian birr and 
$10 796.95 US dollars. These figures may seem like a relatively small amount, but they become far 
more significant when considering that this amount represents 1% of the 1992 drug and medical supply 
budget for Addis Ababa, 2% of the 1992 drug and medical supply budget for hospitals and health 
centres in the remainder of the country, or the monthly salary for 87 doctors or 176 nurses.
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8-2:2a Smear Microscopy versus Chest x-rays
Indeed, even if smear microscopy proved to be more expensive than chest x-rays, their use would 
still be justified for the diagnosis of tuberculosis until the cost of the total amount of incorrect 
diagnoses from x-rays was less than the cost of correct diagnoses with smear microscopy in smear­
positive patients. Smear microscopy is an essential method for quickly identifying the most infectious 
cases of tuberculosis. It is a more effective method by definition in identifying smear-positive cases 
due to the fact that a decisive x-ray solely for tuberculosis does not exist. Although it could be said 
that this is especially true in the HIV era where a large proportion of x-rays for TB/HIV co-infected 
patients prove to be anormal, this is not that relevant when only a very small proportion of TB/HIV 
patients are smear-positive.
Obviously, smears are extremely important since in order to decrease the transmission of the 
disease, identifying smear-positive cases as quickly as possible becomes imperative. An x-ray, a 
smear test and a culture might be very helpful in determining information about a patient's 
tuberculosis. Nevertheless, in countries as financially constrained as Ethiopia, where drug treatment 
and health service are unavailable to a large proportion of the population, quick and effective efforts in 
determining tuberculosis become the focus for diagnosis. The use of several methods to check for 
false diagnosis and discover information on the overall nature of a patient's TB proves an unaffordable 
luxury when the need for low cost diagnosis is demanded.
Table 8-3: Activity Report from Addis Ababa Hospitals, 31 May, 1994
Menilik Yekatit Berla T.A.H. E.S.C.H.** Zewditu Ras Desta
TB Manifestation
Smear-positive 120 233 2 236 10 50 29
Smear-Negative 243 76 131 207 194 50 51
EP 39 15 11 180 75 28 17
Total 402 324 144 623 279 128 97
Referred Out
Pilot Area 212 147 26 227 55 12 16
Non-pilot Area 190 94 64 396 247 198 73
Total 402 241 90 623 302 210 89
Admissions 39 43 29 4* 94 29
Under Follow-up 40 54 All 128
Deaths 3 1 10 8
Sputum Tests
Total 1027 1286 6 1516 204 569
For Diagnosis 5 4 1488 204 502
For Follow-up 1022 2 28 67
Courtesy of: Region 14 Health Bureau, Addis Ababa 
* From SCC Area Only
**E.S.C.H. Refers Patents for their daily treatment, but tracks follow-up for all patients
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8-2:3 Other Local Hospital’s Diagnostic Procedures
The use of superfluous, automatic diagnostic tests for patients is not just particular to the TB 
Centre in Addis Ababa. The Black Lion Hospital in Addis Ababa screens suspected patients with a 
sputum smear, blood test and x-ray. According to the sputum register, a total of 294 of 2294 patients 
screened had smear-positive tuberculosis (excluding 24 follow-up tests). Considering that blood tests 
(CBCs) cost 5 birr and x-rays cost 15.25 birr (costs of each procedure are the courtesy of Region 14 
Health Bureau in 1994), extra costs for these 294 patients amount to 1470 birr in blood test costs and 
4484 birr in x-ray costs. Likewise at the Saqudito Memorial Hospital, of 1400 screened patients, there 
were 143 smear-positive patients, and their corresponding blood tests amounted to 715 birr and x-rays 
amounted to 2181 birr. Indeed, the use of smear microscopy will serve to screen out all smear-positive 
patients, before x-rays and blood tests need to be used to identify smear-negative patients. The amount 
saved in each hospital would prove to be relatively small, but considering that this is the policy year 
after year, in just the TB Centre alone, the excess cost from x-rays would amount to 80 000 dollars 
over ten years if costs remained constant. On a national scale, if an automatic x-ray policy were 
adopted for all patients, extra costs would be quite significant. Of the 154 000 cases of TB that were 
predicted to be detected in 1993, if 69 300 (45%) of those were smear-positive, total x-ray costs would 
amount to 1 056 825 birr. This 1 056 825 birr amounts to 19% of the total drug and supply budget for 
Addis Ababa, 25% of the budget for hospitals and health centres in the rest of the country, and 6% of 
the total 1992 budget for drug supplies.
8-2:4 Optimum Screening Procedures for TB
The process of screening TB itself needs to be seriously re-considered. Indeed, the TB Centre 
screens an incredible number of patients for TB. At the Addis Ababa TB Centre, analysis of over 
7 000 x-rays in 1980 found that only 6.5% had cavitary disease. In contrast a total of 72.9% were 
normal and 13.4% had pulmonary disease of apparently non-tuberculosis origin (Teklu, Bayu and 
Kassegn, 1982). Using the number of those screened between September 1992 and September 1993 as 
a per-year estimate of total screening: of those 29 295, 5 353 (18%) had tuberculosis and 23 942 (82%) 
were non-TB patients. Subtracting an extra generous 10% diagnosis of non-TB pulmonary disease, 
this leaves a total of 21 547.8 (72%) normal patients who are needlessly screened per year. Indeed, the 
patient's piece of mind accounts for some benefits in this screening, but this screening represents 
323 217 birr in x-rays, and 145 642 birr in smear costs. This method of deciding if a patient has 
tuberculosis is inefficient as proven by the TB Centre where 72% of those screened proved normal.
The question arises as to how to selectively reduce the large number of those screened for TB 
each year without jeopardising efforts to find those with tuberculosis. There are several challenges that
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arise in trying to achieve this objective: (1) The more patients that are denied TB screening, the more 
TB patients will not be found for treatment. In essence, some TB patients will slip through the 
screening matrix. (2) Screening all patients who walk into a health facility represents wasted resources 
from needlessly screening normal patients. (3) Indescriminantly distributing broad spectrum 
antibiotics to all patients requesting screening in order to determine if the patient has another 
pulmonary infections means that 72% of the group are needlessly receiving antibiotics which will 
contribute to a problem in resistance, especially when considering large numbers such as 20-30 000. 
(4) In some instances, patients travel long distances to receive treatment and cannot afford long waiting 
periods before they are diagnosed. At the TB Centre, for example, many patients come from outside 
Addis Ababa and have no time to sit about and wait to see if antibiotic treatment works or not. They 
want to be diagnosed for TB right away so that they can be referred for treatment. A delicate balance 
has to be found between identifying patients that absolutely do not have TB, those patients who are 
suspected with TB but also might have another infection, and those that most definitely do have TB.
When considering tests in diagnosing patients for TB: (1) patients should have been suffering 
from a cough for more than 3 weeks or (2) have blood in their sputum as well or (3) fever, malaise and 
weight loss. Other pulmonary diseases are equally as common as TB and can sometimes be mistaken 
for it. For example, pneumonia is ranked as the 4th disease seen in health centres and hospitals and 
therefore, pneumonia is far more likely to be present in patients experiencing symptoms of pulmonary 
disease than tuberculosis, which is ranked as 12th (see Table 7-4, Section 7-1). Hence, it is just as 
likely that those showing symptoms of tuberculosis could also have had pneumonia due to an 
overlapping similarity between some symptoms of the two diseases.
Those individuals initially appearing at a health centre should be carefully considered by doctors 
when deciding if they are suspected cases of TB. Unfortunately, with a large caseload, such careful 
consideration is not always possible. Nevertheless, one option is that instead of automatically using 
diagnostic tests for patients with a cough for more than 3 week, patients would be given only a smear 
test. If these smears prove to be positive, then the patient would obviously go on to receive treatment. 
However, if the patient was negative, a broad spectrum antibiotic would be given for 7-10 days and an 
appointment would made in 2 weeks to look for improvement. Those patients showing no 
improvement would then be given a chest x-ray. There are obvious exceptions to this procedure. If a 
patient shows very critical signs of disease, he or she should immediately be screened for TB with all 
available diagnostic tools. Likewise, those cases where TB strikes or progresses quickly, such as in 
children and HIV patients, should be immediately screened for TB with both x-rays and sputum 
microscopy.
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The question arises as to the opportunity cost of the money spent on screening such a large 
proportion of normal individuals for TB. The national cost of screening normal patients in 1993 is 
staggering as only 28% of patients are found to have TB or some other respiratory disease. If 72% of 
screened patients are normal, this would amount to 7 484 400 birr ((6.75)[(0.72)( 1540000)]) in sputum 
smears, 5 544 000 birr ((5)[(0.72)(1540000)]) in blood tests, and 16 909 200 birr 
((15.25)[(.72)(1540000)]) in CXRs, making a total of 29 947 600 birr, which translates to $4.6 million 
US dollars per year. This is enough money to treat 113 309 patients or 74% of the total TB case load 
for 1993 with SCC, and represents 1.5 times the total budget allocated for drugs and medical supplies 
in Ethiopia in 1992. Indeed, there must be a less costly method of looking at a patient and predicting 
whether he or she might have tuberculosis, before screening them. Indeed, the number of and cost of 
screening normal patients is high. If suspected TB patients could be more effectively identified, more 
funds would be free to treat a greater number of TB patients.
8-2:5 Summary of Section 8-2
The large proportion of patients screened for TB offers an unusually large sample in order to 
analyse the epidemiological patterns of TB in Ethiopia, including the sex and age structure of those 
affected by the disease as well smear status. When analysing these data, the diagnostic procedures at 
the TB Centre come into question due to its automatic use of x-rays for smear-positive patients who 
could be identified by smear microscopy. This represents a large body of wasted resources. It is 
significant because such automatic use of x-rays for all suspected TB patients is not just particular to 
the TB Centre, but is also seen in other hospitals in Addis Ababa. In addition to screening techniques, 
the process of identifying suspected TB patients is inefficient. As much as 72% of those individuals 
tested for TB are diagnosed as normal, suggesting a great inefficiency in the use of resources and 
patient time in these tests. A more standardised efficient procedure needs to be established in 
screening for TB as well as identifying suspected TB patients, or TB programme resources that could 
be used more optimally in treatment will continue to be wasted.
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Section 8-3
A Cost-effectiveness Analysis between see and the 
Standard regimen in the Public Sector of Addis Ababa
In this section, the question of what impact resistance has on the cost of TB treatment in Addis 
Ababa is answered in a cost-effectiveness analysis of two treatments for TB: SCC and SDR. As well 
as presenting the impact of resistance on cost, the impact of drug reactions from HIV, non-compliance 
to treatment and death are shown. The section begins with a description of the organisation of 
treatment of TB, incidence of TB, management of drug and laboratory supplies and the process of 
diagnosis within the public health sector of the city. It then proceeds to describe materials and 
methods used to perform this study, including the number of patients and health centres that 
participated in the study and their location. The results of the analysis are then given, including the 
treatment results of those in both the pilot sample and the non-pilot sample, and an analysis of the 
components influencing the costs of treatment, including resistance. Here the impact of TB resistance 
on the cost of TB treatment is assessed. Following this, cost-effectiveness ratios are presented for both 
the pilot and the non-pilot samples along with an incremental analysis. A sensitivity analysis of those 
factors affecting these results, including the changes in resistance, are then considered. This is 
followed by a discussion of treatment, supported by interviews from each health centre that 
participated in this study.
In 1993, in Addis Ababa, tuberculosis remained the leading cause of death in hospitals and the 
third largest reason for hospital admissions. Tuberculosis is responsible for 1 500-2 000 deaths per 
year in the city alone. Epidemiological statistics for Addis Ababa present a grave picture of 3 000­
4 000 new cases of smear-positive tuberculosis per year, 6 000-8 000 new tuberculosis cases per year, 
and a 13 200-17 600 total case prevalence of TB per year. Past tuberculosis treatment in the city has 
been relatively impotent in treating tuberculosis. Treatment was crippled by the fact that the burden of 
treatment was thought solely to be the task of the Tuberculosis Training and Demonstration Centre in 
Addis Ababa. Efforts to rectify this problem by putting more of the responsibility of the treatment and 
follow-up of patients on the health centres and providing each of them with their own laboratory for 
sputum smear microscopy were wholly ineffective due to poorly designed referral systems and ill 
defined health regions. To improve this situation, a pilot programme was developed using short course 
chemotherapy with three years of support from the WHO emergency fund. Likewise, six months later, 
a non-pilot programme in the remaining regions was initiated for the standard regimen.
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8-3:1 The Pilot Programme
In September 1994, the tuberculosis pilot programme was 14 months old, and operating in five 
hospitals, seven health centres, and one clinic covering 8 woredas (areas). The goal of the programme 
was to achieve a cure rate of 85% of all smear-positive cases. From each pilot area, one doctor, one 
nurse and one lab technician were trained for one week as tuberculosis co-ordinators.
It is hoped that this programme can be replicated in the remaining non-pilot health centres 
covering 20 woredas (areas). The current woredas were chosen for the pilot programme on the basis 
that they were the most populated areas and would take the greatest case load. Patients are placed on 
short-course chemotherapy if they are diagnosed as smear-positive and they are placed on the standard 
drug regimen if they are diagnosed as smear-negative or extra-pulmonary tuberculosis. Short course 
chemotherapy consists of a two-month intensive phase treatment with pyrazinamide, streptomycin, 
rifampicin and isoniazid and a continuous phase treatment with isoniazid and thiacetazone or 'TB450' 
(2SHRZ, 6TH). Severe shortages of drugs were reported in these areas, previous to this study. 
However, the National Leprosy and Tuberculosis Control Programme, Christian Relief and 
Development Association, the Goal and Italian Cooperation Tuberculosis Control have been 
instrumental in helping to secure drugs.
8-3:2 The Non-Pilot Programme
In order to better facilitate the treatment of tuberculosis in the non-pilot areas, a tuberculosis 
programme had to be established in the remaining 20 areas of Addis Ababa. This became the non-pilot 
Programme which offers standardised tuberculosis treatment of SDR to patients living in non-pilot 
areas. Like the pilot programme, one doctor, one nurse and one lab technician were chosen as 
tuberculosis co-ordinators from each area and were sent on a training course.
Primarily the standard drug regimen is given in the non-pilot programme, and it consists of a 
two-month long intensive-phase treatment with streptomycin, isoniazid and thiacetazone and a 10- 
month continuous phase treatment with isoniazid and thiacetazone, 'TB450' (2STH/10TH). The 
programme is designed so that all patients receive the standard drug regimen regardless of their smear 
classification. Ethambutol is substituted for thiacetazone in all cases of adverse drug reactions or those 
patients suspected as likely to have a reaction (usually suspected TB/HIV co-infected cases). Short- 
course chemotherapy is very rarely administered as the drugs are difficult for these non-pilot health 
centres to obtain.
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8-3:3 Detection Rates, Incidence and Prevalence
The programmes report an 85% detection rate, which is quite high. Part of this high rate of 
detection could be due to the fact that health service coverage is low and facilities for treating 
tuberculosis in rural areas within a reasonable travel distance are inadequate. Hence, many travel from 
outside of the city to receive treatment, making the detection rate seem artificially high. Ignoring this 
urban bias, real detection rates are more inclined to be 50%. This is likely to be true when even 
considering that there might be more cases in Addis Ababa because of such a high population 
concentration (which allows the disease to spread more easily). As shown in Tables 8-4 and 8-5, the 
total population that these health facilities cover is 2 451 493. This gives a total incidence in this area 
of 13 074. Hence, there are 436.8 reported cases per 100 000. This means that there is a 0.44% 
incidence of detected cases per 100 000 population and a 0.88% prevalence of detected cases per 
100 000 population. The real incidence is estimated to be twice these values, assuming a detection rate 
of 50%.
Table 8-4: Estimated Epidemiological 
Indices in the Non-Pilot Woredas (Areas) in 1994
Health
Centre/Clinic
Population Smear-positive
Cases
Smear-negative
Cases
Incidence Prevalence
Arada 70 783 86 103 189 378
T/Haimanot e 103 571 125 150 275 550
Addis Ketema 121 438 147 176 323 646
97 612 118 142 260 520
TB Centre 118 976 144 173 317 634
Gefersa 91 546 111 133 244 488
Gulele 66 930 81 97 178 356
92 594 112 134 246 492
Kazanchis 86 056 104 125 229 458
Yeka 81 164 98 118 216 432
Higher 17 114 984 139 167 306 612
Higher 19 86 675 105 126 231 462
Kirkos 118 127 143 172 315 630
Lideta 51 101 62 74 136 272
Higher 23 93 120 113 136 249 498
113 609 137 164 301 602
Kolfe 75 667 92 110 202 404
Akaki 94 011 114 137 251 502
Kality 57 538 70 84 154 308
Kotebe 31 647 38 46 84 168
Total 1 767 149 2 139 2 567 4 706 9 412
*Some health centres and clinics function for two areas, running a 
non-pilot programme and a pilot programme: this is the case for K19
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Table 8-5: Estimated Epidemiological 
Indices in the Pilot Woredas (Areas) in 1994*
Health
Centre/Clinic
Population Smear-positive
Cases
Smear-negative
Cases
Incidence Prevalence
Arada 55 341 70 84 154 308
T/Haimanot and 111 830 135 162 297 594
Beleteshchew
Shiromeda and 106 236 129 155 284 568
Entoto
Entoto No. 1 67 666 82 98 180 360
Higher 13 84 865 103 124 227 454
Baata and Zewditu 86 536 105 126 231 462
Hospital
Higher 18 74 406 90 108 198 396
Higher 19 97 464 118 142 260 520
Total 684 344 832 999 1 831 3 662
*Some health centres and clinics function for two areas, running a 
non-pilot programme and a pilot programme: this is the case for Higher 19
8-3:4 Drug and Laboratory Supplies in the Non-Pilot and Pilot Areas
The amount of drugs consumed in the pilot programme is shown in Table 8-6. From this table, a
large deficit can be observed between projected demand and the actual amount of TB drugs consumed. 
The proportion of drugs actually consumed outweighs the projected amount by a very large margin in 
all but three cases. It seems that the supply of HT combinations is not as much a problem as other 
drugs, possibly due to their lower cost. Also of note is that only a very small proportion of projected 
consumption of R300 + H150 was consumed. This is possibly due to the fact that a majority of patients 
are under weight and are given the R150+H100 dosage instead of the expected R300+R150 dosage. The 
largest deficit was for ethambutol. This is attributed to an unexpected low intolerance to thiacetazone 
whereby ethambutol had to be substituted in many patients.
Table 8-6: Consumption of Drugs as a Proportion of 
Projected Consumption in the Pilot Programme
Serial
Number
Item Quantity
Received
(Tins)
Consumed
(Tins)
Amount Consumed as 
a Percentage of 
Estimated 
Consumption
Estimated
Consumption
(Tins)
1 R3OO + H150 1152 250 27.74% 901
2 R150 + H100 1203 962 751.56% 128
3 Z 233 202 104.66% 193
4 s 1177 911 108.45% 840
5 E 189 163 776.19% 21
6 HT 529 484 98.17% 493
7 H100+T150 140 9 14.28% 63
Courtesy of: Region 14 Health Bureau, Addis Ababa
In the non-pilot programme, drug consumption was again projected in a 6 month balance sheet, as seen 
in Table 8-7. As can be observed in this table, actual drug consumption was observed to be much
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higher than what was projected for Streptomycin, but lower for HT and the paediatric combination of
H100+T50.
Table 8-7: Consumption of Drugs as a Proportion of 
Projected Consumption in the Non-pilot Programme
Serial
Number
Item Quantity
Received
(Tins)
Consumed
(Tins)
Amount Consumed 
as a Percentage of 
Estimated 
Consumption
Estimated
Consumption
(Tins)
1 S 1412 649 110.75% 586
2 HT - 238 67.61% 352
3 HlOO + T50 • 2 7.69% 26
Courtesy of: Region 14 Health Bureau, Addis Ababa (unpublished)
The anticipation of future drug supplies has been calculated from the estimation of past cases. Future 
drugs needed for one year are calculated from Table 8-8. As can be observed, current stocks only 
represent 13-42%, leaving 58-87% yet to be obtained.
Table 8-8: Estimated Anti-TB Drug Requirement for 1995
Serial Number Item Current Stock Quantity Required Estimated Difference
for the Next Year
1 R300 + H150 902 313 589 (65.30%)
2 R150 + H100 241 1200 959 (79.91%)
3 Z 31 252 221 (87.70%)
4 s 266 1138 872 (76.63%)
5 E 86 205 119(58.05%)
6 HT 125 505 380 (75.25%)
Courtesy of: Region 14 Health Bureau, Addis Ababa (unpublished)
Table 8-9: Laboratory Supplies Issued in Addis Ababa, 
Health Region 14 According to a 6-month Review
Item Quantity
Received
Pilot Non-Pilot Total %
Sputum Cups 7976 4670 2050 6720 84.53%
Solution A (500ml) 123 74 32 106 86.18%
Solution B (500ml) 108 52 25 77 71.30%
Courtesy of: Region 14 Health Bureau, Addis Ababa
8-3:4a Laboratory Supplies
A consistent store of laboratory supplies is essential in the proper diagnosis of smear-positive 
tuberculosis cases. In the pilot and non-pilot Areas, between 71-80% of laboratory supplies received 
were used as depicted in Table 8-9. The extra 20-30% accounts for a buffer to meet any unexpected
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arising laboratory supply needs. Nevertheless, there are still some problems in obtaining some of the 
necessary supplies such as the diamond pencil.
8-3:5 Treatment and Diagnosis of Patients
The majority of patients in the health centres and clinics (approx. 85%) are diagnosed at hospitals 
in Addis Ababa and then referred to the health centre or clinic closest to the patient's house. In 
contrast, only a small percentage are diagnosed in the health centre. If a patient comes to the hospital 
complaining of a persistent cough for three weeks or more, he or she is given a blood test, a chest x- 
ray, and a sputum smear test. Patients are classified according to how many sputum tests out of three 
are positive: (1) 2 or more positive smears, (2) 1 positive smear, or (3) all three negative smears, as 
shown in the diagnosis algorithm in Figure 8-16. Those in group (1) who have at least two positive 
sputum tests are assumed to be sputum positive and are referred to their nearest health centre or clinic 
for treatment. Here, he or she receives an 8-month or 12-month treatment depending on whether their 
area is designated as pilot or non-pilot.
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Those patients in group (2), with only one positive sputum slide, are given two more sputum tests and 
are considered sputum positive if one or more of these subsequent tests is positive. If these subsequent 
tests prove to be negative, the patient is then sent away and given general antibiotics for 10 days. An 
appointment is made for the patient to be seen again after 2-4 weeks where if he or she has not 
improved and still has one or more positive sputum smears, he or she is treated as a smear-positive 
patient. In contrast, if this patient is still negative but has not improved, then he or she undergoes a 
chest x-ray if he or she has not already had one and with other clinical support, the likelihood of the 
patient having TB is evaluated. Lastly, those patients in group (3), who have three negative sputum 
smears, are classified as smear-negative, and as in group (2), are given antibiotics for 10 days and then 
reviewed after 2-4 weeks. If they do not responded to the antibiotics, they are then given another 3 
sputum smears and if one or more is positive, they are classified as a smear-positive patient. Again, if 
the patient is still sputum negative, his or her chest x-ray is examined and together with other clinical 
evidence, it is decided as to whether the patient has smear-negative TB or another illness.
8-3:6 Methods for Analysis
A sample size of 1 504 TB patients was observed from 6 non-pilot health centres, 6 pilot health 
centres and one health centre that included both a pilot and a non-pilot programme. Non-pilot health 
centres included Kolfe Health Centre, Kazanchis Health Centre, Addis Ketema Health Centre, 
Kefetegne 17, Kefetegne 23 and Kefetegne 19. The pilot health centres were Kefetegne 18, Kefetegne 
19, Kefetegne 13, Entoto Health Centre, Tekelhamanot Health Centre and Shiromeda Health Centre. 
These health centres serve a total of approximately 1 178 101 million people.
Information on the course of each patient's treatment was recorded from tuberculosis record 
books and treatment cards at each health facility in August and September of 1994 (See Appendix D 
for patient recording forms). Patients were identified according to the treatment regimen that they 
received: SCC, SDR, retreatment or isoniazid-ethambutol regimens. These patient's response to 
treatment was subsequently recorded according to 5 categories: cured, defaulted, death, drug reaction 
or bacteriologically positive (BAC+). From this, a cure rate was established for those patients 
receiving SCC in the pilot areas and SDR in the non-pilot areas.
All costs relevant to each treatment regimen in each area were gathered with the co-operation of 
the epidemiology department of the Region Health 14 Bureau, responsible for health administration 
and support in Addis Ababa. These costs were then used in conjunction with the cure rates to calculate 
the cost-effectiveness of the treatments in terms of cost per cure. In addition, the cost per death averted 
and the cost per life year saved were also calculated.
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8-3:7 Results
8-3:7a Non-Pilot Area
In the non-pilot group, 632 patients were studied of which 384 (60.76%) were male and 248 
(39.24%) were female, with an average age of 29 years, as illustrated in Figure 8-17. Out of this 
sample, 233 (36.87% ) were smear-positive, 328 (51.90%) were smear-negative, 67 (10.60%) had 
extra-pulmonary tuberculosis and 1 (0.16%) had both pulmonary and extra-pulmonary tuberculosis, 
leaving the smear classification of 7 (1.10%) unknown. Also, 37 (5.85%) died, 98 (15.51%) defaulted 
from treatment, and 62 (9.81%) transferred out. All but 95 (12.03%) patients were placed on a 
standard regimen of 2STH/10TH. 76 patients were placed on Isoniazid-Ethambutol instead of 
Isoniazid-Thiacetazone (2SHE/10HE), 8 were on short-course chemotherapy, and 11 were on a 
retreatment regimen. A further 20 (3.16%) suffered adverse drug reactions primarily to thiacetazone.
Figure 8-17: Known Age and Sex Distribution of TB 
Patients in Addis Ababa Pilot and Non-Pilot Areas (N=1499)
8-3:7b Pilot Area
Similarly, in the pilot group, 872 patients were studied, with an average age of 27 years, with 481 
(55.16%) males and 390 (44.72%) females. Out of this sample, 402 (46.10%) were smear-positive, 
375 (43.00%) were smear-negative, 94 (10.78%) were extra-pulmonary, 2 were both extra-pulmonary 
and pulmonary (0.23%), and in 6 (0.69%), classification was unknown. Instead of the short course or 
standard regimen, there were 40 (4.59%) on Isoniazid-Ethambutol (HE) instead of Isoniazid- 
Thiacetazone (TB450) and 4 (0.46%) on Isoniazid-Rifampicin instead of Isoniazid-Thiacetazone. A 
further 8 (0.92%) patients were on a retreatment regimen.
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As shown in Table 8-10, of the total patients, there were 60 (6.88%) deaths, 116 (13.30%) 
defaulters and 47 (5.39%) transfers. 47 (5.39%) experienced drug reactions primarily to thiacetazone.
Table 8-10: Results of Patient Treatment
Categorj^ Pilot# Pilot % Non-Pilot # Non-Pilot %
Total Number N=872 N=632
Mean Age 27.46 28.73
Total Males 481 55.16% 384 60.76%
Total Females 390 44.72% 248 39.24%
Smear-Positive (P+) 402 46.10% 233 36.87%
Smear-Negative (P-) 375 43.00% 328 51.90%
Extra-Pulmonary (EP) 94 10.78% 67 10.60%
P&EP 2 0.23% 1 0.16%
Unknown 6 0.69% 7 1.10%
Deaths 60 6.88% 37 5.85%
Default 116 13.30% 98 15.51%
Transfers 47 5.39 62 9.81%
HE Continuous Phase 40 4.59% 76 12.03%
SCC in Non-pilot Area
HR Continuous Phase 4 0.46%
8 1.26%
Drug Reaction 47 5.39% 20 3.16%
Retreatment 8 0.92% 11 1.74%
Figure 8-18: Age and Sex Distribution of Smear-Positive Patients in Addis Ababa
Age
8-3:7c Ethambutol Substitution for Thiacetazone (HT-HE)
The high percentage (12.03%) of those patients placed on HE treatment in the non-pilot area as
compared to the pilot area could account for the lower number of drug reactions to thiacetazone 
observed in the non-pilot (3.16%) as opposed to the pilot area (5.39%). Those patients initially placed 
on HE or HR treatment suggests the amount of patients suspected or known to be HIV-seropositive.
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Clinical evidence shows that HP/ patients are far more likely to have an adverse drug reaction to 
Thiacetazone than those who are HIV-seronegative (Kelly et al., 1994). Thiacetazone, although a 
relatively cheap drug, is not an effective drug in the treatment of patients who are HIV-seropositive. 
Some of the doctors in Addis Ababa that were interviewed thought that Ethiopians in general could not 
tolerate thiacetazone, but in actuality, HIV patients cannot tolerate it, influencing the perceived 
tolerance of the total population. Nevertheless, little is known about the number of the TB/HIV co­
infected patients in this sample because HIV screening is not only too expensive, but also would place 
a further stigma on TB treatment, making it appear a completely AIDS-related disease. Such a stigma 
would hamper case-finding in TB because patients would be inclined to wait until their TB was quite 
life-threatening before risking or being forced into the perceived disgrace of treatment.
8-3:7dAge Correlation with Productivity
Looking at the respective average ages of 27 and 29 for the pilot and the non-pilot programmes 
in addition to the overall age distribution (see Figure 8-17) would suggest that TB strikes those in 
Addis Ababa at their most economically productive stage of life: a time when they are expected to 
raise children and act as community leaders in society. Figure 8-18 clearly illustrates that the highest 
age range for TB occurs in the age-group between 15-24 years, followed by 25-34 years, 35-44 years 
and 45-54 years. TB is clearly an illness that primarily strikes between the ages of 15-55. Several 
reasons could be attributed to this such as BCG effectiveness in childhood, greater accessibility to the 
health care system increasing detection and undoubtedly, tuberculosis's association with AIDS in this 
age group.
8-3:8 Results of Smear-Positive Cure Rates between SCC and SDR
There were 233 smear-positive cases of tuberculosis in the non-pilot study. Of these, 34 
(14.59%) had not finished treatment, 5 (2.15%) were on SCC chemotherapy and 19 (8.16%) were on 
isoniazid and ethambutol instead of TB450, 19 had transferred (8.16%) and 1 (0.43%) was on a 
retreatment regimen. This left a total of 155 (66.52%) patients on SDR whose results of treatment 
were known. Of these 155, 10 (6.45%) died, 47 (30.32%) defaulted, 0 were bacteriologically positive 
(failures), and 7 (4.52%) had adverse drug reactions primarily to thiacetazone. This left a cure rate of 
91 (58.70%) not including those in the default group who were cured and 105 (67.74%) including 
those in the default group who were cured.
In the pilot Group 402 patients were smear-positive. Of these patients, 9 (2.24%) were 
unfinished with treatment, 23 (5.72%) were on isoniazid and ethambutol instead of TB450, 2 (0.49%) 
were on isoniazid and rifampicin instead of TB450, 19 (4.73%) transferred to other areas, and 5
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(1.37%) were on a retreatment regimen, leaving 344 (85.57%) smear-positive patients on SCC who 
had finished treatment. In these 344 patients, 21 (6.10%) died, 48 (13.95%) defaulted, 5 (1.45%) were 
bacteriologically positive, and 26 (7.59%) had adverse drug reactions primarily to thiacetazone. From 
this, 244 (70.93%) were cured, not including those in the default group, and 273 (79.36%) patients 
were cured, including those in the default group. Cured patients in both the SCC and SDR samples 
were defined as having completed treatment with a follow-up smear to verify conversion, although a 
follow-up smear could not be obtained for some patients in this group. Results of treatment are shown 
in Table 8-11 (See Appendix A for all data for Non-Pilot and Pilot Groups).
Table 8-11: Results of Smear-Positive Treatment
Category Non-pilot # 
(SDR)
Non-pilot % Pilot#
(SCC)
Pilot %
N=233 N=402
Smear-positive 233 402
Smear-positive on SCC/SDR 
regimens with known results
155 66.52% 344 85.57%
Unknown 34 14.59% 9 2.24%
HE Treatment 19 8.16% 23 5.72%
SCC Treatment (in non-pilot Areas)
HR Treatment (in pilot Areas)
5 2.15% 2 0.49%
Transfers 19 8.16% 19 4.73%
% Transfers Uncured 0.33(19)= 1.88% 0.33(19)= 1.09%
6.27 6.27
0.7(6.27)= 0.7(6.27)=
4.39 4.39
Retreatment Cases 1 0.43% 5 1.37%
Ld=155 L=344
Death Rate 10 Dd=6.45% 21 D=6.10%
Default Rate 47 30.32% 48 13.95%
% Defaulters Uncured 0.7(47)=32.9
=33
Fd=21.29% 0.4(48)=19.2
=19
F=5.52%
Bac.+ (Failures) 0 Bd=0 5 B=1.45%
Drug Reactions 7 Rd=4.52% 26 R=7.59%
Cure Rate w/o added default calculations 91 58.70% 244 70.93%
Cure Rate inc. Default % Cured Nd=105 67.74% N=273 79.36%
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Figure 8-19: The Algorithm of TB 
Treatment in Both the Pilot and Non-pilot Areas
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8-3:9 Differences Between Treatment Groups Determining Smear-Positive Cure Rates
Cure rates were estimated to be 74.40% for SDR and 85.84% for the SCC treatment. The 
difference in these cure rates was thought to be primarily dependent on the high rate of default 
experienced in the standard regimen. Figure 8-19 shows the algorithm for treatment of smear-positive 
patients in both the pilot and the non-pilot group. Most default occurred after two months and 
therefore, for this analysis, this was the time estimated for all defaulters. As taken from Murray, 
Styblo and Rouillon, (1993) after two months, 40% of defaulters were assumed uncured for SCC and 
70% of defaulters were assumed uncured for SDR.
Most treatment results are a reflection on the ability of SCC to decrease default. Default rates in 
this study were much higher for SCC and much lower for SDR than past studies (Murray et al., 1991; 
Arandottir, 1993; Kamolratanakul, 1993). However, this is an unusual case where both of these 
studies were performed in the same environment. As suspected in Murray et al (1991) and 
Kamolratanakul (1993) where SCC results appeared to be taken from a very controlled atmosphere, 
likely to have been run by an NGO and then compared to an SDR programme that was run on a wider 
scale for a longer time by each country's ministry of health. Unlike these, results for SCC and SDR 
came from a programme implemented in the same area, in identical facilities by the same body. 
Hence, cure rates are closer.
8-3:10 Costs
Costs of both the pilot and the non-pilot treatments were calculated from all stages of treatment 
and diagnosis. Costs included variable costs, such as labour, supplies, stationary and drug costs, and 
fixed costs, such as equipment and buildings. Costs were derived from the laboratory costs, drug 
costs, nursing time, doctor time, technician time, pharmacist time, administration time, screening costs 
and administration. As is illustrated in Table 8-12 treatment costs were divided into categories. 
Screening costs were calculated from the fact that only approximately 10% of 15 040 of those screened 
actually had TB and approximately half of these were smear-positive (See Appendix B for a more 
thorough description of costs). Indirect costs represent the total cost of death from lost earnings, 
assuming an average age of 27 and a daily wage of 3 birr. This was thought to be a fair assessment 
because a proportion of patients were employed. Of 201 recorded patients at K19, 32% were 
employed whereas 68% were unknown. The cost in lost earnings were subsequently expressed as 
indirect costs in the total cost of deaths. The average incremental cost was estimated as the sum of 
variable and fixed costs divided by the total number of patients treated.
All but one serious drug reaction proved to be exfoliative dermatitis to thiacetazone rather than 
other adverse reactions, (one case was isoniazid hepatitis). For this reason, in the analysis, all drug
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reactions were assumed to be reactions to thiacetazone in TB450. The cost of drug reactions was 
calculated from the cost of prednisolone and chlorpheniramine treatment, the cost of switching over a 
patient to HE instead of TB 450, and the cost of hospital treatment in approximately 33% of cases. 
This value was then multiplied by the number of drug reactions and then divided by the total number 
of patients cured.
8-3:10a Overview of Costs
In looking at Table 8-13 of costs, one can note that the highest cost is from death, however, a 
high proportion of costs are determined by labour, screening and drugs. Because of daily streptomycin 
injections for the first two months and the fact that there are nurses and health assistants who solely 
work in tuberculosis, labour costs are high. In addition, is the cost of screening per smear-positive 
patient. These costs reflect that only approximately 10% of those patients screened for tuberculosis 
actually have the disease and even fewer are smear-positive. Finally, as mentioned before, the major 
differences in costs between treatments are dependent on the cost of each drug regimen and the cost of 
retreatment for defaulters. Variables that will be the primary determinants of the cost-effectiveness of 
each will depend on drug costs and rates of default.
8-3:11 The Impact of TB Resistance on the Cost of TB treatment
All smear-positive defaulters either remain infectious, die or seek retreatment. In this analysis, it 
was assumed that all defaulters would seek retreatment. Defaulters were assumed to be isoniazid 
susceptible so that TB450 could be used in their retreatment regimen. The cost of H-susceptible 
retreatment was 434.55 birr in drugs making a total cost of 790.69 birr. Therefore, retreatment costs 
were calculated by multiplying the cost of retreatment per patient with the number of defaulters and 
dividing this by the number of patients cured.
For the non-pilot group, no bacteriologically positive cases were found, but 5 cases (1.45%) in 
the pilot group were BAC+. This is possibly because of the fact that some chronic cases do not always 
reveal the fact that they have received prior treatment, and since until recently, record keeping was less 
than ideal, these patients' treatment is difficult to document. Chronic cases are usually defaulters who 
begin treatment and then stop it when they feel better. Hence, these cases can move from facility to 
facility receiving some treatment and then disappearing (for instance to the country), only to reappear 
when their TB again becomes a problem. There is also the potential for chronic patients to be 
incorrectly referred to SCC instead of a retreatment regimen. In addition, the smear-positive sample in 
the pilot region was over twice the size of the non-pilot region, partially accounting for the fact that 
more resistant cases were found.
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Retreatment costs for bacteriologically positive patients were estimated by multiplying the cost 
per case of retreating BAC+ cases with the number of BAC+ patients and subsequently dividing this 
figure by the number of patients cured. Those who were bacteriologically positive were assumed to be 
at least resistant to isoniazid because of repeated supervised treatment with no result. The cost of 
treating these drug resistant patients was higher than H-susceptible treatment due to the fact that more 
expensive drugs had to be used. The cost of the H-resistant retreatment regimen was estimated to be 
603.38 birr in drugs and 959.52 birr in total cost. The treatment of these patients included 90 days of 
R, H, Z, E and S and then continued with R, H and E for a further 64 days. H-susceptible retreatment 
drug regimens cost 60% more than SCC. However, more significantly, the cost of and H-resistant 
regimens cost 378.05% of SDR and 228.29% of SCC. Hence, in terms of drugs costs, for every one 
resistant TB case that is treated, 3.78 SDR patients and 2.28 SCC patients could be treated. In terms of 
total treatment, excluding screening and fixed costs, 5.70 SDR patients and 3.52 SCC patients could be 
treated for the cost of treating one drug-resistant patient. In some cases, not only are more drugs 
required, but more expensive drugs are required, depending on the drug that a patient's TB becomes 
resistant to. In many cases, regimens in Ethiopia use cheaper drugs such as thiacetazone, streptomycin 
and isoniazid to treat susceptible cases, leaving only more expensive drugs to treat resistant TB cases.
In addition to this are the costs from past treatment where TB resistance originated (assuming 
secondary resistance) and costs from increased deaths from resistant TB cases. The time a patient 
stops treatment and develops resistance is variable as is the number of treatment regimens that he or 
she receives before developing resistance. However, assuming a patient defaults from treatment after 
two months and then must receive a retreatment regimen, the cost of treating this patient not only 
includes the retreatment regimen, but also the forgone costs of the initial treatment when the patient 
was first diagnosed. For this case, forgone drug costs of the initial treatment would be an extra 147 
birr for SDR and 258 birr for SCC.
It is difficult to assess the death rate from resistance to various drugs, but it is known that 
combined resistance to R and H has a 40-60% death rate associated with it according to Bloom and 
Murray (1992). Assuming a 50% death rate from multi-drug resistance, if in this study there was the 
hypothetical scenario where all cases were multi-drug resistant, the total cost of death would become 
7.75 and 8.91 times the total cost of death observed from susceptible SDR and SCC cases in this study 
(SDR: [(155/2)44844]/448440 = 7.75) (SCC: [(344/2)44844]/941724 = 8.91).
In summary, the impact of each resistant case is such that it raises TB treatment cost to at least 
3.52-5.70 times the treatment of susceptible TB, depending on the regimen it is compared to (SCC or 
SDR). This is because of the fact that treatment of TB resistance requires more drugs, more resources 
and more time.
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Table 8-12: A Breakdown of Costs for SDR and 
SCC in the Non-Pilot and Pilot Areas (in Ethiopian Birr)
Type of Cost SDR SCC
Screening Costs/Smear+ Patient
microscopy cost 53.49 53.49
lab technician 14.1 14.1
x-ray cost 150 150
x-ray technician 1.88 1.88
x-ray machine 1.71 1.71
Total Cost per Successfully Screened Smear+ Patient 221.18 221.18
Total Screening Costs of Treatment Sd=34282.9 S=60382.14
Variable Costs per Patient (excluding screening)
microscopy 3.08 2.33
drugs Pd=159.6 P=264.3
printing formats 1.64 1.64
& registration books
stationary 2.26 2.26
telephone 0.45 0.45
electricity 0.75 0.75
water 0.45 0.45
Total Variable Costs per Patient 168.23 272.18
Total Variable Costs of Treatment Vd=26075.65 V=74305.14
Fixed Costs per Patient (excluding screening)
microscope 0.82 0.82
labour 41.08 40.14
administration 3.40 3.89
pharmacy administration 0.49 0.49
building cost per patient 2.23 2.23
Total Fixed Cost Per Patient 48.02 47.08
Total Fixed Costs of Treatment Xd=7443.1 X=12852.84
Direct Costs (including screening) per Patient 437.43 540.54
Cost Per Death in Lost Earnings 44 844.00 44 844.00
Total Death Cost for all Deaths Ddc=448440 Dc=941724
Cost of Retreatment for Defaulters
Drug Cost 434.55 434.55
Total Cost per Retreatment 790.69 790.69
Total Retreatment Costs for all Retreatment Cases Md=26092.77 M=15023.11
Retreatment for BAC+ (Resistant) Cases
Drug Cost 603.38 603.38
Total Cost of Retreatment for BAC+ 959.52 959.52
Total Retreatment Costs for all BAC+ Cases Bdc=0 Bc=4797.6
Cost of Drug Reactions
Hospitalisation Cost/Treatment
HE Drug Substitution Cost 1140.75 1140.75
4.08 2.04
(1140)(2.31) (1140X8.58)
Total Cost of All Hospitalised Drug Reaction Cases Rhd=2635.13 Rh=9787.64
(4.08)(7) (2.04)(26)
Total Cost of All HE Drug Substitution Cases Bhed=^®,56 Rhe=53.04
TOTAL COST OF TREATMENT Csdr=544998.11 CSCC=1118925.51
(Including Costs from Default, Death, BAC+ and Drug
Reactions)
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8-3:12 Cost-Effectiveness of Treatments
8-3:12a Cost per Cure
The average total cost per cure when using each treatment's respective cure rates, was estimated 
to be 5190.46 birr (US $798.53) for SDR and 4098.63 birr (US $630.56) for SCC These were 
calculated from all costs to treatment, and then divided by the number of patients that were cured. The 
difference between these two ratios represents a 1091.83 birr (US $167.97) difference in cost per cure.
8-3:12b Cost per Death Averted
Data on individuals who have not received treatment before in the modem age in developing 
countries are sparse. Hence, the cost per death averted was estimated using data from an article by Fox 
(1990) in India, where 50% of those who never received treatment died. The actual death rate that 
occurred with treatment in this study was then subtracted from this value in order to obtain the total 
amount of deaths averted as shown in the following equations for cost per death averted for SCC 
(CDAscc) and cost per death averted for SDR (CDAsdrY-
CDAscc Tscc
[(.50)(L)]-D„
Where:
Tscc =Total cost of treating all SCC patients 
L =Total Patients Treated 
D =Number of patients that died in the SCC sample
CDASDR
______ Tsdr______
[(O.SOXLJJ-D^
Where:
Tsdr =Total cost of treating all SDR patients 
Lj =Total Patients Treated
Dsdr =Number of patients that died in the SDR sample
Hence, from this, the cost per death averted was estimated to be 8074.05 birr ((544998.11 )/(77.5-10)) 
or $1242.16 US dollars for SDR and 7410.10 birr ((1118925.51)/(172-21)) or $1140.02 US dollars for 
SCC. The difference in cost per death averted between SCC and SDR is 663.95 birr or US $102.15.
If the hypothetical situation arose whereby all cases were multi-drug resistant, assuming all other 
variables are held constant, this same analysis above could be used when considering averted deaths
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from multi-drug resistance through correct treatment because of the same survival rate associated with 
both no treatment and multi-drug resistant TB. If the patient develops multi-drug resistance (resistance 
to both H and R) using a 50% death rate from Bloom and Murray (1992) (the same as untreated TB) 
one can see that the cost per TB deaths from multi-drug resistance averted through properly 
implemented SCC and SDR is also approximately 248.61 birr and 663.95 birr, respectively.
8-3:12c Cost per Total Death Averted, Including Transmission
This is the amount of death that would occur if all smear-positive cases in this study were to
remain untreated and continue to infect others. According to Murray et al. (1991), each smear-positive 
case will go on to cause 5.6 deaths and 3.8 discounted deaths over a cycle of 18.5 years. The number 
of patients (defaulters) that would remain uncured and infectious for each treatment was calculated and 
multiplied by 3.8 and then subtracted from 3.8 times the number of patients that would have 
hypothetically remained infectious without treatment (subtracting those who died in the sample). To 
this was added the number of deaths in the sample that were averted (from the previous paragraph). 
Hence the equations used for calculating cost per death averted for SCC (CDAtscc) and cost per death 
for SDR (CDAtSDR) were the following:
CDA„=[(W-Dl„)(3.8)]-[3.8Fra] + r^F3^
Where:
N =The number of patients cured
Dscc =the number of patients that died in the SCC sample 
Fscc =the number of patietns that defaulted in the SCC sample 
Tscc =the total cost of treating all patients in the SCC sample 
L =the total number of patients treated
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=[(iV-D,J(3.8)]-[3.8^] + [(o
Where:
N =The number of patients cured
Dsdr =the number of patients that died in the SCC sample
Fsdr =the number of patients that defaulted in the SCC sample
T$dr =the total cost of treating all patients in the SCC sample
L =the total number of patients treated
According to this, in the non-pilot programme, there would be 493.1 total deaths averted and in the 
pilot programme, there would be 1306.20 total deaths averted. From this, the total cost per total death 
averted is 1105.24 birr (544998.11/493.1) (US $170.04) for SDR and 856.63 birr 
(1118925.51/1306.20) (US $131.80) for SCC.
8-3:12d Cost per Life Year Saved in the Non-Pilot and Pilot Samples
The cost per life year saved was difficult to calculated due to difficulty in establishing a life 
expectancy for each year of life. Life expectancy is estimated to be between 46 and 53.4 years at the 
age of birth in Ethiopia in 1992 (World Bank, 1993; Cross and Millar, 1994; Transitional Government 
of Ethiopia, 1992). For this analysis, it was estimated that by 1994, the life expectancy at birth would 
be at least 53.
The cost per life year saved was calculated for each treatment according to the potential years of 
life lost (PYLL), standard expected years of life lost (SEYLL) and the period expected years of life lost 
(PEYLL). Three approaches were used because no one method seemed to be ideal for the calculation. 
Cohort expected years of life lost could not be calculated due to problems in getting specific data on 
cohort age groups of those in Ethiopia. For the PYLL and the PEYLL methods, a potential life 
expectancy of 53 was used based on lower past estimates by the World Bank and other sources from 
1992 (See Table 8-14 for a comparison of life years lost without treatment according to different 
methods).
With the PYLL method the cost per life year saved was calculated using a fixed life expectancy 
of 53 for both the pilot and non-pilot area. For the pilot area, a total of 3790 years of life were saved 
and in the non-pilot area, 1488 years of life were saved. From this, the cost per life year saved was 
295.23 birr (US $45.42) for the pilot area and 366.26 birr (US $56.35) for the non-pilot area. SCC is 
71.03 birr (US $10.93) less than SDR per life year saved according to the PYLL method.
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Table 8-13: Derivation of an Ethiopian Model Life-Table
Age Female Age 
Fraction from 
West Level 26
(A)=Life 
Expectancy @ 
Age/82.5
Male Age 
Fraction 
From West 
Level 26 
(B)=Life 
Expectancy @ 
Age/82.5
Female
Ethiopian Life 
Expectancy 
Fraction From 
Graph 
(C)
Ethiopian Male 
Life
Expectancy 
Fraction 
From Graph
(D)
Female 
Ethiopian Life 
Expectancy 
(E)=(C)(53)
Male Ethiopian 
Life Expectancy 
(F)=(D)(53)
0 0.000 0.000 1.000 1.000 53.000 53.000
1 0.012 0.013 0.992 0.992 52.576 52.576
5 0.061 0.063 0.945 0.942 50.077 49.939
10 0.121 0.125 0.885 0.880 46.891 46.64
15 0.182 0.188 0.824 0.818 43.698 43.334
20 0.242 0.250 0.765 0.755 40.524 40.041
25 0.303 0.313 0.705 0.693 37.370 36.749
30 0.364 0.375 0.646 0.631 34.222 33.463
35 0.424 0.438 0.586 0.570 31.080 30.183
40 0.485 0.500 0.528 0.508 27.965 26.924
45 0.545 0.563 0.469 0.447 24.875 23.698
50 0.606 0.625 0.412 0.387 21.836 20.531
55 0.667 0.688 0.356 0.329 18.868 17.437
60 0.727 0.750 0.301 0.273 15.951 14.449
65 0.788 0.813 0.248 0.219 13.131 11.594
70 0.848 0.875 0.196 0.170 10.407 8.997
75 0.909 0.938 0.149 0.127 7.889 6.738
80 0.970 1.000 0.108 0.093 5.718 4.936
By using the SEYLL method, life lost due to premature death from tuberculosis in the pilot and 
non-pilot group was found. Years of life lost were calculated by multiplying life expectancy and then 
subtracting the year of premature death, using increments of 5 as a midpoint. According to the SEYLL 
method of calculating life lost due to premature death, tuberculosis in this sample was responsible for 
3824.61 male and 4051.97 female years of life saved, making a total of 7876.58 years of life saved by 
SCC. In the non-pilot group, 2015.52 male and 1184.99 female years of life saved gave a total of 
3200.51 years of life saved by SDR. This is assuming a 50% death rate from tuberculosis without 
treatment. From this, the cost per life year saved for SCC is 142.06 birr (US $21.85) and the cost per 
life year saved for SDR is 170.28 (US $26.20): SCC is 28.22 birr (US $4.34) less per life year saved 
according to the SEYLL method.
Since there is no current life table specific to Ethiopia, in order to use the PEYLL method, a table 
had to be derived as shown in Table 8-13. The table was derived by condensing the West Level 26 
table to correspond to a life-expectancy of 53. There are undeniably inconsistencies between this table 
and the morbidity patterns experienced in Ethiopia. Child mortality, for instance, would be much 
higher than that experienced in many industrialised countries. Nevertheless, in absence of data on life 
expectancies at each age, this table is the closest representation of the premature burden of death in 
Addis Ababa because it takes into account the life years lost from the elderly.
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Table 8-14: Total Life Years Lost Without Treatment According to PYLL, SEYLL and 
PEYLL Methods of Calculating Years of Life Lost Due to Premature Mortality
Area PYLL
All
SEYLL
Males
SEYLL
Females
PEYLL
Males
PEYLL
Females
Pilot
Died/ Defaulted 
/Drug Reactions 
/Bac+
2449.000 2791.070 2467.450 1762.846 1463.217
Cured 6607.000 6345.59 7212.360 4088.399 4718.049
Total 9056.000 9136.660 9679.810 5851.245 6181.266
Non-pilot
Died/ Defaulted 
/Drug Reactions 
/Bac+
1501.000 1927.850 1368.130 1310.661 878.917
Cured 2252.000 3152.870 1619.000 2088.750 994.454
Total 3753.000 5080.720 2987.130 3399.411 1873.371
Using the derived Ethiopian model life-table in Table 8-13, the cost per period expected life year saved 
was derived (See Appendix E for the derivation of this model life-table). In the pilot region, 2449.33 
male and 2587.36 female years of life formed a total of 5036.81 years of life saved. In the non-pilot 
region, 1348.55 male and 743.17 female years of life formed total of 2091.72 years of life saved. With 
these values, the cost per period expected life year saved was 222.15 (US $34.18) for the pilot area and 
260.55 (US $40.08) for the non-pilot area. The difference between these cost per life years saved is 
38.40 birr (US $5.91).
8-3:13 Summary of Cost-Effectiveness Ratio Results
In all cases, cost-effectiveness ratios for SCC were observed to be lower than SDR. As observed 
in Table 8-15, the largest difference in cost-effectiveness was in the cost per cure followed by the cost 
per death averted. Cost per life year saved ratios varied between 28.03 and 70.57 according to the 
method used to measure life years lost due to premature mortality. Difference were attributed to the 
fact that the number of life years saved in the SEYLL method produced the most years of life lost, 
followed by the PEYLL method and the PYLL method. All these results, except for the cost per total 
death averted, were not discounted because tuberculosis treatment is an intervention where the benefits 
and costs occur immediately.
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Table 8-15: A Summary of Cost Effectiveness Between SDR and SCC (Ethiopian Birr)
Cost-Effectiveness Measure SDR SCC Difference More Cost- 
Effective 
Regimen
Average Total Cost per Cure
Excluding Cost of Deaths
5190.46 birr 4098.63 birr 1091.83birr
US$167.97
SCC
Total Cost per Death Averted
Per Death 8074.05 birr 7410.10 birr 663.95 birr SCC
US$102.15
Per Total death (including Indirect
Death from Smear-Positive Transmission)
1105.24 birr 856.63 birr 248.61 birr
US $38.25
see
Cost per Life Year Saved of Entire Smear­
positive Group
Potential Years of Life Lost (PYLL) 366.26 birr 295.23 birr 71.03 birr SCC
US $10.93
Standard Expected Years of Life Lost (SEYLL) 170.28 birr 142.06 birr 28.22 birr SCC
US $4.34
Period Expected Years of Life Lost (PEYLL) 260.55 birr 222.15 birr 38.40 birr SCC
US $5.91
8-3:14 Incremental Analysis
A summary of incremental cost-effectiveness ratios are shown in Table 8-16. The differences in 
cure rates including drug reactions were 11.6% and the difference in total cost was 573927.39 birr. 
The average cost per patient was 3516.12 for SDR and 3252.69 for SDR. With an incremental 
analysis, the incremental cost for SCC was estimated to be 3416.23 birr (573927.39/168). This means 
that each extra cure from the short course regimen costs 3416.23 bin (US $525.57). Incremental cost 
per death averted of SCC over SDR is 6873.38 (573927.39/83.5); (US $1057.44) and per extra total 
death averted of SCC over SDR is 705.85 birr (573927.39/813.1); (US $108.59). The incremental 
cost according to the PYLL method is 249.32 birr (573927.39/2302); (US $38.36), according to the 
SEYLL method is 122.74 birr (573927.39/4676.07); (US $18.88) and according to the PEYLL method 
is 194.88 birr (573927.39/2945.09); (US $29.98).
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Table 8-16: Incremental Cost Effectiveness of SCC over SDR
Measure Incremental Cost
Incremental cost per cure 3416.23 birr/US $524.28
Incremental cost per death averted 6873.38 birr/US $1057.44
Incremental cost per total death averted 705.85 birr/US $108.59
Incremental cost per PYLL 249.32 birr/US $38.35
Incremental cost per SEYLL 122.74 birr/US $18.88
Incremental cost per PEYLL 194.88 birr/US $29.98
8-3:15 Sensitivity Analysis
In order to find the sensitivity of these cost-effectiveness results, the cost per cure threshold 
values were found using the programme Mathcad®, holding all other variables constant using both the 
equations for calculating the cost per cure ratio for SCC,
rF _S + V + X + Dc + M + Rhe + Rh + Bc 
scc L(l.Q-[D +F + B + R])
Where:
S =Total Screening Costs for All patients
V =Total Variable Cost for All Patients
X =Fixed Cost for All Patients
Dc =Total Cost of Deaths
M = Total Retreatment Cost for all Defaulters
Bc =Total Retreatment Cost for All Bac+ Cases
Rhe =Total HE Replacement Cost for all Drug Reaction Cases 
Rh =Total Cost for all Drug Reaction Cases that Required Hospitalisation 
L =Total Number of Patients Treated
D =Death Rate
F =Default Rate
B =Bac+ Rate
R =Drug Reaction Rate
and the cost per cure ratio for SDR
CEvnB = + + Ddc + Md + Rhed + Rhd + Bcd
L^-O-lD. + F. + B^R,])
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Where:
Sd =TotaI Screening Costs for AH patients
Vd =Total Variable Cost for All Patients
Xd =Fixed Cost for All Patients
Dcd =Total Cost of Deaths
Md = Total Retreatment Cost for all Defaulters
Bcd =Total Retreatment Cost for All Bac+ Cases
Rhed =Total HE Replacement Cost for all Drug Reaction Cases
Rhd =Total Cost for all Drug Reaction Cases that Required Hospitalisation
Ld =Total Number of Patients Treated
Dd =Death Rate
Fd =Default Rate
Bd =Bac+ Rate
Rd =Drug Reaction Rate
Table 8-17: Actual Values and Threshold Variables 
for SCC and SDR in the Pilot and Non-Pilot Areas
Variable Actual Value for 
SCC
Threshold Values 
for SCC*
Actual Value for 
SDR
Threshold Values 
for SDR**
Total Screening Costs for All 60382.14 <358451.72 34282.9 >-80359.24
patients
Total Variable Cost for All Patients 74305.14 <372374.72 26075.65 >-88566.49
Fixed Cost for A11 Patients 12852.84 <310922.42 7443.1 >-107199.04
Total Cost of Deaths 941724 <1239793.58 448440 > 333797.86
Total Retreatment Cost for all 15023.11 <313092.69 26092.77 >-88549.37
Defaulters
Total HE Replacement Cost for all 53.04 <298122.62 28.56 >-114613.58
Drug Reaction Cases
Total Cost for all Drug Reaction 9787.63 <307857.22 2635.13 >-112007.01
Cases that Required Hospitalisation
Total Retreatment Cost for All 4797.6 <302867.18 0 >-114642.14
Bac+ Cases
Death Rate 0.0610 <0.2278 0.0645 >-0.1158
Default Rate 0.0552 <0.2220 0.2129 > 0.0326
Bac+ Rate 0.0145 <0.1810 0.0000 >-0.1803
Adverse Drug Reaction Rate 0.0759 <0.2427 0.0452 >-0.1350
♦Values for SCC must remain smaller (<) than these threshold values to maintain cost-effectiveness conclusion 
♦♦Values for SDR must remain greater (>) than these threshold values to maintain cost-effectiveness conclusion
In the case of SCC, once variables increase above these threshold variables, SCC will no longer 
be more cost-effective. Likewise, once values for SDR decrease below the SDR threshold variables, 
the cost-effectiveness ratio will no longer be valid. As is depicted in Table 8-17, threshold values for 
SDR are implausible for all but the cost of death per patient cured and the rate of default. For SCC, the 
only variable that is close to its threshold value is the total cost of deaths (difference of 296 245). The
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SCC death rate, default rate, BAC+ rate, and the drug reaction rate must rise by approximately 16.64% 
in order to shift the cost-effectiveness ratios to favour SDR in cost-effectiveness.
In order to look at the sensitivity of the cost-effectiveness ratios of both SCC and SDR, these 
respective variables are compared to those used to calculate cure rates in other studies (Murray et al., 
1991; Kamolratanakul, 1993; and Amadottir, 1992). In these studies, the highest death rate for SCC 
was 6.5% whereas the lowest was 1.5%, well within the range of sensitivity shown in Table 8-17. For 
bacteriologically positive cases, the range was 1.3% to 2.4% from other studies, also placing the value 
in this study well within the range of SCC sensitivity shown in Table 8-17 Side effects for SCC could 
only be obtained from one study (Thailand) and it was 25%, whereas the value in this study was only 
7.59%. However, values above the threshold value of 24.27% for drug reactions would make this cost- 
effectiveness ratio no longer valid, if all other variables were held constant. The rate of default found 
in differing studies ranged between 2.2% and 25%. As the SCC rate of default in this study needs to 
rise above 22.20% to no longer be cost-effective, a 25% default rate would make the cost-effectiveness 
ratio of SCC more than SDR. For SDR, the only cure rate variable that its cost-effectiveness ratio 
could possibly be sensitive to was the default rate. Ranges for the literature place default at between 
15.7% and 73%. As the threshold value for SDR default must fall below 3.26% to become more cost- 
effective than SCC and the actual default rate was 21.29%, this is considered well within the limit of 
the given range from the literature. The rate of default in patients for both the SCC and SDR sample as 
a function of cost per cure are shown in Figure 8-20.
Figure 8-20: Default of SCC and SDR as a Function of Cost-Effectiveness
Percent Default
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In looking at costs, it was estimated that the cost of death was the variable that this analysis was 
the most sensitive to, perhaps because it is so large in comparison to the other costs. The cost- 
effectiveness ratio of both SDR and SCC were perceived to be sensitive to changes in the total cost of 
deaths. The function for the cost of death as a function of cost per cure are shown in Figure 8-21 for 
SCC and Figure 8-22 for SDR. In these figures, the influence of cost of death on the cost per cure are 
illustrated. Nevertheless, the cost for each patient who died was the same for both SCC and SDR and 
considering that the death rates were the same, it is unlikely that different calculations of the cost per 
death will change the overall analysis considerably. Substantiating this, the cost per cure excluding the 
cost per death, was 649.09 birr for SCC and 919.60 for SDR. Hence, even without the cost per death, 
SCC still is more cost-effective than SDR. This is significant because there is the argument that the 
cost of death of an Ethiopian is not worth a day labourer's wages lost from the time of premature death 
to life expectancy.
Figure 8-21: Cost of Death as a Function of SCC Cost-effectiveness (CE)
Cost of Death
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Figure 8-22: Cost of Death as a Function of SDR Cost-effectiveness (CE)
Cost of Death
The cure rate variables for SDR are considered on the low end of the possible range of variables 
in the literature. Death rates, default rates, and failure rates are all low. Likewise, for SCC, the cure 
rate variables are considered to be on the high end of the range of variables in available literature, and 
indeed, death rates, default rates and failure rates all prove to be high. However, for the rate of adverse 
drug reactions, both SDR and SCC have relatively low rates compared to the reported rates of 
approximately 18-25% in available literature (Kelly et al, 1994: Kamolratanakul et al., 1993). These 
values are primarily dependent on HIV and the amount of substitution in HIV patients of ethambutol 
for thiacetazone. Since both regimens in this study use thiacetazone, and most reactions occur within 
the first two weeks, the rate of drug reactions for both regimen should logically be the same. 
Excluding the cost of drug reactions and the rate of drug reactions experienced, cost per cure becomes 
4863.95 for SDR and 3877.45 for SCC. It can only be surmised, but it is possible that there were more 
HIV patients in the pilot group because of the higher rate of drug reactions. It should be noted that 
including drug reactions, the cost-effectiveness ratios between these two treatments still finds SCC 
more cost effective, even when drug reactions to it are higher. This is extremely relevant for the future 
when the rate of TB/HIV co-infection is expected to rise.
The possibility of a false-positive diagnosis has not been discussed so far in this analysis because 
it could not be measured. It should be noted that more often than not, there would be a high proportion 
of false negatives due to the fact that patient often give saliva rather than sputum. However, although 
this phenomenon occurs making case detection low, estimates on this are completely unavailable. In 
contrast, false-positive diagnosis suggest that a patient is incorrectly diagnosed and then treated for TB 
when he or she does not have the disease. Assuming, for instance, that 5% (as observed by Murray et 
al. , 1991) of those diagnosed and cured were false positive, leaving 13.75 needlessly treated patients
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in the SCC sample and 5.25 patients needlessly treated in the SDR sample, cost-effectiveness for false 
positive diagnosis can be calculated for SCC with:
rp _ 13.75(s + v + x) + C 
SCCfr - —N_13>75
Where
s =screening cost per patient successfully screened in SCC sample 
v =variable cost per patient in SCC sample 
x =fixed cost per patient in SCC sample 
N =total patients cured in SCC sample 
C =total cost of SCC
and for SDR:
CE,SDRfp
5.25(sd + vd + xd^ + Cd 
Nd-5.25 ’
Where:
Sd =screening cost per patient successfully screened in SDR sample 
Vd ^variable cost per patient in SDR sample 
xd =fixed cost per patient in SDR sample 
Nd =total patients cured in SDR sample 
Cd =total cost of SDR
This raises the cost per patient cured by SDR to 5548.66 and the cost per patient cured by SCC to 
4335.27.
The cost per cure when only considering the drugs, the major predictor of the difference in costs 
between treatments, was also calculated. The cost per patient for drugs was 159.6 (US $24.55) for 
SDR and 264.30 (US $40.66) for SCC, making a difference of 104.7 (US $16.10) in drug cost per 
patient. When only drug costs were calculated, excluding screening costs, all other variable costs, 
fixed costs and costs of death, the cost per cure for SCC was 441.69 birr (US $67.95) and for SDR, 
509.47 birr (US $78.38). The difference between these values in treatment is 61.10 birr (US $9.4).
It was assumed in this analysis that all defaulters would seek retreatment. In actuality, some 
would seek retreatment, some would continue to infect others and some would die. Since the cost of 
death and the cost of treating those subsequently infected with TB is so much higher than retreatment 
costs, and since there are so many more defaulters in the SDR group, a change in this assumption is not 
estimated to affect the conclusion that SCC is more cost-effective than SDR.
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Another estimate was that all patients were diagnosed in hospital. It was difficult to measure 
this, but in actuality, only 80-90% are thought to be diagnosed in hospital, the other 10-20% are 
diagnosed in the health centres. This might affect the overall screening costs, decreasing them slightly. 
However, screening costs are identical for both the SCC and the SDR regimen and since screening 
costs for SCC have to rise above 358451.72 birr or those for SDR have to drop below -80359.24 birr to 
nullify SCC's better cost-effective ratio, the cost-effectiveness ratio is not sensitive to changes in this 
assumption. With the removal of screening costs, the cost per cure ratio was 4863.95 for SDR and 
3877.45 for SCC (See Table 8-18 for a summary of sensitivity measures).
A possible bias in this study might have developed from the small sample size of SDR compared 
to the size of the SCC sample. The sample size of SDR proved to be smaller because the programme 
had a longer treatment period and had been started later than the SCC programme. Data from before 
the non-pilot project was started would definitely suggest that SCC was more cost-effective because 
cure rates ranged from 20-50% at most. Nevertheless, to preserve the integrity of this study, patient 
results from a similar environment were used. Indeed, both programmes were new, both programmes 
occurred in the same environments and in the same area.
8-3:15a Sensitivity of Cost per Cure Ratios to Resistance
The assumption was made that all retreatment cases after default would be isoniazid sensitive 
and all BAC+ cases would be isoniazid resistant. Although unlikely, if all BAC+ cases were actually 
H-susceptible, this would decrease the cost of SCC because of the use of the H-susceptible retreatment 
regimen. However, considering the current amount of BAC+ cases, this would have a very 
insignificant impact on the cost per cure for SCC.
A range for bacteriologically positive cases of 1.3% to 2.4% was found from other studies 
presented in Chapter 6. This places the value in this study well within the range of SCC sensitivity as 
shown in Table 8-17. Costs for resistant cases of SCC must rise above 302867.18 birr for the SDR 
cost per cure to be less than SCC. The BAC+ rate, or assumed resistance rate must rise above 18% in 
order for SDR to become more cost-effective However, this is assuming that resistance is not 
occurring to drugs in the SDR regimen (also contained in the SCC regimen).
There is the possibility that a proportion of defaulters will develop resistant TB because of their 
receiving intermittent therapy. If all retreatment cases were drug resistant and had to be given the 
more expensive H-resistant regimen, this would increase the cost of SDR over SCC, since there are far 
more defaulters in this group. When all SCC and SDR retreatment cases are resistant, retreatment 
costs rise 21%. In addition, the cost per cure ratios for SCC change to 4111.38 birr from 4098.63 birr 
and for SDR change to 5243.52 birr from 5190.46. Hence, cost per cures rise 3.11% for SCC and
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1.02% for SDR. Hence, it can be seen that changes in retreatment assumptions have some impact on 
these respective cost-effectiveness ratios. However, changes in retreatment assumptions in this 
analysis have little impact on the conclusions of the cost-effectiveness analysis of these two treatments 
in this study. Hypothetically, if resistance were to rise significantly, this would start to have 
substantial consequences on the cost of treatments and possibly on the cost-effectiveness ratios of these
treatments.
Table 8-18: A Summary of Sensitivity Measures
SCC SDR More Cost-Effective 
Regimen
Minus Total Death Costs 649.09 919.601 SCC
Minus Total Screening Costs 3877.45 4863.95 SCC
Minus Drug Reaction Costs 4099.69 4842.14 SCC
Looking at Drug Costs (minus 
total screening, variable, fixed 
and death)
441.69 509.47 SCC
With a False Positive Diagnosis 
of 5%
4335.27 5486.66 SCC
If all Retreatment Cases Prove H- 
Resistant
4110.38 5243.52 SCC
8-3:15b Summary of Sensitivity Analysis
SCC proves to be cost effective in all relevant instances when parameters of the study are 
changed. Both SDR and SCC could be sensitive to changes in the cost of death if they were to differ 
from each other. For SDR, the only plausible cure rate variable that could affect these results was the 
default rate and it was not considered sensitive to changes as its threshold value is so very low that it is 
unlikely that it could be achieved. SCC could possibly be sensitive to large changes in the default rate 
and the drug reaction rate, but this is unlikely. Looking at costs, the SCC cost per cure remains more 
cost-effective even with the elimination of screening costs, death costs, and drug reaction costs. It also 
remains more cost-effective when there is a 5% false positive diagnosis, when eliminating death costs, 
screening costs, fixed costs and all variable costs except for drugs, and it when retreatment cases are 
isoniazid resistant.
8-3:16 Summary of Cost-Effectiveness
The improvements of SCC over SDR on the cure rate is primarily a function of the high default 
rate experienced in SDR. Because of this high default rate and the cost associated with it, it is likely 
that SDR will continue to have a higher cost per cure associated with it. Nevertheless, efforts to
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maintain case holding have been effective, even in SDR. By standardising treatment, increasing 
efforts of defaulter tracing and implementing an effective NTP programme, this programme in Addis 
Ababa has produced amazing results. Looking at data from the Arsi project in 1992 in Table 8-19, one 
can see that default rates were 25% and 72% for SCC and SDR respectively, making cure rates a 
sparse 66% for SCC and 18.1% for SDR. Likewise, default rates around this same time in Addis 
Ababa reached 80%. The administration and management of treatment has not only improved SCC 
treatment results, but also has improved SDR results.
Table 8-19: Results of SCC and SDR Treatment 
reported by Arnadottir's for the IUATLD in Ethiopia, 1992
SCC SDR
Total Treated 72 121
Total Cured 48 (66%) 22(18.1%)
Treatment Complete 2 (2.7%) 4 (3.3%)
Failure 1 (1.4%) 1 (0.8%)
Died 3 (4.2%) 1 (0.8%)
Lost 18(25%) 88 (72%)
Transferred 1 (1.4%) 5 (4.1%)
8-3:17 Discussion of Treatment in the Pilot and Non-Pilot Areas
8-3:17a Drug Reactions
Drug reactions to thiacetazone are predominant among the number of patients that experience 
drug reactions. For instance, the non-pilot area in the May 1994 Annual Review Report by Region 14, 
showed 65 total drug reactions so far and out of these, 5 (7.6%) were to Streptomycin, 1 (1.5%) was to 
Isoniazid, and 59 (90.77%) were to thiacetazone in TB450. According to the TB coordinator doctor at 
the Black Lion Hospital, most thiacetazone reactions occur within the first 14 days. Indeed, in a 
survey of thiacetazone reactions at St. Peter's Sanatorium, a large proportion of reactions occurred 
within the first 20 days. Unfortunately, because of the inexpensive nature of this drug, even the SCC 
regimen implements it.
HIV tolerance to thiacetazone has proven to be relatively low. In some studies, the percentages 
of drug reactions has been as much as 25% and in screened HIV patients, reactions in one study in 
Zambia (Kelly et al., 1994) reached 18.7%. If the cost of thiacetazone drug reactions rise enough, 
using this drug will no longer prove cost-effective, even though it is such an inexpensive drug. In this 
study, efforts to substitute ethambutol for thiacetazone in drug regimens for those suspected of HIV is 
probably the determining factor in the comparatively low rate of drug reactions in this study. Also, as 
these reactions are primarily associated with HIV , it is possible that fewer HIV cases in Ethiopia mean 
fewer drug reactions as compared to other African countries. Thiacetazone drug reactions are the 
significant problem in drug reactions to tuberculosis treatment. Should the rate of drug reactions rise
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so that their overall cost is greater than the cost of the regimens, then it will prove more cost effective 
to substitute ethambutol for thiacetazone in all regimens. The only other alternative would be to screen 
all patients for HIV, which would also prove costly.
8-3:17b Over-Utilisation of Secondary Care
The high numbers of patients diagnosed in hospitals reflects the patients' over-dependence on 
secondary care rather than on primary care, a pattern observed in other areas of health in Ethiopia. 
Treatment could be made cheaper and more cost effective if more patients were given the incentive 
(i.e. monetary) to seek diagnosis on the primary level as opposed to the secondary level. Indeed the 
benefits of this would be two-fold due to the lessened expense of primary care, as well as the cheaper 
smear microscopy method of diagnosing TB in the health centres rather than the blanket method of 
initially giving all patients x-rays, blood tests and smear microscopy in hospitals.
8-3:18 Health Centre Interviews
In all health centres surveyed, a tuberculosis coordinator was interviewed and a laboratory 
technician (where possible) in order to ascertain the approach to treatment in each health facility (See 
Appendix C for Health Centre Interviews). Laboratories are relatively basic, using a microscope and 
staining solutions to identify sputum positive samples (See Figure 8-23 and 8-24). For laboratory 
supplies, there were problems getting the diamond pencil, wire loop, and solution A and B (for bacilli 
analysis). There is also a problem in getting sputum samples from some patients who cannot produce 
them. In some cases, only saliva is given instead of sputum. Laboratory technicians keep a detailed 
laboratory register of sputum samples and sputum follow-ups. A proportion of technicians at the 
health centres visited were trained in Cuba during the Dergue regime.
Drug supplies in general were not a problem. Drugs were organised, often according to the 
supplier (MOH, Other External Aid, WHO), in a large room by the pharmacist (See Figure 8-25 and 8­
26). Some coordinators in the pilot area observed that ethambutol and rifampicin were difficult to 
obtain in some of the non-pilot areas. Since drugs had been made free for all patients approximately 
two months before treatment, they were observed to no longer be a problem in treatment. All those 
interviewed said that drugs were ordered from their last quarterly report and that drug needs were 
rising.
Another of the problems observed was the process of referral of patients from hospital. Some of 
those interviewed said that patients often arrived with wrong or incomplete information, or the wrong 
drug regimen prescribed for the referral area. Extremely critical patients arriving referred from the 
hospital was another problem. Dr. Yocabel at Kezanchez Health Centre said that sometimes patients
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arrive at the health centre on stretchers when the health centre has no beds to take care of these 
patients. In contrast, a doctor interviewed at Yekatit Hospital said that he was eager to get TB patients 
out of the hospital as quickly as possible because there is no isolation between most patients. In any 
given hospital, for some classes of treatment, there will be 20 people in one room, each with a different 
infectious disease (See Figure 8-27 and 8-28). A trip to the hospital might make one sicker than they 
were beforehand. Referring a patient back to a hospital was another problem. Sometimes there was no 
room, patients were HIV positive and therefore had less (unspoken) priority, or a patient would pay a 
large sum to travel to the hospital just to be told to come back the following day, which he or she could 
not afford in travel costs.
All patients who transferred to another area were given a referral note, however, those in their 
intensive phase were not given any treatment, but those in their continuous phase were given up to two 
months of treatment. Case finding was primarily passive, and the predominance of patients were 
referred from hospital. Patients often wait longer to be treated at a health centre because they are 
ignorant of their symptoms. One boy of 15 that I spoke to, who works in one of the main Italian 
shopping areas, has had a bad cough for more than two years. When I asked him if he had ever 
thought about having this treated, he said that he did not think he could afford it, nor did he know 
where he could be treated. He said that not only does he have a cough, but he suffers from night 
sweats. At 15, this boy was not more than five feet tall. If he did in fact have tuberculosis, he could 
have been treated free of charge at a local health centre. Another problem is that patients seek help 
from traditional healers before seeking care from a health centre. The man in Figure 8-29 and 8-30 is a 
traditional healer and he sold me what resembled a small mixture of dirt and pieces of bark that he 
claimed would help my 'TB' if I boiled it and drank it like tea twice a week. This is not to discount 
traditional healing, but there is no traditional cure for TB. Mohammed Abadir Mussee estimates that a 
large proportion of individuals seek care from traditional healers before approaching a recognised 
health facility.
Defaulter tracing usually consisted of the coordinator nurse giving the patient or person 
responsible for the patient a call, or calling a local administration centre in the area of a patient and 
having a worker from there go to the patient's house (many patients do not have telephones). A 
problem in defaulter tracing is the fact that patients who desperately want treatment give false 
telephone numbers and addresses. In some cases such as at K13, defaulter follow-up was poor because 
there was no coordinator nurse there. Dr. Kidist at this health centre observed that tuberculosis was 
not a popular area to work in because nurses were afraid of getting the disease, and although this was 
rare, the TB coordinator doctor at K18 could not be interviewed because she was being treated for TB. 
In other instances, such as Tekelehamanot, the coordinator Nurse Negassa was so good that he would
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walk to the house of the defaulter to find them. At Entoto, the health centre director had obtained 
bicycles from UNICEF and had given them to the local administration offices where workers there 
would ride them, get defaulters and ride back together (double) to the health centre. Also at Entoto, in 
order to make treatment more convenient, a health station was built by the Italian government because 
it is a more rural part of Addis Ababa (See Figure 8-31). The director of the Entoto Health Centre said 
that she recommends that patients consume three eggs per week (~1 birr for three), unfortunately, 
travel to and from Entoto #1 is more than this cost. The construction of this health station nearer to 
many of these patients allows them to receive treatment for less cost. Travel to various health centres 
varies because some are in relatively populated areas, whereas others are in more sparsely populated 
areas, as shown in Figures 8-32 and 8-33.
There is no environmental control of tuberculosis spread nor TB patient isolation. TB patients, 
especially smear-positive patients, are encouraged to cover their cough at all times when they are 
infectious. Educational posters in TB treatment rooms and health personnel emphasise this (See 
Figure 8-34). At the Shiromeda Health Centre, as depicted in Figure 8-35, 8-36 and 8-37, patients 
come to receive treatment during their intensive phase each day and wait outside covering their cough 
until they can be injected and be given their pills.
In all but one health facility in this study, syringes and needles were boiled or sterilised in an 
oven, unless the patient was suspected to be HIV-positive (See Figures 8-38, 8-39 and 8-40). Patients 
had the option to buy new syringes if they could afford them. Disposable syringes were reused up to 5 
times and reusable syringes were used over 100 times. Many of the nurses commented on how dull the 
syringes became and this was also evident in observing treatment.
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Figures 8-23 and 8-24: Laboratories and Lab Technicians from the Pilot and Non-Pilot Areas
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Figure 8-25: Kazanchez Health Centre
Figure 8-26: An Example of Drug Supply Organisation at Kazanchez:
Pink Slips indicate Drugs from the Ministry of Health, Blue slips indicate drugs from aid 
organisations and yellow slips (on wall not shown) indicate drugs from the WHO
!■ ji
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Figure 8-27: Yekatit Hospital
Figure 8-28: Average Hospital Room for Poor Patients 
Accommodating Over 20 Patients With Different Diseases
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Figure 8-29 and 8-30: A Local Traditional Healer 
Near the Main Mosque in the Addis Ketema Area
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Figure 8-31: Health Station for Entoto #1 Health Centre
Figure 8-32: Higher 23 Health Centre
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Figure 8-33: Outside Addis Ketema Health Centre
Figure 8-34: Informational Poster in Amharic Telling TB Patients to Cover their Cough
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Figure 8-35: Shiromeda Health Centre
Figure 8-36: Treatment Nurse and Patients 
Awaiting Treatment at Shiromeda Health Centre
1 1 tlf I • ■
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Figure 8-37: Patients Waiting to Receive Treatment at Shiromeda Health Centre
Figure 8-38: Nurses Removing Syringes from a Boiler 
in Order to Begin Treating the Day's Patients
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Figure 8-39: Common Boiler for Syringes
Figure 8-40: Used Syringes after Injection
329
8-3:19 Summary to Section 8-3
In a study of 499 smear-positive patients in the public health sector of Addis Ababa, short course 
chemotherapy and the standard drug regimen were compared. It was in this context that it was shown 
that resistance to anti-TB drugs does indeed, have an impact on the cost of TB treatment. Retreatment 
costs for resistance can raise costs of treatment to 2.28-3.78 times the cost of susceptible cases and 
when including variable costs, to 3.52-5.70 times the cost of treating susceptible cases. This study also 
showed that resistance has an impact on cost-effectiveness ratios, but conclusions from this study are 
not sensitive to resistance until resistance for SCC rises above 18%.
Short Course Chemotherapy, although a more expensive regimen for tuberculosis proved to be a 
more cost-effective regimen in all measures of cost per cure, cost per death averted and cost per life 
year saved. SDR has a higher non-compliance rate because its treatment time is 4 months longer than 
SCC. Because of this high rate of non-compliance for SDR, treatment with SDR incurs the added 
costs of retreatment of all defaulters. This is a major determinant of cost-effectiveness ratios between 
these treatments. If the ultimate goal for TB treatment is to treat as many patients as possible, then 
SDR is the answer, however, if the goal is to cure more patients, then SCC is the more ideal regimen. 
Objectives of treatment must be defined, but because of the costs incurred by treating patients and not 
curing them, increased cures must be the final objective of an NTP.
Rates of drug reactions to thiacetazone are high and could prove to threaten the cost-effective use 
of thiacetazone in HIV patients. Treatment of drug reactions proves to be costly. Also, affecting costs 
is the possibility for isoniazid resistant tuberculosis in defaulters increasing retreatment regimens by 
21%. The implementation of a standardised tuberculosis control programme has had some problems in 
drug supply, laboratory supply and patient defaulter tracing. Nevertheless, the increase of these cure 
rates shows remarkable results from just two years ago, due to the presence of an effective National 
Tuberculosis Programme in Ethiopia.
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Section 8-4
Conclusion to Chapter Eight
The effects of HIV are starting to be felt more acutely in the area of tuberculosis. At the St. 
Peter's Sanatorium, TB/HIV co-infection is becoming more and more common, making TB more 
difficult to treat, especially in critical patients. Screening for HIV in TB patients is uncommon and is 
only done in hospitalised patients. The rate of TB/HIV co-infection in hospitalised patients tested at 
St. Peter's Sanatorium was approximately 30%. This is an interesting reflection of the synergistic 
action between these two diseases, but it is unknown whether this value is a representation of TB/HIV 
co-infection in the general population due to the small sample size of those screened and the critical, 
nature of their disease. Anti-TB drug resistance at the St. Peter's Sanatorium was estimated at 10-20%.
St. Peter's Sanatorium functions as the hospital for critical TB patients from the TB Centre in 
Addis Ababa. The TB Centre Screens an astounding number of patients per year for TB, but its 
approach to diagnosis is less than optimal. Unnecessary costs are incurred in chest x-rays for smear­
positive patients. On closer analysis, other local hospitals also use a technique of automatic smear 
microscopy tests, chest x-rays and blood tests for patients suspected of TB. A proportion of this 
screening expenditure could be saved if all patients were given a smear test to separate smear-positive 
patients and the remainder were then given chest x-rays and blood tests. These costs can be significant 
because over 85% of patients are diagnosed in a hospital and then referred to a health centre for 
treatment. This also reflects patients' over-dependence on secondary care for initial contact for 
diagnosis, which could be done more inexpensively at a health centre. Another striking feature of 
diagnosis is the large proportion of normal patients that are screened for TB. Of those screened, only 
approximately 10% actually have any form of TB.
Optimisation of TB treatment was shown in a study of 499 smear-positive patients in a pilot and 
non-pilot programme in Addis Ababa. SDR, a less expensive treatment regimen, is often the regimen 
of choice in developing countries, nevertheless, the final cost per cure of this regimen was proven to 
actually be higher than the more expensive but more effective regimen, SCC. In choosing the correct 
treatment, the objective should not always be to treat as many patients as possible, but to cure as many 
patients as possible. In this example, short course chemotherapy is the optimal choice for TB 
treatment and control of its spread.
In addition, resistance to anti-TB drugs was shown to increase the cost of TB treatment because 
it increases the drug costs and variable costs of treatment. This increased cost represents a potential 
burden for the public sector of health in Addis Ababa. This sector depends on the ERRP and other 
external aid in order to maintain all of its SCC regimens and a large proportion of its SDR regimens.
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Should the incidence of TB resistance rise, the cost of giving more and more patients retreatment 
regimens for resistance will have to be met. In some cases there will be the problem whereby those 
with resistant TB will be unable to obtain the proper regimens from health facilities, leaving a poor 
prognosis for survival. As almost all TB resistance arises from improper use of the drugs, in order to 
contain resistance, it is extremely important for TB case holding to be strongly enforced, education in 
drug use to be widened and drug quality to be ensured. Likewise, drug supplies must be well regulated 
so that patients can get a consistent supply of drugs, not intermittent therapy.
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CHAPTER NINE
CONCLUSION
Developing countries are faced with a continuing challenge of providing an efficacious health 
care system with available funds that is suitable to its needs. Health is an imperative investment 
because of its influence on well-being and productivity. Health and development are closely related, 
and investment in health is investment in human capital. The relationship between health and 
productivity is circular in developing countries. As health increases, productivity can increase and as 
productivity increases, living environments improve and as living environments improve health 
increases. Increased health status is a fundamental human need and allows for stronger future 
generations, greater stamina, better child health and mental acuity. Improved health status not only 
increases the amount of human capital available, but by extending an individual’s life, increases the 
amount of time that he or she can work.
Unfortunately, most developing countries have extremely poor health service coverage with a 
large concentration of health facilities only located in cities. In several of these countries, only a small 
amount per capita is spent on health. Investment in health can often take a low priority and depending 
on the government, is sacrificed for investments, such as military hardware and urban growth. For this 
reason, medical supplies and drugs are quickly depleted and there are not enough trained health 
personnel to meet health care demands. Impeding bureaucracy is rampant and all transactions can take 
much longer. The health care system can therefore be riddled with an over-concentration on rules, 
paperwork, systems and guidelines that never allow anything effective to be done. Referral systems in 
developing countries are poor: for many in developing countries, if individuals manage to travel to one 
health facility, those that they are referred to are virtually inaccessible to these patients due to cost and 
transportation. Transportation is difficult and patients seeking care may have to travel across 
extremely rural areas that can only be travelled by foot. Where there are roads, mostly dirt, they can be 
flooded and impossible to drive. Facilities for providing health care are often dilapidated and 
overwhelmed. Patients may find themselves in hospitals with several other patients with other
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infectious diseases. In some of these hospitals patients must rely on their family to feed them. In 
addition, many are rushed out of hospital in order to make room for new patients. Also, those patients 
who need care may not receive it because they cannot afford it, or a there is no room for them at a 
health facility.
Health problems that are seldom seen in industrialised countries are highly visible in developing 
countries. In many cases the very ill lie on crowded city streets because they have no other place to go. 
Death and morbidity are a more common part of life, especially in low income countries. In poor 
countries, many come from extremely large families and most have lost a brother, mother, sister, 
father, daughter, son, aunt, uncle, niece or nephew from a premature death.
This thesis has approached the rationalisation of health care in relation to infectious bacterial 
disease, and namely, the effect of the cost of resistance on tuberculosis treatment in developing 
countries. Chemotherapy was a large focus for this thesis because of its high cost-effective impact as a 
health intervention. Drugs have the potential to be well regulated, well organised and appropriately 
utilised. They are an ideal intervention for developing countries because in many cases they can be 
consumed away from a health facility with little effort or discomfort. The paradigm is antibiotics. The 
use of antibiotics for bacterial diseases proves to be extremely rewarding in terms of their high cures 
for their cost. Antibiotics represent a low-technology intensive intervention that is far more effective 
than many other drugs and procedures. The benefits of these drugs are not only experienced by 
individuals but also by society. Antibiotics can easily cure an infection and in the case of an infectious 
bacterial disease, can work to quickly and effectively contain its spread. The savings in costs of these 
indirect benefits are difficult to measure, but they undoubtedly have a significant impact on society.
Unfortunately, with the use of antibiotics there comes bacterial resistance to them, rendering 
some antibiotics useless in treating infections. This is an inevitable negative externality of use, but this 
should not be accepted in the case of inappropriate antibiotic use. Inappropriate use is most often the 
cause of TB resistance. Resistance of other diseases to antibiotics is not only due to inappropriate use, 
but due to use itself because of the development of exogenous resistance. This is not the case with 
anti-tuberculosis drugs because the bacilli can only develop endogenous resistance, meaning resistance 
primarily develops through improper treatment. Indeed, some antibiotics are so important and 
resistance is such a threat in their treatment of life-threatening diseases, that they should only be used 
for these indications.
Most health care problems in developing countries can be illustrated with the example of 
tuberculosis. It is a disease that is viewed as such a strong health threat that in many cases, treatment 
for patients is provided by the government free of charge. The costs of tuberculosis are grave, 
expressed not only in the illness and premature death of individuals, but in that it can spread quickly
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and affect individuals in their socially and economically most productive part of life. Tuberculosis is a 
disease that thrives in the poor sanitation, malnutrition, HIV and crowded conditions of developing 
countries. It is a curable disease that has a very virulent impact in terms of morbidity and mortality. It 
can be effectively and relatively inexpensively treated and is ranked by the WHO on the top of the list 
of effective health care interventions. While this thesis was written, tuberculosis once again has 
become prominent in international news and there is suddenly rising pressure for containment efforts.
Efforts to start systematic standardised national tuberculosis programmes have in some cases 
been impotent because of poor financial backing. Priorities are often skewed and very little is given by 
the governments themselves to support TB programmes: a scenario that inevitably ends in failure to 
control the disease. For example in Ethiopia, although it had a programme aided and instigated by the 
support of the WHO, only recently did this programme really start to be effective when it was 
supported by a new government. Drug management has been poor and drugs are often obtained from 
expensive sources. Also, the regulation of these drugs is not well controlled so that drugs are 
inappropriately used for other infections, contributing to the development of resistance. In other cases, 
drugs necessary for treatment are not available or are intermittently given, amounting to treatment, but 
no cure and again resistance.
Resistance has been a real threat to tuberculosis chemotherapy because once multi-drug 
resistance occurs, the prognosis for the disease is a 40-60% death rate, the same as untreated 
tuberculosis. Resistance in TB is attributed to many factors including poor administration, poor patient 
compliance, poor drug quality and incorrect use. Efforts to control tuberculosis have also been 
hampered by the inability to manage treatment. Without proper patient tracing, patients are treated for 
the disease for a short period of time only to default. Administration of this disease is reliant on 
recording patient information in order to calculate future demands in treatment.
The impact of HIV on TB also cannot be ignored. More than any other disease, TB is able to 
exploit the growth of HIV to its own advantage. Where many diseases that affect those with HIV find 
HIV-negative individuals unsusceptible, tuberculosis can affect both populations. As a third of the 
global population is estimated to be already infected with the disease, TB can grow in the TB-infected 
who contract HIV and in those with HIV who become infected with TB.
The management of tuberculosis and problems encountered with it were shown in Ethiopia. 
Here, where GNP per capita per year at most reaches $110 US dollars and the average life expectancy 
is only approximately 50, poverty is an accepted part of their life. Tropical diseases plague Ethiopia 
which has several different climates due to its altitude, and therefore, complex epidemiological 
patterns of disease: these disease patterns mean that the system of health care delivery must be 
versatile. Investment in health is still less than $1 US dollar per capita, health service coverage, at
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most, amounts to 50% of the population, and the urban concentration of health facilities is high. 
Correlating with this, total expenditure for medical supplies and drugs in 1992 amounted to 
approximately $3.2 million dollars, meaning that there has been less than US 5 cents spent per person 
in this area. However, in this environment, infectious disease is the greatest health challenge to the 
health care system and therefore, a sound priority for interventions. All complications to health care 
delivery in bacterial diseases, such as HIV and drug resistance, consume resources which could be 
used more efficiently to treat more patients in the absence of these complications.
Tuberculosis for Ethiopia is a very visible health threat with an annual risk of infection of 1.5%. 
HIV infection is starting to grow in Ethiopia threatening not only the population, but tuberculosis 
control. At the St. Peter's Sanatorium, an estimated 30% of screened patients were TB/HIV co­
infected. Although this cannot be generalised to all TB patients, the high rate of drug reactions to 
thiacetazone, primarily a phenomenon in HIV patients, is evidence that HIV is creeping into the TB 
case loads of health facilities. Efforts to establish a powerful TB control programme have become 
more effective and tuberculosis eradication has become a more prominent goal in Ethiopia, especially 
in the urban areas where administration for the disease involves those who only work in TB. 
Management of tuberculosis containment has been forced to be resourceful. Problems in treatment 
that are difficult to address, due to poor funding, have been dealt with in the most inexpensive but 
effective way. Case holding, one of the greatest challenges to tuberculosis treatment has been aided by 
the efforts of conscientious nurses, doctors and medical directors who will go to the houses of 
defaulters to find them. Unfortunately tuberculosis treatment is at risk from the lack of supplies. 
Recently, drug supply in Addis Ababa has been consistent with the strong support of the WHO, but 
other supplies, such as syringes and needles must be re-used and boiled. In contrast, in areas outside of 
Addis Ababa, drug supply is not consistent. Because the support of these programmes are so 
dependent on WHO funding, they are in a precarious position.
The system of referral for patients is weak because of the poor quality and capacity of secondary 
health care facilities. Hospitalisation of critical patients in Addis Ababa has also proved a problem. 
Health facilities are eager to get their patients into hospital, but there is sometimes no room. Hospitals 
on the other hand try to get TB patients out of secondary care as soon as possible and in many cases, 
prematurely. Critical patients arriving on stretchers at health care centres, who have no facilities for 
this, are not uncommon.
The system for information recording has been improved with the use of a tuberculosis registrar, 
patient treatment cards, quarterly reports, annual reports, and sputum laboratory record books. 
Utilisation of health care facilities has been eased by the building of health stations near patients in the 
more rural parts of the city. However, many patients still have little knowledge of the existence of this
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free and comprehensive tuberculosis treatment and many rely on traditional healers. Case finding is 
still passive, which is unlikely to change considering the available resources.
Since the change in government, and the instigation of SCC, the potential for better treatment has 
developed. However, this is likely to bring in resistance to those drugs in the SCC drug regimen that 
are not used in the SDR regimen. Resistance to drugs like rifampicin, pyrazinamide and ethambutol, 
which were not used to any large degree before, is likely to become a larger health threat, also allowing 
the potential for multi-drug resistance. However, with a good implementation of a tuberculosis 
programme, ensuring only limited amounts of default, resistance to these drugs can be contained. 
Tuberculosis is a disease that is curable and its resistance is primarily determined by human actions in 
implementing treatment. Poor treatment leads to resistance which was shown to increase tuberculosis 
treatment costs, because more drugs and more time and resources must be used to treat these patients. 
Not including the cost of treatment before resistance has been detected in a patient, approximately 3-5 
more susceptible patients may be treated than drug resistant patients, depending on the regimen 
chosen. In addition, as costs rise, so do the relative cost per cures and other measures of cost- 
effectiveness for SDR and SCC. However, SCC still remains more cost-effective than SDR until 
resistance to SCC rises to 18% (assuming resistance to SDR remains constant).
Choices, Priorities and Decision Making
Better organisation and administration of health care is demanded in developing countries and 
this is where health care management can be instrumental. By examining each situation and 
instigating a simple, but workable management plan, diseases and health problems can be more readily 
attended to.
Making choices in drug treatment is another area where TB is a relevant example to the 
rationalisation of chemotherapy. This is an area that is closely tied to deciding the ultimate objectives 
of an intervention. It seems that all too often, low income countries compromise the quality of 
treatment for the quantity of those treated. In essence, the desire to treat as many patients as possible 
for as little expenditure as possible has become an end in itself. This emphasis has overshadowed the 
need to treat patients with effective results. Drug treatments and interventions are either valued 
because of the fact that they integrate some high and often inappropriate technology or because they 
are inexpensive. Developing countries are proud of the abilities of their staff in hospital to perform 
highly technical procedures such as open-heart surgery, when for the price of such interventions and 
technology, thousands could be saved with something as fundamental as ORT. In Ethiopia at the TB 
Centre and in hospitals in Addis Ababa, there is an over-reliance on chest x-rays for the diagnosis of 
tuberculosis in smear-positive patients when much could be saved by first using smear microscopy in
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order to screen these patients out of the group of patients will all types of TB. For the amount of 
money that is used sub-optimally on x-rays for TB diagnosis a large proportion of patients could 
receive short-course chemotherapy. The high emphasis on treating, rather than curing the most 
patients was expressed by the case of tuberculosis drug therapy. SDR has been used extensively in 
many developing countries, especially sub-Saharan Africa. The question has, nevertheless, arisen as to 
how effective it is in dealing with the threat of tuberculosis. In this thesis, SDR was shown to be 
inferior in curing tuberculosis when compared with SCC. In fact, for the price paid for each cure, SCC 
was approximately $170 US dollars less. It also proved cheaper in deaths averted, total deaths averted 
and the cost per life year saved (no matter which method was used in calculating years of life lost).
Developing countries must balance their efforts in order to optimise the effects of their 
expenditure. It is essential that priorities be set for interventions in order that appropriate technology, 
training, supplies, drugs and infrastructure can be established. It is making these decisions in priorities 
that becomes difficult. One of the most appropriate tools for this decision making is the use of health 
economic analysis and tools to explore the best combination of options that will minimise opportunity 
costs and maximise the desired benefits from expenditure. Available funds are scarce and since the 
greatest benefits are desired for the amount of expenditure, there is no better tool for analysing this 
than health economics. Health economic analysis was shown in this thesis to be a superior method for 
identifying the optimal health care interventions and concentrations. It is also an area that is under­
utilised.
This thesis showed that in Ethiopia, resistant cases of tuberculosis increase the cost of 
tuberculosis treatment. This is a country that is one of the very poorest of developing countries. Until 
only recently, it was relatively isolated from those around it, possibly explaining its lower levels of 
HIV and resistant TB. Unlike more resource-rich developing countries, Ethiopia has only just begun 
to develop a standardised treatment for tuberculosis. Therefore in many places, resistance to drugs, 
especially those particular to the SCC regimen, is non-existent because of little use. If programmes are 
not implemented correctly, it is likely that with greater implementation of tuberculosis treatment, 
resistance will also rise to the levels observed in other countries. If TB resistance rises, the cost of 
treatment will also rise.
Although Ethiopia has been relatively isolated until recently, and although particular TB 
treatments have not been in use for as long as those in other developing countries, the conclusions of 
this thesis are not entirely context-dependent. In other developing countries, if tuberculosis resistance 
requires the use of a greater number of drugs and a greater amount of time and resources, then the cost 
of treating this resistance will also rise, likewise representing a larger economic burden for these 
countries. Indeed, this may not only be the case for tuberculosis. If other resistant bacterial diseases
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require more drugs and resources, then the cost of treating these will also rise. Indeed, resistance has 
the potential to present a grave challenge in containing costs of infectious diseases, an effect for which 
in developing countries with their limited resources, will have serious consequences.
APPENDIX A
NON-PILOT DATA
*Data will appear starting from the first patient recorded in the patient register at each representative 
health facility. Each patient number appears on the sheet according to how it appears in the patient 
register as does his or her age, sex and smear classification
GUIDE TO SYMBOLS USED ON THE NON-PILOT DATA SHEET
#
S
1
0
E
P
2
5
8
12
Patient number 
Sex
Male
Female
Extra-pulmanary Tuberculosis 
Pulmonary Tuberculosis
Second Month Smear 
Fifth Month Smear
Eighth Month Smear 
Twelfth Month Smear
C
c
D
F
T
HE
Drug React 
TB-450
Treatment Complete 
Cured
Died
Defaulted
Transferred 
Ethambutol-Isoniazid Substitution 
Drug Reaction
Reaction to Thiacetazone
Place
K17
KEZ
ADD
K23
K19
K25
Health Facility Location 
Kefetegne 17
Kezanchez 
Addis Ketema
Kefetegne 23 
Kefetegne 19
Kefetegne 25 (Kolfe)
7 SEX Aae PS 2. 5 8 12 C c D F T HE DRUG REACT PLACE
1 1 29 2+ - - - c KEFETEGNE-17
2 0 26 2+ - - - c TB450-HE K17
3 0 40 D K17
4 1 36 3+ - - - c HE K17
5 0 10 HE K17
6 0 25 T TB450-Hhep/T K17
7 0 36 T K17
8 1 29 F K17
9A 0 10 K17
9B 1 30 + - - F K17
10 1 37 HE K17
11 1 20 K17
12 1 25 2+ - - - c HE K17
13 1 20 HE K17
14 1 37 D K17
15 1 10 T K17
16 1 23 3- - 3+ T K17
17 1 17 + - - F K17
18 1 36 + T K17
19 1 47 3+ - - c K17
20 0 48 D K17
21 1 46 3+ - TB450-HE K17
22 1 29 TB450-HE K17
23 0 35 + - - c K17
24 0 42 T K17
25 0 24 HE K17
26 1 28 2+ F K17
27 1 75 D K17
28 0 35 HE K17
29 0 30 + - - c TB450-HE K17
30 0 39 3+ F K17
31A 1 15 ? K17
31B 1 32 K17
32 1 39 K17
33 1 17 3+ - - c K17
34 0 20 K17
35 1 39 HER K17
36 0 26 3+ - - c K17
37 0 42 3+ - - c K17
38 0 30 2+ - - c HE K17
39 0 11 TB450-HE K17
40 1 24 2+ - - c HE K17
41 1 20 K17
42 0 27 HE K17
43 1 23 TB450gastr-HE K17
44 1 52 + F K17
45 1 49 D K17
46 1 14 F K17
47 1 23 TB450-HE K17
48 0 26 HE K17
49 1 11 HE K17
50 0 28 K17
51 1 18 K17
52 0 22 3+ - D K17
53 0 28 HE K17
54 1 36 2+ - c HE K17
55 0 20 3+ - F K17
56 1 32 K17
57 1 33 3+ - c K17
58 0 32 HE K17
59 1 28 2+ - K17
60 1 68 K17
61 1 35 2+ - D K17
62 1 38 K17
63 1 48 K17
64 0 30 K17
65 1 26 F K17
66 0 26 2+ - K17
67 0 17 2+ - F K17
68 1 18 2+ - - c K17
1 1 18 + - - c KEZANCHEZ
2 0 26 + - - c KEZ
3 1 32 KEZ
4 1 38 3+ - - c KEZ
5 1 15 3+ - c KEZ
6 0 50 4+ - - c KEZ
7 0 15 3+ - c KEZ
8 1 20 2+ - c KEZ
9 1 9 3+ - c KEZ
10 1 20 2+ - - c KEZ
11 1 39 T KEZ
12 1 18 KEZ
13 0 16 2+ - c KEZ
14 0 23 2+ - - - c KEZ
15 1 65 D KEZ
16 1 22 KEZ
17 1 14 2+ - c KEZ
18 1 16 + - KEZ
19 0 30 KEZ
20 0 20 KEZ
21 1 34 3+ F KEZ
22 1 57 F KEZ
23A 1 48 KEZ
23B 0 21 KEZ
24 0 21 + - c KEZ
25 0 12 KEZ
26 1 16 2+ - - c KEZ
27 0 3 KEZ
28 0 40 3+ - c KEZ
29 0 20 T KEZ
30 1 30 2+ - c KEZ
31 1 34 KEZ
32 1 14 2+ - c HE KEZ
33 0 40 T KEZ
34 1 19 2+ - c KEZ
35 0 30 TB450-HE KEZ
36 1 27 2+ 2+ c KEZ
37 0 75 KEZ
38 1 28 3+ - TB450-HE KEZ
39 1 23 T KEZ
40 0 56 KEZ
41 0 23 KEZ
42 1 33 3+ F KEZ
43 1 23 HE KEZ
44 1 19 2+ - KEZ
45 1 28 2+ - KEZ
46 1 37 3+ - KEZ
47 1 17 KEZ
48 1 45 KEZ
49 0 19 2+ HE KEZ
50 0 28 KEZ
51 0 35 2+ KEZ
52 1 40 3+ - HE KEZ
53 1 29 F KEZ
54 1 32 2+ - KEZ
55 0 24 + - KEZ
56 0 20 KEZ
57 1 18 HE KEZ
58 0 28 2+ KEZ
59 1 41 2+ - KEZ
60 1 37 2+ - HE KEZ
61 1 24 HE KEZ
62 0 45 HE KEZ
63 0 75 KEZ
64 0 30 3+ T KEZ
65 1 28 + TB450-HE KEZ
1 1 27 + - - - c ADDIS KETEMA
2 1 22 + - - - 0 c ADD
3 1 26 ADD
4 1 49 + - - - c ADD
5 0 35 HE ADD
6 1 22 ADD
7 0 20 ADD
8 0 14 + - - - c ADD
9 0 35 ADD
10 1 30 + D ADD
11 1 29 ADD
12 0 38 ADD
13 0 14 ADD
14 0 34 ADD
15 0 20 D ADD
16 1 25 + - - F ADD
17 1 18 ADD
18 1 33 ADD
19 1 30 ADD
20 0 49 ADD
21 1 50 + - - F ADD
22 1 18 + - - c ADD
23 1 21 2+ - - c ADD
24 1 7 F ADD
25 1 25 ADD
26 0 ADD
27 0 50 F ADD
28 0 27 - - - c ADD
29 1 62 D ADD
30 1 29 ADD
31 1 29 ADD
32 1 14 ADD
33 1 30 ADD
34 1 23 + - - - c ADD
35 0 33 ADD
36 0 30 3+ D ADD
37 1 60 F ADD
38 0 25 T T-HOSPITAL ADD
39 1 15 F ADD
40 1 10 ADD
41 1 28 T ADD
42 1 55 ADD
43 0 10 ADD
44 1 18 T ADD
45 1 18 + - - - c ADD
46 1 22 TB450-HE ADD
47 0 20 + - F ADD
48 0 23 + - - T ADD
49 1 23 + - - - T ADD
50 1 49 T ADD
51 1 5 ADD
52 1 24 3+ - - - c ADD
53 0 64 TB450-HE ADD
54 0 3 ADD
55 1 22 T ADD
56 0 21 ADD
57 1 32 3+ - D ADD
58 1 31 3+ - - - c ADD
59 0 25 ADD
60 1 25 + - - - F ADD
61 0 28 2+ - - - F ADD
62 1 25 ADD
63 1 58 D ADD
64 1 39 T ADD
65 6 40 + + - - c HE ADD
66 1 16 ADD
67 1 32 2+ - F ADD
68 0 15 F ADD
69 1 11 ADD
70 1 29 3+ - F ADD
71 1 28 + - - - c ADD
72 0 38 + - - - c ADD
73 0 35 + - - - c ADD
74 0 25 ADD
75 0 20 F ADD
76 1 33 ADD
77 0 26 2+ - - - c ADD
78 0 17 ADD
79 1 30 + - - - c ADD
80 1 28 + - - T ADD
81 1 18 ADD
82 1 40 + F ADD
83 0 15 F HE ADD
84 0 34 + - - - c ADD
85A 1 15 ADD
85B 1 32 2+ - - - T SCC T-HOSPITAL ADD
86 1 23 2+ - SCC ADD
87 1 15 ADD
88 0 36 + - - - c ADD
89 0 27 + F ADD
90 1 18 F ADD
91 1 16 3+ F ADD
92 1 17 F ADD
93 1 14 T ADD
94 1 28 4+ - T SCC ADD
95 1 5 HE ADD
96 1 18 2+ F ADD
97 1 30 ADD
98A 1 36 4+ - - - F ADD
98B 0 46 T ADD
99 1 22 + - F ADD
100 1 26 + ADD
101 1 17 F ADD
102 0 16 ADD
103 1 48 2+ c ADD
104 1 16 + - HE ADD
105 0 25 ADD
106 0 20 + - F ADD
107 1 25 ADD
108 0 4 F ADD
109 0 35 + - - - c ADD
110 0 40 F ADD
111 0 50 F ADD
112 1 45 + - - - c ADD
113 0 60 ADD
114 1 40 T ADD
115 1 49 D ADD
116 0 20 F ADD
117 0 30 + - F ADD
118 0 20 ADD
119 1 69 ADD
120 0 35 3+ - - - c ADD
121 0 34 ADD
122 0 30 + - - - F ADD
123 0 75 F ADD
124 0 22 ADD
125 0 39 + T SCC ADD
126 0 26 3+ D ADD
127 1 20 F ADD
128 1 35 3+ - T SCC ADD
129 1 23 ADD
130 0 23 ADD
132 1 39 F ADD
133 1 30 ADD
134 1 20 F ADD
135 1 30 F ADD
136 1 32 ADD
137 0 20 ADD
138 0 8 ADD
139 1 42 ADD
140 1 25 2+ - - - F ADD
141 1 20 4+ - T ADD
142 1 17 2+ - - - F ADD
143 1 15 ADD
144 0 28 3+ - - - F ADD
145 1 14 F ADD
146 1 33 3+ - - - c ADD
147 1 25 3+ - - - c ADD
148 0 65 4+ - - - F ADD
149 1 29 ADD
150 0 36 D ADD
151 0 47 ADD
152 0 15 + - F ADD
153 1 31 2+ - - - F ADD
154 0 35 2+ - - - c ADD
155 1 26 + - - - c TB450-HE ADD
156 1 21 ADD
157 1 33 2+ - F ADD
158 1 42 + - T ADD
159 0 16 ADD
160 0 16 ADD
161 1 25 F ADD
162 1 32 + D ADD
163 0 13 T ADD
164 1 20 ADD
165 1 19 F ADD
166 0 19 ADD
167 1 40 ADD
168 0 14 ADD
169 0 19 F ADD
170 1 18 F ADD
171 1 28 + - - F ADD
172 0 62 ADD
173 1 35 F ADD
174 1 24 F ADD
175 0 24 ADD
176 0 50 ADD
177 1 30 ADD
178 0 30 3+ - - - F ADD
179 1 55 F ADD
180 0 35 + - • D ADD
181 1 55 3+ F ADD
182 1 20 4+ - - - F ADD
183 0 14 4+ - - - c ADD
184 1 20 ADD
185 0 15 F ADD
186 1 12 ADD
187 0 32 ADD
188 1 45 F ADD
189 1 17 2+ F ADD
190 0 15 ADD
191 1 16 F ADD
192 0 2 F ADD
193 0 19 3+ - - F ADD
194 1 19 + - - T ADD
195 0 50 3+ - T ADD
196 1 19 F ADD
197 1 36 T ADD
198 0 11 T ADD
199 1 6 T ADD
1 0 50 KEFETEGNE-23
2 0 33 K23
3 0 6 HE PE K23
4 1 49 TB450-HE K23
5 1 16 + - - - c K23
6 0 30 K23
7 1 35 TB450-HE K23
8 1 36 HE K23
9 0 40 TB450-HE K23
10 0 21 3+ - - c K23
11 1 50 D K23
12 1 12 K23
13 1 61 D K23
14 1 50 D HE K23
15 0 29 F K23
16 1 53 3+ - - - c K23
17 1 25 K23
18 1 29 + - - - K23
19 0 26 T K23
20 0 25 K23
21 1 15 D HE K23
22 1 29 2+ - F K23
23 0 34 F HE K23
24 0 30 K23
25 1 42 K23
26 0 21 2+ - - - c TB450-HE K23
27 0 38 K23
28 1 26 2+ - c K23
29 1 20 HE K23
30 1 18 K23
31 1 45 3+ - K23
32 1 30 + - K23
33 0 36 K23
34 1 24 K23
35 1 23 HE K23
36 1 40 T K23
37 1 4 K23
38 1 24 K23
39 0 19 HE K23
40 1 17 3+ - - K23
41 1 34 TB450-HE K23
42 1 29 K23
43 0 32 K23
44 0 36 TB450-HE K23
45 1 26 3+ - K23
46 1 30 K23
47 1 36 K23
48 1 40 K23
49 1 10 HE K23
50 1 40 3+ - T T-HOSPITAL K23
51 1 48 K23
52 0 37 D K23
53 0 30 K23
54 1 52 HE K23
55 0 29 T K23
56 0 28 4+ - K23
57 1 28 K23
58 1 38 2+ - D K23
59 1 33 K23
60 1 35 D K23
61 0 35 + - HE K23
62 1 42 + - K23
63 1 24 K23
64 0 18 K23
65 1 12 K23
66 1 22 T K23
89 1 19 K23
90 0 20 K23
91 0 20 2+ - K23
92 1 45 K23
93 1 34 HE K23
94 1 46 2+ - HE K23
95 1 30 HE K23
96 0 16 K23
97 1 30 D K23
98 1 32 K23
99 1 40 HE K23
100 0 11 HE K23
101 0 28 K23
102 0 28 2+ - K23
103 0 26 HE K23
104 1 14 K23
105 1 35 K23
106 0 16 + - K23
107 0 30 + - K23
108 0 33 K23
109 0 43 2+ - K23
110 1 2 HE K23
111 0 14 + - K23
112 1 26 HE K23
113 0 28 + - K23
114 1 14 + - K23
115 1 23 + HE K23
116 1 28 HE K23
117 0 30 + - HE K23
118 0 29 HE K23
119 1 28 + - HE K23
120 0 13 HE K23
121 0 40 2+ - T K23
122 0 16 HE K23
123 1 28 K23
124 1 30 T K23
125 1 25 K23
126 1 54 K23
127 0 16 K23
128 1 45 K23
129 0 40 + - HE K23
130 0 20 K23
131 1 24 HE K23
132 1 23 2+ K23
1 0 23 T KEFETEGNE 19
2 0 18 + T K19
3 1 17 F K19
4 0 20 F K19
5 0 46 K19
6 0 15 + SCC K19
7 1 25 + - - - - c K19
8 0 15 T K19
9 0 50 + - - - - F K19
10 1 33 F K19
11 0 50 K19
12 0 20 + - - - c K19
13 1 15 + - - - c K19
14 1 19 + F K19
15 0 43 + T K19
16 0 17 + T K19
17 1 26 c K19
18 1 28 + T K19
19 1 20 + - - - F K19
20 1 67 c K19
21 1 30 F K19
22 1 26 c K19
23 1 20 T K19
24 6 21 K19
25 1 23 K19
26 1 41 + - - - c K19
27 1 40 K19
28 1 18 K19
29 1 65 K19
30 1 23 K19
31 1 22 + - - - c K19
32 1 20 K19
33 0 28 + - - - c SCC K19
34 0 29 + - - - c K19
35 0 T K19
36 1 40 K19
37 1 20 F K19
38 1 18 + - - - c K19
39 1 34 F K19
40 0 20 K19
41 0 20 T K19
42 0 45 K19
43 1 55 + - - - F K19
44 1 20 + - - - c K19:3-1-86
45 1 20 T T-HOSPITAL K19
46 1 15 + - - - c K19
47 0 38 + - - - F K19
48 0 52 K19
49 1 23 + - - - c K19
50 0 74 T T-HOSPITAL K19
51 1 32 K19
52 1 6 K19
53 1 52 + - - c K19
54 0 25 K19
55 1 44 + - - c K19
56 0 25 K19
57 1 22 F K19
58 0 12 K19
59 0 42 D K19
60 1 15 K19
61 1 33 K19-
62 1 31 F K19
63 0 25 + - T T-HOSPITAL K19
64 1 50 K19
65 1 24 F K19:26-2-86
66 0 29 K19
67 1 33 F K19
68 0 22 K19
69 1 24 + - - c K19
70 0 24 F K19
71 1 41 + - - c K19
72 1 19 K19
73 0 56 K19
74 1 26 F K19
75 1 35 K19
76 0 34 K19
77 1 36 K19
78 1 44 K19
79 0 30 K19
80 1 27 + - - c K19
81 1 23 K19
82 1 40 K19
83 0 40 + - - c K19
84 1 23 K19
85 1 26 + - c K19
86 1 24 + - - F K19
87 1 22 K19
88 1 20 K19: 8-4-86
89 1 32 D K19
90 0 50 4- - - T K19
91 1 42 + - c K19
92 1 35 + F K19
93 1 25 K19
94 0 28 K19
95 1 46 D K19
96 0 23 K19
97 0 26 K19
98 1 44 + - - c K19
99 0 19 4" - - c K19
100 1 42 + - c K19
101 1 31 + - - c K19
102 1 32 K19
103 1 31 K19
104 1 36 + - - c K19
105 1 36 K19
106 1 40 K19
107 1 19 + - - c K19
108 1 19 K19: 6-15-86
1 1 21 KEFETEGNE-25
2 0 28 2+ - - - c HE K25: 12-3-86
3 0 18 K25
4 0 2 K25
5 1 27 K25
6 1 15 K25
7 1 32 K25
8 1 17 3+ - c K25
9 0 14 3+ - - - c K25
10 1 32 D K25
11 1 8 K25
12 1 30 2+ - c K25
13 0 21 K25
14 1 23 2+ - - c K25
15 1 53 T K25
16 0 49 K25
17 0 35 3+ - - - c SCC K25
18 1 57 3+ - - c K25
19 0 1 K25
20 1 29 RETREATMENT K25
21 0 15 K25
22 0 9 K25: 12-4-86
23 1 16 HE K25: 21-4-86
24 0 17 K25
25 1 66 K25
26 1 40 K25
27 1 20 K25
28 1 18 D K25
29 1 16 K25
30 1 14 K25
31 0 25 3+ - c K25
32 1 47 D K25
33 0 20 3+ c K25
34 0 32 D K25
35 1 23 3+ - - c K25
36 1 20 K25
37 0 16 3+ - - c HE K25
38 1 11 K25
39 1 43 3+ - - c K25
40 1 18 2+ - c K25
41 0 30 K25
42 1 3 K25
43 1 21 HE K25
44 0 19 T K25: 21-5-86
45 0 27 T K25
46 0 40 2+ c K25
47 0 20 3+ - - T K25
48 1 21 D K25
49 0 24 HE K25
50 1 8 T K25
51 0 5 HE K25
52 1 17 K25
53 1 48 3+ D K25
54 1 23 2+ K25
55 1 26 2+ K25
56 0 25 RETREATMENT K25
57 1 17 3+ K25
58 1 17 K25
59 1 46 T K25
60 1 50 K25
60 1 23 T K25
61 1 45 D K25
62 0 30 HE K25
63 1 54 K25
64 0 28 3+ - K25: 25-6-86
65 0 25 K25
66 1 28 K25
67 1 21 K25
68 1 18 K25
69 1 47 - 2+ K25
70 0 45 HE K25
71 1 18 K25
72 0 50 HE K25
73 1 55 K25
74 1 19 2+ - K25
75 1 14 3+ - K25
76 0 18 K25: 7-7-86
77 1 27 - - - 0 HE
384
28.7
PILOT DATA
♦Data will appear starting from the first patient recorded in the patient register at each representative 
health facility. Each patient number appears on the sheet according to how it appears in the patient 
register as does his or her age, sex and smear classification
GUIDE TO SYMBOLS USED ON THE PILOT DATA SHEET
no. Patient number
S Sex
1 Male
0 Female
E
S
L
P
2
5
8
Extra-pulmanary Tuberculosis 
Short-Course Chemotherapy 
Standard Drug Regimen
Primary Smear 
Second Month Smear
Fifth Month Smear 
Eighth Month Smear
X
c
D
F
T
HE
Drug React
TB-450
Treatment Complete 
Cured 
Died
Defaulted
Transferred
Ethambutol-Isoniazid Substitution 
Drug Reaction
Reaction to Thiacetazone
Place
K19
K13
TEK
K18
ENT
SHE
Health Facility Location 
Kefetegne 19 
Kefetegne 13
Tekelehamanot 
Kefetegne 18
Entoto #1 
Sheromeda
no. SEX AGE CL P 2 5 8 c D F jr HE DRUG REACT PLACE
1 20 2+ - - - X H/hep T/A.D. KEFETEGNE-19
2 1 27 c K19: 13-8-85
3 1 28 c K19
4 0 28 4+ 2+ bac+ K19
5 0 36 4+ + - X c K19
6 1 38 T K19
7 1 22 3+ - - - X c K19
8 0 13 3+ - - - X c K19
9 0 2 c K19
10 0 13 3+ - - - X c K19
11 1 18 c K19
12 1 4 c K19
13 0 22 3+ - - - X c K19
14 1 20 c K19
15 0 46 3+ - - - X c K19
16 0 18 3+ - c K19
17 1 18 3+ - - - c K19
18 0 22 3+ - - - X HE K19
19 1 46 3+ - - - X c K19
20 1 43 c T T-HOSPITAL K19
21 1 17 3+ - - - X c K19
22 1 4 3+ - - - X c K19
23 1 30 c K19
24 0 26 3+ - - - X c K19
25 1 27 3+ F K19
26 1 30 3+ - - T K19
27 0 27 3+ - - - X K19
28 0 34 c K19
1 1 3+ - - 0 c K19
2 0 25 c K19
3 1 34 3+ - - - X c K19
4 0 21 c K19
5 1 45 D K19
6 0 15 3+ - - - X c K19
7 1 30 D K19
8 1 T K19
9 0 18 3+ T T-HOSPITAL K19
10 1 34 c K19
11 0 10 T K19
12 1 45 K19
13 1 26 4+ - - - X c K19
13 0 4 K19: 7-12-85
14 0 29 2+ - F K19
15 1 41 2+ - - X c K19
16 0 17 2+ T K19
17 1 40 K19
18 1 20 3+ + 0 0 F K19
19 0 17 4+ - - - X c K19
20 1 30 F K19
21 0 24 3+ - - - X c K19
22 0 18 T K19
23 1 24 K19
24 1 46 3+ - - - X F K19
25 1 30 F K19
26 0 11 K19
27 1 20 2+ F K19
28 1 20 2+ - - - X c K19
29 1 27 2+ F K19
30 1 66 2+ - - - X c K19
31 0 19 3+ - - - X c K19
32 0 50 2+ - - X c K19
33 1 48 2+ T K19: 3-1-86
34 1 47 3+ - - - X c K19
35 1 20 3+ - - - X c K19
36 0 23 K19
37 1 52 2+ 2+ T T-HOSPITAL K19
38 1 35 K19
39 1 20 K19
40 0 11 - c K19
41 1 21 K19
42 0 37 F K19
43 1 17 2+ - - - X c K19
44 0 29 + - - - X c K19
45 0 18 3+ - - - X c K19
46 1 22 + - - - X c K19
47 0 7 - - T K19
48 0 39 K19
49 1 30 K19
50 1 22 3+ - - - X c K19
51 0 45 2+ - - - X c K19
52 0 24 4+ - - - X c K19
53 1 32 F K19
54 0 24 K19
55 1 23 K19
56 1 17 2+ - - - X c K19
57 0 35 K19
58 0 18 2+ - - - X c K19
59 0 20 2+ - - - X c K19
60 1 27 - c K19
61 0 21 3+ - - - X c K19
62 1 73 2+ - - - X TB450-HE K19
63 0 3 2+ - - - X c K19
64 1 25 2+ - - - X c K19
65 1 35 2+ - - - X c K19
66 0 24 D K19
67 1 16 2+ - - - X c K19
68 0 32 K19
69 0 32 2+ - - - c K19
70 0 25 K19
71 1 30 K19
72 1 31 2+ - - c K19
73 0 35 + - - - c K19
74 1 23 3+ - - - X c K19
75 1 25 3+ - - c K19
1 1 28 F KEFETEGNE-13
2 1 22 T 2+ - T K13: 29-8-85
3 0 35 K13
4 1 60 T K13
5 1 35 T K13
6 1 38 3+ - T K13
7 1 25 3+ - - - c K13
8 0 16 4+ - - - c K13
9 0 20 K13
10 1 16 K13
11 1 34 4+ - F K13
12 1 27 2+ - - - c K13
13 1 37 + - F K13
14 0 19 3+ - - - c K13
15 0 14 T K13
16 1 32 3+ - - - c K13
17 0 18 T K13
18 1 36 D K13
19 0 27 3+ - - - c K13
20 0 11 3+ - - - c K13
21 0 11 K13
22 1 30 F K13
23 0 38 c HE K13
24 0 20 4+ - - - X TB450-HE K13
25 1 49 K13
25 0 20 3+ - - - X c K13
26 0 20 3+ - - - X c K13
27 0 37 c K13
28 0 40 c K13
29 0 16 c K13
30 0 18 4+ - - - X c K13
31 1 16 c K13
31 0 16 T 2+ c K13
32 0 27 T 3+ - X K13
33 1 17 T F K13
34 1 50 T 4+ 3+ X c K13
35 1 15 T 2+ - c K13
36 0 30 3+ ? K13
37 1 70 T F K13
38 1 35 T K13
39 1 33 T 4- - X K13
40 1 22 T 3+ - X K13
41 1 13 T 3+ - F K13
42 1 18 T F K13
43 0 25 T 3+ - c K13: 3-3-86
44 1 48 T 3+ 3+ 2+ CHRONIC K13
45 0 25 T 4+ - X c K13
46 1 29 T 3+ - X c K13
47 1 30 - F K13
48 1 21 T 4+ - F K13
49 0 55 T K13
50 0 24 T 3+ - X RETREATMENT K13
51 1 15 T K13
52 1 38 T 2+ - X D K13
53 1 52 T + - X c K13
54 1 2 T K13
55 1 20 T 2+ - X F K13
56 0 22 T + - X c K13
57 1 16 T K13
58 0 33 T 3+ - X D K13
59 1 22 T K13
60 1 14 T c K13
61 0 22 T K13
62 1 31 T K13
63 1 12 T K13
64 0 48 T 2+ - X c K13: 14-4-86
65 1 11 T K13
66 1 20 T K13
67 0 10 T c K13
68 1 20 T c K13
69 1 54 T K13
70 0 20 T K13
71 0 9 T F K13
72 0 11 c K13
73 0 24 K13
74 0 70 K13
75 1 53 D K13
76 1 40 3+ - X c K13
77 0 25 3+ - X c K13
78 0 12 T c K13
79 0 30 2+ F K13
80 1 16 T K13
81 1 5 K13
82 1 23 K13
83 1 32 D K13
84 0 50 K13
85 0 22 K13
86 0 23 D K13
109 1 30 K13: 30-6-86
110 1 26 K13
111 0 38 K13
112 1 28 K13
113 0 45 K13
114 1 26 K13
115 0 29 T T-HOSPITAL K13
116 0 20 + - X c K13
117 1 48 K13
118 0 38 3+ - X F K13
119 0 32 T 2+ X c K13
120 0 38 2+ X c K13
121 1 35 2+ T K13
122 1 31 K13
123 0 18 3+ X c K13
124 0 - T TB450-HE K13
125 0 22 X K13
126 1 31 K13
127 1 23 K13
128 0 5 TB450-HE K13
129 1 70 K13
130 0 30 K13
131 0 28 + F K13
132 1 28 K13
133 1 67 K13
134 1 28 + X c K13
135 0 28 K13
136 1 19 + + X c K13: 27-7-86
137 1 30 K13
138 1 29 + - X TB450-HE K13
139 0 55 K13
140 0 16 TB450-HE K13
141 0 30 + - X TB450-HE K13
142 0 45 K13
143 0 45 + ? K13
144 1 27 + F K13
145 0 23 K13
146 1 18 K13
147 1 21 2+ - X D TB450-HE K13
148 1 50 R 2+ - X R K13
149 1 39 + - X c K13
150 1 67 F K13
151 0 19 + - X TB450-HE K13
152 1 38 K13
153 0 54 D K13
154 0 24 3+ - X c K13
155 1 14 2+ - X c K13
156 0 23 + - X c K13
157 1 23 K13
158 0 21 + F HE UNCOOPERATIVE K13
159 1 35 D K13
160 1 21 TB450-HE K13
161 0 27 TB450-HE K13
162 0 28 K13
163 1 21 K13
164 0 20 X K13
165 0 23 K13
166 1 28 + F K13
167 0 - TB450-HE K13
168 0 19 4- X c K13
169 0 17 K13
170 1 60 K13
171 0 36 + X c K13
172 1 46 + X D K13
173 0 25 + TB450-HE K13
174 1 45 D K13
175 1 45 K13
176 0 28 K13
177 1 40 + X c K13
178 1 42 T K13
179 0 19 + X c K13
180 1 19 + X K13: 22-9-86
181 0 30 + X c K13
182 1 20 + X c K13
183 0 18 F K13
184 1 32 T K13
185 0 58 F K13
186 1 23 + X F K13
187 0 35 + X D HR K13
188 0 23 K13
189 1 11 X K13
190 1 67 F K13
191 0 20 + X c K13
192 1 10 X K13
193 0 9 X K13
194 1 45 K13
195 0 30 F K13
196 0 32 K13
197 0 25 2+ F K13
198 0 36 2+ F K13
199 0 60 + X c K13
200 0 22 3+ X c K13
201 0 4 K13: 15-10-86
202 1 22 3+ X K13: 15-10-86
203 0 4 X K13
204 1 4 X K13
205 1 26 X K13
206 0 25 K13
207 1 25 2+ K13
208 0 25 2+ X F K13
209 1 30 2+ c K13
210 1 46 3+ c K13
211 1 21 X K13
212 0 16 K13
213 1 23 K13
214 1 40 K13
215 0 37 3+ F K13
216 0 2 T K13
217 1 20 K13
218 0 8 T 3+ X F K13
219 1 36 T K13
220 0 0.83 K13: 16-12-86
1 0 7 c TEKELHAMANO1
2 0 35 + - - - X c 24-9-85
3 0 21 c TEK
4 1 20 3+ - - - F TKE
5 1 24 2+ - - - X c TEK
6 0 7 c TEK
7 1 2 c TEK
8 1 30 2+ - - - X c TEK
9 0 25 3+ - - - X TB450-HE TEK
10 0 22 2+ - - - X c TEK
11 1 19 2+ - - - X c TEK
12 0 16 + - - - X c TEK
13 0 19 2+ - - - X c TEK
14 1 36 4+ - - - X c TEK
15 1 50 3+ - - - X c TEK
16 1 15 + - - - X HE TEK
17 1 15 + - - • X c TEK
18 1 36 + D TEK
19 1 24 2+ - - - X c TEK
20 1 45 2+ - - - X c TEK
21 1 18 2+ - - - X c TEK
22 0 16 c TEK: 24-10-85
1 1 33 c TEK
2 0 28 c TEK
3 0 11 F TEK
4 1 34 F TEK
5 1 59 F TEK
6 1 18 c TEK
7 1 18 D TB450-HE(HIV) TEK
8 0 25 c TEK
9 0 20 c TEK
10 1 30 F TEK
11 0 32 c TEK
12 0 17 D TEK
13 0 40 F TEK
14 0 23 c TEK
15 1 14 c TEK
16 0 50 2+ - - - X c TEK
17 1 19 c TEK
18 1 18 3+ - - - X c TEK
19 0 21 F TEK
20 1 21 + - - - X HR TEK
21 0 30 + - - - X c TEK
22 0 22 F TEK
23 1 26 TEK
23 1 23 c HR TEK
24 0 30 F TEK
25 1 35 c TEK
26 1 36 + - - - X c TEK
27 0 23 c TEK
28 0 20 c TEK
29 0 27 c TEK
30 1 32 2+ - - - X c TEK
31 0 21 c HE TEK
32 1 29 F TEK
33 0 20 2+ - - F TEK
34 1 31 F TEK
35 0 38 c TEK
36 1 24 + - - - X c TEK
37 1 20 F TEK
38 0 23 c TEK
39 0 20 F TEK
40 1 61 3+ - - c F TEK
41 0 30 X TEK
42 0 23 F TEK
43 0 35 3+ - - X c TEK
44 0 16 4+ - - - X c TEK: 7-1-86
45 1 22 F TEK
46 1 18 2+ - - - c TEK
47 1 18 X TEK
48 0 27 c TEK
49 1 25 D TB450-HE(HIV) TEK
50 0 20 c TEK
51 0 23 3+ - - - X c TEK
52 1 20 2+ - - - X c TEK
53 1 18 2+ - - - X c TEK
54 1 18 3+ - - - X c TEK
55 0 38 2+ - - X c TEK
56 1 42 TEK
57 1 35 F TEK
58 0 8 TEK
59 1 15 3+ - - - X c TEK
60 0 25 c HE TEK
61 0 12 3+ - - T TEK
62 1 25 3+ - - T TEK
63 1 36 T TEK
64 0 40 TEK
65 1 51 T TEK
66 0 10 T TEK
67 0 24 TEK
68 1 50 2+ - - - X c TEK
69 1 22 TEK
70 0 25 c HR TEK
71 0 16 TEK
72 1 20 TEK
73 0 16 TEK
74 1 4 TEK
75 1 32 F TEK
76 0 50 F TEK
77 1 10 + - - - X c TEK
78 0 18 3+ - - - X c TEK
79 1 16 TEK
80 0 18 F TEK
81 1 55 D TEK
82 0 15 TEK
83 0 15 TEK
84 0 50 TEK
85 0 23 3+ F TEK
86 1 25 4+ - F TEK
87 1 24 TEK
88 1 28 + - + BAC+ TEK: 9-3-86
89 0 30 3+ - - - X c TEK
90 1 20 + - - - X c TEK
91 0 24 + - - - c TEK
92 0 20 F TEK
93 1 22 TEK
94 0 23 F TEK
95 1 29 F TEK
96 0 18 + - D TEK
97 1 40 TEK
98 1 35 TEK
99 0 34 F TEK
100 0 25 T TEK
101 1 25 + - - - c TEK
102 1 22 TEK
103 0 30 2+ D TEK
104 0 40 F TEK
105 1 28 2+ - - - X c TEK
106 0 18 2+ - - - X c TEK
107 1 23 2+ - - - X c TEK
108 0 25 TEK
109 1 28 TEK
110 0 22 + + + BAC+ TEK: 30-3-86
111 0 40 T + D TEK: 4-4-86
112 1 65 TEK
113 0 50 TEK
114 1 20 c TEK
115 0 26 TEK
116 1 28 + - - - X c TEK
117 1 21 R + - - - X R TEK
118 1 20 3+ - F TEK
119 1 21 D TEK
120 1 20 + - - 0 X c TEK
121 1 19 TEK
122 0 37 TEK
123 0 49 TEK
124 0 25 + - - TB450-HE TEK
125 0 37 2+ D TEK
126 0 35 2+ - D TEK
127 0 18 3+ - - - X c TEK
128 1 18 TEK
129 1 52 R 3+ - - D TEK
130 1 35 TEK
131 0 50 TEK
132 1 30 R 4+ - - c TEK: 5-5-86
1 0 27 + - - - X c KEFETEGNE-18
2 1 32 + - - - X c K18: 20-8-85
3 0 16 + - - - X c K18
4 1 27 + - - - X c K18
5 0 48 c K18
6 1 16 c K18
7 1 40 K18
8 1 19 K18
9 1 57 T K18
10 0 38 + - D K18
11 1 17 c K18
12 1 15 2+ - - - X c K18
13 1 13 c K18
14 0 46 c K18
15 1 14 F K18
16 1 25 + - - - X c K18
17 0 19 c K18
18 1 35 + - - - X c K18
19 1 36 2+ F K18
20 1 70 K18
21 0 29 + - + - B+ RETREATMENT K18
1 0 20 c K18:2-11-85
2 1 32 HE K18: 21-11-85
3 1 17 F K18
4 1 26 F K18
5 0 13 - - - X c K18
6 0 15 + - - - X c K18
7 0 25 K18
8 1 20 2+ - - - X c K18
9 1 49 D K18
10 1 30 D K18
11 1 18 + - - - X c K18
12 0 16 K18
13 1 28 K18
14 1 25 2+ - - - X c K18
15 1 18 + - - - X c K18
16 0 18 + - - - X c K18
17 0 14 K18
18 0 25 3+ - F K18
19 0 25 3+ - - - X c K18
20 1 27 2+ - - - X c K18
21 1 48 F K18
22 1 58 K18
23 1 22 K18: 15-2-86
24 1 25 + D K18
25 0 22 + - D K18
26 0 30 TB450-HE K18
27 1 3 K18
28 0 19 2+ - - - X c K18
29 0 16 2+ - - - X c K18
30 1 30 3+ - - - c K18
31 0 20 K18
32 1 44 D K18
33 1 26 K18
34 0 27 T HOSPITAL K18
35 1 14 + - - c K18
36 0 30 D TB450-HE(HOS) K18
37 1 36 K18
38 1 42 TB450-HE(HOS) K18
39 0 23 + - - - X c K18
40 1 28 + - - c K18
41 0 20 2+ - - TB450-HE K18
42 0 12 K18
43 0 8 K18
44 1 12 K18
45 0 17 + - - D K18
46 1 6 F K18: 6-5-86
47 1 39 TD D K18
48 1 15 + - - c K18
49 1 31 K18
50 1 40 2+ - T K18
51 1 23 3+ - F K18
52 1 22 + - - c K18
53 0 39 3+ - + c K18
54 0 18 2+ D K18
55 0 22 K18
56 1 20 2+ - D K18
57 0 40 K18
58 0 5 K18
59 1 19 2+ - - C c K18
60 0 1 T F K18
61 1 36 D F K18
62 0 30 2+ - - C c K18
63 0 43 + - + C c K18
64 0 58 F K18
65 1 27 K18
66 1 3 K18
67 1 10 K18: 21-7-86
1 1 15 TB450-HE ENTOTO #1
2 0 28 2+ - - - X c ENT: 7-8-85
3 1 62 F ENT
4 1 21 2+ - - - X HE ENT
5 0 50 ENT
6 0 16 3+ - - - X c ENT
7 1 24 2+ - - - X c ENT
8 1 19 ENT
9 0 22 ENT
10 0 28 ENT
11 0 18 3+ - - - X c ENT
12 1 26 F ENT
13 1 26 3+ - - - X c ENT
14 1 26 F ENT
15 1 35 F ENT
16 1 18 2+ - - - X c ENT
17 1 22 HE ENT
18 1 17 ENT
19 0 55 F HE ENT
20 0 35 3+ - - - X c ENT
21 1 19 2+ - - - X c ENT
22 1 22 ENT: 11-10-85
23 1 30 2+ - F ENT
24 0 35 2+ - - - X c ENT
25 1 50 2+ - - 0 X c ENT
26 1 37 3+ - - - X c ENT
27 1 22 2+ - - - X c ENT
1 1 52 2+ - - F HE ENT
2 0 35 2+ F ENT
3 0 25 F ENT
4 1 10 ENT
5 0 25 F ENT
6 0 26 ENT
7 1 13 ENT
8 0 18 ENT
9 0 40 F ENT
10 0 13 2+ + - - X c ENT
11 0 18 F ENT
12 1 38 3+ T HE ENT
13 1 47 2+ - - - X c ENT
14 0 2 ENT
15 1 14 2+ - - - X c ENT
16 1 52 HE ENT
17 0 17 3+ - - - X c ENT: 11-12-85
18 0 5 3+ - - - X c ENT
19 1 47 2+ - - - c ENT
20 1 37 2+ - - - X c ENT
21 0 35 ENT
22 1 22 3+ - - - X c ENT
23 0 20 2+ - - - X c ENT
24 0 40 T ENT
25 1 18 ENT
26 1 37 ENT
27 1 17 ENT
28 0 50 ENT
29 0 19 3+ - - - X c ENT
30 1 18 ENT
31 1 45 2+ - - - X c ENT
32 1 72 2+ - - F HE ENT
33 1 25 2+ - - - X c ENT
34 1 31 ENT
35 0 20 3+ - - - X c ENT
36 0 28 2+ - - - X c ENT: 25-1-86
37 1 14 ENT: 1-2-86
38 1 23 2+ F ENT
39 1 28 3+ - 2+ F ENT
40 1 28 2+ - - X c ENT
41 0 3 ENT
42 1 6 ENT
43 1 52 F ENT
44 1 12 2+ - - c ENT
45 1 22 3+ - - c ENT
46 0 23 2+ - - - X HE ENT
47 0 28 D ENT
48 1 22 ENT
49 1 36 ENT
50 1 57 2+ D ENT
51 0 50 D ENT
52 0 35 2+ - - - X c ENT
53 1 30 3+ - X c HE ENT
54 1 77 ENT
55 1 50 T ENT
56 1 22 3+ T ENT
57 0 18 ENT
58 0 23 D ENT: 14-3-86
59 0 4 T ENT
60 1 18 ENT
61 0 50 ENT
62 1 20 F ENT
63 1 54 2+ - - - X c ENT
64 1 17 3+ - - X c ENT
65 0 16 2+ - c ENT
66 1 20 3+ - X c ENT
67 1 60 D ENT
68 1 30 3+ F ENT
69 1 32 T ENT
70 1 50 ENT
71 0 20 3+ - - - X c ENT
72 1 26 3+ - D ENT
73 1 7 ENT
74 0 25 ENT
75 1 28 2+ - - X c ENT
-A:
76 0 42 2+ - - X c ENT
77 1 18 ENT
78 1 65 ENT
79 1 29 3+ - D TB450-HE ENT
80 1 39 2+ - - - X c ENT: 15-4-86
81 1 52 ENT: 15-4-86
82 0 33 2+ - 2+ - c ENT
83 0 18 2+ - - - X c ENT
84 0 25 ENT
85 1 35 ENT
86 0 25 T HE ENT
87 1 18 ENT
88 1 35 TD D ENT
89 0 15 2+ - F ENT
90 1 18 ENT
91 0 15 3+ - - c HE ENT
92 1 30 ENT
93 0 26 3+ D ENT
94 0 18 ENT
95 1 52 ENT
96 0 40 ENT
97 1 22 ENT
98 1 30 2+ - D ENT
99 1 18 ENT
100 1 18 3+ - c ENT
101 1 18 ENT: 10-8-86
102 1 - ENT
103 1 30 D ENT
104 1 12 ENT
105 0 45 2+ F ENT
106 0 4 ENT
107 1 37 ENT
108 1 26 3+ - T ENT
109 0 16 ENT
110 1 15 ENT
111 1 35 ENT
112 0 15 HE ENT
113 0 60 ENT
114 0 3 ENT
115 0 40 ENT
116 0 26 HE ENT
117 0 20 ENT
118 0 39 ENT
119 0 75 T ENT
120 0 21 2+ - c ENT
121 1 22 2+ - c ENT
122 0 21 3+ - - c ENT
123 1 58 ENT: 28-6-86
1 1 35 F SHEROMEDA
2 1 22 2+ - - X c TB450-HE SHE: 20-8-85
3 1 26 3+ - - X c SHE
4 0 44 + - - - X HE SHE
5 1 28 TB450-HE SHE
6 1 28 3+ - - D HE SHE
7 1 34 + - F SHE
8 0 12 TB450-HE SHE
9 0 21 F SHE
10 0 23 SHE
11 0 45 2+ - T SHE
12 0 25 T SHE
13 1 53 + - D HE SHE
14 1 19 3+ - - - X c SHE
15 1 10 2+ - - X T SHE
16 1 25 2+ + - - X c SHE
17 1 20 3+ - F SHE
18 0 18 HE SHE
19 1 34 2+ - - - X TB450-HE SHE
20 1 19 2+ - T HE SHE
21 0 23 3+ - - - X c SHE
22 1 22 + - - - X c SHE: 3-10-85
23 1 52 2+ - - - X HE SHE
24 1 16 X SHE
25 0 16 2+ - - X c HE SHE
26 0 50 2+ - - - X c SHE
27 1 40 + - - - X c SHE
28 0 4 SHE
29 1 33 TB450-HE SHE
30 0 8 SHE
31 0 21 3+ + - + BAC+ SHE
32 0 20 SHE
33 0 25 3+ - - - X c SHE
1 1 18 F SHE
2 0 16 SHE
3 0 17 SENSITIV. TST SHE
4 0 23 SHE
5 0 29 3+ - - - X TB450-HE SHE
6 1 12 SHE
7 0 16 TB450-HE SHE
8 1 13 SHE
9 1 25 2+ - - - X TB450-HE SHE
10 1 15 + - - - X c SHE
11 1 19 2+ - - - F SHE: 3-13-86
12 0 22 SHE
13 0 11 3+ - - - X F SHE
14 1 19 + - F SHE
15 1 19 2+ - - - X HE SHE
16 0 22 SHE
23 0 26 T SHE
18 0 20 D TB450-HE SHE
19 1 33 + + - - X c SHE
20 0 60 F SHE
21 1 25 2+ - - - X TB450-HE SHE
22 1 21 3+ 2+ - - X c SHE
24 1 35 3+ - - X c SHE
25 1 30 2+ + - - c SHE
26 1 20 + - - X c SHE
27 1 49 3+ - - - X c SHE
28 0 38 2+ - - - X TB450-HE SHE
29 1 21 2+ - - - X c SHE
30 1 20 SHE
31 0 0.75 F SHE
32 0 50 SHE
33 1 28 3+ - - X c SHE
17 1 59 + - - X c SHE: 28-11-86
34 0 20 2+ - - X c SHE
35 0 13 2+ + - X c TB450-HE SHE
36 1 31 3+ - - - X TB450-HE SHE
37 1 20 2+ - - - X RETREATMENT SHE
38 0 35 3+ - - X c SHE
39 1 22 2+ 2+ - - X c SHE
40 0 27 + - - - X c SHE
41 0 25 +■ - - X c SHE
42 1 73 + - - c SHE
43 0 17 D SHE
44 1 20 2+ - F SHE
45 1 3 SHE
46 0 38 3+ D SHE
47 0 17 2+ - - X c SHE
48 1 17 TB450-HE SHE
49 1 2 SHE
50 1 20 SHE
51 1 23 SHE
52 0 45 3+ c T SHE
53 1 4 SHE
54 1 18 SHE
55 1 22 2+ - c SHE: 9-2-86
56 0 19 2+ - - - X TB450-HE SHE
57 0 38 2+ - F SHE
58 1 1 T SHE
59 1 32 3+ - F SHE
60 1 18 SHE
61 1 31 2+ - - - c SHE
62 0 25 2+ - - - X c SHE
63 1 54 + - - - X TB450-HE SHE
64 0 16 SHE
65 1 28 2+ - - - X TB450-HE SHE
66 1 32 3+ - - X c HE SHE
67 0 21 2+ - - X c TB450-HE SHE
68 0 25 - + TB450-HE SHE
69 0 14 T SHE
70 0 56 2+ - - - X c SHE
71 0 22 3+ - - - X c SHE
72 1 65 SHE
73 1 19 T SHE
74 1 19 SHE
75 0 28 3+ - - X c SHE
76 1 24 T HE SHE
77 0 18 2+ - - - X c SHE: 3-3-86
78 1 18 + - - - X c SHE
79 0 30 D SHE
80 0 23 SHE
81 1 35 2+ - - X c SHE
82 0 25 SHE
83 0 35 SHE
84 1 67 SHE
85 0 22 SHE
86 1 42 SHE
87 1 19 SHE
88 1 27 SHE
89 1 31 + - - c TB450-HE SHE
90 1 67 SHE
91 0 17 SHE
92 1 37 3+ - - X c TB450-HE SHE
93 1 20 SHE
94 1 31 R 3+ - - X c RETREATMENT SHE
95 1 19 + - - TB450-HE SHE
96 1 12 SHE
97 1 12 T SHE
98 1 17 3+ - c SHE
99 0 24 T + - c HE SHE: 12-3-86
100 0 40 SHE
101 0 48 SHE
102 0 64 SHE
103 1 20 2+ - - - X c SHE
104 1 10 SHE
105 1 28 T HE SHE
106 1 15 SHE
107 1 21 3+ - - X c SHE
108 0 18 T 2+ - - - X HE SHE
109 1 22 3+ - c SHE
110 1 15 2+ - F SHE
111 1 61 HE SHE
112 1 10 SHE
113 1 14 T 3+ - X c SHE
114 1 28 HE SHE
115 1 41 SHE
116 1 40 R RETREATMENT SHE
117 0 30 3+ - F SHE
118 1 20 SHE
119 1 13 SHE
120 1 55 SHE
121 1 18 SHE: 11-7-86
122 0 35 3+ - c SHE
123 0 25 3+ - - - HE SHE
124 1 22 F TB450-HE SHE
125 1 33 SHE
126 1 28 D HE SHE
127 0 18 SHE
128 1 20 SHE
129 1 32 SHE
130 1 18 SHE
131 0 55 D SHE
132 1 75 2+ - D SHE
133 1 26 2+ - - X c SHE
134 0 20 HE SHE
135 0 32 + - - X c HE SHE
136 0 25 SHE
137 1 24 + - - c SHE
138 0 15 + - - X c SHE
139 0 37 3+ - - c HE SHE
140 1 39 SHE
141 1 26 2+ - ■ c HE SHE
142 0 40 SHE
481 27.5
APPENDIX B
LABORATORY COSTS Item Unit Cost (birr) Per Unit /Eatient: LCC /Patient: SCC Total LCC/Area Total SCC/Area
Screening Cost Solution A, 500 ml /bottle 12.80 (0.2694X3)=.81
3X ea. Solution B, 500 ml. /bottle 16.90 (03557X3)=1.07
Sputum Sample Cups Zea 0.13 (,13X3)=390
Cost/Patient Successfully Screened
(236X15040X635 53.49 53.49
4XLCC Microscope (last 6-7 years) Zea 4,257.20 (.33X4257.2)=1404.88/(268)(6.5)=.82 0.82 0.82
3XSCC Micro Slides /ca 0.04 insignificant
Micro Cover Slides Zea 0.04 insignificant
Assume 268 Patients Solution A, 500 ml. /bottle 12.80 0.2694 1.08 0.81
per year Solution B, 500 ml. /bottle 16.90 0.3557 1.42 1.07
Sputum Sample Cups Zea 0.13 0.13 0.52 039
Microscope Bulbs (2-3 bulbs/year) /ea us.80/5.2b 0.06 0.06
Diamond Pencil UNICEF re-used repeatedly/unsignificant
Wire Loop UNICEF re-used repeatedly/unsignificant
TOTAL
DRUGS ft. ASS. Streptomycin 1 gm /vial 1.71 60 days @ 1.71/day 102.6 102.6
Disposable Syringe: 2 cc w/ needle /ea 0.23
Disposable Syringe: 5 cc w/ needle Zea 0.26 60 days @ 0.26/day 15.6 15.6
Water for injection: 2 cc /vial 0.48 60 days @ 0.48/day 28.8 28.8
Isoniazid: 300 mg /tab 0.06
Isoniazid: 100 mg /2tabs 0.04 60 days @ 0.04/day 24
Rifiampicin: 300 mg /2caps 1.06 60 days @ I.03/day 61.8
Rifampicin: 100 mg /2caps 0.94
Pyrazinamide: 500 mg /4tabs 0.78 60 days @ 0.78/day 46.8
TB150 /2tabs 0.06
TB 450:1 Table /2tabs 0.07 180/360 days @ 0.035/day 12.6 63 159.6 2643
Ethambutol: 400mg /2tabs 0.28 18 birr/12 birr
Vitamin B6:25 mg /tab 0.05
Boiler 10 years/2680 patients=.559 /ea 1300.00 syringes assumed new
Salvon: 25 litcis/2 years=75/536=.13 /bottle 75.00 syringes assumed new
STAFF COSTS Nurses /month 450 bin 20.45 20.45 100.00%
Lab Tcch/screening cost® hospital 33.4 33.4
20 min/patient Lab Technicians @ Health Centres /month 450biiT 3.76 2.82
# slides? Health Assitants /month 300 birr 13.63 13.63 100.00%
-U/2.day per week) Physicians /month 867.5 birr 3.236 3336 6.67%
X-RAY X-Ray Machine
(Smear -1 Cost of those successfully X-Rayed Zea 10-15 birr 150 150
Tfrom.Black Lion and
Yekatit)
X-Ray Technician 450 birr 1.88 1.88
(private cost 29-35 bin)
J.OTAT.STATIONARY Printing Formats & Registration Books total 20374.80 1.64 1.64
Office Stationary total 14,000.00 2.26 236
Contingency Fee 10% total 1,226.20
i-----------------------------------------------------------------------
TRAINING Pilot Training in Arsi 38,662.45
N-Pilol Training 7.007.00
IN-PATIENT COSTS Per Bed
Doctor Costs 950.00
Nurses 400.00
Technician
Ovethead/Utilides
Building 1930's ???
OUT-PATIENT COSTS
Telephone w/ delivery 300.00
Telephone w/o delivery 100.00 0.45 0.45
Electricity w/ delivery 1,000.00
Electricity w/o delivery 300.00 0.75 0.75
Water w/delivery 200.00
Water w/o delivery 100.00 0.45 0.45
Building /health ent 1. 2000.000
ADMINISTRATION Coordinator /month 950.00 1.84 1.84
Sister Enesh /month 710.00 137 137
Dr. Eyob 10% of time /month 980.00 0.19 0.19
PHARMACY Coordinator 10% of time /mo 980.00 0.19 0.19
Pharmacist 1/2 day each 45 days Ano 600.00 03 03
(stocking and ordering)
TRAVEL Fuel/Driver /week/HC 10.00 insignificant-driver doesn’t just do TB
(Defaulter cost integrated w/other)
CVC DIAGNOSIS Nurse Time 400-500 234 234
Lab Technician 400-500
CVC Health Centres 1.5
CVC Hospitals 5 50 50
Stool/Urine Private 3-7
TOTAL COST 449.736 553.016
COST PER CURE 603.756 609305
COST PER PATIENT
COST/DEATH AVERTED
COST PER HEALTH CNTR
RETREATMENT
H Sensitive (all defaulters) H Resistant (All Bac. +)
DRUG COSTS RIFAMPICIN: 300mg 1.06 @ 90 Days 95.4 95.4
ISONIAZID 0.06 5.4 5.4
PYRAZINAMIDE 0.78 70.2 70.2
ETHAMBUTOL 0.42 37.8 37.8
STREPTOMYCIN 1.71 153.9 153.9
Syringe and Needle 0.26 23.4 23.4
Water for Injection 0.48 1 43.2 43.2
TB450 (Daily for 4 months) @ 150 Days 5.25
R (3 times/weck):4(I50) mg. 2.12 @ 64 Days 135.68
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APPENDIX C
KEFETEGNE 17
Interviewed: Dr. Ketsela/Nurse Maseret
TB Patients to Date: 134 from 13/3/86-25/12/86 E.C.
NP/P: NP
Laboratory: on-site
Initial Smear: 3 read by 2 technicians depending on who's working (no form of 
quality control)
Staining method: Ziehl-Neelsen Method/Gram stain
Laboratory Supplies: No problem
Drug Supply: No Problem with supplies but suffered two months ago before drugs 
were free and patients had to get a letter saying they could get them free of charge. 
Source of Drugs: Zone 14 health bureau
Drug Ordering: done in conjunction with pharmacist analysis of last quarter report, 
drug needs are increasing
Patient Referral Information from hospitals: complete
Ease of hospitalisation of patients: no problem
Defaulter Follow-up: give person responsible for the patient (i.e. family member) a 
call, if contacted, get the patient to sign that he will come in.
How are those transferring to rural areas treated: 2 months continuation phase 
treatment administered.
Case Finding: Most are referred from hospitals or the TB centre
Problems: defaulters often do not give their real address or phone number. Those 
coming from rural areas for treatment are often quite critical, but having no place to live, 
they only take two weeks of intensive treatment.
Forms: Tuberculosis register, identity cards, patient cards, smear requests 
Syringes: New
KEFETEGNE 19
Interviewed: Dr. Mulu
TB Patients to Date: 211 P and ? NP from 13/8/85-3/1/86 E.C.
NP/P: P and NP
Laboratory: on-site
Initial Smear: 3 read by 2 technicians depending on who's working (no form of 
quality control)
Staining method: solution a and b, 112+/735 with 85 follow-ups
Laboratory Supplies: No problem
Drug Supply: some problems procuring Ethambutol for those with reactions 
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: complete
Ease of hospitalisation of patients: no problem
Defaulter Follow-up: give patient (i.e. family member) a call, if contacted, get the 
patient to sign that he will come in, if cannot get the patient, then contact person 
responsible.
How are those transferring to rural areas treated: 1 month continuation phase 
treatment for those moving. If they are in the intensive phase, there is no treatment 
without an address- if you cannot stay, you get a referral slip and that's the end of it. 
Case Finding: Almost all smear negatives and extra-pulmonary cases come from the 
hospital, some smear positive cases come from the hospital, but many also come from 
off of the street.
Problems: It is the patients who are smear positive who are the most likely to die. 
This is probably due to complications from AIDS. Rarely do the smear positive 
patients die. I find this interesting because it is the smear negative patients who are the 
most expensive to treat as they often require X-rays both to verify diagnosis and to 
verify a cure.
Forms: Tuberculosis register, identity cards, patient cards, smear requests 
Syringes: Boiled syringes, unless the patients can afford to buy them. Syringes are 
treated with Savlon and then boiled for 30 minutes or more. There is also a separate 
boiler just for those patients with tuberculosis. The doctor admitted that some of the 
syringes are a little dull and difficult to get into the patient sometimes.
KEFETEGNE 13
Interviewed: Dr. Kidist
TB Patients to Date: -
NP/P: Pilot'
Laboratory: on-site
Initial Smear: 3 read by 2 technicians depending on who's working (no form of 
quality control), after patient appears to be negative, no more smears are done 
Staining method: solution a and b
Laboratory Supplies: No problem, except with wire loop and diamond pencil 
Drug Supply: always enough drugs 
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: not always complete previously, 
after repeatedly sending patients back for more information, this is less of a problem. 
Ease of hospitalisation of patients: there are real problems, patients are not 
admitted when requested, they say that it is "useless to admit HIV+ patients". Cannot 
handle critical cases that need to be hospitalised as they have not beds or IV foods. 
Defaulter Follow-up: give patient (i.e. family member) a call and tell them to come 
in, the previous nurse who was trained is now gone, therefore only telephone the 
patient. If the patient doesn't have a phone, there is no follow-up as there is no car 
provided to go to the patient's house. Also, patients for fear of not being treated 
without a phone number, often give a fake one. Chronic patients have developed a 
hierarchy at this treatment centre and order the new
patients to come for treatment. This is the only other form of follow-up for the patients. 
How are those transferring to rural areas treated: 1 month continuation phase 
treatment for those moving. If they are in the intensive phase, there is no treatment 
without an address- if you cannot stay, you get a referral slip and that's the end of it. 
Case Finding: Almost all cases come from the hospital,
Problems: The nurse that was trained to treat the TB. patients left the centre and now 
it is very difficult to get nurses to treat the disease. TB. patients are unpopular to treat at 
the health centre as they can be irritable. Also, nurses are afraid of contamination. 
Nurses are put on a three month revolving work schedule for treatment of TB. patients 
which effectively means that nurses must be trained every three months. Smear should 
have been taken at regular intervals. Pre-pilot times suggest a random taking care of 
patients, no smear information was recorded nor default, death or record of continuous 
treatment. Also, treatment occurring in the clinic includes a weird variety of regimens 
such as SER for one month or RH given for nine months and that's it. Patients are not 
always weighed.
Forms: Tuberculosis register, identity cards, patient cards, smear requests
Syringes: Syringes are boiled for the patients, but if the patients is suspected of being 
HIV+, he or she is given disposable syringes.
KAZANCHEZ
Interviewed: Yocabel
TB Patients to Date: 114
NP/P: Non-Pilot
Laboratory: on-site
Initial Smear: 3 read by 2 technicians depending on who’s working (no form of 
quality control), after patient appears to be negative, no more smears are done 
Staining method: solution a and b
Laboratory Supplies: No problem
Smear+ Examination: 14/145, 3-5 examinations are done per day, sometimes none. 
Drug Supply: it is sometimes difficult to get ethambutol or rifampicin 
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: incomplete information 
sometimes- if this is the case, they just send the patient back for more information 
Critical Patients: there is a real problem, some very critical patients arrive at the 
health
centre from the hospitals often on stretchers and they have to be sent back but the 
hospitals sometimes will not take them.
Ease of Hospitalisation of Patients: There is a problem
Defaulter Follow-up: telephone the patient and if this does not work, go to the 
patient's house
How are those transferring to rural areas treated: 1 month continuation phase 
treatment for those moving. If they are in the intensive phase, there is no treatment 
without an address- if you cannot stay, you get a referral slip and that's the end of it. 
Case Finding: Almost all cases come from the hospital,
Forms: Tuberculosis register, identity cards, patient cards, smear requests Syringes: 
Syringes: are boiled but disposable syringes are used for the HIV+ patients. Syringes 
are used for one week.
TEKELEHAMANOT
Interviewed: Nurse Negassa
TB Patients to Date: 294'
NP/P: Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b
Laboratory Supplies: There is a problem getting solution a and b as often they have 
not been mixed properly and they have expired. They should service at least for a year. 
Smear+ Examination: 34/186 100 follow-ups, 5 minutes for solution A and 3 
minutes for solution B. It takes 5-10 minutes to read each slide.
Drug Supply: No problem with drugs, those who are on SDR and can afford
rifampicin.
are given it.
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: incomplete information 
sometimes- if this is the case, they just send the patient back for more information
Critical Patients: there is a real problem, some very critical patients arrive at the 
health centre from the hospitals often on stretchers and hospitals do not want to take 
them or do not have room. Don't want the TB patients infecting the other patients. TB- 
HIV cases are seen as hope less and therefore are given little attention.
Ease of Hospitalisation of Patients: There is a problem
Defaulter Follow-up: There are many defaulters, usually they have economic 
problems. Nurse Negassa goes to the patient's houses to find them. He is exceptional, 
cares about the patients. The profile of the defaulters are ex-soldiers who are mostly 
HIV positive. These soldiers served as ton of the main mechanisms for the 
transmission of AIDS during the Dergue regime due to sex/rape compounded with 
frequent movement.
Case Finding: Almost all cases come from the hospital.
Syringes: Syringes are boiled, those who can afford to buy syringes do. Syringes 
can be used in excess of 100 times. The needles gets very dull and become painful to 
inject. A special problem, (notes: Case of Critical mother-both children of 6 and 7 also 
got TB. Negassa works entirely on TB with the other nurse.)
ADDIS KETEMA
Interviewed: Dr. Etsegenet (medical director) and Nurse Kassye
TB Patients to Date: 501
NP/P: Non-pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b
Laboratory Supplies: No problem
Smear+ Examination: 21+/334 smears 2 minutes for solution A and 2 minutes for 
solution B. It takes 10 minutes to read each slide.
Drug Supply: No problem with drugs in the past-two months ago- before drugs were 
free- this was a problem.
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: complete
Critical Patients: very critical patients arrive
Ease of Hospitalisation of Patients: There is a problem
Defaulter Follow-up: Often defaulters give false telephone numbers, it can be very 
difficult to get them. Often they come from extremely rural areas and live with relatives 
who claim that they are from Addis. Treatment for those moving to rural areas: 2 
months treatment and a transfer letter to the appropriate hospital or health centre 
Syringes: Syringes are boiled use disposable syringes for one week. Patients can also 
buy new syringes.
KEFETEGNE 23
Interviewed: Nurse Fanakebede, Nurse Getalma, HA Temeselew Asefa (spend all of
their time working on TB
TB Patients to Date: 306
NP/P: Non-Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b
Laboratory Supplies: No problem
Smear+ Examination: 46+/713 smears 381 follow-ups, 5 minutes for solution A 
and 3 minutes for solution B. It takes 15-20 minutes to read each slide.
Drug Supply: there are not sufficient supplies for drugs, approximately 120,000 birr 
per year is allocated for each health centre and out of this must come TB drugs, 
sometimes there is a problem getting ethambutol or rifampicin, but this is not suiprising 
since this is a non-pilot institution, (from pharmacist)
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: complete
Critical Patients: very critical patients arrive
Ease of Hospitalisation of Patients: Hospitals won;t always admit patients due to 
lack of space- nurse says that even HIV's must be accepted
Defaulter Follow-up: Patients are given a phone-call and ask them to come in- not 
problem with patient-compliance.
Treatment for those moving to rural areas: 1-2 months treatment and asked to 
return after that.
Syringes: They are not getting syringes and have many problems- use a syringe 3-4 
times-or for one week. Use old syringes from around the centre-i.e. penicillin 
injections. Boil, disposable syringes and needles are observed to sometimes get very 
dull.
KEFETEGNE 18
Interviewed: Nurse Samrawite Bhere Tibebe (spends all her time on TB) also OPD 
nurse spends afternoons on TB. Dr. Mertework has contracted TB- the doctor who 
was trained l-2nd month on TB treatment.
TB Patients to Date: 269
NP/P: Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician, collects slides for later 
quality control- students read them 
Staining method: solution a and b
Laboratory Supplies: No problem, solution is re-prepared after three months 
Smear+ Examination: 68+/535 smears 266 follow-ups, 5 minutes for solution A 
and 3 minutes for solution B. It takes 30 minutes to read each slide.
Drug Supply: always enough
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing, drugs are ordered every 45 days. Eyob says there is not a 3 month buffer 
of drugs. Pharmacist takes 1/2 day every 45 days stocking, dispensing the drugs. 
Patient Referral Information from hospitals: complete
Critical Patients: very critical patients arrive and are kept at the health centre 
Ease of Hospitalisation of Patients: no problem
Defaulter Follow-up: Patients are given a phone-call and if this doesn't work, they 
go to his house.
Treatment for those moving to rural areas: inject and send away- no medicine is 
given to them.
Syringes: Boil syringes and use them 5 times
ENTOTO #1
Interviewed: Nurse Lakew and Nurse Sewagegne
TB Patients to Date: 270
NPZP: Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b
Laboratory Supplies: No problem
Smear+ Examination : 37/402 smears 128 follow-ups, 2-3 minutes for solution A 
and 4 minutes for solution B. It takes 5 minutes to read each slide.'
Drug Supply: fine
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: complete
Critical Patients: very critical patients arrive and will give them their medicine at 
home.
Ease of Hospitalisation of Patients: The patient himself is what limits 
hospitalisation- it is a question of economics- if he or she cannot afford transport to 
hospital. Also professionals may not be co-operative, there may be not beds and 
patients may be told to come again after the patient has paid much to travel there and 
when some come alone without relatives.
Defaulter Follow-up: See below
Syringes: One or two patient bring syringes. Otherwise, they use a drive oven to 
sterilise syringes.
Notes: The maximum spent with a patient is 10 minutes per day. The doctor spends 
about a 1/2 day per week or 3-5 days helping during the month. Many of the staff are 
trained in Cuba from the Dergue regime. Often they will have spent 10 years in Cuba. 
500 or so received military scholarships to study there. The medical director showed 
me the catchment area. 7 bikes are provided by donation from UNICEF. Telephone 
the Kebele of the defaulter and a representative from the Kebele will go to their house, 
pick them up on the bicycle and ride the patient to the health centre. It costs 1.6 birr to 
get to the health centre ad 3 eggs cost 1 birr. Medical director said that she will go 
herself if she has problem in getting hold of someone at the Kebele. A patient is 
considered a defaulter (i.e. he/she is chased) if they miss 4-5 days of treatment. One of 
the things that the medical director has not considered is that not all that many people 
know how to ride a bicycle.
KOLFE HEALTH CENTRE
Interviewed: Dr. Dejene T/haimanot
TB Patients to Date: 188
NP/P: Non-Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b, used methyline blue before.
Laboratory Supplies: No problem
Smear+ Examination: 45+/357 with 75 follow-ups, 5 minutes sol A, 3-4 for 
solution B. 20 TB slides per day (6 patients per day come in). Gloves are a problem. 
Rechecks positive slides- kept in a box- students come and look. No wire loop- use a 
stick instead. Heat and it dries, stain, blot, then read for 10 minutes per total smear. 
Must wear a mask to collect sputum samples. .
Drug Supply: fine
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: inappropriate referrals come from 
the hospitals- patients started on SCC must can only be given SDR in this non-pilot 
area. Some patients are sent with a prescription only and no other information. 75% 
come from hospitals.
Critical Patients: very critical patients arrive and will give them their medicine at 
home.
Ease of Hospitalisation of Patients: Difficult to hospitalise patients.
Defaulter Follow-up: Call defaulters and send name to Kebele- there is a problem in 
motivating health workers sometimes. Many come from the South for treatment and are 
accepted but then leave. The real defaulters are often not the area residents. Also 
residents often rent and are made to move and do not notify the health centre. Most 
workers are weavers and low business traders.
Syringes: Boil syringes- all TB drugs are free- 5% bring syringes maybe. Syringes 
are used 3-5 times before thrown away. After that- the disposable syringes loses its 
elasticity and the needle gets dull. Want to use re-usable syringes.
SHEROMEDA HEALTH CENTRE
Interviewed: Nurse Tesfaye Geleta and Dr. Assefu
TB Patients to Date: 417
NP/P: Pilot
Laboratory: on-site
Initial Smear: three are done and read by one technician
Staining method: solution a and b, used methyline blue before.
Laboratory Supplies: sometimes need more solution
Smear+ Examination: 136+/421, with 126 follow-ups. takes 15-20 minutes for the 
entire reading process. Read 8-12 slides per day, 3-5 minutes solution A, 5-10 
minutes +solution B. Positive slides are rechecked'
Drug Supply: fine
Source of Drugs: Zone 14 health bureau
Drug Ordering: done by pharmacist analysis of last quarter report, drug needs are 
increasing
Patient Referral Information from hospitals: complete
Critical Patients: maybe 1-2 per month
Ease of Hospitalisation of Patients: Admission is a problem, hospitals won’t 
take patients.
Defaulter Follow-up: contact person is called and contact at home through Kebele. 
For those leaving for rural areas: Use referral slip and give 2 months treatment if on the 
continuous phase
Syringes: Most (80%) cannot afford to buy syringes- boil syringes. Use re-usable 
100 times and disposable 4-5 times. Nurses give 70 injection per day?
Occupations: local traders, wazaders (day labourer)
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APPENDIX E
1
Distribution of life expectancies calculated from model life table west data 
taken from data in C. J. L. Murray (1994)
Number of data points is: i = o.. 17
Life expectancies at birth from Murray are: femaleexatbirth = 82.5 maleexatbirth - 80
Data from Murray follows
age
0
1
5
10
15
20
25
30
35
40 femaleexpectancy =
82.5
81.84
77.95
72.99
68.02
63.08
58.17
53.27
48.38
43.53 maleexpectancy
80.00 '
79.36
75.38
70.4
65.41
60 44
55.47
50.51
45.56
40.64
45 38.72 35.77
50 33.99 30.99
55 29.37 26.32
60 24.83 21.81
65 20.44 17.50
70 16.20 13.58
75 12.28 10.17
80 8.9 7.45
The ages are "normalised" to the lile expectancy at birth (i.e. divided by life expectancy at birth) so.
fcmaleagefrac =---------^C maleagefrac =------------------
femaleexatbirth maleexatbirth
The fractional ages from Murray therefore become:
femaleagefrac =
0.364
0.424
0.485
0.545
0.606
0.667
0.727
0.788
malcagefrac =
Similarly, the life expectancies for each age are "normalised" to the life expectancy at birth i.e.
, , , femaleexpectancvfemaleexfrac =----------- --------- —
femaleexatbirth
, , maleexpectancvmaleexfrac =-------------------
maleexatbirth
femaleexfrac = maleexfrac =
1
0.992
0.942
0.88
0.818
0.755
0.693
0.631
0.57
0.508
0.447
0.387
0.329
0.273
0.219
0.17
0.127
0.093
Ethiopian life expectancies at birth are: femaleethiopianexatbirth = 53 maleethiopianexatbirth 53
The age data from Murray can then be converted into "equivalent" Ethiopian ages by multiplying bv the 
"normalised" age data, above, by the Ethiopian life expectancy at birth, ie:
femaleethiopianage = femaleagefrac femaleethiopianexatbirth 
maleethiopianage = maleagefrac maleethiopianexatbirth
This gives:
femaleethiopianage = maleethiopianage =
Similarly,the life expectancy data from Murray can then be converted into "equivalent" Ethiopian life 
expectancies by multiplying by the "normalised" life expectancy data. above, by the Ethiopian life expectant} 
at birth, ie:
femaleethiopianex = femaleexfrac femaleethiopianexatbirth
maleethiopianex = maleexfrac maleethiopianexatbirth
This gives
53
52.576
I 50.077
46.891
43.698
femaleethiopianex = 40.524 maleethiopianex =
37.37
34.222
31.08
27.965
24.875
21.836
18.868
15.951
13.131
10.407
7.889
5.718
53
52.576
49.939
46.64
43.334
40.041
36.749
33.463
30.183
26.924
23.698
20.531
17.437
14.449
11.594
8.997
6.738
4.936
The calculated Ethiopian life expectancy data are shown as a function of calculated Ethiopian age
To give intermediate values for the data (i.e. a life expectancy for each year of age), curves 
were fitted to the data using parabolic spline fits:
vsfemalc = psplinc(femaleethiopianage, femaleethiopianex)
vsmale = pspline( maleethiopianage, maleethiopianex)
In order to obtain life expectancies for patients older than the life expectancy at birth, the data was then 
interpolated for ages up to 65 years old 
age2 =0..65
exfemaleagc2 - interp( vsfemale, femaleethiopianage, femaleethiopianex, age2 )
exmak^ 2 : = interp( vsmale, maleethiopianage, maleethiopianex, age2)
The interpolated data, together with the fitted data are plotted below
Data is then output to files
WRITEPRN(femes) = exfemale WRITEPRN(maleex) = exmale WRITEPRN( ages) = age2
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